Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,14601469,Peak concentrations,"Peak concentrations of trimethoprim in plasma and skin blister fluid were 8.5 +/- 1.1 mumol/L after 3 +/- 1 h and 5.6 +/- 0.8 mumol/L after 7 +/- 2 h, respectively.",[Skin penetration of sulfamethoxazole and trimethoprim after oral administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14601469/),[μM] / [l],8.5,1041,DB00440,Trimethoprim
,14601469,Peak concentrations,"Peak concentrations of trimethoprim in plasma and skin blister fluid were 8.5 +/- 1.1 mumol/L after 3 +/- 1 h and 5.6 +/- 0.8 mumol/L after 7 +/- 2 h, respectively.",[Skin penetration of sulfamethoxazole and trimethoprim after oral administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14601469/),[μM] / [l],5.6,1042,DB00440,Trimethoprim
,14601469,peak concentration,"In the theoretical peripheral compartment, peak concentration was 5.8 +/- 2.2 mumol/L after 9 +/- 6 h.",[Skin penetration of sulfamethoxazole and trimethoprim after oral administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14601469/),[μM] / [l],5.8,1043,DB00440,Trimethoprim
,14601469,Half-times,"Half-times of trimethoprim in plasma and skin blister fluid were 11.1 +/- 4.5 h and 12.3 +/- 4.9 h, respectively, and did not differ significantly.",[Skin penetration of sulfamethoxazole and trimethoprim after oral administration]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14601469/),h,11.1,1044,DB00440,Trimethoprim
,14601469,Half-times,"Half-times of trimethoprim in plasma and skin blister fluid were 11.1 +/- 4.5 h and 12.3 +/- 4.9 h, respectively, and did not differ significantly.",[Skin penetration of sulfamethoxazole and trimethoprim after oral administration]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14601469/),h,12.3,1045,DB00440,Trimethoprim
,14601469,Peak concentrations,"Peak concentrations of sulphamethoxazole in plasma and skin blister fluid were 295 +/- 47 mumol/L after 3 +/- 1 h and 182 +/- 46 mumol/L after 8 +/- 2 h, respectively.",[Skin penetration of sulfamethoxazole and trimethoprim after oral administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14601469/),[μM] / [l],295,1046,DB00440,Trimethoprim
,14601469,Peak concentrations,"Peak concentrations of sulphamethoxazole in plasma and skin blister fluid were 295 +/- 47 mumol/L after 3 +/- 1 h and 182 +/- 46 mumol/L after 8 +/- 2 h, respectively.",[Skin penetration of sulfamethoxazole and trimethoprim after oral administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14601469/),[μM] / [l],182,1047,DB00440,Trimethoprim
,14601469,peak concentration,"In the theoretical peripheral compartment, peak concentration was 239 +/- 58 mumol/L after 7 +/- 4 h.",[Skin penetration of sulfamethoxazole and trimethoprim after oral administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14601469/),[μM] / [l],239,1048,DB00440,Trimethoprim
,14601469,Half-times,"Half-times of sulphamethoxazole in skin blister fluid and plasma were 9.7 +/- 3.3 h and 10.0 +/- 1.1 h, respectively and did not differ significantly.",[Skin penetration of sulfamethoxazole and trimethoprim after oral administration]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14601469/),h,9.7,1049,DB00440,Trimethoprim
,14601469,Half-times,"Half-times of sulphamethoxazole in skin blister fluid and plasma were 9.7 +/- 3.3 h and 10.0 +/- 1.1 h, respectively and did not differ significantly.",[Skin penetration of sulfamethoxazole and trimethoprim after oral administration]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14601469/),h,10.0,1050,DB00440,Trimethoprim
,14601469,degree of penetration,"The drug penetrated into blister fluid to a high extent, although less than trimethoprim, the degree of penetration being 0.82 +/- 0.21.",[Skin penetration of sulfamethoxazole and trimethoprim after oral administration]. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14601469/),,0.82,1051,DB00440,Trimethoprim
,3438229,elimination half-life,The elimination half-life was much shorter in goats (23 +/- 4 min.) than in pigs (169 +/- 17 min.).,Pharmacokinetics and metabolism of metioprim in pigs and goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438229/),min,23,2187,DB00440,Trimethoprim
,3438229,elimination half-life,The elimination half-life was much shorter in goats (23 +/- 4 min.) than in pigs (169 +/- 17 min.).,Pharmacokinetics and metabolism of metioprim in pigs and goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438229/),min,169,2188,DB00440,Trimethoprim
exceeded,3438229,apparent volume of distribution,The apparent volume of distribution exceeded 1.0 1/kg b.wt. in both species indicating accumulation in tissues.,Pharmacokinetics and metabolism of metioprim in pigs and goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438229/),[1] / [b·kg·wt],1.0,2189,DB00440,Trimethoprim
,2705795,half life,In these infants trimethoprim had a mean half life of 4.6 hours; this was comparable with the values found in young and school age children (3.8 and 5.4 hours respectively) and about a quarter of the half life in newborns.,Changes in trimethoprim pharmacokinetics after the newborn period. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2705795/),h,4.6,8310,DB00440,Trimethoprim
,2705795,half life,In these infants trimethoprim had a mean half life of 4.6 hours; this was comparable with the values found in young and school age children (3.8 and 5.4 hours respectively) and about a quarter of the half life in newborns.,Changes in trimethoprim pharmacokinetics after the newborn period. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2705795/),h,3.8,8311,DB00440,Trimethoprim
,2705795,half life,In these infants trimethoprim had a mean half life of 4.6 hours; this was comparable with the values found in young and school age children (3.8 and 5.4 hours respectively) and about a quarter of the half life in newborns.,Changes in trimethoprim pharmacokinetics after the newborn period. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2705795/),h,5.4,8312,DB00440,Trimethoprim
,2705795,volume of distribution,The volume of distribution (1.5 l/kg) was smaller than in newborns but larger than in young or school age children (0.9 and 1.1 l/kg respectively).,Changes in trimethoprim pharmacokinetics after the newborn period. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2705795/),[l] / [kg],1.5,8313,DB00440,Trimethoprim
,2705795,volume of distribution,The volume of distribution (1.5 l/kg) was smaller than in newborns but larger than in young or school age children (0.9 and 1.1 l/kg respectively).,Changes in trimethoprim pharmacokinetics after the newborn period. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2705795/),[l] / [kg],0.9,8314,DB00440,Trimethoprim
,2705795,volume of distribution,The volume of distribution (1.5 l/kg) was smaller than in newborns but larger than in young or school age children (0.9 and 1.1 l/kg respectively).,Changes in trimethoprim pharmacokinetics after the newborn period. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2705795/),[l] / [kg],1.1,8315,DB00440,Trimethoprim
,2705795,plasma clearance,The plasma clearance in these infants (3-3 ml/min/kg) was slightly larger than in newborns or in either group of older children (2.9 and 2.4 ml/min/kg respectively).,Changes in trimethoprim pharmacokinetics after the newborn period. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2705795/),[ml] / [kg·min],3-3,8316,DB00440,Trimethoprim
,2705795,plasma clearance,The plasma clearance in these infants (3-3 ml/min/kg) was slightly larger than in newborns or in either group of older children (2.9 and 2.4 ml/min/kg respectively).,Changes in trimethoprim pharmacokinetics after the newborn period. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2705795/),[ml] / [kg·min],2.9,8317,DB00440,Trimethoprim
,2705795,plasma clearance,The plasma clearance in these infants (3-3 ml/min/kg) was slightly larger than in newborns or in either group of older children (2.9 and 2.4 ml/min/kg respectively).,Changes in trimethoprim pharmacokinetics after the newborn period. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2705795/),[ml] / [kg·min],2.4,8318,DB00440,Trimethoprim
,15025742,t((1/2)),"Trimethoprim raised the AUC(0, infinity ) and C(max) of repaglinide by 61% (range, 30-117%; P= 0.0008) and 41% (P = 0.005), respectively, and prolonged the t((1/2)) of repaglinide from 0.9 to 1.1 h (P = 0.001).",The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025742/),h,0.9,9234,DB00440,Trimethoprim
,15025742,t((1/2)),"Trimethoprim raised the AUC(0, infinity ) and C(max) of repaglinide by 61% (range, 30-117%; P= 0.0008) and 41% (P = 0.005), respectively, and prolonged the t((1/2)) of repaglinide from 0.9 to 1.1 h (P = 0.001).",The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025742/),h,1.1,9235,DB00440,Trimethoprim
,8741597,Tmax,Tmax of SMX after nipple-bucket dosing was about 40 min shorter than that after catheter dosing.,The effect of reflex closure of the esophageal groove on bioavailability of oral sulfamethoxazole-trimethoprim in ruminating calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741597/),min,40,9769,DB00440,Trimethoprim
,8840373,bioavailabilities,"The calculated bioavailabilities of oral TMP and SMX (mean +/- SD) were 102.7% +/- 19.8% and 109.4% +/- 19.4%, respectively.",Oral absorption of trimethoprim-sulfamethoxazole in patients with AIDS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8840373/),%,102.7,10576,DB00440,Trimethoprim
,8840373,bioavailabilities,"The calculated bioavailabilities of oral TMP and SMX (mean +/- SD) were 102.7% +/- 19.8% and 109.4% +/- 19.4%, respectively.",Oral absorption of trimethoprim-sulfamethoxazole in patients with AIDS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8840373/),%,109.4,10577,DB00440,Trimethoprim
,8502619,total body clearance,"The mean (+/- SD) total body clearance of 26.9 +/- 2.3 mL/min per kg BW was high when compared with that determined for other species, presumably a consequence of the higher metabolic rate of birds.",Research note: pharmacokinetics of aditoprim in turkeys after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8502619/),[ml] / [kg·min],26.9,12004,DB00440,Trimethoprim
,8502619,elimination half-life,"Consequently, mean aditoprim elimination half-life was relatively short (3.3 +/- .2 h).",Research note: pharmacokinetics of aditoprim in turkeys after intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8502619/),h,3.3,12005,DB00440,Trimethoprim
,10604820,plasma concentrations,"The mean and SEM plasma concentrations (g/mL) of TMP, SMX, and AcSMX 2 hours after the first treatment dose were 2.0 +/- 1.0 (range 0.5-6), 53 +/- 22 (range 24-146), and 13.5 +/- 12 (range 0-65), respectively.",A reversed-phase high-performance liquid chromatography method for the determination of cotrimoxazole (trimethoprim/ sulphamethoxazole) in children treated for malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604820/),[g] / [ml],2.0,12682,DB00440,Trimethoprim
,10604820,plasma concentrations,"The mean and SEM plasma concentrations (g/mL) of TMP, SMX, and AcSMX 2 hours after the first treatment dose were 2.0 +/- 1.0 (range 0.5-6), 53 +/- 22 (range 24-146), and 13.5 +/- 12 (range 0-65), respectively.",A reversed-phase high-performance liquid chromatography method for the determination of cotrimoxazole (trimethoprim/ sulphamethoxazole) in children treated for malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604820/),[g] / [ml],53,12683,DB00440,Trimethoprim
,10604820,plasma concentrations,"The mean and SEM plasma concentrations (g/mL) of TMP, SMX, and AcSMX 2 hours after the first treatment dose were 2.0 +/- 1.0 (range 0.5-6), 53 +/- 22 (range 24-146), and 13.5 +/- 12 (range 0-65), respectively.",A reversed-phase high-performance liquid chromatography method for the determination of cotrimoxazole (trimethoprim/ sulphamethoxazole) in children treated for malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604820/),[g] / [ml],13.5,12684,DB00440,Trimethoprim
,2231218,Plasma clearance,"Plasma clearance of total MTX did not change significantly, whereas clearance of free MTX decreased significantly (from 12.5 +/- 4 to 7.6 +/- 1.5 ml/kg/min; p less than 0.05).",Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231218/),[ml] / [kg·min],12.5,13112,DB00440,Trimethoprim
,2231218,clearance,"Plasma clearance of total MTX did not change significantly, whereas clearance of free MTX decreased significantly (from 12.5 +/- 4 to 7.6 +/- 1.5 ml/kg/min; p less than 0.05).",Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231218/),[ml] / [kg·min],12.5,13113,DB00440,Trimethoprim
,2231218,clearance,"Plasma clearance of total MTX did not change significantly, whereas clearance of free MTX decreased significantly (from 12.5 +/- 4 to 7.6 +/- 1.5 ml/kg/min; p less than 0.05).",Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231218/),[ml] / [kg·min],7.6,13114,DB00440,Trimethoprim
,2231218,renal clearance,There was a consistent decrease in the renal clearance of free MTX (from 12.1 +/- 6.8 to 5.6 +/- 2.4 ml/kg/min; p less than 0.05).,Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231218/),[ml] / [kg·min],12.1,13115,DB00440,Trimethoprim
,2231218,renal clearance,There was a consistent decrease in the renal clearance of free MTX (from 12.1 +/- 6.8 to 5.6 +/- 2.4 ml/kg/min; p less than 0.05).,Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231218/),[ml] / [kg·min],5.6,13116,DB00440,Trimethoprim
,12803768,elimination half-life,"The elimination half-life for trimethoprim from plasma was longer in SM rats with a median of 3.15 h; in WN rats, it was 0.390 h.",Effect of severe protein-calorie malnutrition on the penetration kinetics of trimethoprim and sulfamethoxazole to the deep tissues of Wistar rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12803768/),h,3.15,14172,DB00440,Trimethoprim
,12803768,elimination half-life,"The elimination half-life for trimethoprim from plasma was longer in SM rats with a median of 3.15 h; in WN rats, it was 0.390 h.",Effect of severe protein-calorie malnutrition on the penetration kinetics of trimethoprim and sulfamethoxazole to the deep tissues of Wistar rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12803768/),h,0.390,14173,DB00440,Trimethoprim
,12803768,Clearance,Clearance was slower in SM rats: 646.72 mL microg(-1) h(-1) vs 3036.38 mL microg(-1) h(-1) in WN rats (P < 0.05).,Effect of severe protein-calorie malnutrition on the penetration kinetics of trimethoprim and sulfamethoxazole to the deep tissues of Wistar rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12803768/),[ml] / [h·μg],646.72,14174,DB00440,Trimethoprim
,12803768,Clearance,Clearance was slower in SM rats: 646.72 mL microg(-1) h(-1) vs 3036.38 mL microg(-1) h(-1) in WN rats (P < 0.05).,Effect of severe protein-calorie malnutrition on the penetration kinetics of trimethoprim and sulfamethoxazole to the deep tissues of Wistar rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12803768/),[ml] / [h·μg],3036.38,14175,DB00440,Trimethoprim
,12803768,penetration indexes,"Tissue penetration was much higher for trimethoprim, with penetration indexes of 0.80-5.66 in WN rats, compared with 0.35-2.14 in SM rats.",Effect of severe protein-calorie malnutrition on the penetration kinetics of trimethoprim and sulfamethoxazole to the deep tissues of Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12803768/),,0.80-5.66,14176,DB00440,Trimethoprim
,12803768,penetration indexes,"Tissue penetration was much higher for trimethoprim, with penetration indexes of 0.80-5.66 in WN rats, compared with 0.35-2.14 in SM rats.",Effect of severe protein-calorie malnutrition on the penetration kinetics of trimethoprim and sulfamethoxazole to the deep tissues of Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12803768/),,0.35-2.14,14177,DB00440,Trimethoprim
,12803768,penetration index,"In the case of sulfamethoxazole, penetration indexes were 0.029-1.13 for WN and 0.075-0.657 for SM rats.",Effect of severe protein-calorie malnutrition on the penetration kinetics of trimethoprim and sulfamethoxazole to the deep tissues of Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12803768/),,0.029-1.13,14178,DB00440,Trimethoprim
,12803768,penetration index,"In the case of sulfamethoxazole, penetration indexes were 0.029-1.13 for WN and 0.075-0.657 for SM rats.",Effect of severe protein-calorie malnutrition on the penetration kinetics of trimethoprim and sulfamethoxazole to the deep tissues of Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12803768/),,0.075-0.657,14179,DB00440,Trimethoprim
,2231873,half-lives,"After i.v. injection of TMP (20 mg/kg body wt) and sulphadiazine (100 mg/kg body wt), both compounds were rapidly eliminated from plasma with half-lives of 1 and 2.7 h, respectively.",Drug plasma levels following administration of trimethoprim and sulphonamide combinations to broilers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231873/),h,1,16492,DB00440,Trimethoprim
,2231873,half-lives,"After i.v. injection of TMP (20 mg/kg body wt) and sulphadiazine (100 mg/kg body wt), both compounds were rapidly eliminated from plasma with half-lives of 1 and 2.7 h, respectively.",Drug plasma levels following administration of trimethoprim and sulphonamide combinations to broilers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231873/),h,2.7,16493,DB00440,Trimethoprim
,2231873,Apparent volumes of distribution,"Apparent volumes of distribution (3.3 and 0.96 l/kg, respectively) indicated that the tissue distribution of TMP was more extensive than that of the sulphonamide.",Drug plasma levels following administration of trimethoprim and sulphonamide combinations to broilers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231873/),[l] / [kg],3.3,16494,DB00440,Trimethoprim
,2231873,Apparent volumes of distribution,"Apparent volumes of distribution (3.3 and 0.96 l/kg, respectively) indicated that the tissue distribution of TMP was more extensive than that of the sulphonamide.",Drug plasma levels following administration of trimethoprim and sulphonamide combinations to broilers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231873/),[l] / [kg],0.96,16495,DB00440,Trimethoprim
,2231873,Bioavailability,"Bioavailability after oral administration was approximately 100% of sulphadiazine, but only about 60% for TMP.",Drug plasma levels following administration of trimethoprim and sulphonamide combinations to broilers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231873/),%,100,16496,DB00440,Trimethoprim
,2231873,Bioavailability,"Bioavailability after oral administration was approximately 100% of sulphadiazine, but only about 60% for TMP.",Drug plasma levels following administration of trimethoprim and sulphonamide combinations to broilers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231873/),%,60,16497,DB00440,Trimethoprim
,8787912,areas under the concentration-time curves,"ZDV areas under the concentration-time curves were (means +/- standard deviations) 1.80 +/- 0.70 and 1.69 +/- 0.64 micrograms.h/ml in the absence and presence of trimethoprim-sulfamethoxazole, respectively.",Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787912/),[h·μg] / [ml],1.80,16777,DB00440,Trimethoprim
,8787912,areas under the concentration-time curves,"ZDV areas under the concentration-time curves were (means +/- standard deviations) 1.80 +/- 0.70 and 1.69 +/- 0.64 micrograms.h/ml in the absence and presence of trimethoprim-sulfamethoxazole, respectively.",Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787912/),[h·μg] / [ml],1.69,16778,DB00440,Trimethoprim
,8787912,clearances,"ZDV clearances were 1.57 +/- 0.61 and 1.74 +/- 0.66 liters/h/kg, respectively.",Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787912/),[l] / [h·kg],1.57,16779,DB00440,Trimethoprim
,8787912,clearances,"ZDV clearances were 1.57 +/- 0.61 and 1.74 +/- 0.66 liters/h/kg, respectively.",Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787912/),[l] / [h·kg],1.74,16780,DB00440,Trimethoprim
,1476314,volume of distribution,"Pharmacokinetic characteristics of aditoprim in healthy cows were a large volume of distribution (6.28 L/kg), a systemic clearance of 0.82 L/h/kg, and an elimination half-life of 7.26 hours.",Effects of endotoxin-induced mastitis on the pharmacokinetic properties of aditoprim in dairy cows. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1476314/),[l] / [kg],6.28,16869,DB00440,Trimethoprim
,1476314,systemic clearance,"Pharmacokinetic characteristics of aditoprim in healthy cows were a large volume of distribution (6.28 L/kg), a systemic clearance of 0.82 L/h/kg, and an elimination half-life of 7.26 hours.",Effects of endotoxin-induced mastitis on the pharmacokinetic properties of aditoprim in dairy cows. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1476314/),[l] / [h·kg],0.82,16870,DB00440,Trimethoprim
,1476314,elimination half-life,"Pharmacokinetic characteristics of aditoprim in healthy cows were a large volume of distribution (6.28 L/kg), a systemic clearance of 0.82 L/h/kg, and an elimination half-life of 7.26 hours.",Effects of endotoxin-induced mastitis on the pharmacokinetic properties of aditoprim in dairy cows. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1476314/),h,7.26,16871,DB00440,Trimethoprim
,1476314,systemic clearance,"The systemic clearance (1.00 L/h/kg) and the volume of distribution (12.25 L/kg) were significantly higher in cows with mastitis, but elimination half-life was not significantly different.",Effects of endotoxin-induced mastitis on the pharmacokinetic properties of aditoprim in dairy cows. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1476314/),[l] / [h·kg],1.00,16872,DB00440,Trimethoprim
,1476314,volume of distribution,"The systemic clearance (1.00 L/h/kg) and the volume of distribution (12.25 L/kg) were significantly higher in cows with mastitis, but elimination half-life was not significantly different.",Effects of endotoxin-induced mastitis on the pharmacokinetic properties of aditoprim in dairy cows. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1476314/),[l] / [kg],12.25,16873,DB00440,Trimethoprim
,10605144,t1/2,Elimination of sulphadiazine was not affected by the route of administration (median t1/2 4.4-5.0 h) while elimination of trimethoprim was strongly limited by slow absorption from the injection site after s.c. and i.m. administration (median for apparent t1/2 21-25 h) compared to that after i.v. administration (median t1/2 1.2 h; p < 0.05).,Pharmacokinetics of sulphadiazine-trimethoprim in lactating dairy cows. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10605144/),h,4.4-5.0,17963,DB00440,Trimethoprim
,10605144,apparent t1/2,Elimination of sulphadiazine was not affected by the route of administration (median t1/2 4.4-5.0 h) while elimination of trimethoprim was strongly limited by slow absorption from the injection site after s.c. and i.m. administration (median for apparent t1/2 21-25 h) compared to that after i.v. administration (median t1/2 1.2 h; p < 0.05).,Pharmacokinetics of sulphadiazine-trimethoprim in lactating dairy cows. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10605144/),h,21-25,17964,DB00440,Trimethoprim
,10605144,t1/2,Elimination of sulphadiazine was not affected by the route of administration (median t1/2 4.4-5.0 h) while elimination of trimethoprim was strongly limited by slow absorption from the injection site after s.c. and i.m. administration (median for apparent t1/2 21-25 h) compared to that after i.v. administration (median t1/2 1.2 h; p < 0.05).,Pharmacokinetics of sulphadiazine-trimethoprim in lactating dairy cows. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10605144/),h,1.2,17965,DB00440,Trimethoprim
,10605144,bioavailability,"The median bioavailability of trimethoprim was also decreased, being 37% and 55% after s.c. and i.m. administration, respectively.",Pharmacokinetics of sulphadiazine-trimethoprim in lactating dairy cows. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10605144/),%,37,17966,DB00440,Trimethoprim
,10605144,bioavailability,"The median bioavailability of trimethoprim was also decreased, being 37% and 55% after s.c. and i.m. administration, respectively.",Pharmacokinetics of sulphadiazine-trimethoprim in lactating dairy cows. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10605144/),%,55,17967,DB00440,Trimethoprim
,10605144,Cmax,"Median Cmax values in milk were only 0.07 mg/l and 0.10 mg/l for s.c. and i.m. administrations, respectively.",Pharmacokinetics of sulphadiazine-trimethoprim in lactating dairy cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10605144/),[mg] / [l],0.07,17968,DB00440,Trimethoprim
,10605144,Cmax,"Median Cmax values in milk were only 0.07 mg/l and 0.10 mg/l for s.c. and i.m. administrations, respectively.",Pharmacokinetics of sulphadiazine-trimethoprim in lactating dairy cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10605144/),[mg] / [l],0.10,17969,DB00440,Trimethoprim
,33051249,F:M ratio,The model-predicted F:M ratio (approx. 0.88) is consistent with reported in vivo values [mean (95% confidence interval): 1.10 (0.69-1.51)].,Development of a Pharmacokinetic Model of Transplacental Transfer of Metformin to Predict In Vivo Fetal Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051249/),,0.,24847,DB00440,Trimethoprim
,19646090,elimination half-life (t(1/2beta)),"Following i.v. administration, the elimination half-life (t(1/2beta)), the mean residence time (MRT), volume of distribution at steady-state (V(d(ss))), volume of distribution based on terminal phase (V(d(z))), and the total body clearance (Cl(B)) were (13.23 +/- 2.24 and 1.95 +/- 0.19 h), (10.06 +/- 0.33 and 2.17 +/- 0.20 h), (0.60 +/- 0.08, and 2.35 +/- 0.14 L/kg), (0.79 +/- 0.12 and 2.49 +/- 0.14 L/kg) and (0.69 +/- 0.03 and 16.12 +/- 1.38 mL/min/kg), for sulfadiazine and trimethoprim, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),h,13.23,25831,DB00440,Trimethoprim
,19646090,mean residence time (MRT),"Following i.v. administration, the elimination half-life (t(1/2beta)), the mean residence time (MRT), volume of distribution at steady-state (V(d(ss))), volume of distribution based on terminal phase (V(d(z))), and the total body clearance (Cl(B)) were (13.23 +/- 2.24 and 1.95 +/- 0.19 h), (10.06 +/- 0.33 and 2.17 +/- 0.20 h), (0.60 +/- 0.08, and 2.35 +/- 0.14 L/kg), (0.79 +/- 0.12 and 2.49 +/- 0.14 L/kg) and (0.69 +/- 0.03 and 16.12 +/- 1.38 mL/min/kg), for sulfadiazine and trimethoprim, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),h,1.95,25832,DB00440,Trimethoprim
,19646090,volume of distribution at steady-state (V(d(ss))),"Following i.v. administration, the elimination half-life (t(1/2beta)), the mean residence time (MRT), volume of distribution at steady-state (V(d(ss))), volume of distribution based on terminal phase (V(d(z))), and the total body clearance (Cl(B)) were (13.23 +/- 2.24 and 1.95 +/- 0.19 h), (10.06 +/- 0.33 and 2.17 +/- 0.20 h), (0.60 +/- 0.08, and 2.35 +/- 0.14 L/kg), (0.79 +/- 0.12 and 2.49 +/- 0.14 L/kg) and (0.69 +/- 0.03 and 16.12 +/- 1.38 mL/min/kg), for sulfadiazine and trimethoprim, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),h,1.95,25833,DB00440,Trimethoprim
,19646090,volume of distribution at steady-state (V(d(ss))),"Following i.v. administration, the elimination half-life (t(1/2beta)), the mean residence time (MRT), volume of distribution at steady-state (V(d(ss))), volume of distribution based on terminal phase (V(d(z))), and the total body clearance (Cl(B)) were (13.23 +/- 2.24 and 1.95 +/- 0.19 h), (10.06 +/- 0.33 and 2.17 +/- 0.20 h), (0.60 +/- 0.08, and 2.35 +/- 0.14 L/kg), (0.79 +/- 0.12 and 2.49 +/- 0.14 L/kg) and (0.69 +/- 0.03 and 16.12 +/- 1.38 mL/min/kg), for sulfadiazine and trimethoprim, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),h,10.06,25834,DB00440,Trimethoprim
,19646090,volume of distribution based on terminal phase (V(d(z))),"Following i.v. administration, the elimination half-life (t(1/2beta)), the mean residence time (MRT), volume of distribution at steady-state (V(d(ss))), volume of distribution based on terminal phase (V(d(z))), and the total body clearance (Cl(B)) were (13.23 +/- 2.24 and 1.95 +/- 0.19 h), (10.06 +/- 0.33 and 2.17 +/- 0.20 h), (0.60 +/- 0.08, and 2.35 +/- 0.14 L/kg), (0.79 +/- 0.12 and 2.49 +/- 0.14 L/kg) and (0.69 +/- 0.03 and 16.12 +/- 1.38 mL/min/kg), for sulfadiazine and trimethoprim, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),h,1.95,25835,DB00440,Trimethoprim
,19646090,volume of distribution based on terminal phase (V(d(z))),"Following i.v. administration, the elimination half-life (t(1/2beta)), the mean residence time (MRT), volume of distribution at steady-state (V(d(ss))), volume of distribution based on terminal phase (V(d(z))), and the total body clearance (Cl(B)) were (13.23 +/- 2.24 and 1.95 +/- 0.19 h), (10.06 +/- 0.33 and 2.17 +/- 0.20 h), (0.60 +/- 0.08, and 2.35 +/- 0.14 L/kg), (0.79 +/- 0.12 and 2.49 +/- 0.14 L/kg) and (0.69 +/- 0.03 and 16.12 +/- 1.38 mL/min/kg), for sulfadiazine and trimethoprim, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),h,10.06,25836,DB00440,Trimethoprim
,19646090,total body clearance (Cl(B)),"Following i.v. administration, the elimination half-life (t(1/2beta)), the mean residence time (MRT), volume of distribution at steady-state (V(d(ss))), volume of distribution based on terminal phase (V(d(z))), and the total body clearance (Cl(B)) were (13.23 +/- 2.24 and 1.95 +/- 0.19 h), (10.06 +/- 0.33 and 2.17 +/- 0.20 h), (0.60 +/- 0.08, and 2.35 +/- 0.14 L/kg), (0.79 +/- 0.12 and 2.49 +/- 0.14 L/kg) and (0.69 +/- 0.03 and 16.12 +/- 1.38 mL/min/kg), for sulfadiazine and trimethoprim, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),[l] / [kg],0.79,25837,DB00440,Trimethoprim
,19646090,total body clearance (Cl(B)),"Following i.v. administration, the elimination half-life (t(1/2beta)), the mean residence time (MRT), volume of distribution at steady-state (V(d(ss))), volume of distribution based on terminal phase (V(d(z))), and the total body clearance (Cl(B)) were (13.23 +/- 2.24 and 1.95 +/- 0.19 h), (10.06 +/- 0.33 and 2.17 +/- 0.20 h), (0.60 +/- 0.08, and 2.35 +/- 0.14 L/kg), (0.79 +/- 0.12 and 2.49 +/- 0.14 L/kg) and (0.69 +/- 0.03 and 16.12 +/- 1.38 mL/min/kg), for sulfadiazine and trimethoprim, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),[l] / [kg],2.49,25838,DB00440,Trimethoprim
,19646090,total body clearance (Cl(B)),"Following i.v. administration, the elimination half-life (t(1/2beta)), the mean residence time (MRT), volume of distribution at steady-state (V(d(ss))), volume of distribution based on terminal phase (V(d(z))), and the total body clearance (Cl(B)) were (13.23 +/- 2.24 and 1.95 +/- 0.19 h), (10.06 +/- 0.33 and 2.17 +/- 0.20 h), (0.60 +/- 0.08, and 2.35 +/- 0.14 L/kg), (0.79 +/- 0.12 and 2.49 +/- 0.14 L/kg) and (0.69 +/- 0.03 and 16.12 +/- 1.38 mL/min/kg), for sulfadiazine and trimethoprim, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),[ml] / [kg·min],0.69,25839,DB00440,Trimethoprim
,19646090,total body clearance (Cl(B)),"Following i.v. administration, the elimination half-life (t(1/2beta)), the mean residence time (MRT), volume of distribution at steady-state (V(d(ss))), volume of distribution based on terminal phase (V(d(z))), and the total body clearance (Cl(B)) were (13.23 +/- 2.24 and 1.95 +/- 0.19 h), (10.06 +/- 0.33 and 2.17 +/- 0.20 h), (0.60 +/- 0.08, and 2.35 +/- 0.14 L/kg), (0.79 +/- 0.12 and 2.49 +/- 0.14 L/kg) and (0.69 +/- 0.03 and 16.12 +/- 1.38 mL/min/kg), for sulfadiazine and trimethoprim, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),[ml] / [kg·min],16.12,25840,DB00440,Trimethoprim
,19646090,C(max),"No significant difference in C(max) (35.47 +/- 2.52 and 37.50 +/- 3.39 microg/mL), t(max) (2.47 +/- 0.31 and 2.47 +/- 0.36 h), t((1/2)beta) (11.79 +/- 0.79 and 10.96 +/- 0.56 h), V(d(z))/F (0.77 +/- 0.06 and 0.89 +/- 0.07 L/kg), Cl(B)/F (0.76 +/- 0.04 and 0.89 +/- 0.07) and MRT (12.39 +/- 0.40 and 12.08 +/- 0.36 h) were found in sulfadiazine after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),[μg] / [ml],35.47,25841,DB00440,Trimethoprim
,19646090,C(max),"No significant difference in C(max) (35.47 +/- 2.52 and 37.50 +/- 3.39 microg/mL), t(max) (2.47 +/- 0.31 and 2.47 +/- 0.36 h), t((1/2)beta) (11.79 +/- 0.79 and 10.96 +/- 0.56 h), V(d(z))/F (0.77 +/- 0.06 and 0.89 +/- 0.07 L/kg), Cl(B)/F (0.76 +/- 0.04 and 0.89 +/- 0.07) and MRT (12.39 +/- 0.40 and 12.08 +/- 0.36 h) were found in sulfadiazine after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),[μg] / [ml],37.50,25842,DB00440,Trimethoprim
,19646090,t(max),"No significant difference in C(max) (35.47 +/- 2.52 and 37.50 +/- 3.39 microg/mL), t(max) (2.47 +/- 0.31 and 2.47 +/- 0.36 h), t((1/2)beta) (11.79 +/- 0.79 and 10.96 +/- 0.56 h), V(d(z))/F (0.77 +/- 0.06 and 0.89 +/- 0.07 L/kg), Cl(B)/F (0.76 +/- 0.04 and 0.89 +/- 0.07) and MRT (12.39 +/- 0.40 and 12.08 +/- 0.36 h) were found in sulfadiazine after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),h,2.47,25843,DB00440,Trimethoprim
,19646090,t(max),"No significant difference in C(max) (35.47 +/- 2.52 and 37.50 +/- 3.39 microg/mL), t(max) (2.47 +/- 0.31 and 2.47 +/- 0.36 h), t((1/2)beta) (11.79 +/- 0.79 and 10.96 +/- 0.56 h), V(d(z))/F (0.77 +/- 0.06 and 0.89 +/- 0.07 L/kg), Cl(B)/F (0.76 +/- 0.04 and 0.89 +/- 0.07) and MRT (12.39 +/- 0.40 and 12.08 +/- 0.36 h) were found in sulfadiazine after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),h,2.47,25844,DB00440,Trimethoprim
,19646090,t((1/2)beta),"No significant difference in C(max) (35.47 +/- 2.52 and 37.50 +/- 3.39 microg/mL), t(max) (2.47 +/- 0.31 and 2.47 +/- 0.36 h), t((1/2)beta) (11.79 +/- 0.79 and 10.96 +/- 0.56 h), V(d(z))/F (0.77 +/- 0.06 and 0.89 +/- 0.07 L/kg), Cl(B)/F (0.76 +/- 0.04 and 0.89 +/- 0.07) and MRT (12.39 +/- 0.40 and 12.08 +/- 0.36 h) were found in sulfadiazine after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),h,11.79,25845,DB00440,Trimethoprim
,19646090,t((1/2)beta),"No significant difference in C(max) (35.47 +/- 2.52 and 37.50 +/- 3.39 microg/mL), t(max) (2.47 +/- 0.31 and 2.47 +/- 0.36 h), t((1/2)beta) (11.79 +/- 0.79 and 10.96 +/- 0.56 h), V(d(z))/F (0.77 +/- 0.06 and 0.89 +/- 0.07 L/kg), Cl(B)/F (0.76 +/- 0.04 and 0.89 +/- 0.07) and MRT (12.39 +/- 0.40 and 12.08 +/- 0.36 h) were found in sulfadiazine after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),h,10.96,25846,DB00440,Trimethoprim
,19646090,V(d(z))/F,"No significant difference in C(max) (35.47 +/- 2.52 and 37.50 +/- 3.39 microg/mL), t(max) (2.47 +/- 0.31 and 2.47 +/- 0.36 h), t((1/2)beta) (11.79 +/- 0.79 and 10.96 +/- 0.56 h), V(d(z))/F (0.77 +/- 0.06 and 0.89 +/- 0.07 L/kg), Cl(B)/F (0.76 +/- 0.04 and 0.89 +/- 0.07) and MRT (12.39 +/- 0.40 and 12.08 +/- 0.36 h) were found in sulfadiazine after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),[l] / [kg],0.77,25847,DB00440,Trimethoprim
,19646090,V(d(z))/F,"No significant difference in C(max) (35.47 +/- 2.52 and 37.50 +/- 3.39 microg/mL), t(max) (2.47 +/- 0.31 and 2.47 +/- 0.36 h), t((1/2)beta) (11.79 +/- 0.79 and 10.96 +/- 0.56 h), V(d(z))/F (0.77 +/- 0.06 and 0.89 +/- 0.07 L/kg), Cl(B)/F (0.76 +/- 0.04 and 0.89 +/- 0.07) and MRT (12.39 +/- 0.40 and 12.08 +/- 0.36 h) were found in sulfadiazine after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),[l] / [kg],0.89,25848,DB00440,Trimethoprim
,19646090,Cl(B)/F,"No significant difference in C(max) (35.47 +/- 2.52 and 37.50 +/- 3.39 microg/mL), t(max) (2.47 +/- 0.31 and 2.47 +/- 0.36 h), t((1/2)beta) (11.79 +/- 0.79 and 10.96 +/- 0.56 h), V(d(z))/F (0.77 +/- 0.06 and 0.89 +/- 0.07 L/kg), Cl(B)/F (0.76 +/- 0.04 and 0.89 +/- 0.07) and MRT (12.39 +/- 0.40 and 12.08 +/- 0.36 h) were found in sulfadiazine after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),,0.76,25849,DB00440,Trimethoprim
,19646090,Cl(B)/F,"No significant difference in C(max) (35.47 +/- 2.52 and 37.50 +/- 3.39 microg/mL), t(max) (2.47 +/- 0.31 and 2.47 +/- 0.36 h), t((1/2)beta) (11.79 +/- 0.79 and 10.96 +/- 0.56 h), V(d(z))/F (0.77 +/- 0.06 and 0.89 +/- 0.07 L/kg), Cl(B)/F (0.76 +/- 0.04 and 0.89 +/- 0.07) and MRT (12.39 +/- 0.40 and 12.08 +/- 0.36 h) were found in sulfadiazine after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),,0.89,25850,DB00440,Trimethoprim
,19646090,MRT,"No significant difference in C(max) (35.47 +/- 2.52 and 37.50 +/- 3.39 microg/mL), t(max) (2.47 +/- 0.31 and 2.47 +/- 0.36 h), t((1/2)beta) (11.79 +/- 0.79 and 10.96 +/- 0.56 h), V(d(z))/F (0.77 +/- 0.06 and 0.89 +/- 0.07 L/kg), Cl(B)/F (0.76 +/- 0.04 and 0.89 +/- 0.07) and MRT (12.39 +/- 0.40 and 12.08 +/- 0.36 h) were found in sulfadiazine after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),h,12.39,25851,DB00440,Trimethoprim
,19646090,MRT,"No significant difference in C(max) (35.47 +/- 2.52 and 37.50 +/- 3.39 microg/mL), t(max) (2.47 +/- 0.31 and 2.47 +/- 0.36 h), t((1/2)beta) (11.79 +/- 0.79 and 10.96 +/- 0.56 h), V(d(z))/F (0.77 +/- 0.06 and 0.89 +/- 0.07 L/kg), Cl(B)/F (0.76 +/- 0.04 and 0.89 +/- 0.07) and MRT (12.39 +/- 0.40 and 12.08 +/- 0.36 h) were found in sulfadiazine after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),h,12.08,25852,DB00440,Trimethoprim
,19646090,C(max),"There were also no differences in C(max) (0.71 +/- 0.06 and 0.78 +/- 0.10 microg/mL), t(max) (2.07 +/- 0.28 and 3.27 +/- 0.28 h), t((1/2)beta) (3.30 +/- 0.25 and 3.83 +/- 0.33 h), V(d(z))/F (6.2 +/- 0.56 and 6.27 +/- 0.77 L/kg), Cl(B)/F (21.9 +/- 1.46 and 18.83 +/- 1.72) and MRT (3.68 +/- 0.19 and 4.34 +/- 0.14 h) for trimethoprim after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),[μg] / [ml],0.71,25853,DB00440,Trimethoprim
,19646090,C(max),"There were also no differences in C(max) (0.71 +/- 0.06 and 0.78 +/- 0.10 microg/mL), t(max) (2.07 +/- 0.28 and 3.27 +/- 0.28 h), t((1/2)beta) (3.30 +/- 0.25 and 3.83 +/- 0.33 h), V(d(z))/F (6.2 +/- 0.56 and 6.27 +/- 0.77 L/kg), Cl(B)/F (21.9 +/- 1.46 and 18.83 +/- 1.72) and MRT (3.68 +/- 0.19 and 4.34 +/- 0.14 h) for trimethoprim after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),[μg] / [ml],0.78,25854,DB00440,Trimethoprim
,19646090,t(max),"There were also no differences in C(max) (0.71 +/- 0.06 and 0.78 +/- 0.10 microg/mL), t(max) (2.07 +/- 0.28 and 3.27 +/- 0.28 h), t((1/2)beta) (3.30 +/- 0.25 and 3.83 +/- 0.33 h), V(d(z))/F (6.2 +/- 0.56 and 6.27 +/- 0.77 L/kg), Cl(B)/F (21.9 +/- 1.46 and 18.83 +/- 1.72) and MRT (3.68 +/- 0.19 and 4.34 +/- 0.14 h) for trimethoprim after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),h,2.07,25855,DB00440,Trimethoprim
,19646090,t(max),"There were also no differences in C(max) (0.71 +/- 0.06 and 0.78 +/- 0.10 microg/mL), t(max) (2.07 +/- 0.28 and 3.27 +/- 0.28 h), t((1/2)beta) (3.30 +/- 0.25 and 3.83 +/- 0.33 h), V(d(z))/F (6.2 +/- 0.56 and 6.27 +/- 0.77 L/kg), Cl(B)/F (21.9 +/- 1.46 and 18.83 +/- 1.72) and MRT (3.68 +/- 0.19 and 4.34 +/- 0.14 h) for trimethoprim after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),h,3.27,25856,DB00440,Trimethoprim
,19646090,t((1/2)beta),"There were also no differences in C(max) (0.71 +/- 0.06 and 0.78 +/- 0.10 microg/mL), t(max) (2.07 +/- 0.28 and 3.27 +/- 0.28 h), t((1/2)beta) (3.30 +/- 0.25 and 3.83 +/- 0.33 h), V(d(z))/F (6.2 +/- 0.56 and 6.27 +/- 0.77 L/kg), Cl(B)/F (21.9 +/- 1.46 and 18.83 +/- 1.72) and MRT (3.68 +/- 0.19 and 4.34 +/- 0.14 h) for trimethoprim after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),h,3.30,25857,DB00440,Trimethoprim
,19646090,t((1/2)beta),"There were also no differences in C(max) (0.71 +/- 0.06 and 0.78 +/- 0.10 microg/mL), t(max) (2.07 +/- 0.28 and 3.27 +/- 0.28 h), t((1/2)beta) (3.30 +/- 0.25 and 3.83 +/- 0.33 h), V(d(z))/F (6.2 +/- 0.56 and 6.27 +/- 0.77 L/kg), Cl(B)/F (21.9 +/- 1.46 and 18.83 +/- 1.72) and MRT (3.68 +/- 0.19 and 4.34 +/- 0.14 h) for trimethoprim after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),h,3.83,25858,DB00440,Trimethoprim
,19646090,V(d(z))/F,"There were also no differences in C(max) (0.71 +/- 0.06 and 0.78 +/- 0.10 microg/mL), t(max) (2.07 +/- 0.28 and 3.27 +/- 0.28 h), t((1/2)beta) (3.30 +/- 0.25 and 3.83 +/- 0.33 h), V(d(z))/F (6.2 +/- 0.56 and 6.27 +/- 0.77 L/kg), Cl(B)/F (21.9 +/- 1.46 and 18.83 +/- 1.72) and MRT (3.68 +/- 0.19 and 4.34 +/- 0.14 h) for trimethoprim after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),[l] / [kg],6.2,25859,DB00440,Trimethoprim
,19646090,V(d(z))/F,"There were also no differences in C(max) (0.71 +/- 0.06 and 0.78 +/- 0.10 microg/mL), t(max) (2.07 +/- 0.28 and 3.27 +/- 0.28 h), t((1/2)beta) (3.30 +/- 0.25 and 3.83 +/- 0.33 h), V(d(z))/F (6.2 +/- 0.56 and 6.27 +/- 0.77 L/kg), Cl(B)/F (21.9 +/- 1.46 and 18.83 +/- 1.72) and MRT (3.68 +/- 0.19 and 4.34 +/- 0.14 h) for trimethoprim after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),[l] / [kg],6.27,25860,DB00440,Trimethoprim
,19646090,Cl(B)/F,"There were also no differences in C(max) (0.71 +/- 0.06 and 0.78 +/- 0.10 microg/mL), t(max) (2.07 +/- 0.28 and 3.27 +/- 0.28 h), t((1/2)beta) (3.30 +/- 0.25 and 3.83 +/- 0.33 h), V(d(z))/F (6.2 +/- 0.56 and 6.27 +/- 0.77 L/kg), Cl(B)/F (21.9 +/- 1.46 and 18.83 +/- 1.72) and MRT (3.68 +/- 0.19 and 4.34 +/- 0.14 h) for trimethoprim after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),,21.9,25861,DB00440,Trimethoprim
,19646090,Cl(B)/F,"There were also no differences in C(max) (0.71 +/- 0.06 and 0.78 +/- 0.10 microg/mL), t(max) (2.07 +/- 0.28 and 3.27 +/- 0.28 h), t((1/2)beta) (3.30 +/- 0.25 and 3.83 +/- 0.33 h), V(d(z))/F (6.2 +/- 0.56 and 6.27 +/- 0.77 L/kg), Cl(B)/F (21.9 +/- 1.46 and 18.83 +/- 1.72) and MRT (3.68 +/- 0.19 and 4.34 +/- 0.14 h) for trimethoprim after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),,18.83,25862,DB00440,Trimethoprim
,19646090,MRT,"There were also no differences in C(max) (0.71 +/- 0.06 and 0.78 +/- 0.10 microg/mL), t(max) (2.07 +/- 0.28 and 3.27 +/- 0.28 h), t((1/2)beta) (3.30 +/- 0.25 and 3.83 +/- 0.33 h), V(d(z))/F (6.2 +/- 0.56 and 6.27 +/- 0.77 L/kg), Cl(B)/F (21.9 +/- 1.46 and 18.83 +/- 1.72) and MRT (3.68 +/- 0.19 and 4.34 +/- 0.14 h) for trimethoprim after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),h,3.68,25863,DB00440,Trimethoprim
,19646090,MRT,"There were also no differences in C(max) (0.71 +/- 0.06 and 0.78 +/- 0.10 microg/mL), t(max) (2.07 +/- 0.28 and 3.27 +/- 0.28 h), t((1/2)beta) (3.30 +/- 0.25 and 3.83 +/- 0.33 h), V(d(z))/F (6.2 +/- 0.56 and 6.27 +/- 0.77 L/kg), Cl(B)/F (21.9 +/- 1.46 and 18.83 +/- 1.72) and MRT (3.68 +/- 0.19 and 4.34 +/- 0.14 h) for trimethoprim after i.m. and oral dosing, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),h,4.34,25864,DB00440,Trimethoprim
,19646090,absolute bioavailability (F),"The absolute bioavailability (F) was 95.41% and 86.20% for sulfadiazine and 70.02% and 79.58% for trimethoprim after i.m. and oral administration, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),%,95.41,25865,DB00440,Trimethoprim
,19646090,absolute bioavailability (F),"The absolute bioavailability (F) was 95.41% and 86.20% for sulfadiazine and 70.02% and 79.58% for trimethoprim after i.m. and oral administration, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),%,86.20,25866,DB00440,Trimethoprim
,19646090,absolute bioavailability (F),"The absolute bioavailability (F) was 95.41% and 86.20% for sulfadiazine and 70.02% and 79.58% for trimethoprim after i.m. and oral administration, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),%,70.02,25867,DB00440,Trimethoprim
,19646090,absolute bioavailability (F),"The absolute bioavailability (F) was 95.41% and 86.20% for sulfadiazine and 70.02% and 79.58% for trimethoprim after i.m. and oral administration, respectively.","Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646090/),%,79.58,25868,DB00440,Trimethoprim
,12604533,area under the concentration-time curve (AUC),"After the first dose on day 1, the mean area under the concentration-time curve (AUC) for amoxicillin after the 25-mg/kg dose was 54.7 versus 24.9 micro g. h/ml after the 15-mg/kg dose.",Comparing pharmacokinetics of amoxicillin given twice or three times per day to children older than 3 months with pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604533/),[h·μg] / [ml],54.7,28898,DB00440,Trimethoprim
,12604533,area under the concentration-time curve (AUC),"After the first dose on day 1, the mean area under the concentration-time curve (AUC) for amoxicillin after the 25-mg/kg dose was 54.7 versus 24.9 micro g. h/ml after the 15-mg/kg dose.",Comparing pharmacokinetics of amoxicillin given twice or three times per day to children older than 3 months with pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604533/),[h·μg] / [ml],24.9,28899,DB00440,Trimethoprim
,12604533,AUC,"After the first dose on day 3, the mean AUC was 44.1 versus 28.5 micro g. h/ml.",Comparing pharmacokinetics of amoxicillin given twice or three times per day to children older than 3 months with pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604533/),[h·μg] / [ml],44.1,28900,DB00440,Trimethoprim
,12604533,AUC,"After the first dose on day 3, the mean AUC was 44.1 versus 28.5 micro g. h/ml.",Comparing pharmacokinetics of amoxicillin given twice or three times per day to children older than 3 months with pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604533/),[h·μg] / [ml],28.5,28901,DB00440,Trimethoprim
,1478984,recovery,"The average recovery of sulphadiazine varied from 74% in liver to 92% in plasma, whereas that of trimethoprim varied from 60% in liver to 97% in plasma.",Simultaneous determination of sulphadiazine and trimethoprim in plasma and tissues of cultured fish for residual and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1478984/),%,74,29130,DB00440,Trimethoprim
,1478984,recovery,"The average recovery of sulphadiazine varied from 74% in liver to 92% in plasma, whereas that of trimethoprim varied from 60% in liver to 97% in plasma.",Simultaneous determination of sulphadiazine and trimethoprim in plasma and tissues of cultured fish for residual and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1478984/),%,92,29131,DB00440,Trimethoprim
,1478984,recovery,"The average recovery of sulphadiazine varied from 74% in liver to 92% in plasma, whereas that of trimethoprim varied from 60% in liver to 97% in plasma.",Simultaneous determination of sulphadiazine and trimethoprim in plasma and tissues of cultured fish for residual and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1478984/),%,60,29132,DB00440,Trimethoprim
,1478984,recovery,"The average recovery of sulphadiazine varied from 74% in liver to 92% in plasma, whereas that of trimethoprim varied from 60% in liver to 97% in plasma.",Simultaneous determination of sulphadiazine and trimethoprim in plasma and tissues of cultured fish for residual and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1478984/),%,97,29133,DB00440,Trimethoprim
,1478984,limit of quantification,"The sample pretreatment procedures were simple, selective and robust, having a limit of quantification of 250 ng/ml for trimethoprim and 50 ng/ml for sulphadiazine in plasma, 15 ng/g for sulphadiazine and 80 ng/g for trimethoprim in muscle, and 30 ng/g for sulphadiazine and 160 ng/g for trimethoprim in liver.",Simultaneous determination of sulphadiazine and trimethoprim in plasma and tissues of cultured fish for residual and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1478984/),[ng] / [ml],250,29134,DB00440,Trimethoprim
,1478984,limit of quantification,"The sample pretreatment procedures were simple, selective and robust, having a limit of quantification of 250 ng/ml for trimethoprim and 50 ng/ml for sulphadiazine in plasma, 15 ng/g for sulphadiazine and 80 ng/g for trimethoprim in muscle, and 30 ng/g for sulphadiazine and 160 ng/g for trimethoprim in liver.",Simultaneous determination of sulphadiazine and trimethoprim in plasma and tissues of cultured fish for residual and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1478984/),[ng] / [ml],50,29135,DB00440,Trimethoprim
,1478984,limit of quantification,"The sample pretreatment procedures were simple, selective and robust, having a limit of quantification of 250 ng/ml for trimethoprim and 50 ng/ml for sulphadiazine in plasma, 15 ng/g for sulphadiazine and 80 ng/g for trimethoprim in muscle, and 30 ng/g for sulphadiazine and 160 ng/g for trimethoprim in liver.",Simultaneous determination of sulphadiazine and trimethoprim in plasma and tissues of cultured fish for residual and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1478984/),[ng] / [g],15,29136,DB00440,Trimethoprim
,1478984,limit of quantification,"The sample pretreatment procedures were simple, selective and robust, having a limit of quantification of 250 ng/ml for trimethoprim and 50 ng/ml for sulphadiazine in plasma, 15 ng/g for sulphadiazine and 80 ng/g for trimethoprim in muscle, and 30 ng/g for sulphadiazine and 160 ng/g for trimethoprim in liver.",Simultaneous determination of sulphadiazine and trimethoprim in plasma and tissues of cultured fish for residual and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1478984/),[ng] / [g],80,29137,DB00440,Trimethoprim
,1478984,limit of quantification,"The sample pretreatment procedures were simple, selective and robust, having a limit of quantification of 250 ng/ml for trimethoprim and 50 ng/ml for sulphadiazine in plasma, 15 ng/g for sulphadiazine and 80 ng/g for trimethoprim in muscle, and 30 ng/g for sulphadiazine and 160 ng/g for trimethoprim in liver.",Simultaneous determination of sulphadiazine and trimethoprim in plasma and tissues of cultured fish for residual and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1478984/),[ng] / [g],30,29138,DB00440,Trimethoprim
,1478984,limit of quantification,"The sample pretreatment procedures were simple, selective and robust, having a limit of quantification of 250 ng/ml for trimethoprim and 50 ng/ml for sulphadiazine in plasma, 15 ng/g for sulphadiazine and 80 ng/g for trimethoprim in muscle, and 30 ng/g for sulphadiazine and 160 ng/g for trimethoprim in liver.",Simultaneous determination of sulphadiazine and trimethoprim in plasma and tissues of cultured fish for residual and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1478984/),[ng] / [g],160,29139,DB00440,Trimethoprim
,18333865,Renal clearance,Renal clearance of maraviroc plus placebo was 8.3 l h(-1) and 8.5 l h(-1) and was 7.8 l h(-1) for maraviroc plus cotrimoxazole and maraviroc plus tenofovir.,The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333865/),[l] / [h],8.3,29250,DB00440,Trimethoprim
,18333865,Renal clearance,Renal clearance of maraviroc plus placebo was 8.3 l h(-1) and 8.5 l h(-1) and was 7.8 l h(-1) for maraviroc plus cotrimoxazole and maraviroc plus tenofovir.,The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333865/),[l] / [h],8.5,29251,DB00440,Trimethoprim
,18333865,Renal clearance,Renal clearance of maraviroc plus placebo was 8.3 l h(-1) and 8.5 l h(-1) and was 7.8 l h(-1) for maraviroc plus cotrimoxazole and maraviroc plus tenofovir.,The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333865/),[l] / [h],7.8,29252,DB00440,Trimethoprim
,2658792,50% effective dose (ED50),The 50% effective dose (ED50) of zidovudine (9.6 to 11.8 mg/kg of body weight) compared favorably with that of trimethoprim (19.4 to 22.2 mg/kg) in mice with systemic E. coli infection.,In vivo efficacy of zidovudine (3'-azido-3'-deoxythymidine) in experimental gram-negative-bacterial infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2658792/),[mg] / [kg],9.6 to 11.8,29577,DB00440,Trimethoprim
,2658792,50% effective dose (ED50),The 50% effective dose (ED50) of zidovudine (9.6 to 11.8 mg/kg of body weight) compared favorably with that of trimethoprim (19.4 to 22.2 mg/kg) in mice with systemic E. coli infection.,In vivo efficacy of zidovudine (3'-azido-3'-deoxythymidine) in experimental gram-negative-bacterial infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2658792/),[mg] / [kg],19.4 to 22.2,29578,DB00440,Trimethoprim
,8195842,bioavailability,The bioavailability of brodimoprim tablets given orally is 80-90%; their relative bioavailability compared to an aqueous solution is 100%.,Pharmacokinetic profile of brodimoprim: oral bioavailability and penetration into interstitial fluid. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195842/),%,80-90,31003,DB00440,Trimethoprim
,8195842,relative bioavailability,The bioavailability of brodimoprim tablets given orally is 80-90%; their relative bioavailability compared to an aqueous solution is 100%.,Pharmacokinetic profile of brodimoprim: oral bioavailability and penetration into interstitial fluid. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195842/),%,100,31004,DB00440,Trimethoprim
,8195842,Penetration,Penetration of brodimoprim to suction skin blisters is 73 +/- 8%.,Pharmacokinetic profile of brodimoprim: oral bioavailability and penetration into interstitial fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195842/),%,73,31005,DB00440,Trimethoprim
,27322715,clearance,"Among 176 patients (555 courses) on the low-risk arm (HDMTX=2.5 g/m/24 h), there was no difference in clearance (110.7 [1.8%] vs. 108.2 [0.9%] mL/min/m, P=0.3) nor in 42 hour methotrexate concentration (0.37 [5.1%] vs. 0.40 (5.0%) μM, P=0.23).",Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27322715/),[ml] / [m·min],110.7,31209,DB00440,Trimethoprim
,27322715,clearance,"Among 176 patients (555 courses) on the low-risk arm (HDMTX=2.5 g/m/24 h), there was no difference in clearance (110.7 [1.8%] vs. 108.2 [0.9%] mL/min/m, P=0.3) nor in 42 hour methotrexate concentration (0.37 [5.1%] vs. 0.40 (5.0%) μM, P=0.23).",Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27322715/),[ml] / [m·min],108.2,31210,DB00440,Trimethoprim
,27322715,42,"Among 176 patients (555 courses) on the low-risk arm (HDMTX=2.5 g/m/24 h), there was no difference in clearance (110.7 [1.8%] vs. 108.2 [0.9%] mL/min/m, P=0.3) nor in 42 hour methotrexate concentration (0.37 [5.1%] vs. 0.40 (5.0%) μM, P=0.23).",Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27322715/),μ,0.37,31211,DB00440,Trimethoprim
,27322715,concentration,"Among 176 patients (555 courses) on the low-risk arm (HDMTX=2.5 g/m/24 h), there was no difference in clearance (110.7 [1.8%] vs. 108.2 [0.9%] mL/min/m, P=0.3) nor in 42 hour methotrexate concentration (0.37 [5.1%] vs. 0.40 (5.0%) μM, P=0.23).",Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27322715/),μ,0.37,31212,DB00440,Trimethoprim
,27322715,concentration,"Among 176 patients (555 courses) on the low-risk arm (HDMTX=2.5 g/m/24 h), there was no difference in clearance (110.7 [1.8%] vs. 108.2 [0.9%] mL/min/m, P=0.3) nor in 42 hour methotrexate concentration (0.37 [5.1%] vs. 0.40 (5.0%) μM, P=0.23).",Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27322715/),μ,0.40,31213,DB00440,Trimethoprim
,27322715,clearance,"Among 248 patients (830 courses) on the standard/high-risk arm (HDMTX ~5 g/m/24 h), there was slightly higher clearance (95.5 [1.4%] vs. 91.2 [0.8%] mL/min/m, P=0.005) in those receiving TMP/SMX, with no difference in the 42 hour methotrexate concentration (0.59 [4.1%] vs. 0.66 [4.2%] μM, P=0.06).",Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27322715/),[ml] / [m·min],95.5,31214,DB00440,Trimethoprim
,27322715,clearance,"Among 248 patients (830 courses) on the standard/high-risk arm (HDMTX ~5 g/m/24 h), there was slightly higher clearance (95.5 [1.4%] vs. 91.2 [0.8%] mL/min/m, P=0.005) in those receiving TMP/SMX, with no difference in the 42 hour methotrexate concentration (0.59 [4.1%] vs. 0.66 [4.2%] μM, P=0.06).",Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27322715/),[ml] / [m·min],91.2,31215,DB00440,Trimethoprim
,20110016,binding,"The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),%,6.0,31969,DB00440,Trimethoprim
,20110016,binding,"The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),%,6.9,31970,DB00440,Trimethoprim
,20110016,binding,"The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),%,9.3,31971,DB00440,Trimethoprim
,20110016,t((1/2)),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),h,9.30,31972,DB00440,Trimethoprim
,20110016,t((1/2)),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),h,10.37,31973,DB00440,Trimethoprim
,20110016,t((1/2)),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),h,11.15,31974,DB00440,Trimethoprim
,20110016,mean residence time (MRT(0-48)),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),h,12.06,31975,DB00440,Trimethoprim
,20110016,mean residence time (MRT(0-48)),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),h,13.15,31976,DB00440,Trimethoprim
,20110016,mean residence time (MRT(0-48)),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),h,13.00,31977,DB00440,Trimethoprim
,20110016,elimination rate constant (k(e)),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),1/[hours],0.076,31978,DB00440,Trimethoprim
,20110016,elimination rate constant (k(e)),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),1/[hours],0.067,31979,DB00440,Trimethoprim
,20110016,elimination rate constant (k(e)),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),1/[hours],0.063,31980,DB00440,Trimethoprim
,20110016,AUC(0-48),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),[μ] / [h·ml],1202.5,31981,DB00440,Trimethoprim
,20110016,AUC(0-48),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),[μ] / [h·ml],1416.3,31982,DB00440,Trimethoprim
,20110016,AUC(0-48),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),[μ] / [h·ml],1298.5,31983,DB00440,Trimethoprim
,20110016,clearance (CL),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),[l] / [h·kg],1.01,31984,DB00440,Trimethoprim
,20110016,clearance (CL),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),[l] / [h·kg],0.83,31985,DB00440,Trimethoprim
,20110016,clearance (CL),"The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h.","Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110016/),[l] / [h·kg],0.92,31986,DB00440,Trimethoprim
,8011968,elimination half-life,The elimination half-life of aditoprim (6.14 h) was nearly twice as long as that of trimethoprim (3.08 h) and compares well with values observed in heifers.,Pharmacokinetics of aditoprim and trimethoprim in buffalo calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011968/),h,6.14,32601,DB00440,Trimethoprim
,8011968,elimination half-life,The elimination half-life of aditoprim (6.14 h) was nearly twice as long as that of trimethoprim (3.08 h) and compares well with values observed in heifers.,Pharmacokinetics of aditoprim and trimethoprim in buffalo calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011968/),h,3.08,32602,DB00440,Trimethoprim
,3499619,peak levels,"The TMP peak levels were 1.44 +/- 0.18 (B) and 1.40 +/- 0.26 mg/l (V), respectively after 1.5 and 1.0 h on an average.",[The relative bioavailability of co-trimoxazole suspensions]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499619/),[mg] / [l],1.44,36793,DB00440,Trimethoprim
,3499619,peak levels,"The TMP peak levels were 1.44 +/- 0.18 (B) and 1.40 +/- 0.26 mg/l (V), respectively after 1.5 and 1.0 h on an average.",[The relative bioavailability of co-trimoxazole suspensions]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499619/),[mg] / [l],1.40,36794,DB00440,Trimethoprim
,3499619,AUC,The AUC amounted to 18.94 +/- 2.25 (B) and 17.19 +/- 3.62 mg .,[The relative bioavailability of co-trimoxazole suspensions]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499619/),mg,18.94,36795,DB00440,Trimethoprim
,3499619,AUC,The AUC amounted to 18.94 +/- 2.25 (B) and 17.19 +/- 3.62 mg .,[The relative bioavailability of co-trimoxazole suspensions]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499619/),mg,17.19,36796,DB00440,Trimethoprim
,3499619,peak levels,The SMZ peak levels run to 37.2 +/- 10.3 (B) and 38.6 +/- 5.4 mg/l (V) after 3.6 +/- 3.5 and 1.3 +/- 0.8 h.,[The relative bioavailability of co-trimoxazole suspensions]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499619/),[mg] / [l],37.2,36797,DB00440,Trimethoprim
,3499619,peak levels,The SMZ peak levels run to 37.2 +/- 10.3 (B) and 38.6 +/- 5.4 mg/l (V) after 3.6 +/- 3.5 and 1.3 +/- 0.8 h.,[The relative bioavailability of co-trimoxazole suspensions]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499619/),[mg] / [l],38.6,36798,DB00440,Trimethoprim
,3499619,AUC,The AUC were identical: 682.3 +/- 126.2 (B) vs. 686.9 +/- 165.8 mg . h/l (V).,[The relative bioavailability of co-trimoxazole suspensions]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499619/),[h·mg] / [l],682.3,36799,DB00440,Trimethoprim
,3499619,AUC,The AUC were identical: 682.3 +/- 126.2 (B) vs. 686.9 +/- 165.8 mg . h/l (V).,[The relative bioavailability of co-trimoxazole suspensions]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499619/),[h·mg] / [l],686.9,36800,DB00440,Trimethoprim
,16507618,trough vancomycin concentration,The median trough vancomycin concentration was 12.6 microg/mL (range 7.3-24.1) through his course of therapy.,Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16507618/),[μg] / [ml],12.6,36801,DB00440,Trimethoprim
,8195840,Cmax,"Approximately 4 hours after single oral administration of 150, 400 and 600 mg, Cmax-values of 1.5, 3.3 and 6.2 mg/l were observed.",Pharmacokinetics of brodimoprim. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195840/),[mg] / [l],1.5,37517,DB00440,Trimethoprim
,8195840,Cmax,"Approximately 4 hours after single oral administration of 150, 400 and 600 mg, Cmax-values of 1.5, 3.3 and 6.2 mg/l were observed.",Pharmacokinetics of brodimoprim. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195840/),[mg] / [l],3.3,37518,DB00440,Trimethoprim
,8195840,Cmax,"Approximately 4 hours after single oral administration of 150, 400 and 600 mg, Cmax-values of 1.5, 3.3 and 6.2 mg/l were observed.",Pharmacokinetics of brodimoprim. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195840/),[mg] / [l],6.2,37519,DB00440,Trimethoprim
,8195840,AUC-,"The corresponding AUC-values after these doses were 73, 156 and 290 mg.h/l, respectively, and reflect a good dose proportionality in the investigated range.",Pharmacokinetics of brodimoprim. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195840/),[h·mg] / [l],73,37520,DB00440,Trimethoprim
,8195840,AUC-,"The corresponding AUC-values after these doses were 73, 156 and 290 mg.h/l, respectively, and reflect a good dose proportionality in the investigated range.",Pharmacokinetics of brodimoprim. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195840/),[h·mg] / [l],156,37521,DB00440,Trimethoprim
,8195840,AUC-,"The corresponding AUC-values after these doses were 73, 156 and 290 mg.h/l, respectively, and reflect a good dose proportionality in the investigated range.",Pharmacokinetics of brodimoprim. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195840/),[h·mg] / [l],290,37522,DB00440,Trimethoprim
,8195840,elimination half-life,In the postdistributive phase an elimination half-life of 32-35 h was determined which justifies once-daily administration.,Pharmacokinetics of brodimoprim. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195840/),h,32-35,37523,DB00440,Trimethoprim
,8195840,Total plasma clearance (Cls/F),Total plasma clearance (Cls/F) reached approximately 40 ml/min and renal clearance was approximately 3 ml/min.,Pharmacokinetics of brodimoprim. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195840/),[ml] / [min],40,37524,DB00440,Trimethoprim
,8195840,renal clearance,Total plasma clearance (Cls/F) reached approximately 40 ml/min and renal clearance was approximately 3 ml/min.,Pharmacokinetics of brodimoprim. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195840/),[ml] / [min],3,37525,DB00440,Trimethoprim
,8195840,apparent volume of distribution (V beta/F),The apparent volume of distribution (V beta/F) was high (approximately 1.5 l/kg) and reflects the good penetration of brodimoprim into most body fluids and tissues.,Pharmacokinetics of brodimoprim. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195840/),[l] / [kg],1.5,37526,DB00440,Trimethoprim
,25815573,peak concentrations,"Following the first and second administration of trimethoprim-sulfadimidine, mean ± SD peak concentrations of sulfadimidine were 55.3 ± 10.3 μg/mL and 51.5 ± 8.7 μg/mL, respectively, in plasma and 9.6 ± 4.5 μg/mL and 7.0 ± 3.3 μg/mL, respectively, in the PSM.",Application of in vivo microdialysis for investigation of unbound drug concentrations of intravenously administered sulfadimidine in the paranasal sinus mucosa of horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25815573/),[μg] / [ml],55.3,38218,DB00440,Trimethoprim
,25815573,peak concentrations,"Following the first and second administration of trimethoprim-sulfadimidine, mean ± SD peak concentrations of sulfadimidine were 55.3 ± 10.3 μg/mL and 51.5 ± 8.7 μg/mL, respectively, in plasma and 9.6 ± 4.5 μg/mL and 7.0 ± 3.3 μg/mL, respectively, in the PSM.",Application of in vivo microdialysis for investigation of unbound drug concentrations of intravenously administered sulfadimidine in the paranasal sinus mucosa of horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25815573/),[μg] / [ml],51.5,38219,DB00440,Trimethoprim
,25815573,peak concentrations,"Following the first and second administration of trimethoprim-sulfadimidine, mean ± SD peak concentrations of sulfadimidine were 55.3 ± 10.3 μg/mL and 51.5 ± 8.7 μg/mL, respectively, in plasma and 9.6 ± 4.5 μg/mL and 7.0 ± 3.3 μg/mL, respectively, in the PSM.",Application of in vivo microdialysis for investigation of unbound drug concentrations of intravenously administered sulfadimidine in the paranasal sinus mucosa of horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25815573/),[μg] / [ml],9.6,38220,DB00440,Trimethoprim
,25815573,peak concentrations,"Following the first and second administration of trimethoprim-sulfadimidine, mean ± SD peak concentrations of sulfadimidine were 55.3 ± 10.3 μg/mL and 51.5 ± 8.7 μg/mL, respectively, in plasma and 9.6 ± 4.5 μg/mL and 7.0 ± 3.3 μg/mL, respectively, in the PSM.",Application of in vivo microdialysis for investigation of unbound drug concentrations of intravenously administered sulfadimidine in the paranasal sinus mucosa of horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25815573/),[μg] / [ml],7.0,38221,DB00440,Trimethoprim
,25815573,minimum inhibitory concentration,"For 12 hours, mean PSM sulfadimidine concentration remained greater than the minimum inhibitory concentration indicative of sulfonamide susceptibility of equine bacterial isolates (4.75 μg/mL).",Application of in vivo microdialysis for investigation of unbound drug concentrations of intravenously administered sulfadimidine in the paranasal sinus mucosa of horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25815573/),[μg] / [ml],4.75,38222,DB00440,Trimethoprim
,9534981,peak concentrations,"After a single dose by aerosol, mean peak concentrations of atovaquone averaged 52 microg/mL in plasma and 31 microg/g in lungs of rats infected with P. carinii.","Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9534981/),[μg] / [ml],52,41228,DB00440,Trimethoprim
,9534981,peak concentrations,"After a single dose by aerosol, mean peak concentrations of atovaquone averaged 52 microg/mL in plasma and 31 microg/g in lungs of rats infected with P. carinii.","Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9534981/),[μg] / [g],31,41229,DB00440,Trimethoprim
,9534981,peak concentrations,"When atovaquone was combined with surfactant, mean peak concentrations of 94 microg/mL in plasma and 51 microg/g in lung were achieved.","Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9534981/),[μg] / [ml],94,41230,DB00440,Trimethoprim
,9534981,peak concentrations,"When atovaquone was combined with surfactant, mean peak concentrations of 94 microg/mL in plasma and 51 microg/g in lung were achieved.","Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9534981/),[μg] / [g],51,41231,DB00440,Trimethoprim
,1473196,plasma clearance,There was a significant fall in methotrexate plasma clearance at night (from 5.6 +/- 3 ml/min/kg to 4.7 +/- 2.3 ml/min/kg p < 0.05).,Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],5.6,46800,DB00440,Trimethoprim
,1473196,plasma clearance,There was a significant fall in methotrexate plasma clearance at night (from 5.6 +/- 3 ml/min/kg to 4.7 +/- 2.3 ml/min/kg p < 0.05).,Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],4.7,46801,DB00440,Trimethoprim
,1473196,Renal clearance,Renal clearance of methotrexate tended to decrease at night and unbound renal clearance decreased significantly (from 17.5 +/- 1.7 ml/min/kg to 8.5 +/- 3.6 ml/min/kg p < 0.05).,Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],17.5,46802,DB00440,Trimethoprim
,1473196,unbound renal clearance,Renal clearance of methotrexate tended to decrease at night and unbound renal clearance decreased significantly (from 17.5 +/- 1.7 ml/min/kg to 8.5 +/- 3.6 ml/min/kg p < 0.05).,Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],17.5,46803,DB00440,Trimethoprim
,1473196,unbound renal clearance,Renal clearance of methotrexate tended to decrease at night and unbound renal clearance decreased significantly (from 17.5 +/- 1.7 ml/min/kg to 8.5 +/- 3.6 ml/min/kg p < 0.05).,Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],8.5,46804,DB00440,Trimethoprim
,1473196,nonglomerular clearance,"Creatinine clearance did not exhibit diurnal variation, when comparing two 12-h collections, but there was a significant decrease in the nonglomerular clearance of methotrexate (from 14.8 +/- 5.2 to 6 +/- 4 ml/min/kg).",Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],14.8,46805,DB00440,Trimethoprim
,1473196,nonglomerular clearance,"Creatinine clearance did not exhibit diurnal variation, when comparing two 12-h collections, but there was a significant decrease in the nonglomerular clearance of methotrexate (from 14.8 +/- 5.2 to 6 +/- 4 ml/min/kg).",Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],6,46806,DB00440,Trimethoprim
,6385459,maximal mean plasma concentration,"In contrast drinking water medication with high concentrations of trimethoprim (up to 1,320 mg/liter) resulted in a maximal mean plasma concentration of 1.2 micrograms/ml.","Some pharmacokinetic aspects of four sulphonamides and trimethoprim, and their therapeutic efficacy in experimental Escherichia coli infection in poultry. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6385459/),[μg] / [ml],1.2,51642,DB00440,Trimethoprim
,16236048,AUC((0-24 h)),"On day 6, the mean (95% confidence interval) whole blood sirolimus AUC((0-24 h)) was 1040 (846, 1234) ng ml(-1) and mean C(max) was 109 (88, 129) ng ml(-1).",Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236048/),[ng] / [ml],1040,52517,DB00440,Trimethoprim
,16236048,C(max),"On day 6, the mean (95% confidence interval) whole blood sirolimus AUC((0-24 h)) was 1040 (846, 1234) ng ml(-1) and mean C(max) was 109 (88, 129) ng ml(-1).",Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236048/),[ng] / [ml],109,52518,DB00440,Trimethoprim
,16236048,AUC((0-24 h)),"Corresponding values on day 7 were AUC((0-24 h)) 1060 (826, 1293) ng ml(-1) and C(max) mean 107 (87, 127) ng ml(-1).",Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236048/),[ng] / [ml],1060,52519,DB00440,Trimethoprim
,16236048,C(max),"Corresponding values on day 7 were AUC((0-24 h)) 1060 (826, 1293) ng ml(-1) and C(max) mean 107 (87, 127) ng ml(-1).",Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236048/),[ng] / [ml],107,52520,DB00440,Trimethoprim
,7075646,peak serum levels,"After a single oral dose of TMP 4 mg and SMZ 20 mg per kg, peak serum levels of approximately 2.0 micrograms/ml TMP and 28 micrograms/ml SMZ were achieved at 4 hours for TMP, and at 6 hours for SMZ.",Pharmacokinetics of sulfamethoxazole--trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075646/),[μg] / [ml],2.0,54041,DB00440,Trimethoprim
,7075646,peak serum levels,"After a single oral dose of TMP 4 mg and SMZ 20 mg per kg, peak serum levels of approximately 2.0 micrograms/ml TMP and 28 micrograms/ml SMZ were achieved at 4 hours for TMP, and at 6 hours for SMZ.",Pharmacokinetics of sulfamethoxazole--trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075646/),[μg] / [ml],28,54042,DB00440,Trimethoprim
,7075646,protein binding,The protein binding of TMP was 34.7 +/- 1.1% and its distribution volume was 2.2 +/- 0.51/kg.,Pharmacokinetics of sulfamethoxazole--trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075646/),%,34.7,54043,DB00440,Trimethoprim
,7075646,distribution volume,The protein binding of TMP was 34.7 +/- 1.1% and its distribution volume was 2.2 +/- 0.51/kg.,Pharmacokinetics of sulfamethoxazole--trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075646/),1/[kg],2.2,54044,DB00440,Trimethoprim
,7075646,Total plasma clearance,"Total plasma clearance of TMP was 66.2 +/- 11.5 ml/min, peritoneal dialysance was 5.1 +/- 0.5 ml/min, and renal clearance was negligible.",Pharmacokinetics of sulfamethoxazole--trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075646/),[ml] / [min],66.2,54045,DB00440,Trimethoprim
,7075646,peritoneal dialysance,"Total plasma clearance of TMP was 66.2 +/- 11.5 ml/min, peritoneal dialysance was 5.1 +/- 0.5 ml/min, and renal clearance was negligible.",Pharmacokinetics of sulfamethoxazole--trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075646/),[ml] / [min],5.1,54046,DB00440,Trimethoprim
,7075646,protein binding,The protein binding of SMZ was 48.0 +/- 1.4% and the distribution volume was 0.55 +/- 0.071/kg.,Pharmacokinetics of sulfamethoxazole--trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075646/),%,48.0,54047,DB00440,Trimethoprim
,7075646,distribution volume,The protein binding of SMZ was 48.0 +/- 1.4% and the distribution volume was 0.55 +/- 0.071/kg.,Pharmacokinetics of sulfamethoxazole--trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075646/),1/[kg],0.55,54048,DB00440,Trimethoprim
,7075646,Total plasma clearance,"Total plasma clearance of SMZ was 26.2 +/- 5.7 ml/min, peritoneal dialysance was 1.2 +/- 0.2 ml/min, and renal clearance was negligible.",Pharmacokinetics of sulfamethoxazole--trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075646/),[ml] / [min],26.2,54049,DB00440,Trimethoprim
,7075646,peritoneal dialysance,"Total plasma clearance of SMZ was 26.2 +/- 5.7 ml/min, peritoneal dialysance was 1.2 +/- 0.2 ml/min, and renal clearance was negligible.",Pharmacokinetics of sulfamethoxazole--trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075646/),[ml] / [min],1.2,54050,DB00440,Trimethoprim
,7075646,half lives,"The half lives of TMP and SMZ were 23.7 +/- 4.0 h and 18.1 +/- 3.5 h, respectively.",Pharmacokinetics of sulfamethoxazole--trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075646/),h,23.7,54051,DB00440,Trimethoprim
,7075646,half lives,"The half lives of TMP and SMZ were 23.7 +/- 4.0 h and 18.1 +/- 3.5 h, respectively.",Pharmacokinetics of sulfamethoxazole--trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075646/),h,18.1,54052,DB00440,Trimethoprim
,2471472,renal clearance,Trimethoprim decreased the mean (+/- SD) renal clearance by 45% after the dose of procainamide was administered (487 +/- 129 vs 267 +/- 123 mL/min) and that of N-acetylprocainamide by 26% (275 +/- 78 vs 192 +/- 82 mL/min) compared with placebo.,Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471472/),[ml] / [min],487,57181,DB00440,Trimethoprim
,2471472,renal clearance,Trimethoprim decreased the mean (+/- SD) renal clearance by 45% after the dose of procainamide was administered (487 +/- 129 vs 267 +/- 123 mL/min) and that of N-acetylprocainamide by 26% (275 +/- 78 vs 192 +/- 82 mL/min) compared with placebo.,Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471472/),[ml] / [min],267,57182,DB00440,Trimethoprim
,2471472,renal clearance,Trimethoprim decreased the mean (+/- SD) renal clearance by 45% after the dose of procainamide was administered (487 +/- 129 vs 267 +/- 123 mL/min) and that of N-acetylprocainamide by 26% (275 +/- 78 vs 192 +/- 82 mL/min) compared with placebo.,Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471472/),[ml] / [min],275,57183,DB00440,Trimethoprim
,2471472,renal clearance,Trimethoprim decreased the mean (+/- SD) renal clearance by 45% after the dose of procainamide was administered (487 +/- 129 vs 267 +/- 123 mL/min) and that of N-acetylprocainamide by 26% (275 +/- 78 vs 192 +/- 82 mL/min) compared with placebo.,Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471472/),[ml] / [min],192,57184,DB00440,Trimethoprim
,2471472,area under plasma concentration--time curve 0 to 12 hours,The mean area under plasma concentration--time curve 0 to 12 hours after dosing increased 39% for procainamide (19.8 +/- 4.8 vs 27.6 +/- 7.2 mg.h/L) and 27% for N-acetylprocainamide (9.1 +/- 2.1 vs 11.4 +/- 2.8 mg.h/L).,Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471472/),[h·mg] / [l],19.8,57185,DB00440,Trimethoprim
,2471472,area under plasma concentration--time curve 0 to 12 hours,The mean area under plasma concentration--time curve 0 to 12 hours after dosing increased 39% for procainamide (19.8 +/- 4.8 vs 27.6 +/- 7.2 mg.h/L) and 27% for N-acetylprocainamide (9.1 +/- 2.1 vs 11.4 +/- 2.8 mg.h/L).,Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471472/),[h·mg] / [l],27.6,57186,DB00440,Trimethoprim
,2471472,area under plasma concentration--time curve 0 to 12 hours,The mean area under plasma concentration--time curve 0 to 12 hours after dosing increased 39% for procainamide (19.8 +/- 4.8 vs 27.6 +/- 7.2 mg.h/L) and 27% for N-acetylprocainamide (9.1 +/- 2.1 vs 11.4 +/- 2.8 mg.h/L).,Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471472/),[h·mg] / [l],9.1,57187,DB00440,Trimethoprim
,2471472,area under plasma concentration--time curve 0 to 12 hours,The mean area under plasma concentration--time curve 0 to 12 hours after dosing increased 39% for procainamide (19.8 +/- 4.8 vs 27.6 +/- 7.2 mg.h/L) and 27% for N-acetylprocainamide (9.1 +/- 2.1 vs 11.4 +/- 2.8 mg.h/L).,Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471472/),[h·mg] / [l],11.4,57188,DB00440,Trimethoprim
,21492388,C(max),The C(max) of methadone was significantly different (p=0.016) for Phase 1 (5.5 ng mL(-1)) and Phase 2 (171.9 ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[ng] / [ml],5.5,61646,DB00440,Trimethoprim
,21492388,C(max),The C(max) of methadone was significantly different (p=0.016) for Phase 1 (5.5 ng mL(-1)) and Phase 2 (171.9 ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[ng] / [ml],171.9,61647,DB00440,Trimethoprim
,21492388,AUC(0-LAST),The AUC(0-LAST) was also significantly different (p=0.004) for Phase 1 (13.1 hour ng mL(-1)) and Phase 2 (3075.2 hour ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[h·ng] / [ml],13.1,61648,DB00440,Trimethoprim
,21492388,AUC(0-LAST),The AUC(0-LAST) was also significantly different (p=0.004) for Phase 1 (13.1 hour ng mL(-1)) and Phase 2 (3075.2 hour ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[h·ng] / [ml],3075.2,61649,DB00440,Trimethoprim
,8337486,half-life,The presence of a dimethylamino group on the quinolyl ring of the compound baquiloprim (BQP) conferred a half-life of about 10 hours.,"Baquiloprim, a new antifolate antibacterial: in vitro activity and pharmacokinetic properties in cattle. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8337486/),h,10,62011,DB00440,Trimethoprim
,8146453,volume of distribution,The volume of distribution was 0.5 litre kg-1 bodyweight for SDZ and 1.8 litre kg-1 bodyweight for TMP.,Oral bioavailability of sulphadiazine and trimethoprim in fed and fasted pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8146453/),[l] / [kg],0.5,64068,DB00440,Trimethoprim
,8146453,volume of distribution,The volume of distribution was 0.5 litre kg-1 bodyweight for SDZ and 1.8 litre kg-1 bodyweight for TMP.,Oral bioavailability of sulphadiazine and trimethoprim in fed and fasted pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8146453/),[l] / [kg],1.8,64069,DB00440,Trimethoprim
,8146453,oral bioavailabilities,"The oral bioavailabilities for SDZ and TMP in the fed pigs were 85 per cent and 92 per cent, and in the fasted pigs 89 per cent and 90 per cent, respectively.",Oral bioavailability of sulphadiazine and trimethoprim in fed and fasted pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8146453/),%,85,64070,DB00440,Trimethoprim
,8146453,oral bioavailabilities,"The oral bioavailabilities for SDZ and TMP in the fed pigs were 85 per cent and 92 per cent, and in the fasted pigs 89 per cent and 90 per cent, respectively.",Oral bioavailability of sulphadiazine and trimethoprim in fed and fasted pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8146453/),%,92,64071,DB00440,Trimethoprim
,8146453,oral bioavailabilities,"The oral bioavailabilities for SDZ and TMP in the fed pigs were 85 per cent and 92 per cent, and in the fasted pigs 89 per cent and 90 per cent, respectively.",Oral bioavailability of sulphadiazine and trimethoprim in fed and fasted pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8146453/),%,89,64072,DB00440,Trimethoprim
,8146453,oral bioavailabilities,"The oral bioavailabilities for SDZ and TMP in the fed pigs were 85 per cent and 92 per cent, and in the fasted pigs 89 per cent and 90 per cent, respectively.",Oral bioavailability of sulphadiazine and trimethoprim in fed and fasted pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8146453/),%,90,64073,DB00440,Trimethoprim
,6638987,Plasma half-lives,"Plasma half-lives determined for the beta phase were 10.5 to 11.5 h in young volunteers, 12.0 to 12.9 h in elderly subjects, and 13.2 to 15.3 h in patients with renal impairment.",Pharmacokinetics of metioprim in normal subjects and patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638987/),h,10.5 to 11.5,66426,DB00440,Trimethoprim
,6638987,Plasma half-lives,"Plasma half-lives determined for the beta phase were 10.5 to 11.5 h in young volunteers, 12.0 to 12.9 h in elderly subjects, and 13.2 to 15.3 h in patients with renal impairment.",Pharmacokinetics of metioprim in normal subjects and patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638987/),h,12.0 to 12.9,66427,DB00440,Trimethoprim
,6638987,Plasma half-lives,"Plasma half-lives determined for the beta phase were 10.5 to 11.5 h in young volunteers, 12.0 to 12.9 h in elderly subjects, and 13.2 to 15.3 h in patients with renal impairment.",Pharmacokinetics of metioprim in normal subjects and patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638987/),h,13.2 to 15.3,66428,DB00440,Trimethoprim
,464572,plasma half-lives,"The plasma half-lives of TMP and free SMX, as determined during the first 8-h period, were 7.6 and 8.6 h, respectively.",Clinical pharmacology of intravenously administered trimethoprim-sulfamethoxazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/464572/),h,7.6,68142,DB00440,Trimethoprim
,464572,plasma half-lives,"The plasma half-lives of TMP and free SMX, as determined during the first 8-h period, were 7.6 and 8.6 h, respectively.",Clinical pharmacology of intravenously administered trimethoprim-sulfamethoxazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/464572/),h,8.6,68143,DB00440,Trimethoprim
,511351,half-life,"With respect to plasma half-life after the first dose, sulphadiazine with 8.0 hours was closer to trimethoprim with a half-life of 8.8 hours after cotrimazine and 9.6 hours after co-trimoxazole than to the half-life of sulphamethoxazole which was 7.7 hours.",Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 3: Pharmacokinetic characterization of sulphadiazine and sulphamethoxazole given with trimethoprim. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/511351/),h,8.8,68882,DB00440,Trimethoprim
,511351,half-life,"With respect to plasma half-life after the first dose, sulphadiazine with 8.0 hours was closer to trimethoprim with a half-life of 8.8 hours after cotrimazine and 9.6 hours after co-trimoxazole than to the half-life of sulphamethoxazole which was 7.7 hours.",Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 3: Pharmacokinetic characterization of sulphadiazine and sulphamethoxazole given with trimethoprim. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/511351/),h,9.6,68883,DB00440,Trimethoprim
,511351,half-life,"With respect to plasma half-life after the first dose, sulphadiazine with 8.0 hours was closer to trimethoprim with a half-life of 8.8 hours after cotrimazine and 9.6 hours after co-trimoxazole than to the half-life of sulphamethoxazole which was 7.7 hours.",Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 3: Pharmacokinetic characterization of sulphadiazine and sulphamethoxazole given with trimethoprim. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/511351/),h,7.7,68884,DB00440,Trimethoprim
,3437496,half-life,"The rate of SDZ absorption following oral administration, as determined by the Wagner-Nelson method, was very slow in all the calves in this study with average half-life values ranging from 8.2-12.67 h; absorption was slightly faster in ruminating calves.",The effect of age and diet on sulfadiazine/trimethoprim disposition following oral and subcutaneous administration to calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3437496/),h,8.2-12.67,69166,DB00440,Trimethoprim
,3437496,tmax,"In contrast, absorption of SDZ was very rapid; values for tmax were 1.5-1.8 h.",The effect of age and diet on sulfadiazine/trimethoprim disposition following oral and subcutaneous administration to calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3437496/),h,1.5-1.8,69167,DB00440,Trimethoprim
,6522131,Steady-state volume of distribution,"Steady-state volume of distribution increased from 0.78 L/kg at birth to 1.32 L/kg at 1 week, and 1.83 L/kg at 8 weeks due to changes in plasma protein binding and tissue accumulation.",Pharmacokinetics and metabolism of trimethoprim in neonatal and young pigs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6522131/),[l] / [kg],0.78,69865,DB00440,Trimethoprim
,6522131,Steady-state volume of distribution,"Steady-state volume of distribution increased from 0.78 L/kg at birth to 1.32 L/kg at 1 week, and 1.83 L/kg at 8 weeks due to changes in plasma protein binding and tissue accumulation.",Pharmacokinetics and metabolism of trimethoprim in neonatal and young pigs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6522131/),[l] / [kg],1.32,69866,DB00440,Trimethoprim
,6522131,Steady-state volume of distribution,"Steady-state volume of distribution increased from 0.78 L/kg at birth to 1.32 L/kg at 1 week, and 1.83 L/kg at 8 weeks due to changes in plasma protein binding and tissue accumulation.",Pharmacokinetics and metabolism of trimethoprim in neonatal and young pigs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6522131/),[l] / [kg],1.83,69867,DB00440,Trimethoprim
,6522131,Elimination half-life,"Elimination half-life decreased from 485 minutes at birth to 224 minutes at 1 week, and 120 minutes at 8 weeks leading to a rise in body clearance from 1.18 to 11.8 ml/min/kg during the same period.",Pharmacokinetics and metabolism of trimethoprim in neonatal and young pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6522131/),min,485,69868,DB00440,Trimethoprim
,6522131,Elimination half-life,"Elimination half-life decreased from 485 minutes at birth to 224 minutes at 1 week, and 120 minutes at 8 weeks leading to a rise in body clearance from 1.18 to 11.8 ml/min/kg during the same period.",Pharmacokinetics and metabolism of trimethoprim in neonatal and young pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6522131/),min,224,69869,DB00440,Trimethoprim
,6522131,Elimination half-life,"Elimination half-life decreased from 485 minutes at birth to 224 minutes at 1 week, and 120 minutes at 8 weeks leading to a rise in body clearance from 1.18 to 11.8 ml/min/kg during the same period.",Pharmacokinetics and metabolism of trimethoprim in neonatal and young pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6522131/),min,120,69870,DB00440,Trimethoprim
,6522131,body clearance,"Elimination half-life decreased from 485 minutes at birth to 224 minutes at 1 week, and 120 minutes at 8 weeks leading to a rise in body clearance from 1.18 to 11.8 ml/min/kg during the same period.",Pharmacokinetics and metabolism of trimethoprim in neonatal and young pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6522131/),[ml] / [kg·min],1.18,69871,DB00440,Trimethoprim
,6522131,body clearance,"Elimination half-life decreased from 485 minutes at birth to 224 minutes at 1 week, and 120 minutes at 8 weeks leading to a rise in body clearance from 1.18 to 11.8 ml/min/kg during the same period.",Pharmacokinetics and metabolism of trimethoprim in neonatal and young pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6522131/),[ml] / [kg·min],11.8,69872,DB00440,Trimethoprim
,6608482,concentrations,TMP-concentrations in PF were 3.3 micrograms/ml and 2.6 micrograms/ml three and six hours after peroral application (days two and three) respectively.,[Co-trimoxazole concentration in the prostatic fluid of patients with subacute and chronic prostatitis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6608482/),[μg] / [ml],3.3,75454,DB00440,Trimethoprim
,6608482,concentrations,TMP-concentrations in PF were 3.3 micrograms/ml and 2.6 micrograms/ml three and six hours after peroral application (days two and three) respectively.,[Co-trimoxazole concentration in the prostatic fluid of patients with subacute and chronic prostatitis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6608482/),[μg] / [ml],2.6,75455,DB00440,Trimethoprim
,2930028,elimination half-life (t1/2(beta)),"Between 1 and 42 days of age, the elimination half-life (t1/2(beta)) of SDZ decreased from 5.7 to 3.6 hours, and total body clearance (CLtot) increased from 1.43 to 1.88 ml/min/kg; the area under the curve (AUC0----infinity) decreased from 291.5 to 225.4 mg/L.h.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),h,5,76574,DB00440,Trimethoprim
,2930028,total body clearance (CLtot),"Between 1 and 42 days of age, the elimination half-life (t1/2(beta)) of SDZ decreased from 5.7 to 3.6 hours, and total body clearance (CLtot) increased from 1.43 to 1.88 ml/min/kg; the area under the curve (AUC0----infinity) decreased from 291.5 to 225.4 mg/L.h.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),[ml] / [kg·min],1.43,76575,DB00440,Trimethoprim
,2930028,total body clearance (CLtot),"Between 1 and 42 days of age, the elimination half-life (t1/2(beta)) of SDZ decreased from 5.7 to 3.6 hours, and total body clearance (CLtot) increased from 1.43 to 1.88 ml/min/kg; the area under the curve (AUC0----infinity) decreased from 291.5 to 225.4 mg/L.h.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),[ml] / [kg·min],1,76576,DB00440,Trimethoprim
,2930028,area under the curve (AUC0----infinity),"Between 1 and 42 days of age, the elimination half-life (t1/2(beta)) of SDZ decreased from 5.7 to 3.6 hours, and total body clearance (CLtot) increased from 1.43 to 1.88 ml/min/kg; the area under the curve (AUC0----infinity) decreased from 291.5 to 225.4 mg/L.h.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),[mg] / [h·l],291.5,76577,DB00440,Trimethoprim
,2930028,area under the curve (AUC0----infinity),"Between 1 and 42 days of age, the elimination half-life (t1/2(beta)) of SDZ decreased from 5.7 to 3.6 hours, and total body clearance (CLtot) increased from 1.43 to 1.88 ml/min/kg; the area under the curve (AUC0----infinity) decreased from 291.5 to 225.4 mg/L.h.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),[mg] / [h·l],225.4,76578,DB00440,Trimethoprim
,2930028,distribution coefficient (Vd(area),"The distribution coefficient (Vd(area)/kg of body weight) decreased with age, changing from 0.72 to 0.59 L/kg, between 1 and 42 days of age.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),[l] / [kg],0.72,76579,DB00440,Trimethoprim
,2930028,distribution coefficient (Vd(area),"The distribution coefficient (Vd(area)/kg of body weight) decreased with age, changing from 0.72 to 0.59 L/kg, between 1 and 42 days of age.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),[l] / [kg],0.59,76580,DB00440,Trimethoprim
,2930028,t1/2(beta),"The elimination rate of TMP increased about 9-fold; t1/2(beta) was 8.4, 2.1, and 0.9 hours, respectively, at 1, 7, and 42 days of age.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),h,8.4,76581,DB00440,Trimethoprim
,2930028,t1/2(beta),"The elimination rate of TMP increased about 9-fold; t1/2(beta) was 8.4, 2.1, and 0.9 hours, respectively, at 1, 7, and 42 days of age.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),h,2.1,76582,DB00440,Trimethoprim
,2930028,t1/2(beta),"The elimination rate of TMP increased about 9-fold; t1/2(beta) was 8.4, 2.1, and 0.9 hours, respectively, at 1, 7, and 42 days of age.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),h,0.9,76583,DB00440,Trimethoprim
,2930028,CLtot,"Other values also reflected an increase in TMP elimination rate with age: CLtot increased from 2.8 to 12 to 28.9 ml/min/kg, k13 increased from 0.336 to 0.654 to 1.664/h and AUC0----infinity decreased from 32.8 to 7.9 to 3.1 mg/L.h, respectively.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),[ml] / [kg·min],2.8,76584,DB00440,Trimethoprim
,2930028,CLtot,"Other values also reflected an increase in TMP elimination rate with age: CLtot increased from 2.8 to 12 to 28.9 ml/min/kg, k13 increased from 0.336 to 0.654 to 1.664/h and AUC0----infinity decreased from 32.8 to 7.9 to 3.1 mg/L.h, respectively.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),[ml] / [kg·min],12,76585,DB00440,Trimethoprim
,2930028,CLtot,"Other values also reflected an increase in TMP elimination rate with age: CLtot increased from 2.8 to 12 to 28.9 ml/min/kg, k13 increased from 0.336 to 0.654 to 1.664/h and AUC0----infinity decreased from 32.8 to 7.9 to 3.1 mg/L.h, respectively.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),[ml] / [kg·min],28.9,76586,DB00440,Trimethoprim
,2930028,k13,"Other values also reflected an increase in TMP elimination rate with age: CLtot increased from 2.8 to 12 to 28.9 ml/min/kg, k13 increased from 0.336 to 0.654 to 1.664/h and AUC0----infinity decreased from 32.8 to 7.9 to 3.1 mg/L.h, respectively.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),1/[h],0.336,76587,DB00440,Trimethoprim
,2930028,k13,"Other values also reflected an increase in TMP elimination rate with age: CLtot increased from 2.8 to 12 to 28.9 ml/min/kg, k13 increased from 0.336 to 0.654 to 1.664/h and AUC0----infinity decreased from 32.8 to 7.9 to 3.1 mg/L.h, respectively.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),1/[h],0.654,76588,DB00440,Trimethoprim
,2930028,k13,"Other values also reflected an increase in TMP elimination rate with age: CLtot increased from 2.8 to 12 to 28.9 ml/min/kg, k13 increased from 0.336 to 0.654 to 1.664/h and AUC0----infinity decreased from 32.8 to 7.9 to 3.1 mg/L.h, respectively.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),1/[h],1.664,76589,DB00440,Trimethoprim
,2930028,AUC0----infinity,"Other values also reflected an increase in TMP elimination rate with age: CLtot increased from 2.8 to 12 to 28.9 ml/min/kg, k13 increased from 0.336 to 0.654 to 1.664/h and AUC0----infinity decreased from 32.8 to 7.9 to 3.1 mg/L.h, respectively.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),[mg] / [h·l],32.8,76590,DB00440,Trimethoprim
,2930028,AUC0----infinity,"Other values also reflected an increase in TMP elimination rate with age: CLtot increased from 2.8 to 12 to 28.9 ml/min/kg, k13 increased from 0.336 to 0.654 to 1.664/h and AUC0----infinity decreased from 32.8 to 7.9 to 3.1 mg/L.h, respectively.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),[mg] / [h·l],7.9,76591,DB00440,Trimethoprim
,2930028,AUC0----infinity,"Other values also reflected an increase in TMP elimination rate with age: CLtot increased from 2.8 to 12 to 28.9 ml/min/kg, k13 increased from 0.336 to 0.654 to 1.664/h and AUC0----infinity decreased from 32.8 to 7.9 to 3.1 mg/L.h, respectively.",Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2930028/),[mg] / [h·l],3.1,76592,DB00440,Trimethoprim
,6335067,half-life,The half-life of TMP and SMXA determined by model independent methods were 33.7 +/- 10.5 h (mean +/- SD) and 13.8 +/- 2.2 h respectively.,Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6335067/),h,33.7,77763,DB00440,Trimethoprim
,6335067,half-life,The half-life of TMP and SMXA determined by model independent methods were 33.7 +/- 10.5 h (mean +/- SD) and 13.8 +/- 2.2 h respectively.,Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6335067/),h,13.8,77764,DB00440,Trimethoprim
,6335067,Total body clearance,Total body clearance of TMP was 32.8 +/- 10.1 ml/min and SMXA was 21.9 +/- 6.4 ml/min.,Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6335067/),[ml] / [min],32.8,77765,DB00440,Trimethoprim
,6335067,Total body clearance,Total body clearance of TMP was 32.8 +/- 10.1 ml/min and SMXA was 21.9 +/- 6.4 ml/min.,Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6335067/),[ml] / [min],21.9,77766,DB00440,Trimethoprim
,6335067,clearance,CAPD clearance of TMP was 2.27 +/- 0.81 ml/min and SMXA was 1.72 +/- 0.93 ml/min.,Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6335067/),[ml] / [min],2.27,77767,DB00440,Trimethoprim
,6335067,SMXA,CAPD clearance of TMP was 2.27 +/- 0.81 ml/min and SMXA was 1.72 +/- 0.93 ml/min.,Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6335067/),[ml] / [min],1.72,77768,DB00440,Trimethoprim
,6335067,peritoneal dialysate concentrations,The average peritoneal dialysate concentrations over the 72-hour collection period of TMP and SMXA were 0.9 +/- 0.1 mg/l and 5.3 +/- 0.8 mg/l respectively.,Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6335067/),[mg] / [l],0.9,77769,DB00440,Trimethoprim
,6335067,peritoneal dialysate concentrations,The average peritoneal dialysate concentrations over the 72-hour collection period of TMP and SMXA were 0.9 +/- 0.1 mg/l and 5.3 +/- 0.8 mg/l respectively.,Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6335067/),[mg] / [l],5.3,77770,DB00440,Trimethoprim
,1949541,elimination half-lives,"SMZ and TMP were quickly eliminated (mean elimination half-lives: 2.7 and 2.4 h, respectively).",Pharmacokinetics of a sulphamethoxazole/trimethoprim formulation in pigs after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1949541/),h,2.7,77898,DB00440,Trimethoprim
,1949541,elimination half-lives,"SMZ and TMP were quickly eliminated (mean elimination half-lives: 2.7 and 2.4 h, respectively).",Pharmacokinetics of a sulphamethoxazole/trimethoprim formulation in pigs after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1949541/),h,2.4,77899,DB00440,Trimethoprim
,8231243,half-life,"In two of these patients, pharmacokinetic analysis demonstrated delayed terminal excretion of methotrexate with a half-life of 3-3.5 days, compared to a previously reported t1/2 of 8-15 hours in subjects with normal clearance.",Toxicity following concurrent intrathecal and moderate-dose intravenous methotrexate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8231243/),d,3-3.5,78930,DB00440,Trimethoprim
,8231243,t1/2,"In two of these patients, pharmacokinetic analysis demonstrated delayed terminal excretion of methotrexate with a half-life of 3-3.5 days, compared to a previously reported t1/2 of 8-15 hours in subjects with normal clearance.",Toxicity following concurrent intrathecal and moderate-dose intravenous methotrexate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8231243/),h,8-15,78931,DB00440,Trimethoprim
,23305245,apparent systemic metformin clearance (CL/F),"In the population as a whole, trimethoprim significantly reduced the apparent systemic metformin clearance (CL/F) from 74 to 54 l h(-1) and renal metformin clearance from 31 to 21 l h(-1) , and prolonged half-life from 2.7 to 3.6 h (all P < 0.01).",Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23305245/),[l] / [h],74 to 54,80986,DB00440,Trimethoprim
,23305245,renal metformin clearance,"In the population as a whole, trimethoprim significantly reduced the apparent systemic metformin clearance (CL/F) from 74 to 54 l h(-1) and renal metformin clearance from 31 to 21 l h(-1) , and prolonged half-life from 2.7 to 3.6 h (all P < 0.01).",Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23305245/),[l] / [h],31 to 21,80987,DB00440,Trimethoprim
,23305245,half-life,"In the population as a whole, trimethoprim significantly reduced the apparent systemic metformin clearance (CL/F) from 74 to 54 l h(-1) and renal metformin clearance from 31 to 21 l h(-1) , and prolonged half-life from 2.7 to 3.6 h (all P < 0.01).",Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23305245/),h,2.7 to 3.6,80988,DB00440,Trimethoprim
,7625796,peak concentration,"Expressed as means +/- standard deviations (ranges), the pharmacokinetic parameters were as follows: peak concentration in plasma, 1.12 +/- 0.48 (0.44 to 1.81) mg/liter; time to peak concentration in plasma, 3.8 +/- 1.3 (2 to 6) h; half-life at elimination phase, 24.2 +/- 7.1 (14.4 to 35.0) h; clearance from plasma divided by bioavailability (CL/F), 1.15 +/- 0.67 (0.37 to 2.63) ml/min/kg; and volume of distribution divided by bioavailability (V/F), 2.25 +/- 1.20 (1.00 to 4.57) liters/kg.",Pharmacokinetics of dapsone in human immunodeficiency virus-infected children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625796/),[mg] / [l],1.12,81306,DB00440,Trimethoprim
,7625796,time to peak concentration,"Expressed as means +/- standard deviations (ranges), the pharmacokinetic parameters were as follows: peak concentration in plasma, 1.12 +/- 0.48 (0.44 to 1.81) mg/liter; time to peak concentration in plasma, 3.8 +/- 1.3 (2 to 6) h; half-life at elimination phase, 24.2 +/- 7.1 (14.4 to 35.0) h; clearance from plasma divided by bioavailability (CL/F), 1.15 +/- 0.67 (0.37 to 2.63) ml/min/kg; and volume of distribution divided by bioavailability (V/F), 2.25 +/- 1.20 (1.00 to 4.57) liters/kg.",Pharmacokinetics of dapsone in human immunodeficiency virus-infected children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625796/),h,3.8,81307,DB00440,Trimethoprim
,7625796,half-life at elimination phase,"Expressed as means +/- standard deviations (ranges), the pharmacokinetic parameters were as follows: peak concentration in plasma, 1.12 +/- 0.48 (0.44 to 1.81) mg/liter; time to peak concentration in plasma, 3.8 +/- 1.3 (2 to 6) h; half-life at elimination phase, 24.2 +/- 7.1 (14.4 to 35.0) h; clearance from plasma divided by bioavailability (CL/F), 1.15 +/- 0.67 (0.37 to 2.63) ml/min/kg; and volume of distribution divided by bioavailability (V/F), 2.25 +/- 1.20 (1.00 to 4.57) liters/kg.",Pharmacokinetics of dapsone in human immunodeficiency virus-infected children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625796/),h,24.2,81308,DB00440,Trimethoprim
,7625796,clearance from plasma divided by bioavailability (CL/F),"Expressed as means +/- standard deviations (ranges), the pharmacokinetic parameters were as follows: peak concentration in plasma, 1.12 +/- 0.48 (0.44 to 1.81) mg/liter; time to peak concentration in plasma, 3.8 +/- 1.3 (2 to 6) h; half-life at elimination phase, 24.2 +/- 7.1 (14.4 to 35.0) h; clearance from plasma divided by bioavailability (CL/F), 1.15 +/- 0.67 (0.37 to 2.63) ml/min/kg; and volume of distribution divided by bioavailability (V/F), 2.25 +/- 1.20 (1.00 to 4.57) liters/kg.",Pharmacokinetics of dapsone in human immunodeficiency virus-infected children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625796/),[ml] / [kg·min],1.15,81309,DB00440,Trimethoprim
,7625796,volume of distribution divided by bioavailability (V/F),"Expressed as means +/- standard deviations (ranges), the pharmacokinetic parameters were as follows: peak concentration in plasma, 1.12 +/- 0.48 (0.44 to 1.81) mg/liter; time to peak concentration in plasma, 3.8 +/- 1.3 (2 to 6) h; half-life at elimination phase, 24.2 +/- 7.1 (14.4 to 35.0) h; clearance from plasma divided by bioavailability (CL/F), 1.15 +/- 0.67 (0.37 to 2.63) ml/min/kg; and volume of distribution divided by bioavailability (V/F), 2.25 +/- 1.20 (1.00 to 4.57) liters/kg.",Pharmacokinetics of dapsone in human immunodeficiency virus-infected children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625796/),[l] / [kg],2.25,81310,DB00440,Trimethoprim
,7853455,biological half-lives,"Mean biological half-lives of the drugs were 2.89 +/- 0.11 and 2.38 +/- 0.33 h, respectively.",Pharmacokinetics of sulphamethoxazole and trimethoprim administered intravenously and orally to Japanese quails. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853455/),h,2.89,81448,DB00440,Trimethoprim
,7853455,biological half-lives,"Mean biological half-lives of the drugs were 2.89 +/- 0.11 and 2.38 +/- 0.33 h, respectively.",Pharmacokinetics of sulphamethoxazole and trimethoprim administered intravenously and orally to Japanese quails. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853455/),h,2.38,81449,DB00440,Trimethoprim
,7853455,distribution volumes (V area),The distribution volumes (V area) were 0.475 +/- 0.026 l/kg (sulphamethoxazole) and 3.89 +/- 0.61 l/kg (trimethoprim).,Pharmacokinetics of sulphamethoxazole and trimethoprim administered intravenously and orally to Japanese quails. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853455/),[l] / [kg],0.475,81450,DB00440,Trimethoprim
,7853455,distribution volumes (V area),The distribution volumes (V area) were 0.475 +/- 0.026 l/kg (sulphamethoxazole) and 3.89 +/- 0.61 l/kg (trimethoprim).,Pharmacokinetics of sulphamethoxazole and trimethoprim administered intravenously and orally to Japanese quails. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853455/),[l] / [kg],3.89,81451,DB00440,Trimethoprim
,7853455,bioavailability,The bioavailability was 81% for sulphamethoxazole and 41% for trimethoprim.,Pharmacokinetics of sulphamethoxazole and trimethoprim administered intravenously and orally to Japanese quails. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853455/),%,81,81452,DB00440,Trimethoprim
,7853455,bioavailability,The bioavailability was 81% for sulphamethoxazole and 41% for trimethoprim.,Pharmacokinetics of sulphamethoxazole and trimethoprim administered intravenously and orally to Japanese quails. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853455/),%,41,81453,DB00440,Trimethoprim
,7377748,Serum half-lives,"Serum half-lives of SD and TMP were 10.8 and 11.8 hrs, respectively.",Pharmacokinetics and clinical experiences of the combination sulfadiazine-trimethoprim in the short-term treatment of acute urinary tract infections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7377748/),h,10.8,81765,DB00440,Trimethoprim
,7377748,Serum half-lives,"Serum half-lives of SD and TMP were 10.8 and 11.8 hrs, respectively.",Pharmacokinetics and clinical experiences of the combination sulfadiazine-trimethoprim in the short-term treatment of acute urinary tract infections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7377748/),h,11.8,81766,DB00440,Trimethoprim
,15156077,Maximum trimethoprim concentrations,"Maximum trimethoprim concentrations of 8.5 +/- 1.1 micromol/l in plasma, 5.6 +/- 0.8 micromol/l in blister fluid and 5.8 +/- 2.2 micromol/l in theoretical peripheral compartment were found after 3 +/- 1, 7 +/- 2 and 9 +/- 6 h, respectively.",Penetration of cotrimoxazole components into skin after a single oral dose. Theoretical versus experimental approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15156077/),[μM] / [l],8.5,82069,DB00440,Trimethoprim
,15156077,Maximum trimethoprim concentrations,"Maximum trimethoprim concentrations of 8.5 +/- 1.1 micromol/l in plasma, 5.6 +/- 0.8 micromol/l in blister fluid and 5.8 +/- 2.2 micromol/l in theoretical peripheral compartment were found after 3 +/- 1, 7 +/- 2 and 9 +/- 6 h, respectively.",Penetration of cotrimoxazole components into skin after a single oral dose. Theoretical versus experimental approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15156077/),[μM] / [l],5.6,82070,DB00440,Trimethoprim
,15156077,Maximum trimethoprim concentrations,"Maximum trimethoprim concentrations of 8.5 +/- 1.1 micromol/l in plasma, 5.6 +/- 0.8 micromol/l in blister fluid and 5.8 +/- 2.2 micromol/l in theoretical peripheral compartment were found after 3 +/- 1, 7 +/- 2 and 9 +/- 6 h, respectively.",Penetration of cotrimoxazole components into skin after a single oral dose. Theoretical versus experimental approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15156077/),[μM] / [l],5.8,82071,DB00440,Trimethoprim
,15156077,Degree of penetration into blister fluid,"Degree of penetration into blister fluid and theoretical peripheral compartment was 0.94 +/- 0.23 and 1.05 +/- 0.09, respectively.",Penetration of cotrimoxazole components into skin after a single oral dose. Theoretical versus experimental approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15156077/),,0.94,82072,DB00440,Trimethoprim
,15156077,Degree of penetration into blister fluid,"Degree of penetration into blister fluid and theoretical peripheral compartment was 0.94 +/- 0.23 and 1.05 +/- 0.09, respectively.",Penetration of cotrimoxazole components into skin after a single oral dose. Theoretical versus experimental approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15156077/),,1.05,82073,DB00440,Trimethoprim
,15156077,Maximum sulfamethoxazole concentrations,"Maximum sulfamethoxazole concentrations of 295 +/- 47 micromol/l in plasma, 182 +/- 46 micromol/l in blister fluid and 239 +/- 58 micromol/l in theoretical peripheral compartment were found after 3 +/- 1, 8 +/- 2 and 7 +/- 4 h, respectively.",Penetration of cotrimoxazole components into skin after a single oral dose. Theoretical versus experimental approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15156077/),[μM] / [l],295,82074,DB00440,Trimethoprim
,15156077,Maximum sulfamethoxazole concentrations,"Maximum sulfamethoxazole concentrations of 295 +/- 47 micromol/l in plasma, 182 +/- 46 micromol/l in blister fluid and 239 +/- 58 micromol/l in theoretical peripheral compartment were found after 3 +/- 1, 8 +/- 2 and 7 +/- 4 h, respectively.",Penetration of cotrimoxazole components into skin after a single oral dose. Theoretical versus experimental approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15156077/),[μM] / [l],182,82075,DB00440,Trimethoprim
,15156077,Maximum sulfamethoxazole concentrations,"Maximum sulfamethoxazole concentrations of 295 +/- 47 micromol/l in plasma, 182 +/- 46 micromol/l in blister fluid and 239 +/- 58 micromol/l in theoretical peripheral compartment were found after 3 +/- 1, 8 +/- 2 and 7 +/- 4 h, respectively.",Penetration of cotrimoxazole components into skin after a single oral dose. Theoretical versus experimental approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15156077/),[μM] / [l],239,82076,DB00440,Trimethoprim
,15156077,Degree of penetration into blister fluid,"Degree of penetration into blister fluid and theoretical peripheral compartment was 0.82 +/- 0.20 and 1.04 +/- 0.02, respectively.",Penetration of cotrimoxazole components into skin after a single oral dose. Theoretical versus experimental approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15156077/),,0.82,82077,DB00440,Trimethoprim
,15156077,Degree of penetration into blister fluid,"Degree of penetration into blister fluid and theoretical peripheral compartment was 0.82 +/- 0.20 and 1.04 +/- 0.02, respectively.",Penetration of cotrimoxazole components into skin after a single oral dose. Theoretical versus experimental approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15156077/),,1.04,82078,DB00440,Trimethoprim
,15606443,apparent K(i),"Inhibition of rosiglitazone para-hydroxylation by trimethoprim in vitro was found to be competitive with apparent K(i) and IC(50) values of 29 microm and 54.5 microm, respectively.",The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606443/),μm,29,85890,DB00440,Trimethoprim
,15606443,IC(50),"Inhibition of rosiglitazone para-hydroxylation by trimethoprim in vitro was found to be competitive with apparent K(i) and IC(50) values of 29 microm and 54.5 microm, respectively.",The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606443/),μm,54.5,85891,DB00440,Trimethoprim
,15606443,plasma AUC,"In the presence of trimethoprim, rosiglitazone plasma AUC was increased by 31% (P = 0.01) from 2774 +/- 645 microg l(-1) h to 3643 +/- 1051 microg l(-1) h (95% confidence interval (CI) for difference 189, 1549), and half-life was increased by 27% (P = 0.006) from 3.3 +/- 0.5 to 4.2 +/- 0.8 h (95% CI for difference 0.36, 1.5).",The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606443/),[h·μg] / [l],2774,85892,DB00440,Trimethoprim
,15606443,plasma AUC,"In the presence of trimethoprim, rosiglitazone plasma AUC was increased by 31% (P = 0.01) from 2774 +/- 645 microg l(-1) h to 3643 +/- 1051 microg l(-1) h (95% confidence interval (CI) for difference 189, 1549), and half-life was increased by 27% (P = 0.006) from 3.3 +/- 0.5 to 4.2 +/- 0.8 h (95% CI for difference 0.36, 1.5).",The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606443/),[h·μg] / [l],3643,85893,DB00440,Trimethoprim
,15606443,half-life,"In the presence of trimethoprim, rosiglitazone plasma AUC was increased by 31% (P = 0.01) from 2774 +/- 645 microg l(-1) h to 3643 +/- 1051 microg l(-1) h (95% confidence interval (CI) for difference 189, 1549), and half-life was increased by 27% (P = 0.006) from 3.3 +/- 0.5 to 4.2 +/- 0.8 h (95% CI for difference 0.36, 1.5).",The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606443/),h,3.3,85894,DB00440,Trimethoprim
,15606443,half-life,"In the presence of trimethoprim, rosiglitazone plasma AUC was increased by 31% (P = 0.01) from 2774 +/- 645 microg l(-1) h to 3643 +/- 1051 microg l(-1) h (95% confidence interval (CI) for difference 189, 1549), and half-life was increased by 27% (P = 0.006) from 3.3 +/- 0.5 to 4.2 +/- 0.8 h (95% CI for difference 0.36, 1.5).",The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606443/),h,4.2,85895,DB00440,Trimethoprim
,16369884,bioavailability,Sulphadiazine bioavailability (+/-SD) was 69.00%+/-10.51%.,"Bioavailability and pharmacokinetics of sulphadiazine, N4-acetylsulphadiazine and trimethoprim following intravenous and intramuscular administration of a sulphadiazine/trimethoprim combination in sheep. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369884/),%,69.00,87823,DB00440,Trimethoprim
,16369884,half-life of the terminal phase,"The half-life of the terminal phase (4.10+/-0.58 h after i. v., and 4.03+/-0.31 h after i.m. administration) was significantly higher than the respective value for trimethoprim (0.59+/-0.19 h) after i.v. administration.","Bioavailability and pharmacokinetics of sulphadiazine, N4-acetylsulphadiazine and trimethoprim following intravenous and intramuscular administration of a sulphadiazine/trimethoprim combination in sheep. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369884/),h,4.10,87824,DB00440,Trimethoprim
,16369884,half-life of the terminal phase,"The half-life of the terminal phase (4.10+/-0.58 h after i. v., and 4.03+/-0.31 h after i.m. administration) was significantly higher than the respective value for trimethoprim (0.59+/-0.19 h) after i.v. administration.","Bioavailability and pharmacokinetics of sulphadiazine, N4-acetylsulphadiazine and trimethoprim following intravenous and intramuscular administration of a sulphadiazine/trimethoprim combination in sheep. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369884/),h,4.03,87825,DB00440,Trimethoprim
,16369884,half-life of the terminal phase,"The half-life of the terminal phase (4.10+/-0.58 h after i. v., and 4.03+/-0.31 h after i.m. administration) was significantly higher than the respective value for trimethoprim (0.59+/-0.19 h) after i.v. administration.","Bioavailability and pharmacokinetics of sulphadiazine, N4-acetylsulphadiazine and trimethoprim following intravenous and intramuscular administration of a sulphadiazine/trimethoprim combination in sheep. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369884/),h,0.59,87826,DB00440,Trimethoprim
,3536256,half-life,"Both combination drugs have similar serum half-life values in persons with normal renal function (half-life of 8 to 12 hours), but the sulphamethoxazole metabolites are retained more than trimethoprim in reduced renal function.",Clinical pharmacokinetics of co-trimazine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3536256/),h,8 to 12,90380,DB00440,Trimethoprim
,3536256,penetration into peripheral,This measure shows a penetration into peripheral human lymph of 68% for sulphadiazine and 59% for trimethoprim.,Clinical pharmacokinetics of co-trimazine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3536256/),%,68,90381,DB00440,Trimethoprim
,3536256,penetration into peripheral,This measure shows a penetration into peripheral human lymph of 68% for sulphadiazine and 59% for trimethoprim.,Clinical pharmacokinetics of co-trimazine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3536256/),%,59,90382,DB00440,Trimethoprim
,3536256,proportions eliminated,"The proportions eliminated in urine are about 55% for sulphadiazine, 30% for its acetylated metabolite and 75% for trimethoprim.",Clinical pharmacokinetics of co-trimazine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3536256/),,55,90383,DB00440,Trimethoprim
,3536256,proportions eliminated,"The proportions eliminated in urine are about 55% for sulphadiazine, 30% for its acetylated metabolite and 75% for trimethoprim.",Clinical pharmacokinetics of co-trimazine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3536256/),,30,90384,DB00440,Trimethoprim
,582148,total SMZ,The average serum concentrations measured in steady-state between the fourth and seventh days showed a range for total SMZ of 47.86 to 63.38 microgram/ml.,Steady-state pharmacokinetics of sulfamethoxazole and trimethorprim in man after rectal application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582148/),[μg] / [ml],47.86 to 63.38,91094,DB00440,Trimethoprim
,582148,Free SMZ,Free SMZ was between 40.04 and 51.42 microgram/ml and TMP between 1.44 and 2.20 microgram/ml.,Steady-state pharmacokinetics of sulfamethoxazole and trimethorprim in man after rectal application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582148/),[μg] / [ml],40.04 and 51.42,91095,DB00440,Trimethoprim
,582148,TMP,Free SMZ was between 40.04 and 51.42 microgram/ml and TMP between 1.44 and 2.20 microgram/ml.,Steady-state pharmacokinetics of sulfamethoxazole and trimethorprim in man after rectal application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582148/),[μg] / [ml],1.44 and 2.20,91096,DB00440,Trimethoprim
,582148,serum minimum,Extrapolation from t leads to infinity gave a serum minimum for total SMZ of 51.7 microgram/ml and 1.8 microgram/ml for TMP.,Steady-state pharmacokinetics of sulfamethoxazole and trimethorprim in man after rectal application. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582148/),[μg] / [ml],51.7,91097,DB00440,Trimethoprim
,582148,serum minimum,Extrapolation from t leads to infinity gave a serum minimum for total SMZ of 51.7 microgram/ml and 1.8 microgram/ml for TMP.,Steady-state pharmacokinetics of sulfamethoxazole and trimethorprim in man after rectal application. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582148/),[μg] / [ml],1.8,91098,DB00440,Trimethoprim
,26732683,half-life,"The mefloquine half-life, observed clearance (CL/f), and area-under-the-curve (AUC0→∞) were 12.0 days, 0.035 l/h/kg and 431 µg-h/ml, respectively.",Pharmacokinetics of mefloquine and its effect on sulfamethoxazole and trimethoprim steady-state blood levels in intermittent preventive treatment (IPTp) of pregnant HIV-infected women in Kenya. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26732683/),d,12.0,92972,DB00440,Trimethoprim
,26732683,observed clearance (CL/f),"The mefloquine half-life, observed clearance (CL/f), and area-under-the-curve (AUC0→∞) were 12.0 days, 0.035 l/h/kg and 431 µg-h/ml, respectively.",Pharmacokinetics of mefloquine and its effect on sulfamethoxazole and trimethoprim steady-state blood levels in intermittent preventive treatment (IPTp) of pregnant HIV-infected women in Kenya. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26732683/),[l] / [h·kg],0.035,92973,DB00440,Trimethoprim
,26732683,area-under-the-curve (AUC0→∞),"The mefloquine half-life, observed clearance (CL/f), and area-under-the-curve (AUC0→∞) were 12.0 days, 0.035 l/h/kg and 431 µg-h/ml, respectively.",Pharmacokinetics of mefloquine and its effect on sulfamethoxazole and trimethoprim steady-state blood levels in intermittent preventive treatment (IPTp) of pregnant HIV-infected women in Kenya. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26732683/),[µg-h] / [ml],431,92974,DB00440,Trimethoprim
,3189982,minimal inhibitory concentration (MIC),The tarsocrural joints of 11 horses were inoculated with 1.2 to 2.16 x 10(6) viable Staphylococcus aureus organisms susceptible to a trimethoprim-sulfadiazine (TMP-SDZ) combination with minimal inhibitory concentration (MIC) of 0.25 micrograms of TMP/ml and 4.75 micrograms of SDZ/ml.,Serum and synovial fluid steady-state concentrations of trimethoprim and sulfadiazine in horses with experimentally induced infectious arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189982/),μg,0.25,93309,DB00440,Trimethoprim
,3189982,minimal inhibitory concentration (MIC),The tarsocrural joints of 11 horses were inoculated with 1.2 to 2.16 x 10(6) viable Staphylococcus aureus organisms susceptible to a trimethoprim-sulfadiazine (TMP-SDZ) combination with minimal inhibitory concentration (MIC) of 0.25 micrograms of TMP/ml and 4.75 micrograms of SDZ/ml.,Serum and synovial fluid steady-state concentrations of trimethoprim and sulfadiazine in horses with experimentally induced infectious arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189982/),μg,4.75,93310,DB00440,Trimethoprim
,3189982,MIC,"Administration of the TMP-SDZ combination at a dosage of 30 mg/kg once daily was not effective in maintaining TMP or SDZ concentrations above the MIC of TMP-SDZ for the S aureus (0.25 and 4.75 micrograms/ml for TMP and SDZ, respectively) in the infected synovial fluid or in maintaining adequate TMP concentration in the serum.",Serum and synovial fluid steady-state concentrations of trimethoprim and sulfadiazine in horses with experimentally induced infectious arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189982/),[μg] / [ml],0.25,93311,DB00440,Trimethoprim
,3189982,MIC,"Administration of the TMP-SDZ combination at a dosage of 30 mg/kg once daily was not effective in maintaining TMP or SDZ concentrations above the MIC of TMP-SDZ for the S aureus (0.25 and 4.75 micrograms/ml for TMP and SDZ, respectively) in the infected synovial fluid or in maintaining adequate TMP concentration in the serum.",Serum and synovial fluid steady-state concentrations of trimethoprim and sulfadiazine in horses with experimentally induced infectious arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189982/),[μg] / [ml],4.75,93312,DB00440,Trimethoprim
,6740937,systemic availability,"SD and TMP have systemic availability 94.1 +/- 18.1% and 52.5 +/- 6.2% and produce blood levels, after a single dose of TD, higher than potentiated minimum inhibitory concentrations for 24-48 h and 5(4-8) h, respectively.","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),%,94.1,93356,DB00440,Trimethoprim
,6740937,systemic availability,"SD and TMP have systemic availability 94.1 +/- 18.1% and 52.5 +/- 6.2% and produce blood levels, after a single dose of TD, higher than potentiated minimum inhibitory concentrations for 24-48 h and 5(4-8) h, respectively.","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),%,52.5,93357,DB00440,Trimethoprim
,6740937,t1/2 beta,"The biological half-life of TD--t1/2 beta for SD is 14.36 +/- 1.40 h and for TMP--2.40 +/- 0.31 (for one-compartmental model--1.92 +/- 0.26) h, Vd--429.9 +/- 16.9 ml/kg and for TMP in part of the animals one-compartmental model is applicable).","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),h,14.36,93358,DB00440,Trimethoprim
,6740937,t1/2 beta,"The biological half-life of TD--t1/2 beta for SD is 14.36 +/- 1.40 h and for TMP--2.40 +/- 0.31 (for one-compartmental model--1.92 +/- 0.26) h, Vd--429.9 +/- 16.9 ml/kg and for TMP in part of the animals one-compartmental model is applicable).","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),h,2.40,93359,DB00440,Trimethoprim
,6740937,t1/2 beta,"The biological half-life of TD--t1/2 beta for SD is 14.36 +/- 1.40 h and for TMP--2.40 +/- 0.31 (for one-compartmental model--1.92 +/- 0.26) h, Vd--429.9 +/- 16.9 ml/kg and for TMP in part of the animals one-compartmental model is applicable).","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),h,1.92,93360,DB00440,Trimethoprim
,6740937,Vd,"The biological half-life of TD--t1/2 beta for SD is 14.36 +/- 1.40 h and for TMP--2.40 +/- 0.31 (for one-compartmental model--1.92 +/- 0.26) h, Vd--429.9 +/- 16.9 ml/kg and for TMP in part of the animals one-compartmental model is applicable).","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),[ml] / [kg],429.9,93361,DB00440,Trimethoprim
,6740937,t1/2 beta,"The biological half-life of TD--t1/2 beta for SD is 14.36 +/- 1.40 h and for TMP--2.40 +/- 0.31 (for one-compartmental model--1.92 +/- 0.26) h, Vd--429.9 +/- 16.9 ml/kg and for TMP in part of the animals one-compartmental model is applicable).","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),h,14.36,93362,DB00440,Trimethoprim
,6740937,t1/2 beta,"The biological half-life of TD--t1/2 beta for SD is 14.36 +/- 1.40 h and for TMP--2.40 +/- 0.31 (for one-compartmental model--1.92 +/- 0.26) h, Vd--429.9 +/- 16.9 ml/kg and for TMP in part of the animals one-compartmental model is applicable).","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),h,2.40,93363,DB00440,Trimethoprim
,6740937,t1/2 beta,"The biological half-life of TD--t1/2 beta for SD is 14.36 +/- 1.40 h and for TMP--2.40 +/- 0.31 (for one-compartmental model--1.92 +/- 0.26) h, Vd--429.9 +/- 16.9 ml/kg and for TMP in part of the animals one-compartmental model is applicable).","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),h,1.92,93364,DB00440,Trimethoprim
,6740937,Vd,"The biological half-life of TD--t1/2 beta for SD is 14.36 +/- 1.40 h and for TMP--2.40 +/- 0.31 (for one-compartmental model--1.92 +/- 0.26) h, Vd--429.9 +/- 16.9 ml/kg and for TMP in part of the animals one-compartmental model is applicable).","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),[ml] / [kg],429.9,93365,DB00440,Trimethoprim
,6740937,biological,"The biological half-life of TD--t1/2 beta for SD is 14.36 +/- 1.40 h and for TMP--2.40 +/- 0.31 (for one-compartmental model--1.92 +/- 0.26) h, Vd--429.9 +/- 16.9 ml/kg and 655.8 +/- 77.6 (for one-compartmental model--671.7 +/- 40.0) ml/kg, ClB--0.35 +/- 0.02 ml/kg/min and 2.87 +/- 0.35 (for one-compartmental model--4.15 +/- 0.80) ml/kg/min, respectively.","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),h,14.36,93366,DB00440,Trimethoprim
,6740937,t1/2 beta,"The biological half-life of TD--t1/2 beta for SD is 14.36 +/- 1.40 h and for TMP--2.40 +/- 0.31 (for one-compartmental model--1.92 +/- 0.26) h, Vd--429.9 +/- 16.9 ml/kg and 655.8 +/- 77.6 (for one-compartmental model--671.7 +/- 40.0) ml/kg, ClB--0.35 +/- 0.02 ml/kg/min and 2.87 +/- 0.35 (for one-compartmental model--4.15 +/- 0.80) ml/kg/min, respectively.","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),h,14.36,93367,DB00440,Trimethoprim
,6740937,t1/2 beta,"The biological half-life of TD--t1/2 beta for SD is 14.36 +/- 1.40 h and for TMP--2.40 +/- 0.31 (for one-compartmental model--1.92 +/- 0.26) h, Vd--429.9 +/- 16.9 ml/kg and 655.8 +/- 77.6 (for one-compartmental model--671.7 +/- 40.0) ml/kg, ClB--0.35 +/- 0.02 ml/kg/min and 2.87 +/- 0.35 (for one-compartmental model--4.15 +/- 0.80) ml/kg/min, respectively.","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),h,2.40,93368,DB00440,Trimethoprim
,6740937,t1/2 beta,"The biological half-life of TD--t1/2 beta for SD is 14.36 +/- 1.40 h and for TMP--2.40 +/- 0.31 (for one-compartmental model--1.92 +/- 0.26) h, Vd--429.9 +/- 16.9 ml/kg and 655.8 +/- 77.6 (for one-compartmental model--671.7 +/- 40.0) ml/kg, ClB--0.35 +/- 0.02 ml/kg/min and 2.87 +/- 0.35 (for one-compartmental model--4.15 +/- 0.80) ml/kg/min, respectively.","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),h,1.92,93369,DB00440,Trimethoprim
,6740937,Vd,"The biological half-life of TD--t1/2 beta for SD is 14.36 +/- 1.40 h and for TMP--2.40 +/- 0.31 (for one-compartmental model--1.92 +/- 0.26) h, Vd--429.9 +/- 16.9 ml/kg and 655.8 +/- 77.6 (for one-compartmental model--671.7 +/- 40.0) ml/kg, ClB--0.35 +/- 0.02 ml/kg/min and 2.87 +/- 0.35 (for one-compartmental model--4.15 +/- 0.80) ml/kg/min, respectively.","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),[ml] / [kg],429.9,93370,DB00440,Trimethoprim
,6740937,Vd,"The biological half-life of TD--t1/2 beta for SD is 14.36 +/- 1.40 h and for TMP--2.40 +/- 0.31 (for one-compartmental model--1.92 +/- 0.26) h, Vd--429.9 +/- 16.9 ml/kg and 655.8 +/- 77.6 (for one-compartmental model--671.7 +/- 40.0) ml/kg, ClB--0.35 +/- 0.02 ml/kg/min and 2.87 +/- 0.35 (for one-compartmental model--4.15 +/- 0.80) ml/kg/min, respectively.","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),[ml] / [kg],655.8,93371,DB00440,Trimethoprim
,6740937,Vd,"The biological half-life of TD--t1/2 beta for SD is 14.36 +/- 1.40 h and for TMP--2.40 +/- 0.31 (for one-compartmental model--1.92 +/- 0.26) h, Vd--429.9 +/- 16.9 ml/kg and 655.8 +/- 77.6 (for one-compartmental model--671.7 +/- 40.0) ml/kg, ClB--0.35 +/- 0.02 ml/kg/min and 2.87 +/- 0.35 (for one-compartmental model--4.15 +/- 0.80) ml/kg/min, respectively.","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),[ml] / [kg],671.7,93372,DB00440,Trimethoprim
,6740937,ClB,"The biological half-life of TD--t1/2 beta for SD is 14.36 +/- 1.40 h and for TMP--2.40 +/- 0.31 (for one-compartmental model--1.92 +/- 0.26) h, Vd--429.9 +/- 16.9 ml/kg and 655.8 +/- 77.6 (for one-compartmental model--671.7 +/- 40.0) ml/kg, ClB--0.35 +/- 0.02 ml/kg/min and 2.87 +/- 0.35 (for one-compartmental model--4.15 +/- 0.80) ml/kg/min, respectively.","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),[ml] / [kg·min],0.35,93373,DB00440,Trimethoprim
,6740937,ClB,"The biological half-life of TD--t1/2 beta for SD is 14.36 +/- 1.40 h and for TMP--2.40 +/- 0.31 (for one-compartmental model--1.92 +/- 0.26) h, Vd--429.9 +/- 16.9 ml/kg and 655.8 +/- 77.6 (for one-compartmental model--671.7 +/- 40.0) ml/kg, ClB--0.35 +/- 0.02 ml/kg/min and 2.87 +/- 0.35 (for one-compartmental model--4.15 +/- 0.80) ml/kg/min, respectively.","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),[ml] / [kg·min],2.87,93374,DB00440,Trimethoprim
,6740937,ClB,"The biological half-life of TD--t1/2 beta for SD is 14.36 +/- 1.40 h and for TMP--2.40 +/- 0.31 (for one-compartmental model--1.92 +/- 0.26) h, Vd--429.9 +/- 16.9 ml/kg and 655.8 +/- 77.6 (for one-compartmental model--671.7 +/- 40.0) ml/kg, ClB--0.35 +/- 0.02 ml/kg/min and 2.87 +/- 0.35 (for one-compartmental model--4.15 +/- 0.80) ml/kg/min, respectively.","[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),[ml] / [kg·min],4.15,93375,DB00440,Trimethoprim
,6740937,withdrawal time,After intramuscular injection at the dose used a suitable withdrawal time for meat and internal organs is 5 days and for milk--2 days.,"[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),d,5,93376,DB00440,Trimethoprim
,6740937,withdrawal time,After intramuscular injection at the dose used a suitable withdrawal time for meat and internal organs is 5 days and for milk--2 days.,"[Pharmacokinetics, biological availability and residues of sulfadoxine and trimethoprim when used jointly on calves]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740937/),d,2,93377,DB00440,Trimethoprim
,883811,Peak mean serum concentrations,"Peak mean serum concentrations (+/- standard deviation) of TMP, total SMZ, and free SMZ were 9.2 +/- 2.2, 259.4 +/- 40.9, and 233.7 +/- 33.6 mug/ml, respectively.","Pharmacokinetics and tolerance of a single twelve-tablet dose of trimethoprim (960 mg)-sulfamethoxazole (4,800 mg). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/883811/),[μg] / [ml],9.2,93453,DB00440,Trimethoprim
,883811,Peak mean serum concentrations,"Peak mean serum concentrations (+/- standard deviation) of TMP, total SMZ, and free SMZ were 9.2 +/- 2.2, 259.4 +/- 40.9, and 233.7 +/- 33.6 mug/ml, respectively.","Pharmacokinetics and tolerance of a single twelve-tablet dose of trimethoprim (960 mg)-sulfamethoxazole (4,800 mg). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/883811/),[μg] / [ml],259.4,93454,DB00440,Trimethoprim
,883811,Peak mean serum concentrations,"Peak mean serum concentrations (+/- standard deviation) of TMP, total SMZ, and free SMZ were 9.2 +/- 2.2, 259.4 +/- 40.9, and 233.7 +/- 33.6 mug/ml, respectively.","Pharmacokinetics and tolerance of a single twelve-tablet dose of trimethoprim (960 mg)-sulfamethoxazole (4,800 mg). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/883811/),[μg] / [ml],233.7,93455,DB00440,Trimethoprim
,883811,Elimination half-lives,"Elimination half-lives were 16.7, 14.6, and 12.9 h, respectively.","Pharmacokinetics and tolerance of a single twelve-tablet dose of trimethoprim (960 mg)-sulfamethoxazole (4,800 mg). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/883811/),h,16.7,93456,DB00440,Trimethoprim
,883811,Elimination half-lives,"Elimination half-lives were 16.7, 14.6, and 12.9 h, respectively.","Pharmacokinetics and tolerance of a single twelve-tablet dose of trimethoprim (960 mg)-sulfamethoxazole (4,800 mg). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/883811/),h,14.6,93457,DB00440,Trimethoprim
,883811,Elimination half-lives,"Elimination half-lives were 16.7, 14.6, and 12.9 h, respectively.","Pharmacokinetics and tolerance of a single twelve-tablet dose of trimethoprim (960 mg)-sulfamethoxazole (4,800 mg). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/883811/),h,12.9,93458,DB00440,Trimethoprim
,883811,Percents recovery,"Percents recovery (+/- standard deviation) in urine were 60.6 +/- 10.6, 80.2 +/- 7.8, and 37.4 +/- 6.5%, respectively, during the 48 h after administration.","Pharmacokinetics and tolerance of a single twelve-tablet dose of trimethoprim (960 mg)-sulfamethoxazole (4,800 mg). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/883811/),%,60.6,93459,DB00440,Trimethoprim
,883811,Percents recovery,"Percents recovery (+/- standard deviation) in urine were 60.6 +/- 10.6, 80.2 +/- 7.8, and 37.4 +/- 6.5%, respectively, during the 48 h after administration.","Pharmacokinetics and tolerance of a single twelve-tablet dose of trimethoprim (960 mg)-sulfamethoxazole (4,800 mg). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/883811/),%,80.2,93460,DB00440,Trimethoprim
,883811,Percents recovery,"Percents recovery (+/- standard deviation) in urine were 60.6 +/- 10.6, 80.2 +/- 7.8, and 37.4 +/- 6.5%, respectively, during the 48 h after administration.","Pharmacokinetics and tolerance of a single twelve-tablet dose of trimethoprim (960 mg)-sulfamethoxazole (4,800 mg). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/883811/),%,37.4,93461,DB00440,Trimethoprim
,11519678,elimination half-lives,The elimination half-lives of SMX and TMP were quite similar (2-3 h); SDM had a relatively long half-life of 13 h.,Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after oral single- and multiple-dose administration to healthy pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11519678/),h,2-3,94782,DB00440,Trimethoprim
,11519678,half-life,The elimination half-lives of SMX and TMP were quite similar (2-3 h); SDM had a relatively long half-life of 13 h.,Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after oral single- and multiple-dose administration to healthy pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11519678/),h,13,94783,DB00440,Trimethoprim
,1442059,relative bioavailabilities,"Compared with A, the relative bioavailabilities of B were 0.83, 0.73 and 0.78 for TMP, SD and SMZ, respectively.",[Studies on the dissolution and bioavailability of trimethoprim-sulfadiazine-sulfamethoxazole tablets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442059/),,0.83,100166,DB00440,Trimethoprim
,1442059,relative bioavailabilities,"Compared with A, the relative bioavailabilities of B were 0.83, 0.73 and 0.78 for TMP, SD and SMZ, respectively.",[Studies on the dissolution and bioavailability of trimethoprim-sulfadiazine-sulfamethoxazole tablets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442059/),,0.73,100167,DB00440,Trimethoprim
,1442059,relative bioavailabilities,"Compared with A, the relative bioavailabilities of B were 0.83, 0.73 and 0.78 for TMP, SD and SMZ, respectively.",[Studies on the dissolution and bioavailability of trimethoprim-sulfadiazine-sulfamethoxazole tablets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442059/),,0.78,100168,DB00440,Trimethoprim
,30840200,minimum inhibitory concentration,We performed dosing simulations to target organ and tissue (skin) concentrations greater than the methicillin-resistant Staphylococcus aureus (MRSA) minimum inhibitory concentration (TMP 2 mg/L; SMX 9.5 mg/L) for at least 50% of the dosing interval.,Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30840200/),[mg] / [l],2,100656,DB00440,Trimethoprim
,30840200,minimum inhibitory concentration,We performed dosing simulations to target organ and tissue (skin) concentrations greater than the methicillin-resistant Staphylococcus aureus (MRSA) minimum inhibitory concentration (TMP 2 mg/L; SMX 9.5 mg/L) for at least 50% of the dosing interval.,Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30840200/),[mg] / [l],9.5,100657,DB00440,Trimethoprim
,27434870,MIC50,"The results showed that the MIC50 and MIC90 values for different SMZ-TMP combinations were in the ranges of 0.62-5 and 0.62-10μg/mL, respectively.",Pharmacokinetics and pharmacodynamics of sulfamethoxazole and trimethoprim in swimming crabs (Portunus trituberculatus) and in vitro antibacterial activity against Vibrio: PK/PD of SMZ-TMP in crabs and antibacterial activity against Vibrio. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27434870/),[μg] / [ml],0.62-5,100734,DB00440,Trimethoprim
,27434870,MIC90,"The results showed that the MIC50 and MIC90 values for different SMZ-TMP combinations were in the ranges of 0.62-5 and 0.62-10μg/mL, respectively.",Pharmacokinetics and pharmacodynamics of sulfamethoxazole and trimethoprim in swimming crabs (Portunus trituberculatus) and in vitro antibacterial activity against Vibrio: PK/PD of SMZ-TMP in crabs and antibacterial activity against Vibrio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27434870/),[μg] / [ml],0.62-10,100735,DB00440,Trimethoprim
,27434870,distribution of the MIC,"The distribution of the MIC values of the SMZ-TMP combination at ratios of 1:1 and 5:1 were 0.31-5 and 0.31-10μg/mL, respectively.",Pharmacokinetics and pharmacodynamics of sulfamethoxazole and trimethoprim in swimming crabs (Portunus trituberculatus) and in vitro antibacterial activity against Vibrio: PK/PD of SMZ-TMP in crabs and antibacterial activity against Vibrio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27434870/),[μg] / [ml],0.31-5,100736,DB00440,Trimethoprim
,27434870,distribution of the MIC,"The distribution of the MIC values of the SMZ-TMP combination at ratios of 1:1 and 5:1 were 0.31-5 and 0.31-10μg/mL, respectively.",Pharmacokinetics and pharmacodynamics of sulfamethoxazole and trimethoprim in swimming crabs (Portunus trituberculatus) and in vitro antibacterial activity against Vibrio: PK/PD of SMZ-TMP in crabs and antibacterial activity against Vibrio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27434870/),[μg] / [ml],0.31-10,100737,DB00440,Trimethoprim
,27434870,Cmax,"In the crabs fed SMZ-TMP at a ratio of 5:1, the CmaxSMZ/TMP values in the hemolymph, hepatopancreas, muscle and gill were 104:1.",Pharmacokinetics and pharmacodynamics of sulfamethoxazole and trimethoprim in swimming crabs (Portunus trituberculatus) and in vitro antibacterial activity against Vibrio: PK/PD of SMZ-TMP in crabs and antibacterial activity against Vibrio. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27434870/),,104,100738,DB00440,Trimethoprim
,7707489,peak plasma TMP concentrations,"Mean peak plasma TMP concentrations (+/- SD) were 1.72 +/- 0.36 micrograms/ml, 1.42 +/- 0.37 micrograms/ml and 1.31 +/- 0.36 micrograms/ml, and mean peak plasma SDZ concentrations 12.11 +/- 4.55 micrograms/ml, 12.72 +/- 3.47 micrograms/ml and 15.45 +/- 4.74 micrograms/ml for preparations 1, 2 and 3.",A comparative study of the pharmacokinetics of intravenous and oral trimethoprim/sulfadiazine formulations in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707489/),[μg] / [ml],1.72,105273,DB00440,Trimethoprim
,7707489,peak plasma TMP concentrations,"Mean peak plasma TMP concentrations (+/- SD) were 1.72 +/- 0.36 micrograms/ml, 1.42 +/- 0.37 micrograms/ml and 1.31 +/- 0.36 micrograms/ml, and mean peak plasma SDZ concentrations 12.11 +/- 4.55 micrograms/ml, 12.72 +/- 3.47 micrograms/ml and 15.45 +/- 4.74 micrograms/ml for preparations 1, 2 and 3.",A comparative study of the pharmacokinetics of intravenous and oral trimethoprim/sulfadiazine formulations in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707489/),[μg] / [ml],1.42,105274,DB00440,Trimethoprim
,7707489,peak plasma TMP concentrations,"Mean peak plasma TMP concentrations (+/- SD) were 1.72 +/- 0.36 micrograms/ml, 1.42 +/- 0.37 micrograms/ml and 1.31 +/- 0.36 micrograms/ml, and mean peak plasma SDZ concentrations 12.11 +/- 4.55 micrograms/ml, 12.72 +/- 3.47 micrograms/ml and 15.45 +/- 4.74 micrograms/ml for preparations 1, 2 and 3.",A comparative study of the pharmacokinetics of intravenous and oral trimethoprim/sulfadiazine formulations in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707489/),[μg] / [ml],1.31,105275,DB00440,Trimethoprim
,7707489,peak plasma SDZ concentrations,"Mean peak plasma TMP concentrations (+/- SD) were 1.72 +/- 0.36 micrograms/ml, 1.42 +/- 0.37 micrograms/ml and 1.31 +/- 0.36 micrograms/ml, and mean peak plasma SDZ concentrations 12.11 +/- 4.55 micrograms/ml, 12.72 +/- 3.47 micrograms/ml and 15.45 +/- 4.74 micrograms/ml for preparations 1, 2 and 3.",A comparative study of the pharmacokinetics of intravenous and oral trimethoprim/sulfadiazine formulations in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707489/),[μg] / [ml],12.11,105276,DB00440,Trimethoprim
,7707489,peak plasma SDZ concentrations,"Mean peak plasma TMP concentrations (+/- SD) were 1.72 +/- 0.36 micrograms/ml, 1.42 +/- 0.37 micrograms/ml and 1.31 +/- 0.36 micrograms/ml, and mean peak plasma SDZ concentrations 12.11 +/- 4.55 micrograms/ml, 12.72 +/- 3.47 micrograms/ml and 15.45 +/- 4.74 micrograms/ml for preparations 1, 2 and 3.",A comparative study of the pharmacokinetics of intravenous and oral trimethoprim/sulfadiazine formulations in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707489/),[μg] / [ml],12.72,105277,DB00440,Trimethoprim
,7707489,peak plasma SDZ concentrations,"Mean peak plasma TMP concentrations (+/- SD) were 1.72 +/- 0.36 micrograms/ml, 1.42 +/- 0.37 micrograms/ml and 1.31 +/- 0.36 micrograms/ml, and mean peak plasma SDZ concentrations 12.11 +/- 4.55 micrograms/ml, 12.72 +/- 3.47 micrograms/ml and 15.45 +/- 4.74 micrograms/ml for preparations 1, 2 and 3.",A comparative study of the pharmacokinetics of intravenous and oral trimethoprim/sulfadiazine formulations in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707489/),[μg] / [ml],15.45,105278,DB00440,Trimethoprim
,7707489,bioavailability,"The bioavailability of TMP was 67.0 +/- 20.3%, 57.7 +/- 21.6% and 60.9 +/- 18.9% and of SDZ 57.6 +/- 14.8%, 59.3 +/- 19.5% and 65.9 +/- 5.8% for SDZ for 1, 2 and 3, respectively.",A comparative study of the pharmacokinetics of intravenous and oral trimethoprim/sulfadiazine formulations in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707489/),%,67.0,105279,DB00440,Trimethoprim
,7707489,bioavailability,"The bioavailability of TMP was 67.0 +/- 20.3%, 57.7 +/- 21.6% and 60.9 +/- 18.9% and of SDZ 57.6 +/- 14.8%, 59.3 +/- 19.5% and 65.9 +/- 5.8% for SDZ for 1, 2 and 3, respectively.",A comparative study of the pharmacokinetics of intravenous and oral trimethoprim/sulfadiazine formulations in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707489/),%,57.7,105280,DB00440,Trimethoprim
,7707489,bioavailability,"The bioavailability of TMP was 67.0 +/- 20.3%, 57.7 +/- 21.6% and 60.9 +/- 18.9% and of SDZ 57.6 +/- 14.8%, 59.3 +/- 19.5% and 65.9 +/- 5.8% for SDZ for 1, 2 and 3, respectively.",A comparative study of the pharmacokinetics of intravenous and oral trimethoprim/sulfadiazine formulations in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707489/),%,60.9,105281,DB00440,Trimethoprim
,7707489,bioavailability,"The bioavailability of TMP was 67.0 +/- 20.3%, 57.7 +/- 21.6% and 60.9 +/- 18.9% and of SDZ 57.6 +/- 14.8%, 59.3 +/- 19.5% and 65.9 +/- 5.8% for SDZ for 1, 2 and 3, respectively.",A comparative study of the pharmacokinetics of intravenous and oral trimethoprim/sulfadiazine formulations in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707489/),%,57.6,105282,DB00440,Trimethoprim
,7707489,bioavailability,"The bioavailability of TMP was 67.0 +/- 20.3%, 57.7 +/- 21.6% and 60.9 +/- 18.9% and of SDZ 57.6 +/- 14.8%, 59.3 +/- 19.5% and 65.9 +/- 5.8% for SDZ for 1, 2 and 3, respectively.",A comparative study of the pharmacokinetics of intravenous and oral trimethoprim/sulfadiazine formulations in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707489/),%,59.3,105283,DB00440,Trimethoprim
,7707489,bioavailability,"The bioavailability of TMP was 67.0 +/- 20.3%, 57.7 +/- 21.6% and 60.9 +/- 18.9% and of SDZ 57.6 +/- 14.8%, 59.3 +/- 19.5% and 65.9 +/- 5.8% for SDZ for 1, 2 and 3, respectively.",A comparative study of the pharmacokinetics of intravenous and oral trimethoprim/sulfadiazine formulations in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707489/),%,65.9,105284,DB00440,Trimethoprim
,10543733,half-life,"For the entire population, the median half-life was 22.2 h (range, 7.1 to 40.3 h), the median oral clearance was 0.0365 liter/kg/h (range, 0.0104 to 0.1021 liter/kg/h), and the median oral apparent volume of distribution was 1.13 liters/kg (range, 0.50 to 2.32 liters/kg).",Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543733/),h,22.2,106701,DB00440,Trimethoprim
,10543733,oral clearance,"For the entire population, the median half-life was 22.2 h (range, 7.1 to 40.3 h), the median oral clearance was 0.0365 liter/kg/h (range, 0.0104 to 0.1021 liter/kg/h), and the median oral apparent volume of distribution was 1.13 liters/kg (range, 0.50 to 2.32 liters/kg).",Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543733/),[l] / [h·kg],0.0365,106702,DB00440,Trimethoprim
,10543733,oral apparent volume of distribution,"For the entire population, the median half-life was 22.2 h (range, 7.1 to 40.3 h), the median oral clearance was 0.0365 liter/kg/h (range, 0.0104 to 0.1021 liter/kg/h), and the median oral apparent volume of distribution was 1.13 liters/kg (range, 0.50 to 2.32 liters/kg).",Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543733/),[l] / [kg],1.13,106703,DB00440,Trimethoprim
,10543733,oral clearance,The median dapsone oral clearance was significantly increased in those infants less than 2 years of age compared to the oral clearance in those over 2 years of age (0.0484 versus 0.0278 liter/kg/h; P = 0.011).,Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543733/),[l] / [h·kg],0.0484,106704,DB00440,Trimethoprim
,10543733,oral clearance,The median dapsone oral clearance was significantly increased in those infants less than 2 years of age compared to the oral clearance in those over 2 years of age (0.0484 versus 0.0278 liter/kg/h; P = 0.011).,Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543733/),[l] / [h·kg],0.0278,106705,DB00440,Trimethoprim
,34359213,minimum inhibitory concentration (MIC),"According to the hypothesis, the drug could be administered without adverse effects and the synovial concentrations would remain above the minimum inhibitory concentration (MIC) for trimethoprim-sulphadiazine (0.5 and 9.5 µg/mL) for 24 h.",Synovial Concentration of Trimethoprim-Sulphadiazine Following Regional Limb Perfusion in Standing Horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34359213/),[μg] / [ml],0.5,110778,DB00440,Trimethoprim
,34359213,minimum inhibitory concentration (MIC),"According to the hypothesis, the drug could be administered without adverse effects and the synovial concentrations would remain above the minimum inhibitory concentration (MIC) for trimethoprim-sulphadiazine (0.5 and 9.5 µg/mL) for 24 h.",Synovial Concentration of Trimethoprim-Sulphadiazine Following Regional Limb Perfusion in Standing Horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34359213/),[μg] / [ml],9.5,110779,DB00440,Trimethoprim
,34359213,Cmax (peak drug concentration),The Cmax (peak drug concentration) values were 36 ± 31.1 and 275.3 ± 214.4 µg/mL (TMP and SDZ).,Synovial Concentration of Trimethoprim-Sulphadiazine Following Regional Limb Perfusion in Standing Horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34359213/),[μg] / [ml],36,110780,DB00440,Trimethoprim
,34359213,Cmax (peak drug concentration),The Cmax (peak drug concentration) values were 36 ± 31.1 and 275.3 ± 214.4 µg/mL (TMP and SDZ).,Synovial Concentration of Trimethoprim-Sulphadiazine Following Regional Limb Perfusion in Standing Horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34359213/),[μg] / [ml],275.3,110781,DB00440,Trimethoprim
,34359213,tmax (time to reach Cmax),The respective tmax (time to reach Cmax) values were 20 ± 7.8 and 26.4 ± 7.2 min.,Synovial Concentration of Trimethoprim-Sulphadiazine Following Regional Limb Perfusion in Standing Horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34359213/),min,20,110782,DB00440,Trimethoprim
,34359213,tmax (time to reach Cmax),The respective tmax (time to reach Cmax) values were 20 ± 7.8 and 26.4 ± 7.2 min.,Synovial Concentration of Trimethoprim-Sulphadiazine Following Regional Limb Perfusion in Standing Horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34359213/),min,26.4,110783,DB00440,Trimethoprim
,26669806,absorption half-life (t1/2α ),"The absorption half-life (t1/2α ), elimination half-life (t1/2β ), volume of distribution (Vd /F), and the total body clearance (ClB /F) for SDZ and TMP were 4.3 ± 1.7 to 6.3 ± 1.8 h and 2.4 ± 1.0 to 3.9 ± 0.9 h, 25.9 ± 4.5 to 53.0 ± 5.6 h and 11.8 ± 3.5 to 17.1 ± 3.4 h, 2.34 ± 0.78 to 3.67 ± 0.99 L/kg and 0.39 ± 0.01 to 1.33 ± 0.57 L/kg, and 0.03 ± 0.01 to 0.06 ± 0.01 L/kg·h and 0.02 ± 0.01 to 0.05 ± 0.01 L/kg·h, respectively, after the single dose.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,4.3,114386,DB00440,Trimethoprim
,26669806,elimination half-life (t1/2β ),"The absorption half-life (t1/2α ), elimination half-life (t1/2β ), volume of distribution (Vd /F), and the total body clearance (ClB /F) for SDZ and TMP were 4.3 ± 1.7 to 6.3 ± 1.8 h and 2.4 ± 1.0 to 3.9 ± 0.9 h, 25.9 ± 4.5 to 53.0 ± 5.6 h and 11.8 ± 3.5 to 17.1 ± 3.4 h, 2.34 ± 0.78 to 3.67 ± 0.99 L/kg and 0.39 ± 0.01 to 1.33 ± 0.57 L/kg, and 0.03 ± 0.01 to 0.06 ± 0.01 L/kg·h and 0.02 ± 0.01 to 0.05 ± 0.01 L/kg·h, respectively, after the single dose.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,6.3,114387,DB00440,Trimethoprim
,26669806,elimination half-life (t1/2β ),"The absorption half-life (t1/2α ), elimination half-life (t1/2β ), volume of distribution (Vd /F), and the total body clearance (ClB /F) for SDZ and TMP were 4.3 ± 1.7 to 6.3 ± 1.8 h and 2.4 ± 1.0 to 3.9 ± 0.9 h, 25.9 ± 4.5 to 53.0 ± 5.6 h and 11.8 ± 3.5 to 17.1 ± 3.4 h, 2.34 ± 0.78 to 3.67 ± 0.99 L/kg and 0.39 ± 0.01 to 1.33 ± 0.57 L/kg, and 0.03 ± 0.01 to 0.06 ± 0.01 L/kg·h and 0.02 ± 0.01 to 0.05 ± 0.01 L/kg·h, respectively, after the single dose.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,2.4,114388,DB00440,Trimethoprim
,26669806,elimination half-life (t1/2β ),"The absorption half-life (t1/2α ), elimination half-life (t1/2β ), volume of distribution (Vd /F), and the total body clearance (ClB /F) for SDZ and TMP were 4.3 ± 1.7 to 6.3 ± 1.8 h and 2.4 ± 1.0 to 3.9 ± 0.9 h, 25.9 ± 4.5 to 53.0 ± 5.6 h and 11.8 ± 3.5 to 17.1 ± 3.4 h, 2.34 ± 0.78 to 3.67 ± 0.99 L/kg and 0.39 ± 0.01 to 1.33 ± 0.57 L/kg, and 0.03 ± 0.01 to 0.06 ± 0.01 L/kg·h and 0.02 ± 0.01 to 0.05 ± 0.01 L/kg·h, respectively, after the single dose.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,25.9,114389,DB00440,Trimethoprim
,26669806,elimination half-life (t1/2β ),"The absorption half-life (t1/2α ), elimination half-life (t1/2β ), volume of distribution (Vd /F), and the total body clearance (ClB /F) for SDZ and TMP were 4.3 ± 1.7 to 6.3 ± 1.8 h and 2.4 ± 1.0 to 3.9 ± 0.9 h, 25.9 ± 4.5 to 53.0 ± 5.6 h and 11.8 ± 3.5 to 17.1 ± 3.4 h, 2.34 ± 0.78 to 3.67 ± 0.99 L/kg and 0.39 ± 0.01 to 1.33 ± 0.57 L/kg, and 0.03 ± 0.01 to 0.06 ± 0.01 L/kg·h and 0.02 ± 0.01 to 0.05 ± 0.01 L/kg·h, respectively, after the single dose.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,53.0,114390,DB00440,Trimethoprim
,26669806,volume of distribution (Vd /F),"The absorption half-life (t1/2α ), elimination half-life (t1/2β ), volume of distribution (Vd /F), and the total body clearance (ClB /F) for SDZ and TMP were 4.3 ± 1.7 to 6.3 ± 1.8 h and 2.4 ± 1.0 to 3.9 ± 0.9 h, 25.9 ± 4.5 to 53.0 ± 5.6 h and 11.8 ± 3.5 to 17.1 ± 3.4 h, 2.34 ± 0.78 to 3.67 ± 0.99 L/kg and 0.39 ± 0.01 to 1.33 ± 0.57 L/kg, and 0.03 ± 0.01 to 0.06 ± 0.01 L/kg·h and 0.02 ± 0.01 to 0.05 ± 0.01 L/kg·h, respectively, after the single dose.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,6.3,114391,DB00440,Trimethoprim
,26669806,volume of distribution (Vd /F),"The absorption half-life (t1/2α ), elimination half-life (t1/2β ), volume of distribution (Vd /F), and the total body clearance (ClB /F) for SDZ and TMP were 4.3 ± 1.7 to 6.3 ± 1.8 h and 2.4 ± 1.0 to 3.9 ± 0.9 h, 25.9 ± 4.5 to 53.0 ± 5.6 h and 11.8 ± 3.5 to 17.1 ± 3.4 h, 2.34 ± 0.78 to 3.67 ± 0.99 L/kg and 0.39 ± 0.01 to 1.33 ± 0.57 L/kg, and 0.03 ± 0.01 to 0.06 ± 0.01 L/kg·h and 0.02 ± 0.01 to 0.05 ± 0.01 L/kg·h, respectively, after the single dose.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,2.4,114392,DB00440,Trimethoprim
,26669806,volume of distribution (Vd /F),"The absorption half-life (t1/2α ), elimination half-life (t1/2β ), volume of distribution (Vd /F), and the total body clearance (ClB /F) for SDZ and TMP were 4.3 ± 1.7 to 6.3 ± 1.8 h and 2.4 ± 1.0 to 3.9 ± 0.9 h, 25.9 ± 4.5 to 53.0 ± 5.6 h and 11.8 ± 3.5 to 17.1 ± 3.4 h, 2.34 ± 0.78 to 3.67 ± 0.99 L/kg and 0.39 ± 0.01 to 1.33 ± 0.57 L/kg, and 0.03 ± 0.01 to 0.06 ± 0.01 L/kg·h and 0.02 ± 0.01 to 0.05 ± 0.01 L/kg·h, respectively, after the single dose.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,25.9,114393,DB00440,Trimethoprim
,26669806,volume of distribution (Vd /F),"The absorption half-life (t1/2α ), elimination half-life (t1/2β ), volume of distribution (Vd /F), and the total body clearance (ClB /F) for SDZ and TMP were 4.3 ± 1.7 to 6.3 ± 1.8 h and 2.4 ± 1.0 to 3.9 ± 0.9 h, 25.9 ± 4.5 to 53.0 ± 5.6 h and 11.8 ± 3.5 to 17.1 ± 3.4 h, 2.34 ± 0.78 to 3.67 ± 0.99 L/kg and 0.39 ± 0.01 to 1.33 ± 0.57 L/kg, and 0.03 ± 0.01 to 0.06 ± 0.01 L/kg·h and 0.02 ± 0.01 to 0.05 ± 0.01 L/kg·h, respectively, after the single dose.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,53.0,114394,DB00440,Trimethoprim
,26669806,total body clearance (ClB /F),"The absorption half-life (t1/2α ), elimination half-life (t1/2β ), volume of distribution (Vd /F), and the total body clearance (ClB /F) for SDZ and TMP were 4.3 ± 1.7 to 6.3 ± 1.8 h and 2.4 ± 1.0 to 3.9 ± 0.9 h, 25.9 ± 4.5 to 53.0 ± 5.6 h and 11.8 ± 3.5 to 17.1 ± 3.4 h, 2.34 ± 0.78 to 3.67 ± 0.99 L/kg and 0.39 ± 0.01 to 1.33 ± 0.57 L/kg, and 0.03 ± 0.01 to 0.06 ± 0.01 L/kg·h and 0.02 ± 0.01 to 0.05 ± 0.01 L/kg·h, respectively, after the single dose.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,11.8,114395,DB00440,Trimethoprim
,26669806,total body clearance (ClB /F),"The absorption half-life (t1/2α ), elimination half-life (t1/2β ), volume of distribution (Vd /F), and the total body clearance (ClB /F) for SDZ and TMP were 4.3 ± 1.7 to 6.3 ± 1.8 h and 2.4 ± 1.0 to 3.9 ± 0.9 h, 25.9 ± 4.5 to 53.0 ± 5.6 h and 11.8 ± 3.5 to 17.1 ± 3.4 h, 2.34 ± 0.78 to 3.67 ± 0.99 L/kg and 0.39 ± 0.01 to 1.33 ± 0.57 L/kg, and 0.03 ± 0.01 to 0.06 ± 0.01 L/kg·h and 0.02 ± 0.01 to 0.05 ± 0.01 L/kg·h, respectively, after the single dose.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,17.1,114396,DB00440,Trimethoprim
,26669806,total body clearance (ClB /F),"The absorption half-life (t1/2α ), elimination half-life (t1/2β ), volume of distribution (Vd /F), and the total body clearance (ClB /F) for SDZ and TMP were 4.3 ± 1.7 to 6.3 ± 1.8 h and 2.4 ± 1.0 to 3.9 ± 0.9 h, 25.9 ± 4.5 to 53.0 ± 5.6 h and 11.8 ± 3.5 to 17.1 ± 3.4 h, 2.34 ± 0.78 to 3.67 ± 0.99 L/kg and 0.39 ± 0.01 to 1.33 ± 0.57 L/kg, and 0.03 ± 0.01 to 0.06 ± 0.01 L/kg·h and 0.02 ± 0.01 to 0.05 ± 0.01 L/kg·h, respectively, after the single dose.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),[l] / [kg],2.34,114397,DB00440,Trimethoprim
,26669806,total body clearance (ClB /F),"The absorption half-life (t1/2α ), elimination half-life (t1/2β ), volume of distribution (Vd /F), and the total body clearance (ClB /F) for SDZ and TMP were 4.3 ± 1.7 to 6.3 ± 1.8 h and 2.4 ± 1.0 to 3.9 ± 0.9 h, 25.9 ± 4.5 to 53.0 ± 5.6 h and 11.8 ± 3.5 to 17.1 ± 3.4 h, 2.34 ± 0.78 to 3.67 ± 0.99 L/kg and 0.39 ± 0.01 to 1.33 ± 0.57 L/kg, and 0.03 ± 0.01 to 0.06 ± 0.01 L/kg·h and 0.02 ± 0.01 to 0.05 ± 0.01 L/kg·h, respectively, after the single dose.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),[l] / [kg],3.67,114398,DB00440,Trimethoprim
,26669806,total body clearance (ClB /F),"The absorption half-life (t1/2α ), elimination half-life (t1/2β ), volume of distribution (Vd /F), and the total body clearance (ClB /F) for SDZ and TMP were 4.3 ± 1.7 to 6.3 ± 1.8 h and 2.4 ± 1.0 to 3.9 ± 0.9 h, 25.9 ± 4.5 to 53.0 ± 5.6 h and 11.8 ± 3.5 to 17.1 ± 3.4 h, 2.34 ± 0.78 to 3.67 ± 0.99 L/kg and 0.39 ± 0.01 to 1.33 ± 0.57 L/kg, and 0.03 ± 0.01 to 0.06 ± 0.01 L/kg·h and 0.02 ± 0.01 to 0.05 ± 0.01 L/kg·h, respectively, after the single dose.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),[l] / [kg],0.39,114399,DB00440,Trimethoprim
,26669806,total body clearance (ClB /F),"The absorption half-life (t1/2α ), elimination half-life (t1/2β ), volume of distribution (Vd /F), and the total body clearance (ClB /F) for SDZ and TMP were 4.3 ± 1.7 to 6.3 ± 1.8 h and 2.4 ± 1.0 to 3.9 ± 0.9 h, 25.9 ± 4.5 to 53.0 ± 5.6 h and 11.8 ± 3.5 to 17.1 ± 3.4 h, 2.34 ± 0.78 to 3.67 ± 0.99 L/kg and 0.39 ± 0.01 to 1.33 ± 0.57 L/kg, and 0.03 ± 0.01 to 0.06 ± 0.01 L/kg·h and 0.02 ± 0.01 to 0.05 ± 0.01 L/kg·h, respectively, after the single dose.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),[l] / [kg],1.33,114400,DB00440,Trimethoprim
,26669806,total body clearance (ClB /F),"The absorption half-life (t1/2α ), elimination half-life (t1/2β ), volume of distribution (Vd /F), and the total body clearance (ClB /F) for SDZ and TMP were 4.3 ± 1.7 to 6.3 ± 1.8 h and 2.4 ± 1.0 to 3.9 ± 0.9 h, 25.9 ± 4.5 to 53.0 ± 5.6 h and 11.8 ± 3.5 to 17.1 ± 3.4 h, 2.34 ± 0.78 to 3.67 ± 0.99 L/kg and 0.39 ± 0.01 to 1.33 ± 0.57 L/kg, and 0.03 ± 0.01 to 0.06 ± 0.01 L/kg·h and 0.02 ± 0.01 to 0.05 ± 0.01 L/kg·h, respectively, after the single dose.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),[l] / [h·kg],0.03,114401,DB00440,Trimethoprim
,26669806,total body clearance (ClB /F),"The absorption half-life (t1/2α ), elimination half-life (t1/2β ), volume of distribution (Vd /F), and the total body clearance (ClB /F) for SDZ and TMP were 4.3 ± 1.7 to 6.3 ± 1.8 h and 2.4 ± 1.0 to 3.9 ± 0.9 h, 25.9 ± 4.5 to 53.0 ± 5.6 h and 11.8 ± 3.5 to 17.1 ± 3.4 h, 2.34 ± 0.78 to 3.67 ± 0.99 L/kg and 0.39 ± 0.01 to 1.33 ± 0.57 L/kg, and 0.03 ± 0.01 to 0.06 ± 0.01 L/kg·h and 0.02 ± 0.01 to 0.05 ± 0.01 L/kg·h, respectively, after the single dose.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),[l] / [h·kg],0.06,114402,DB00440,Trimethoprim
,26669806,total body clearance (ClB /F),"The absorption half-life (t1/2α ), elimination half-life (t1/2β ), volume of distribution (Vd /F), and the total body clearance (ClB /F) for SDZ and TMP were 4.3 ± 1.7 to 6.3 ± 1.8 h and 2.4 ± 1.0 to 3.9 ± 0.9 h, 25.9 ± 4.5 to 53.0 ± 5.6 h and 11.8 ± 3.5 to 17.1 ± 3.4 h, 2.34 ± 0.78 to 3.67 ± 0.99 L/kg and 0.39 ± 0.01 to 1.33 ± 0.57 L/kg, and 0.03 ± 0.01 to 0.06 ± 0.01 L/kg·h and 0.02 ± 0.01 to 0.05 ± 0.01 L/kg·h, respectively, after the single dose.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),[l] / [h·kg],0.02,114403,DB00440,Trimethoprim
,26669806,elimination half-life (t1/2β ),"The elimination half-life (t1/2β ) and mean residue time (MRT) for SDZ and TMP were 68.8 ± 7.8 to 139.8 ± 12.3 h and 34.0 ± 5.5 to 56.1 ± 6.8 h, and 99.3 ± 6.1 to 201.7 ± 11.5 h and 49.1 ± 3.5 to 81.0 ± 5.1 h, respectively, after the multiple-dose administration.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,68.8,114404,DB00440,Trimethoprim
,26669806,elimination half-life (t1/2β ),"The elimination half-life (t1/2β ) and mean residue time (MRT) for SDZ and TMP were 68.8 ± 7.8 to 139.8 ± 12.3 h and 34.0 ± 5.5 to 56.1 ± 6.8 h, and 99.3 ± 6.1 to 201.7 ± 11.5 h and 49.1 ± 3.5 to 81.0 ± 5.1 h, respectively, after the multiple-dose administration.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,139.8,114405,DB00440,Trimethoprim
,26669806,elimination half-life (t1/2β ),"The elimination half-life (t1/2β ) and mean residue time (MRT) for SDZ and TMP were 68.8 ± 7.8 to 139.8 ± 12.3 h and 34.0 ± 5.5 to 56.1 ± 6.8 h, and 99.3 ± 6.1 to 201.7 ± 11.5 h and 49.1 ± 3.5 to 81.0 ± 5.1 h, respectively, after the multiple-dose administration.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,99.3,114406,DB00440,Trimethoprim
,26669806,mean residue time (MRT),"The elimination half-life (t1/2β ) and mean residue time (MRT) for SDZ and TMP were 68.8 ± 7.8 to 139.8 ± 12.3 h and 34.0 ± 5.5 to 56.1 ± 6.8 h, and 99.3 ± 6.1 to 201.7 ± 11.5 h and 49.1 ± 3.5 to 81.0 ± 5.1 h, respectively, after the multiple-dose administration.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,139.8,114407,DB00440,Trimethoprim
,26669806,mean residue time (MRT),"The elimination half-life (t1/2β ) and mean residue time (MRT) for SDZ and TMP were 68.8 ± 7.8 to 139.8 ± 12.3 h and 34.0 ± 5.5 to 56.1 ± 6.8 h, and 99.3 ± 6.1 to 201.7 ± 11.5 h and 49.1 ± 3.5 to 81.0 ± 5.1 h, respectively, after the multiple-dose administration.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,34.0,114408,DB00440,Trimethoprim
,26669806,mean residue time (MRT),"The elimination half-life (t1/2β ) and mean residue time (MRT) for SDZ and TMP were 68.8 ± 7.8 to 139.8 ± 12.3 h and 34.0 ± 5.5 to 56.1 ± 6.8 h, and 99.3 ± 6.1 to 201.7 ± 11.5 h and 49.1 ± 3.5 to 81.0 ± 5.1 h, respectively, after the multiple-dose administration.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,56.1,114409,DB00440,Trimethoprim
,26669806,mean residue time (MRT),"The elimination half-life (t1/2β ) and mean residue time (MRT) for SDZ and TMP were 68.8 ± 7.8 to 139.8 ± 12.3 h and 34.0 ± 5.5 to 56.1 ± 6.8 h, and 99.3 ± 6.1 to 201.7 ± 11.5 h and 49.1 ± 3.5 to 81.0 ± 5.1 h, respectively, after the multiple-dose administration.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,201.7,114410,DB00440,Trimethoprim
,26669806,mean residue time (MRT),"The elimination half-life (t1/2β ) and mean residue time (MRT) for SDZ and TMP were 68.8 ± 7.8 to 139.8 ± 12.3 h and 34.0 ± 5.5 to 56.1 ± 6.8 h, and 99.3 ± 6.1 to 201.7 ± 11.5 h and 49.1 ± 3.5 to 81.0 ± 5.1 h, respectively, after the multiple-dose administration.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,49.1,114411,DB00440,Trimethoprim
,26669806,mean residue time (MRT),"The elimination half-life (t1/2β ) and mean residue time (MRT) for SDZ and TMP were 68.8 ± 7.8 to 139.8 ± 12.3 h and 34.0 ± 5.5 to 56.1 ± 6.8 h, and 99.3 ± 6.1 to 201.7 ± 11.5 h and 49.1 ± 3.5 to 81.0 ± 5.1 h, respectively, after the multiple-dose administration.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),h,81.0,114412,DB00440,Trimethoprim
<,26669806,withdrawal time,"The withdrawal time for this oral SDZ/TMP formulation (according to the accepted guidelines in Europe for maximum residue limits, <0.1 mg/kg of tissues for sulfonamides, and <0.05 mg/kg for TMP) should not be <36 days for fish.",A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669806/),d,36,114413,DB00440,Trimethoprim
,1196210,clearance rate,"The initial average creatinine clearance rate of this group was 99-0 ml/min and the final one was 110-7 ml/min (P = 0-15, n.s.).",Effect of long-term co-trimoxazole therapy on renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1196210/),,99,117427,DB00440,Trimethoprim
,1196210,clearance rate,"The initial average creatinine clearance rate of this group was 99-0 ml/min and the final one was 110-7 ml/min (P = 0-15, n.s.).",Effect of long-term co-trimoxazole therapy on renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1196210/),,110,117428,DB00440,Trimethoprim
exceeded,23100498,free AUC0-24/MIC,The free AUC0-24/MIC of sulfamethoxazole exceeded 25 in only one patient.,Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100498/),,25,120102,DB00440,Trimethoprim
,6610881,minimum therapeutic serum concentrations,Independend on the kidney function the minimum therapeutic serum concentrations of 1 microgram/ml at trimethoprime and of 20 micrograms/ml at the sulphonamides were reached during the first hours after medicament application.,[Pharmacokinetics of the sulfonamide-trimethoprim combinations Berlocombin and Sulprim in patients with various degrees of kidney dysfunction]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6610881/),[μg] / [ml],1,123370,DB00440,Trimethoprim
,6610881,minimum therapeutic serum concentrations,Independend on the kidney function the minimum therapeutic serum concentrations of 1 microgram/ml at trimethoprime and of 20 micrograms/ml at the sulphonamides were reached during the first hours after medicament application.,[Pharmacokinetics of the sulfonamide-trimethoprim combinations Berlocombin and Sulprim in patients with various degrees of kidney dysfunction]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6610881/),[μg] / [ml],20,123371,DB00440,Trimethoprim
,7752306,volume of distribution at steady-state (Vd(ss)),"Following intravenous administration, the volume of distribution at steady-state (Vd(ss)) was significantly larger for TMP (1.51 +/- 0.25 L/kg than for SCP (0.26 +/- 0.05 L/kg.","Pharmacokinetics of trimethoprim/sulphachlorpyridazine in horses after oral, nasogastric and intravenous administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752306/),[l] / [kg],1.51,123988,DB00440,Trimethoprim
,7752306,volume of distribution at steady-state (Vd(ss)),"Following intravenous administration, the volume of distribution at steady-state (Vd(ss)) was significantly larger for TMP (1.51 +/- 0.25 L/kg than for SCP (0.26 +/- 0.05 L/kg.","Pharmacokinetics of trimethoprim/sulphachlorpyridazine in horses after oral, nasogastric and intravenous administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752306/),[l] / [kg],0.26,123989,DB00440,Trimethoprim
,7752306,clearance,The clearance was 7.73 +/- 2.26 mL/min.kg for TMP and 2.64 +/- 0.48 mL/min.kg for SCP.,"Pharmacokinetics of trimethoprim/sulphachlorpyridazine in horses after oral, nasogastric and intravenous administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752306/),[ml] / [kg·min],7.73,123990,DB00440,Trimethoprim
,7752306,clearance,The clearance was 7.73 +/- 2.26 mL/min.kg for TMP and 2.64 +/- 0.48 mL/min.kg for SCP.,"Pharmacokinetics of trimethoprim/sulphachlorpyridazine in horses after oral, nasogastric and intravenous administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752306/),[ml] / [kg·min],2.64,123991,DB00440,Trimethoprim
,7752306,Fct,"For both TMP and SCP, mean peak plasma concentrations (Cmax) and the bioavailabilities (F) were reduced significantly when the drugs were mixed with concentrate (ct) as compared with those after nasogastric administration (ngt) (Fct = 44.3 +/- 10.7% vs. Fngt = 68.3 +/- 12.5% for TMP; Fct = 46.3 +/- 8.9% vs. Fngt = 67.3 +/- 13.7% for SCP).","Pharmacokinetics of trimethoprim/sulphachlorpyridazine in horses after oral, nasogastric and intravenous administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752306/),%,44.3,123992,DB00440,Trimethoprim
,7752306,Fngt,"For both TMP and SCP, mean peak plasma concentrations (Cmax) and the bioavailabilities (F) were reduced significantly when the drugs were mixed with concentrate (ct) as compared with those after nasogastric administration (ngt) (Fct = 44.3 +/- 10.7% vs. Fngt = 68.3 +/- 12.5% for TMP; Fct = 46.3 +/- 8.9% vs. Fngt = 67.3 +/- 13.7% for SCP).","Pharmacokinetics of trimethoprim/sulphachlorpyridazine in horses after oral, nasogastric and intravenous administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752306/),%,68.3,123993,DB00440,Trimethoprim
,7752306,Fct,"For both TMP and SCP, mean peak plasma concentrations (Cmax) and the bioavailabilities (F) were reduced significantly when the drugs were mixed with concentrate (ct) as compared with those after nasogastric administration (ngt) (Fct = 44.3 +/- 10.7% vs. Fngt = 68.3 +/- 12.5% for TMP; Fct = 46.3 +/- 8.9% vs. Fngt = 67.3 +/- 13.7% for SCP).","Pharmacokinetics of trimethoprim/sulphachlorpyridazine in horses after oral, nasogastric and intravenous administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752306/),%,46.3,123994,DB00440,Trimethoprim
,7752306,Fngt,"For both TMP and SCP, mean peak plasma concentrations (Cmax) and the bioavailabilities (F) were reduced significantly when the drugs were mixed with concentrate (ct) as compared with those after nasogastric administration (ngt) (Fct = 44.3 +/- 10.7% vs. Fngt = 68.3 +/- 12.5% for TMP; Fct = 46.3 +/- 8.9% vs. Fngt = 67.3 +/- 13.7% for SCP).","Pharmacokinetics of trimethoprim/sulphachlorpyridazine in horses after oral, nasogastric and intravenous administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752306/),%,67.3,123995,DB00440,Trimethoprim
,27423008,relative bioavailability,"The relative bioavailability of N1AS to sulfisoxazole was about two, indicating that a half-dose of N1AS would be equivalent to a dose of sulfisoxazole to achieve the same systemic exposure to sulfisoxazole.","Simultaneous determination of N(1)-acetyl sulfisoxazole and its metabolites, and relative bioavailability compare to sulfisoxazole in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27423008/),,two,124341,DB00440,Trimethoprim
,8195844,serum Cmax,"With a single oral dose of 400 mg (Group I) a computed serum Cmax of 2.9 +/- 0.6 mg/l was observed 5.6h after administration, with a elimination half-life (t1/2 beta) of 32.3 +/- 4.1 h.",Pharmacokinetics and blister fluid penetration of brodimoprim in adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195844/),[mg] / [l],2.9,126657,DB00440,Trimethoprim
,8195844,elimination half-life (t1/2 beta),"With a single oral dose of 400 mg (Group I) a computed serum Cmax of 2.9 +/- 0.6 mg/l was observed 5.6h after administration, with a elimination half-life (t1/2 beta) of 32.3 +/- 4.1 h.",Pharmacokinetics and blister fluid penetration of brodimoprim in adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195844/),h,32.3,126658,DB00440,Trimethoprim
,8195844,peak,"In SBF a mean peak of 1.9 +/- 0.6 mg/l was reached after 6h with a t1/2 beta of 34.7 +/- 5.4 h and a penetration index (Pl), obtained by the AUCSBF/AUCs percent ratio of 61%.",Pharmacokinetics and blister fluid penetration of brodimoprim in adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195844/),[mg] / [l],1.9,126659,DB00440,Trimethoprim
,8195844,t1/2 beta,"In SBF a mean peak of 1.9 +/- 0.6 mg/l was reached after 6h with a t1/2 beta of 34.7 +/- 5.4 h and a penetration index (Pl), obtained by the AUCSBF/AUCs percent ratio of 61%.",Pharmacokinetics and blister fluid penetration of brodimoprim in adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195844/),h,34.7,126660,DB00440,Trimethoprim
,8195844,AUCSBF/AUCs percent ratio,"In SBF a mean peak of 1.9 +/- 0.6 mg/l was reached after 6h with a t1/2 beta of 34.7 +/- 5.4 h and a penetration index (Pl), obtained by the AUCSBF/AUCs percent ratio of 61%.",Pharmacokinetics and blister fluid penetration of brodimoprim in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195844/),%,61,126661,DB00440,Trimethoprim
,8195844,time to reach the peak (Tmax),"With multiple doses serum peak concentrations increased significantly, while the time to reach the peak (Tmax) was shorter (3.7-4.2 h) than after a single dose.",Pharmacokinetics and blister fluid penetration of brodimoprim in adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195844/),h,3.7-4.2,126662,DB00440,Trimethoprim
,17587989,MIC-90,"All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug.",In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587989/),[mg] / [l],0.12,126769,DB00440,Trimethoprim
,17587989,MIC-90,"All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug.",In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587989/),[mg] / [l],2.0,126770,DB00440,Trimethoprim
,3816021,volume of distribution,"They had a shorter elimination half-life (means: 1 to 3 years, 3.7 hours; 8 to 10 years, 5.4 hours; adults, 11.2 hours), because of the smaller volume of distribution (0.86 l/kg; 1.08 l/kg; 1.31 l/kg) and higher total clearance (2.8 ml/min/kg; 2.4 ml/min/kg; 1.4 ml/min/kg).",Age differences in trimethoprim pharmacokinetics: need for revised dosing in children? ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816021/),[l] / [kg],0.86,127689,DB00440,Trimethoprim
,3816021,volume of distribution,"They had a shorter elimination half-life (means: 1 to 3 years, 3.7 hours; 8 to 10 years, 5.4 hours; adults, 11.2 hours), because of the smaller volume of distribution (0.86 l/kg; 1.08 l/kg; 1.31 l/kg) and higher total clearance (2.8 ml/min/kg; 2.4 ml/min/kg; 1.4 ml/min/kg).",Age differences in trimethoprim pharmacokinetics: need for revised dosing in children? ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816021/),[l] / [kg],1.08,127690,DB00440,Trimethoprim
,3816021,volume of distribution,"They had a shorter elimination half-life (means: 1 to 3 years, 3.7 hours; 8 to 10 years, 5.4 hours; adults, 11.2 hours), because of the smaller volume of distribution (0.86 l/kg; 1.08 l/kg; 1.31 l/kg) and higher total clearance (2.8 ml/min/kg; 2.4 ml/min/kg; 1.4 ml/min/kg).",Age differences in trimethoprim pharmacokinetics: need for revised dosing in children? ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816021/),[l] / [kg],1.31,127691,DB00440,Trimethoprim
,3816021,total clearance,"They had a shorter elimination half-life (means: 1 to 3 years, 3.7 hours; 8 to 10 years, 5.4 hours; adults, 11.2 hours), because of the smaller volume of distribution (0.86 l/kg; 1.08 l/kg; 1.31 l/kg) and higher total clearance (2.8 ml/min/kg; 2.4 ml/min/kg; 1.4 ml/min/kg).",Age differences in trimethoprim pharmacokinetics: need for revised dosing in children? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816021/),[ml] / [kg·min],2.8,127692,DB00440,Trimethoprim
,3816021,total clearance,"They had a shorter elimination half-life (means: 1 to 3 years, 3.7 hours; 8 to 10 years, 5.4 hours; adults, 11.2 hours), because of the smaller volume of distribution (0.86 l/kg; 1.08 l/kg; 1.31 l/kg) and higher total clearance (2.8 ml/min/kg; 2.4 ml/min/kg; 1.4 ml/min/kg).",Age differences in trimethoprim pharmacokinetics: need for revised dosing in children? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816021/),[ml] / [kg·min],2.4,127693,DB00440,Trimethoprim
,3816021,total clearance,"They had a shorter elimination half-life (means: 1 to 3 years, 3.7 hours; 8 to 10 years, 5.4 hours; adults, 11.2 hours), because of the smaller volume of distribution (0.86 l/kg; 1.08 l/kg; 1.31 l/kg) and higher total clearance (2.8 ml/min/kg; 2.4 ml/min/kg; 1.4 ml/min/kg).",Age differences in trimethoprim pharmacokinetics: need for revised dosing in children? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816021/),[ml] / [kg·min],1.4,127694,DB00440,Trimethoprim
,22121785,t(1/2),"The main pharmacokinetic parameters t(1/2) of sulfamethoxazole in PH, HNH and HNT were, respectively, 9.30 +/- 1.11, 10.99 +/- 1.23 and 10.44 +/- 1.05 h; tmax were 1.4 +/- 0.3, 2.0 +/- 1.1 and 1.8 +/- 0.4 h; Cmax were 94.42 +/- 15.26, 89.33 +/- 7.67 and 87.43 +/- 11.61 micro x mL(-1); AUC(0-t) were 1202.5 +/- 238.3, 1 434.7 +/- 193.9 and 1302.8 +/- 103.0 microg x h x mL(-1); AUC(0-infinity) were 1240.7 +/- 255.3, 1511.5 +/- 211.9 and 1363.9 +/- 116.5 microg x h x mL(-1); CL were 1.01 +/- 0.22, 0.81 +/- 0.12 and 0.89 +/- 0.08 L x h(-1) x kg(-1); V were 13.27 +/- 1.73, 12.81 +/- 2.15 and 13.28 +/- 1.20 L x kg(-1).",[Pharmacokinetics of sulfamethoxazole in healthy Han volunteers living at plain and in native Han and Tibetan healthy volunteers living at high altitude]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22121785/),h,9.30,128635,DB00440,Trimethoprim
,22121785,t(1/2),"The main pharmacokinetic parameters t(1/2) of sulfamethoxazole in PH, HNH and HNT were, respectively, 9.30 +/- 1.11, 10.99 +/- 1.23 and 10.44 +/- 1.05 h; tmax were 1.4 +/- 0.3, 2.0 +/- 1.1 and 1.8 +/- 0.4 h; Cmax were 94.42 +/- 15.26, 89.33 +/- 7.67 and 87.43 +/- 11.61 micro x mL(-1); AUC(0-t) were 1202.5 +/- 238.3, 1 434.7 +/- 193.9 and 1302.8 +/- 103.0 microg x h x mL(-1); AUC(0-infinity) were 1240.7 +/- 255.3, 1511.5 +/- 211.9 and 1363.9 +/- 116.5 microg x h x mL(-1); CL were 1.01 +/- 0.22, 0.81 +/- 0.12 and 0.89 +/- 0.08 L x h(-1) x kg(-1); V were 13.27 +/- 1.73, 12.81 +/- 2.15 and 13.28 +/- 1.20 L x kg(-1).",[Pharmacokinetics of sulfamethoxazole in healthy Han volunteers living at plain and in native Han and Tibetan healthy volunteers living at high altitude]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22121785/),h,10.99,128636,DB00440,Trimethoprim
,22121785,t(1/2),"The main pharmacokinetic parameters t(1/2) of sulfamethoxazole in PH, HNH and HNT were, respectively, 9.30 +/- 1.11, 10.99 +/- 1.23 and 10.44 +/- 1.05 h; tmax were 1.4 +/- 0.3, 2.0 +/- 1.1 and 1.8 +/- 0.4 h; Cmax were 94.42 +/- 15.26, 89.33 +/- 7.67 and 87.43 +/- 11.61 micro x mL(-1); AUC(0-t) were 1202.5 +/- 238.3, 1 434.7 +/- 193.9 and 1302.8 +/- 103.0 microg x h x mL(-1); AUC(0-infinity) were 1240.7 +/- 255.3, 1511.5 +/- 211.9 and 1363.9 +/- 116.5 microg x h x mL(-1); CL were 1.01 +/- 0.22, 0.81 +/- 0.12 and 0.89 +/- 0.08 L x h(-1) x kg(-1); V were 13.27 +/- 1.73, 12.81 +/- 2.15 and 13.28 +/- 1.20 L x kg(-1).",[Pharmacokinetics of sulfamethoxazole in healthy Han volunteers living at plain and in native Han and Tibetan healthy volunteers living at high altitude]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22121785/),h,10.44,128637,DB00440,Trimethoprim
,22121785,tmax,"The main pharmacokinetic parameters t(1/2) of sulfamethoxazole in PH, HNH and HNT were, respectively, 9.30 +/- 1.11, 10.99 +/- 1.23 and 10.44 +/- 1.05 h; tmax were 1.4 +/- 0.3, 2.0 +/- 1.1 and 1.8 +/- 0.4 h; Cmax were 94.42 +/- 15.26, 89.33 +/- 7.67 and 87.43 +/- 11.61 micro x mL(-1); AUC(0-t) were 1202.5 +/- 238.3, 1 434.7 +/- 193.9 and 1302.8 +/- 103.0 microg x h x mL(-1); AUC(0-infinity) were 1240.7 +/- 255.3, 1511.5 +/- 211.9 and 1363.9 +/- 116.5 microg x h x mL(-1); CL were 1.01 +/- 0.22, 0.81 +/- 0.12 and 0.89 +/- 0.08 L x h(-1) x kg(-1); V were 13.27 +/- 1.73, 12.81 +/- 2.15 and 13.28 +/- 1.20 L x kg(-1).",[Pharmacokinetics of sulfamethoxazole in healthy Han volunteers living at plain and in native Han and Tibetan healthy volunteers living at high altitude]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22121785/),h,1.4,128638,DB00440,Trimethoprim
,22121785,tmax,"The main pharmacokinetic parameters t(1/2) of sulfamethoxazole in PH, HNH and HNT were, respectively, 9.30 +/- 1.11, 10.99 +/- 1.23 and 10.44 +/- 1.05 h; tmax were 1.4 +/- 0.3, 2.0 +/- 1.1 and 1.8 +/- 0.4 h; Cmax were 94.42 +/- 15.26, 89.33 +/- 7.67 and 87.43 +/- 11.61 micro x mL(-1); AUC(0-t) were 1202.5 +/- 238.3, 1 434.7 +/- 193.9 and 1302.8 +/- 103.0 microg x h x mL(-1); AUC(0-infinity) were 1240.7 +/- 255.3, 1511.5 +/- 211.9 and 1363.9 +/- 116.5 microg x h x mL(-1); CL were 1.01 +/- 0.22, 0.81 +/- 0.12 and 0.89 +/- 0.08 L x h(-1) x kg(-1); V were 13.27 +/- 1.73, 12.81 +/- 2.15 and 13.28 +/- 1.20 L x kg(-1).",[Pharmacokinetics of sulfamethoxazole in healthy Han volunteers living at plain and in native Han and Tibetan healthy volunteers living at high altitude]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22121785/),h,2.0,128639,DB00440,Trimethoprim
,22121785,tmax,"The main pharmacokinetic parameters t(1/2) of sulfamethoxazole in PH, HNH and HNT were, respectively, 9.30 +/- 1.11, 10.99 +/- 1.23 and 10.44 +/- 1.05 h; tmax were 1.4 +/- 0.3, 2.0 +/- 1.1 and 1.8 +/- 0.4 h; Cmax were 94.42 +/- 15.26, 89.33 +/- 7.67 and 87.43 +/- 11.61 micro x mL(-1); AUC(0-t) were 1202.5 +/- 238.3, 1 434.7 +/- 193.9 and 1302.8 +/- 103.0 microg x h x mL(-1); AUC(0-infinity) were 1240.7 +/- 255.3, 1511.5 +/- 211.9 and 1363.9 +/- 116.5 microg x h x mL(-1); CL were 1.01 +/- 0.22, 0.81 +/- 0.12 and 0.89 +/- 0.08 L x h(-1) x kg(-1); V were 13.27 +/- 1.73, 12.81 +/- 2.15 and 13.28 +/- 1.20 L x kg(-1).",[Pharmacokinetics of sulfamethoxazole in healthy Han volunteers living at plain and in native Han and Tibetan healthy volunteers living at high altitude]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22121785/),h,1.8,128640,DB00440,Trimethoprim
,22121785,Cmax,"The main pharmacokinetic parameters t(1/2) of sulfamethoxazole in PH, HNH and HNT were, respectively, 9.30 +/- 1.11, 10.99 +/- 1.23 and 10.44 +/- 1.05 h; tmax were 1.4 +/- 0.3, 2.0 +/- 1.1 and 1.8 +/- 0.4 h; Cmax were 94.42 +/- 15.26, 89.33 +/- 7.67 and 87.43 +/- 11.61 micro x mL(-1); AUC(0-t) were 1202.5 +/- 238.3, 1 434.7 +/- 193.9 and 1302.8 +/- 103.0 microg x h x mL(-1); AUC(0-infinity) were 1240.7 +/- 255.3, 1511.5 +/- 211.9 and 1363.9 +/- 116.5 microg x h x mL(-1); CL were 1.01 +/- 0.22, 0.81 +/- 0.12 and 0.89 +/- 0.08 L x h(-1) x kg(-1); V were 13.27 +/- 1.73, 12.81 +/- 2.15 and 13.28 +/- 1.20 L x kg(-1).",[Pharmacokinetics of sulfamethoxazole in healthy Han volunteers living at plain and in native Han and Tibetan healthy volunteers living at high altitude]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22121785/),1/[μml],94.42,128641,DB00440,Trimethoprim
,22121785,Cmax,"The main pharmacokinetic parameters t(1/2) of sulfamethoxazole in PH, HNH and HNT were, respectively, 9.30 +/- 1.11, 10.99 +/- 1.23 and 10.44 +/- 1.05 h; tmax were 1.4 +/- 0.3, 2.0 +/- 1.1 and 1.8 +/- 0.4 h; Cmax were 94.42 +/- 15.26, 89.33 +/- 7.67 and 87.43 +/- 11.61 micro x mL(-1); AUC(0-t) were 1202.5 +/- 238.3, 1 434.7 +/- 193.9 and 1302.8 +/- 103.0 microg x h x mL(-1); AUC(0-infinity) were 1240.7 +/- 255.3, 1511.5 +/- 211.9 and 1363.9 +/- 116.5 microg x h x mL(-1); CL were 1.01 +/- 0.22, 0.81 +/- 0.12 and 0.89 +/- 0.08 L x h(-1) x kg(-1); V were 13.27 +/- 1.73, 12.81 +/- 2.15 and 13.28 +/- 1.20 L x kg(-1).",[Pharmacokinetics of sulfamethoxazole in healthy Han volunteers living at plain and in native Han and Tibetan healthy volunteers living at high altitude]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22121785/),1/[μml],89.33,128642,DB00440,Trimethoprim
,22121785,Cmax,"The main pharmacokinetic parameters t(1/2) of sulfamethoxazole in PH, HNH and HNT were, respectively, 9.30 +/- 1.11, 10.99 +/- 1.23 and 10.44 +/- 1.05 h; tmax were 1.4 +/- 0.3, 2.0 +/- 1.1 and 1.8 +/- 0.4 h; Cmax were 94.42 +/- 15.26, 89.33 +/- 7.67 and 87.43 +/- 11.61 micro x mL(-1); AUC(0-t) were 1202.5 +/- 238.3, 1 434.7 +/- 193.9 and 1302.8 +/- 103.0 microg x h x mL(-1); AUC(0-infinity) were 1240.7 +/- 255.3, 1511.5 +/- 211.9 and 1363.9 +/- 116.5 microg x h x mL(-1); CL were 1.01 +/- 0.22, 0.81 +/- 0.12 and 0.89 +/- 0.08 L x h(-1) x kg(-1); V were 13.27 +/- 1.73, 12.81 +/- 2.15 and 13.28 +/- 1.20 L x kg(-1).",[Pharmacokinetics of sulfamethoxazole in healthy Han volunteers living at plain and in native Han and Tibetan healthy volunteers living at high altitude]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22121785/),1/[μml],87.43,128643,DB00440,Trimethoprim
,22121785,AUC(0-t),"The main pharmacokinetic parameters t(1/2) of sulfamethoxazole in PH, HNH and HNT were, respectively, 9.30 +/- 1.11, 10.99 +/- 1.23 and 10.44 +/- 1.05 h; tmax were 1.4 +/- 0.3, 2.0 +/- 1.1 and 1.8 +/- 0.4 h; Cmax were 94.42 +/- 15.26, 89.33 +/- 7.67 and 87.43 +/- 11.61 micro x mL(-1); AUC(0-t) were 1202.5 +/- 238.3, 1 434.7 +/- 193.9 and 1302.8 +/- 103.0 microg x h x mL(-1); AUC(0-infinity) were 1240.7 +/- 255.3, 1511.5 +/- 211.9 and 1363.9 +/- 116.5 microg x h x mL(-1); CL were 1.01 +/- 0.22, 0.81 +/- 0.12 and 0.89 +/- 0.08 L x h(-1) x kg(-1); V were 13.27 +/- 1.73, 12.81 +/- 2.15 and 13.28 +/- 1.20 L x kg(-1).",[Pharmacokinetics of sulfamethoxazole in healthy Han volunteers living at plain and in native Han and Tibetan healthy volunteers living at high altitude]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22121785/),[h·μg] / [ml],1202.5,128644,DB00440,Trimethoprim
,22121785,AUC(0-t),"The main pharmacokinetic parameters t(1/2) of sulfamethoxazole in PH, HNH and HNT were, respectively, 9.30 +/- 1.11, 10.99 +/- 1.23 and 10.44 +/- 1.05 h; tmax were 1.4 +/- 0.3, 2.0 +/- 1.1 and 1.8 +/- 0.4 h; Cmax were 94.42 +/- 15.26, 89.33 +/- 7.67 and 87.43 +/- 11.61 micro x mL(-1); AUC(0-t) were 1202.5 +/- 238.3, 1 434.7 +/- 193.9 and 1302.8 +/- 103.0 microg x h x mL(-1); AUC(0-infinity) were 1240.7 +/- 255.3, 1511.5 +/- 211.9 and 1363.9 +/- 116.5 microg x h x mL(-1); CL were 1.01 +/- 0.22, 0.81 +/- 0.12 and 0.89 +/- 0.08 L x h(-1) x kg(-1); V were 13.27 +/- 1.73, 12.81 +/- 2.15 and 13.28 +/- 1.20 L x kg(-1).",[Pharmacokinetics of sulfamethoxazole in healthy Han volunteers living at plain and in native Han and Tibetan healthy volunteers living at high altitude]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22121785/),[h·μg] / [ml],1 434.7,128645,DB00440,Trimethoprim
,22121785,AUC(0-t),"The main pharmacokinetic parameters t(1/2) of sulfamethoxazole in PH, HNH and HNT were, respectively, 9.30 +/- 1.11, 10.99 +/- 1.23 and 10.44 +/- 1.05 h; tmax were 1.4 +/- 0.3, 2.0 +/- 1.1 and 1.8 +/- 0.4 h; Cmax were 94.42 +/- 15.26, 89.33 +/- 7.67 and 87.43 +/- 11.61 micro x mL(-1); AUC(0-t) were 1202.5 +/- 238.3, 1 434.7 +/- 193.9 and 1302.8 +/- 103.0 microg x h x mL(-1); AUC(0-infinity) were 1240.7 +/- 255.3, 1511.5 +/- 211.9 and 1363.9 +/- 116.5 microg x h x mL(-1); CL were 1.01 +/- 0.22, 0.81 +/- 0.12 and 0.89 +/- 0.08 L x h(-1) x kg(-1); V were 13.27 +/- 1.73, 12.81 +/- 2.15 and 13.28 +/- 1.20 L x kg(-1).",[Pharmacokinetics of sulfamethoxazole in healthy Han volunteers living at plain and in native Han and Tibetan healthy volunteers living at high altitude]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22121785/),[h·μg] / [ml],1302.8,128646,DB00440,Trimethoprim
,22121785,AUC(0-infinity),"The main pharmacokinetic parameters t(1/2) of sulfamethoxazole in PH, HNH and HNT were, respectively, 9.30 +/- 1.11, 10.99 +/- 1.23 and 10.44 +/- 1.05 h; tmax were 1.4 +/- 0.3, 2.0 +/- 1.1 and 1.8 +/- 0.4 h; Cmax were 94.42 +/- 15.26, 89.33 +/- 7.67 and 87.43 +/- 11.61 micro x mL(-1); AUC(0-t) were 1202.5 +/- 238.3, 1 434.7 +/- 193.9 and 1302.8 +/- 103.0 microg x h x mL(-1); AUC(0-infinity) were 1240.7 +/- 255.3, 1511.5 +/- 211.9 and 1363.9 +/- 116.5 microg x h x mL(-1); CL were 1.01 +/- 0.22, 0.81 +/- 0.12 and 0.89 +/- 0.08 L x h(-1) x kg(-1); V were 13.27 +/- 1.73, 12.81 +/- 2.15 and 13.28 +/- 1.20 L x kg(-1).",[Pharmacokinetics of sulfamethoxazole in healthy Han volunteers living at plain and in native Han and Tibetan healthy volunteers living at high altitude]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22121785/),[h·μg] / [ml],1240.7,128647,DB00440,Trimethoprim
,22121785,AUC(0-infinity),"The main pharmacokinetic parameters t(1/2) of sulfamethoxazole in PH, HNH and HNT were, respectively, 9.30 +/- 1.11, 10.99 +/- 1.23 and 10.44 +/- 1.05 h; tmax were 1.4 +/- 0.3, 2.0 +/- 1.1 and 1.8 +/- 0.4 h; Cmax were 94.42 +/- 15.26, 89.33 +/- 7.67 and 87.43 +/- 11.61 micro x mL(-1); AUC(0-t) were 1202.5 +/- 238.3, 1 434.7 +/- 193.9 and 1302.8 +/- 103.0 microg x h x mL(-1); AUC(0-infinity) were 1240.7 +/- 255.3, 1511.5 +/- 211.9 and 1363.9 +/- 116.5 microg x h x mL(-1); CL were 1.01 +/- 0.22, 0.81 +/- 0.12 and 0.89 +/- 0.08 L x h(-1) x kg(-1); V were 13.27 +/- 1.73, 12.81 +/- 2.15 and 13.28 +/- 1.20 L x kg(-1).",[Pharmacokinetics of sulfamethoxazole in healthy Han volunteers living at plain and in native Han and Tibetan healthy volunteers living at high altitude]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22121785/),[h·μg] / [ml],1511.5,128648,DB00440,Trimethoprim
,22121785,AUC(0-infinity),"The main pharmacokinetic parameters t(1/2) of sulfamethoxazole in PH, HNH and HNT were, respectively, 9.30 +/- 1.11, 10.99 +/- 1.23 and 10.44 +/- 1.05 h; tmax were 1.4 +/- 0.3, 2.0 +/- 1.1 and 1.8 +/- 0.4 h; Cmax were 94.42 +/- 15.26, 89.33 +/- 7.67 and 87.43 +/- 11.61 micro x mL(-1); AUC(0-t) were 1202.5 +/- 238.3, 1 434.7 +/- 193.9 and 1302.8 +/- 103.0 microg x h x mL(-1); AUC(0-infinity) were 1240.7 +/- 255.3, 1511.5 +/- 211.9 and 1363.9 +/- 116.5 microg x h x mL(-1); CL were 1.01 +/- 0.22, 0.81 +/- 0.12 and 0.89 +/- 0.08 L x h(-1) x kg(-1); V were 13.27 +/- 1.73, 12.81 +/- 2.15 and 13.28 +/- 1.20 L x kg(-1).",[Pharmacokinetics of sulfamethoxazole in healthy Han volunteers living at plain and in native Han and Tibetan healthy volunteers living at high altitude]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22121785/),[h·μg] / [ml],1363.9,128649,DB00440,Trimethoprim
,22121785,CL,"The main pharmacokinetic parameters t(1/2) of sulfamethoxazole in PH, HNH and HNT were, respectively, 9.30 +/- 1.11, 10.99 +/- 1.23 and 10.44 +/- 1.05 h; tmax were 1.4 +/- 0.3, 2.0 +/- 1.1 and 1.8 +/- 0.4 h; Cmax were 94.42 +/- 15.26, 89.33 +/- 7.67 and 87.43 +/- 11.61 micro x mL(-1); AUC(0-t) were 1202.5 +/- 238.3, 1 434.7 +/- 193.9 and 1302.8 +/- 103.0 microg x h x mL(-1); AUC(0-infinity) were 1240.7 +/- 255.3, 1511.5 +/- 211.9 and 1363.9 +/- 116.5 microg x h x mL(-1); CL were 1.01 +/- 0.22, 0.81 +/- 0.12 and 0.89 +/- 0.08 L x h(-1) x kg(-1); V were 13.27 +/- 1.73, 12.81 +/- 2.15 and 13.28 +/- 1.20 L x kg(-1).",[Pharmacokinetics of sulfamethoxazole in healthy Han volunteers living at plain and in native Han and Tibetan healthy volunteers living at high altitude]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22121785/),,1,128650,DB00440,Trimethoprim
,6642070,peak plasma concentration,Peroral administration of the preparation resulted in a mean peak plasma concentration of trimethoprim 1.09 mg/l (SEM 0.06).,Bioavailability of a combination preparation of trimethoprim and folic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6642070/),[mg] / [l],1.09,131030,DB00440,Trimethoprim
,6642070,AUC,"The AUC values for trimethoprim were 12.42 mg.h/l and 12.77 mg.h/l corresponding to combination preparation and plain trimethoprim, p greater than 0.1.",Bioavailability of a combination preparation of trimethoprim and folic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6642070/),[h·mg] / [l],12.42,131031,DB00440,Trimethoprim
,6642070,AUC,"The AUC values for trimethoprim were 12.42 mg.h/l and 12.77 mg.h/l corresponding to combination preparation and plain trimethoprim, p greater than 0.1.",Bioavailability of a combination preparation of trimethoprim and folic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6642070/),[h·mg] / [l],12.77,131032,DB00440,Trimethoprim
,6642070,AUC from 0-8 hours,"The AUC from 0-8 hours was 199.8 nmol.h/l (SEM 8.1) and 166.3 nmol.h/l (SEM 14.2) corresponding to combination preparation and plain trimethoprim, p less than 0.001.",Bioavailability of a combination preparation of trimethoprim and folic acid. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6642070/),[h·nM] / [l],199.8,131033,DB00440,Trimethoprim
,6642070,AUC from 0-8 hours,"The AUC from 0-8 hours was 199.8 nmol.h/l (SEM 8.1) and 166.3 nmol.h/l (SEM 14.2) corresponding to combination preparation and plain trimethoprim, p less than 0.001.",Bioavailability of a combination preparation of trimethoprim and folic acid. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6642070/),[h·nM] / [l],166.3,131034,DB00440,Trimethoprim
> or =,8504623,half-life,"For pentamidine, a long half-life of > or = 4 days implies the need for a loading dose.",Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8504623/),d,4,131379,DB00440,Trimethoprim
,8504623,Plasma concentrations of,Plasma concentrations of the parent drug at steady-state varied between 30 and 100 micrograms/L.,Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8504623/),[μg] / [l],30 and 100,131380,DB00440,Trimethoprim
,18351642,IC(50),The IC(50) (TMP concentration associated with a 50% reduction in FTC excretion) was 1.86 +/- 0.37 microg/mL.,Renal excretion of emtricitabine II. effect of trimethoprim on emtricitabine excretion: In vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18351642/),[μg] / [ml],1.86,131521,DB00440,Trimethoprim
,18351642,clearance,"TMP coadministration significantly decreased FTC clearance (7.4 +/- 1.2 mL/min/kg to 2.7 +/- 0.53 mL/min/kg), and elimination half-life was significantly increased (58 +/- 12 min to 215 +/- 44 min).",Renal excretion of emtricitabine II. effect of trimethoprim on emtricitabine excretion: In vitro and in vivo studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18351642/),[ml] / [kg·min],7.4,131522,DB00440,Trimethoprim
,18351642,clearance,"TMP coadministration significantly decreased FTC clearance (7.4 +/- 1.2 mL/min/kg to 2.7 +/- 0.53 mL/min/kg), and elimination half-life was significantly increased (58 +/- 12 min to 215 +/- 44 min).",Renal excretion of emtricitabine II. effect of trimethoprim on emtricitabine excretion: In vitro and in vivo studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18351642/),[ml] / [kg·min],2.7,131523,DB00440,Trimethoprim
,18351642,elimination half-life,"TMP coadministration significantly decreased FTC clearance (7.4 +/- 1.2 mL/min/kg to 2.7 +/- 0.53 mL/min/kg), and elimination half-life was significantly increased (58 +/- 12 min to 215 +/- 44 min).",Renal excretion of emtricitabine II. effect of trimethoprim on emtricitabine excretion: In vitro and in vivo studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18351642/),min,58,131524,DB00440,Trimethoprim
,18351642,elimination half-life,"TMP coadministration significantly decreased FTC clearance (7.4 +/- 1.2 mL/min/kg to 2.7 +/- 0.53 mL/min/kg), and elimination half-life was significantly increased (58 +/- 12 min to 215 +/- 44 min).",Renal excretion of emtricitabine II. effect of trimethoprim on emtricitabine excretion: In vitro and in vivo studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18351642/),min,215,131525,DB00440,Trimethoprim
,6981173,peak TMP levels,"Thirty-seven children and adults aged 0.2-82 years were treated intravenously with 150 mg of trimethoprim (TMP) and 750 mg of sulfamethoxazole (SMZ)/m2 every 8 hr, usually for known or suspected pneumocystis pneumonia; when necessary dosage was adjusted to maintain peak TMP levels of 5-10 micrograms/ml.",Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6981173/),[μg] / [ml],5-10,131925,DB00440,Trimethoprim
,6981173,peak levels,"On day 2 of treatment, mean peak levels of TMP-SMZ were 7.02 and 148 micrograms/ml, respectively, and mean half-lives were 9.6 and 10.7 hr, respectively.",Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6981173/),[μg] / [ml],7.02,131926,DB00440,Trimethoprim
,6981173,peak levels,"On day 2 of treatment, mean peak levels of TMP-SMZ were 7.02 and 148 micrograms/ml, respectively, and mean half-lives were 9.6 and 10.7 hr, respectively.",Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6981173/),[μg] / [ml],148,131927,DB00440,Trimethoprim
,6981173,half-lives,"On day 2 of treatment, mean peak levels of TMP-SMZ were 7.02 and 148 micrograms/ml, respectively, and mean half-lives were 9.6 and 10.7 hr, respectively.",Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6981173/),h,9.6,131928,DB00440,Trimethoprim
,6981173,half-lives,"On day 2 of treatment, mean peak levels of TMP-SMZ were 7.02 and 148 micrograms/ml, respectively, and mean half-lives were 9.6 and 10.7 hr, respectively.",Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6981173/),h,10.7,131929,DB00440,Trimethoprim
,10211713,plasma protein binding,The plasma protein binding was measured to be 20% for SDZ and 35% for TMP.,"Repeated administration of trimethoprim/sulfadiazine in the horse--pharmacokinetics, plasma protein binding and influence on the intestinal microflora. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211713/),%,20,133396,DB00440,Trimethoprim
,10211713,plasma protein binding,The plasma protein binding was measured to be 20% for SDZ and 35% for TMP.,"Repeated administration of trimethoprim/sulfadiazine in the horse--pharmacokinetics, plasma protein binding and influence on the intestinal microflora. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211713/),%,35,133397,DB00440,Trimethoprim
,6335381,Peak concentrations,"Peak concentrations of TMP and SMX in CSF were 1 microgram/ml and 13.8 micrograms/ml, respectively.",Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6335381/),[μg] / [ml],1,133819,DB00440,Trimethoprim
,6335381,Peak concentrations,"Peak concentrations of TMP and SMX in CSF were 1 microgram/ml and 13.8 micrograms/ml, respectively.",Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6335381/),[μg] / [ml],13.8,133820,DB00440,Trimethoprim
,6335381,CSF-to-serum concentration ratios,"In the postdistribution phase (in CSF), simultaneous CSF-to-serum concentration ratios ranged from 0.23 to 0.53 for TMP and from 0.20 to 0.36 for SMX.",Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6335381/),,0.23 to 0.53,133821,DB00440,Trimethoprim
,6335381,CSF-to-serum concentration ratios,"In the postdistribution phase (in CSF), simultaneous CSF-to-serum concentration ratios ranged from 0.23 to 0.53 for TMP and from 0.20 to 0.36 for SMX.",Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6335381/),,0.20 to 0.36,133822,DB00440,Trimethoprim
,6335381,penetration,CSF penetration (measured by comparison of the area under the curve of the composite CSF and serum concentration-time curves) was 18% for TMP and 12% for SMX.,Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6335381/),%,18,133823,DB00440,Trimethoprim
,6335381,penetration,CSF penetration (measured by comparison of the area under the curve of the composite CSF and serum concentration-time curves) was 18% for TMP and 12% for SMX.,Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6335381/),%,12,133824,DB00440,Trimethoprim
at,6335381,steady-state peak concentrations,A loading dose of TMP-SMX (bases on TMP) of 10 to 12 mg/kg and a maintenance dose of 6 mg/kg every 8 h or 8 mg/kg every 12 h (with a 2-h infusion) should yield steady-state peak concentrations of at least 5 micrograms of TMP per ml of serum and 160 micrograms of SMX per ml of serum.,Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6335381/),μg,5,133825,DB00440,Trimethoprim
,6335381,steady-state peak concentrations,A loading dose of TMP-SMX (bases on TMP) of 10 to 12 mg/kg and a maintenance dose of 6 mg/kg every 8 h or 8 mg/kg every 12 h (with a 2-h infusion) should yield steady-state peak concentrations of at least 5 micrograms of TMP per ml of serum and 160 micrograms of SMX per ml of serum.,Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6335381/),μg,160,133826,DB00440,Trimethoprim
,22106207,area under the concentration-time curve from 0 to 24 h (AUC(0-24)),"The SMX area under the concentration-time curve from 0 to 24 h (AUC(0-24)) for 15 recipients with the NAT2 slow acetylator genotype (NAT2 5/ 6, - 6/ 6, - 6/ 7, and - 7/ 7) was significantly greater than that for 56 recipients with the NAT2 rapid acetylator genotype (homozygous for NAT2 4) (766.4 ± 432.3 versus 537.2 ± 257.5 μg-h/ml, respectively; P = 0.0430), whereas there were no significant differences in the SMX AUC(0-24) between the CYP2C9 1/ 1 and - 1/ 3 groups.",Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22106207/),[μg-h] / [ml],766.4,134433,DB00440,Trimethoprim
,22106207,area under the concentration-time curve from 0 to 24 h (AUC(0-24)),"The SMX area under the concentration-time curve from 0 to 24 h (AUC(0-24)) for 15 recipients with the NAT2 slow acetylator genotype (NAT2 5/ 6, - 6/ 6, - 6/ 7, and - 7/ 7) was significantly greater than that for 56 recipients with the NAT2 rapid acetylator genotype (homozygous for NAT2 4) (766.4 ± 432.3 versus 537.2 ± 257.5 μg-h/ml, respectively; P = 0.0430), whereas there were no significant differences in the SMX AUC(0-24) between the CYP2C9 1/ 1 and - 1/ 3 groups.",Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22106207/),[μg-h] / [ml],537.2,134434,DB00440,Trimethoprim
,15977442,limits of detection,"The limits of detection were 76.3 ng/mL for trimethoprim, and 61.9 ng/mL for sulphamethoxazole at 0.16 aufs.",Bioequivalence study of three generic formulations of co-trimoxazole tablets in human urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15977442/),[ng] / [ml],76.3,135892,DB00440,Trimethoprim
,15977442,limits of detection,"The limits of detection were 76.3 ng/mL for trimethoprim, and 61.9 ng/mL for sulphamethoxazole at 0.16 aufs.",Bioequivalence study of three generic formulations of co-trimoxazole tablets in human urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15977442/),[ng] / [ml],61.9,135893,DB00440,Trimethoprim
,15977442,percentage recoveries,"The linearity (n = 5) for the calibration curve was of the order, 1.0000 for trimethoprim and 0.9998 for sulphamethoxazole; percentage recoveries for trimethoprim and sulphamethoxazole were 89.4 and 87.9% respectively.",Bioequivalence study of three generic formulations of co-trimoxazole tablets in human urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15977442/),%,89.4,135894,DB00440,Trimethoprim
,15977442,percentage recoveries,"The linearity (n = 5) for the calibration curve was of the order, 1.0000 for trimethoprim and 0.9998 for sulphamethoxazole; percentage recoveries for trimethoprim and sulphamethoxazole were 89.4 and 87.9% respectively.",Bioequivalence study of three generic formulations of co-trimoxazole tablets in human urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15977442/),%,87.9,135895,DB00440,Trimethoprim
,15977442,relative bioavailabilities,The relative bioavailabilities of the two generics to the innovator's product were 104.2% (trimethoprim) and 106.8% (sulphamethoxazole); 114.8% (trimethoprim) and 111.8% (sulphamethoxazole) for a product of reputable pharmaceutical company in Nigeria and Indian product respectively.,Bioequivalence study of three generic formulations of co-trimoxazole tablets in human urine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15977442/),%,104.2,135896,DB00440,Trimethoprim
,15977442,relative bioavailabilities,The relative bioavailabilities of the two generics to the innovator's product were 104.2% (trimethoprim) and 106.8% (sulphamethoxazole); 114.8% (trimethoprim) and 111.8% (sulphamethoxazole) for a product of reputable pharmaceutical company in Nigeria and Indian product respectively.,Bioequivalence study of three generic formulations of co-trimoxazole tablets in human urine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15977442/),%,106.8,135897,DB00440,Trimethoprim
,15977442,relative bioavailabilities,The relative bioavailabilities of the two generics to the innovator's product were 104.2% (trimethoprim) and 106.8% (sulphamethoxazole); 114.8% (trimethoprim) and 111.8% (sulphamethoxazole) for a product of reputable pharmaceutical company in Nigeria and Indian product respectively.,Bioequivalence study of three generic formulations of co-trimoxazole tablets in human urine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15977442/),%,114.8,135898,DB00440,Trimethoprim
,15977442,relative bioavailabilities,The relative bioavailabilities of the two generics to the innovator's product were 104.2% (trimethoprim) and 106.8% (sulphamethoxazole); 114.8% (trimethoprim) and 111.8% (sulphamethoxazole) for a product of reputable pharmaceutical company in Nigeria and Indian product respectively.,Bioequivalence study of three generic formulations of co-trimoxazole tablets in human urine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15977442/),%,111.8,135899,DB00440,Trimethoprim
,7937525,K,"Trimethoprim elimination from the diffusion model was faster (K = 0.33 +/- 0.17 versus 0.57 +/- 0.09 hr-1) than from the systemic model, although it appears this was caused by sampling before drug distribution into the middle ear was complete.",Comparison of two otitis media models for the study of middle ear antimicrobial pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937525/),1/[h],0.33,139779,DB00440,Trimethoprim
,7937525,K,"Trimethoprim elimination from the diffusion model was faster (K = 0.33 +/- 0.17 versus 0.57 +/- 0.09 hr-1) than from the systemic model, although it appears this was caused by sampling before drug distribution into the middle ear was complete.",Comparison of two otitis media models for the study of middle ear antimicrobial pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937525/),1/[h],0.57,139780,DB00440,Trimethoprim
,3265624,plasma half-lives,1250 ng/ml of trimethoprim and about 40 micrograms/ml of sulfamethoxazole 1.5-2 h after application; the plasma half-lives were about 9 h for trimethoprim and around 8.5 h for sulfamethoxazole.,[Studies of the pharmacokinetics and bioavailability of a new trimethoprim/sulfamethoxazole preparation in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3265624/),h,9,141435,DB00440,Trimethoprim
,3265624,plasma half-lives,1250 ng/ml of trimethoprim and about 40 micrograms/ml of sulfamethoxazole 1.5-2 h after application; the plasma half-lives were about 9 h for trimethoprim and around 8.5 h for sulfamethoxazole.,[Studies of the pharmacokinetics and bioavailability of a new trimethoprim/sulfamethoxazole preparation in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3265624/),h,8.5,141436,DB00440,Trimethoprim
,11213821,serum concentrations,"The median (range) serum concentrations of TMP were 1.4 (0.7-2.6) mg/L (start) and 1.3 (1.0-2.8) mg/L (end), and of SMZ 35 (15-65) mg/L (start) and 33 mg (13-70) mg/L (end).",Trimethoprim-sulphamethoxazole and metronidazole as prophylaxis in colorectal surgery: a study of bioavailability after an oral single dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11213821/),[mg] / [l],1.4,141662,DB00440,Trimethoprim
,11213821,serum concentrations,"The median (range) serum concentrations of TMP were 1.4 (0.7-2.6) mg/L (start) and 1.3 (1.0-2.8) mg/L (end), and of SMZ 35 (15-65) mg/L (start) and 33 mg (13-70) mg/L (end).",Trimethoprim-sulphamethoxazole and metronidazole as prophylaxis in colorectal surgery: a study of bioavailability after an oral single dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11213821/),[mg] / [l],1.3,141663,DB00440,Trimethoprim
,11213821,serum concentrations,"The median (range) serum concentrations of TMP were 1.4 (0.7-2.6) mg/L (start) and 1.3 (1.0-2.8) mg/L (end), and of SMZ 35 (15-65) mg/L (start) and 33 mg (13-70) mg/L (end).",Trimethoprim-sulphamethoxazole and metronidazole as prophylaxis in colorectal surgery: a study of bioavailability after an oral single dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11213821/),[mg] / [l],35,141664,DB00440,Trimethoprim
,11213821,serum concentrations,"The median (range) serum concentrations of TMP were 1.4 (0.7-2.6) mg/L (start) and 1.3 (1.0-2.8) mg/L (end), and of SMZ 35 (15-65) mg/L (start) and 33 mg (13-70) mg/L (end).",Trimethoprim-sulphamethoxazole and metronidazole as prophylaxis in colorectal surgery: a study of bioavailability after an oral single dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11213821/),[mg] / [l],33,141665,DB00440,Trimethoprim
,11213821,minimal inhibitory concentration,The individual values were above or equal to the minimal inhibitory concentration (TMP 0.8 mg/L; SMZ 15.2 mg/L) for relevant gram-negative species.,Trimethoprim-sulphamethoxazole and metronidazole as prophylaxis in colorectal surgery: a study of bioavailability after an oral single dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11213821/),[mg] / [l],0.8,141666,DB00440,Trimethoprim
,11213821,minimal inhibitory concentration,The individual values were above or equal to the minimal inhibitory concentration (TMP 0.8 mg/L; SMZ 15.2 mg/L) for relevant gram-negative species.,Trimethoprim-sulphamethoxazole and metronidazole as prophylaxis in colorectal surgery: a study of bioavailability after an oral single dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11213821/),[mg] / [l],15.2,141667,DB00440,Trimethoprim
,25663419,LD50,The LD50 calculated was 1400 mg kg(-1) body weight (BW) day(-1) in rats and 1130 mg kg(-1) BW day(-1) in mice.,"Safety assessment of aditoprim acute, subchronic toxicity and mutagenicity studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25663419/),[mg] / [kg],1400,142560,DB00440,Trimethoprim
,25663419,LD50,The LD50 calculated was 1400 mg kg(-1) body weight (BW) day(-1) in rats and 1130 mg kg(-1) BW day(-1) in mice.,"Safety assessment of aditoprim acute, subchronic toxicity and mutagenicity studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25663419/),[mg] / [kg],1130,142561,DB00440,Trimethoprim
,2116704,volume of distribution,"The main pharmacokinetic characteristics of aditoprim in horses were: a large volume of distribution, reaching a mean value of 7.8 l/kg; a mean plasma clearance of 5.0 l/min; a plasma elimination half-life of 12 h.",Plasma disposition and tolerance of aditoprim in horses after single intravenous injection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116704/),[l] / [kg],7.8,143207,DB00440,Trimethoprim
,2116704,plasma clearance,"The main pharmacokinetic characteristics of aditoprim in horses were: a large volume of distribution, reaching a mean value of 7.8 l/kg; a mean plasma clearance of 5.0 l/min; a plasma elimination half-life of 12 h.",Plasma disposition and tolerance of aditoprim in horses after single intravenous injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116704/),[l] / [min],5.0,143208,DB00440,Trimethoprim
,2116704,plasma elimination half-life,"The main pharmacokinetic characteristics of aditoprim in horses were: a large volume of distribution, reaching a mean value of 7.8 l/kg; a mean plasma clearance of 5.0 l/min; a plasma elimination half-life of 12 h.",Plasma disposition and tolerance of aditoprim in horses after single intravenous injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116704/),h,12,143209,DB00440,Trimethoprim
,8838438,Cmax,"2. Coadministration of cotrimoxazole with loperamide oxide did not alter the tmax, Cmax and AUC of loperamide oxide, whereas the Cmax (0.32 +/- 0.14 ng ml-1 without cotrimoxazole; 0.45 +/- 0.18 ng ml-1 with cotrimoxazole; P < 0.05) and AUC (8.13 +/- 1.91 ng ml-1 h without cotrimoxazole; 12.50 +/- 4.60 ng ml-1 h with cotrimoxazole; P < 0.005) of loperamide were significantly increased.",Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838438/),[ng] / [ml],0.32,144023,DB00440,Trimethoprim
,8838438,Cmax,"2. Coadministration of cotrimoxazole with loperamide oxide did not alter the tmax, Cmax and AUC of loperamide oxide, whereas the Cmax (0.32 +/- 0.14 ng ml-1 without cotrimoxazole; 0.45 +/- 0.18 ng ml-1 with cotrimoxazole; P < 0.05) and AUC (8.13 +/- 1.91 ng ml-1 h without cotrimoxazole; 12.50 +/- 4.60 ng ml-1 h with cotrimoxazole; P < 0.005) of loperamide were significantly increased.",Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838438/),[ng] / [ml],0.45,144024,DB00440,Trimethoprim
,8838438,AUC,"2. Coadministration of cotrimoxazole with loperamide oxide did not alter the tmax, Cmax and AUC of loperamide oxide, whereas the Cmax (0.32 +/- 0.14 ng ml-1 without cotrimoxazole; 0.45 +/- 0.18 ng ml-1 with cotrimoxazole; P < 0.05) and AUC (8.13 +/- 1.91 ng ml-1 h without cotrimoxazole; 12.50 +/- 4.60 ng ml-1 h with cotrimoxazole; P < 0.005) of loperamide were significantly increased.",Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838438/),[h·ng] / [ml],8.13,144025,DB00440,Trimethoprim
,8838438,AUC,"2. Coadministration of cotrimoxazole with loperamide oxide did not alter the tmax, Cmax and AUC of loperamide oxide, whereas the Cmax (0.32 +/- 0.14 ng ml-1 without cotrimoxazole; 0.45 +/- 0.18 ng ml-1 with cotrimoxazole; P < 0.05) and AUC (8.13 +/- 1.91 ng ml-1 h without cotrimoxazole; 12.50 +/- 4.60 ng ml-1 h with cotrimoxazole; P < 0.005) of loperamide were significantly increased.",Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838438/),[h·ng] / [ml],12.50,144026,DB00440,Trimethoprim
,8838438,Cmax,"3. Coadministration of cotrimoxazole with loperamide significantly increased the Cmax (0.74 +/- 0.22 ng ml-1 without cotrimoxazole; 1.49 +/- 0.81 ng ml-1 with cotrimoxazole; P < 0.01) and AUC (13.40 +/- 3.80 ng ml-1 h without cotrimoxazole; 25.30 +/- 11.10 ng ml-1 h with cotrimoxazole; P < 0.005) of loperamide, whilst its tmax and t1/2,z were not significantly altered.",Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838438/),[ng] / [ml],0.74,144027,DB00440,Trimethoprim
,8838438,Cmax,"3. Coadministration of cotrimoxazole with loperamide significantly increased the Cmax (0.74 +/- 0.22 ng ml-1 without cotrimoxazole; 1.49 +/- 0.81 ng ml-1 with cotrimoxazole; P < 0.01) and AUC (13.40 +/- 3.80 ng ml-1 h without cotrimoxazole; 25.30 +/- 11.10 ng ml-1 h with cotrimoxazole; P < 0.005) of loperamide, whilst its tmax and t1/2,z were not significantly altered.",Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838438/),[ng] / [ml],1.49,144028,DB00440,Trimethoprim
,8838438,AUC,"3. Coadministration of cotrimoxazole with loperamide significantly increased the Cmax (0.74 +/- 0.22 ng ml-1 without cotrimoxazole; 1.49 +/- 0.81 ng ml-1 with cotrimoxazole; P < 0.01) and AUC (13.40 +/- 3.80 ng ml-1 h without cotrimoxazole; 25.30 +/- 11.10 ng ml-1 h with cotrimoxazole; P < 0.005) of loperamide, whilst its tmax and t1/2,z were not significantly altered.",Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838438/),[h·ng] / [ml],13.40,144029,DB00440,Trimethoprim
,8838438,AUC,"3. Coadministration of cotrimoxazole with loperamide significantly increased the Cmax (0.74 +/- 0.22 ng ml-1 without cotrimoxazole; 1.49 +/- 0.81 ng ml-1 with cotrimoxazole; P < 0.01) and AUC (13.40 +/- 3.80 ng ml-1 h without cotrimoxazole; 25.30 +/- 11.10 ng ml-1 h with cotrimoxazole; P < 0.005) of loperamide, whilst its tmax and t1/2,z were not significantly altered.",Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838438/),[h·ng] / [ml],25.30,144030,DB00440,Trimethoprim
,9697419,body clearance (ClB),"The body clearance (ClB) of SDZ (1.70 +/- 0.14 ml/min/kg) was significantly higher than those of SDM (1.13 +/- 0.18 ml/min/kg), SMPZ (1.10 +/- 0.09 ml/min/kg) and SDMX (0.75 +/- 0.04 ml/min/kg).",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[ml] / [kg·min],1.70,147432,DB00440,Trimethoprim
,9697419,body clearance (ClB),"The body clearance (ClB) of SDZ (1.70 +/- 0.14 ml/min/kg) was significantly higher than those of SDM (1.13 +/- 0.18 ml/min/kg), SMPZ (1.10 +/- 0.09 ml/min/kg) and SDMX (0.75 +/- 0.04 ml/min/kg).",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[ml] / [kg·min],1.13,147433,DB00440,Trimethoprim
,9697419,body clearance (ClB),"The body clearance (ClB) of SDZ (1.70 +/- 0.14 ml/min/kg) was significantly higher than those of SDM (1.13 +/- 0.18 ml/min/kg), SMPZ (1.10 +/- 0.09 ml/min/kg) and SDMX (0.75 +/- 0.04 ml/min/kg).",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[ml] / [kg·min],1.10,147434,DB00440,Trimethoprim
,9697419,body clearance (ClB),"The body clearance (ClB) of SDZ (1.70 +/- 0.14 ml/min/kg) was significantly higher than those of SDM (1.13 +/- 0.18 ml/min/kg), SMPZ (1.10 +/- 0.09 ml/min/kg) and SDMX (0.75 +/- 0.04 ml/min/kg).",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[ml] / [kg·min],0.75,147435,DB00440,Trimethoprim
,9697419,volume of distribution at steady state (Vss),"In contrast, the volume of distribution at steady state (Vss) was similar for the four sulfonamides (0.68 +/- 0.08 L/kg, 0.63 +/- 0.07 L/kg, 0.47 +/- 0.06 L/kg, and 0.46 +/- 0.05 L/kg for SDM, SDZ, SMPZ and SDMX, respectively).",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[l] / [kg],0.68,147436,DB00440,Trimethoprim
,9697419,volume of distribution at steady state (Vss),"In contrast, the volume of distribution at steady state (Vss) was similar for the four sulfonamides (0.68 +/- 0.08 L/kg, 0.63 +/- 0.07 L/kg, 0.47 +/- 0.06 L/kg, and 0.46 +/- 0.05 L/kg for SDM, SDZ, SMPZ and SDMX, respectively).",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[l] / [kg],0.63,147437,DB00440,Trimethoprim
,9697419,volume of distribution at steady state (Vss),"In contrast, the volume of distribution at steady state (Vss) was similar for the four sulfonamides (0.68 +/- 0.08 L/kg, 0.63 +/- 0.07 L/kg, 0.47 +/- 0.06 L/kg, and 0.46 +/- 0.05 L/kg for SDM, SDZ, SMPZ and SDMX, respectively).",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[l] / [kg],0.47,147438,DB00440,Trimethoprim
,9697419,volume of distribution at steady state (Vss),"In contrast, the volume of distribution at steady state (Vss) was similar for the four sulfonamides (0.68 +/- 0.08 L/kg, 0.63 +/- 0.07 L/kg, 0.47 +/- 0.06 L/kg, and 0.46 +/- 0.05 L/kg for SDM, SDZ, SMPZ and SDMX, respectively).",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[l] / [kg],0.46,147439,DB00440,Trimethoprim
,9697419,ClB,Both ClB and Vss were significantly higher for TMP (4.36 +/- 0.60 ml/min/kg and 2.71 +/- 0.86 L/kg) than for sulfonamides.,Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[ml] / [kg·min],4.36,147440,DB00440,Trimethoprim
,9697419,Vss,Both ClB and Vss were significantly higher for TMP (4.36 +/- 0.60 ml/min/kg and 2.71 +/- 0.86 L/kg) than for sulfonamides.,Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[l] / [kg],2.71,147441,DB00440,Trimethoprim
,9697419,ClB,"Antipyrine ClB (3.49 +/- 0.35 ml/min/kg) and Vss (0.66 +/- 0.16 L/kg), determined in order to assess hepatic oxidative function and total body water volume, respectively, were either different from (ClB), or similar to (Vss), values calculated for sulfonamides.",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[ml] / [kg·min],3.49,147442,DB00440,Trimethoprim
,9697419,Vss,"Antipyrine ClB (3.49 +/- 0.35 ml/min/kg) and Vss (0.66 +/- 0.16 L/kg), determined in order to assess hepatic oxidative function and total body water volume, respectively, were either different from (ClB), or similar to (Vss), values calculated for sulfonamides.",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[l] / [kg],0.66,147443,DB00440,Trimethoprim
,9989342,absolute bioavailability,"The absolute bioavailability is approximately 82 and 68% in adults and children, respectively.",Clinical pharmacokinetics of lamivudine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989342/),%,82,148539,DB00440,Trimethoprim
,9989342,absolute bioavailability,"The absolute bioavailability is approximately 82 and 68% in adults and children, respectively.",Clinical pharmacokinetics of lamivudine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989342/),%,68,148540,DB00440,Trimethoprim
,9989342,apparent volume of distribution (Vd),"Lamivudine is widely distributed into total body fluid, the mean apparent volume of distribution (Vd) being approximately 1.3 L/kg following intravenous administration.",Clinical pharmacokinetics of lamivudine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989342/),[l] / [kg],1.3,148541,DB00440,Trimethoprim
,9989342,Systemic clearance,Systemic clearance following single intravenous doses averages 20 to 25 L/h (approximately 0.3 L/h/kg).,Clinical pharmacokinetics of lamivudine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989342/),[l] / [h],20 to 25,148542,DB00440,Trimethoprim
,9989342,Systemic clearance,Systemic clearance following single intravenous doses averages 20 to 25 L/h (approximately 0.3 L/h/kg).,Clinical pharmacokinetics of lamivudine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989342/),[l] / [h·kg],0.3,148543,DB00440,Trimethoprim
,9989342,elimination half-life,"The dominant elimination half-life of lamivudine is approximately 5 to 7 hours, and the in vitro intracellular half-life of its active 5'-triphosphate anabolite is 10.5 to 15.5 hours and 17 to 19 hours in HIV-1 and HBV cell lines, respectively.",Clinical pharmacokinetics of lamivudine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989342/),h,5 to 7,148544,DB00440,Trimethoprim
,9989342,intracellular half-life,"The dominant elimination half-life of lamivudine is approximately 5 to 7 hours, and the in vitro intracellular half-life of its active 5'-triphosphate anabolite is 10.5 to 15.5 hours and 17 to 19 hours in HIV-1 and HBV cell lines, respectively.",Clinical pharmacokinetics of lamivudine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989342/),h,10.5 to 15.5,148545,DB00440,Trimethoprim
,9989342,intracellular half-life,"The dominant elimination half-life of lamivudine is approximately 5 to 7 hours, and the in vitro intracellular half-life of its active 5'-triphosphate anabolite is 10.5 to 15.5 hours and 17 to 19 hours in HIV-1 and HBV cell lines, respectively.",Clinical pharmacokinetics of lamivudine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989342/),h,17 to 19,148546,DB00440,Trimethoprim
,2611358,urinary recovery,"There was a significant difference (p less than 0.05), however, in the urinary recovery of 3-methylxanthine (11.3 +/- 2.6 per cent TH alone versus 13.9 +/- 3.6 per cent TH-CT) and in the total urinary recovery of TH and its metabolites (76.5 +/- 8.2 per cent versus 85.3 +/- 7.0 per cent), the latter finding suggesting that CT may have caused a small increase in the extent of TH absorption.",Lack of effect of co-trimoxazole on the pharmacokinetics of orally administered theophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611358/),%,11.3,149550,DB00440,Trimethoprim
,2611358,urinary recovery,"There was a significant difference (p less than 0.05), however, in the urinary recovery of 3-methylxanthine (11.3 +/- 2.6 per cent TH alone versus 13.9 +/- 3.6 per cent TH-CT) and in the total urinary recovery of TH and its metabolites (76.5 +/- 8.2 per cent versus 85.3 +/- 7.0 per cent), the latter finding suggesting that CT may have caused a small increase in the extent of TH absorption.",Lack of effect of co-trimoxazole on the pharmacokinetics of orally administered theophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611358/),%,13.9,149551,DB00440,Trimethoprim
,2611358,total urinary recovery,"There was a significant difference (p less than 0.05), however, in the urinary recovery of 3-methylxanthine (11.3 +/- 2.6 per cent TH alone versus 13.9 +/- 3.6 per cent TH-CT) and in the total urinary recovery of TH and its metabolites (76.5 +/- 8.2 per cent versus 85.3 +/- 7.0 per cent), the latter finding suggesting that CT may have caused a small increase in the extent of TH absorption.",Lack of effect of co-trimoxazole on the pharmacokinetics of orally administered theophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611358/),%,76.5,149552,DB00440,Trimethoprim
,2611358,total urinary recovery,"There was a significant difference (p less than 0.05), however, in the urinary recovery of 3-methylxanthine (11.3 +/- 2.6 per cent TH alone versus 13.9 +/- 3.6 per cent TH-CT) and in the total urinary recovery of TH and its metabolites (76.5 +/- 8.2 per cent versus 85.3 +/- 7.0 per cent), the latter finding suggesting that CT may have caused a small increase in the extent of TH absorption.",Lack of effect of co-trimoxazole on the pharmacokinetics of orally administered theophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611358/),%,85.3,149553,DB00440,Trimethoprim
,7792777,mean plasma concentration,The mean plasma concentration (n = 4) of sulfadoxine and trimethoprim 30 min after i.v. administration was 71.6 and 1.13 micrograms/g respectively.,[Demonstration of two trimethoprim/sulfonamide combinations in bronchoalveolar lavage fluid of horses and determination of blood levels]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7792777/),[μg] / [g],71.6,150032,DB00440,Trimethoprim
,7792777,mean plasma concentration,The mean plasma concentration (n = 4) of sulfadoxine and trimethoprim 30 min after i.v. administration was 71.6 and 1.13 micrograms/g respectively.,[Demonstration of two trimethoprim/sulfonamide combinations in bronchoalveolar lavage fluid of horses and determination of blood levels]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7792777/),[μg] / [g],1.13,150033,DB00440,Trimethoprim
,7792777,elimination half lives,The average elimination half lives of sulfadoxine and trimethoprim were 7.94 h and 1.35 h respectively.,[Demonstration of two trimethoprim/sulfonamide combinations in bronchoalveolar lavage fluid of horses and determination of blood levels]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7792777/),h,7.94,150034,DB00440,Trimethoprim
,7792777,elimination half lives,The average elimination half lives of sulfadoxine and trimethoprim were 7.94 h and 1.35 h respectively.,[Demonstration of two trimethoprim/sulfonamide combinations in bronchoalveolar lavage fluid of horses and determination of blood levels]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7792777/),h,1.35,150035,DB00440,Trimethoprim
,7792777,elimination half life,The elimination half life of sulfadimethoxine was 9.77 h.,[Demonstration of two trimethoprim/sulfonamide combinations in bronchoalveolar lavage fluid of horses and determination of blood levels]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7792777/),h,9.77,150036,DB00440,Trimethoprim
,10682404,bioavailabilities,"The calculated bioavailabilities of oral TMP and SMZ were 381, 558, 695, 480, 559 and 554 micrograms/mL, respectively, and the preparation containing hydroxyethyl cellulose 4.400 H as a thickness agent showed the best bioavailability (AUC 0-infinity = 695.24; micrograms/mL; Cmax = 35.2 micrograms/mL).",Comparative bioavailability of sulfamethoxazole in co-trimoxazole suspensions containing different thickness agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10682404/),[μg] / [ml],381,151196,DB00440,Trimethoprim
,10682404,bioavailabilities,"The calculated bioavailabilities of oral TMP and SMZ were 381, 558, 695, 480, 559 and 554 micrograms/mL, respectively, and the preparation containing hydroxyethyl cellulose 4.400 H as a thickness agent showed the best bioavailability (AUC 0-infinity = 695.24; micrograms/mL; Cmax = 35.2 micrograms/mL).",Comparative bioavailability of sulfamethoxazole in co-trimoxazole suspensions containing different thickness agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10682404/),[μg] / [ml],558,151197,DB00440,Trimethoprim
,10682404,bioavailabilities,"The calculated bioavailabilities of oral TMP and SMZ were 381, 558, 695, 480, 559 and 554 micrograms/mL, respectively, and the preparation containing hydroxyethyl cellulose 4.400 H as a thickness agent showed the best bioavailability (AUC 0-infinity = 695.24; micrograms/mL; Cmax = 35.2 micrograms/mL).",Comparative bioavailability of sulfamethoxazole in co-trimoxazole suspensions containing different thickness agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10682404/),[μg] / [ml],695,151198,DB00440,Trimethoprim
,10682404,bioavailabilities,"The calculated bioavailabilities of oral TMP and SMZ were 381, 558, 695, 480, 559 and 554 micrograms/mL, respectively, and the preparation containing hydroxyethyl cellulose 4.400 H as a thickness agent showed the best bioavailability (AUC 0-infinity = 695.24; micrograms/mL; Cmax = 35.2 micrograms/mL).",Comparative bioavailability of sulfamethoxazole in co-trimoxazole suspensions containing different thickness agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10682404/),[μg] / [ml],480,151199,DB00440,Trimethoprim
,10682404,bioavailabilities,"The calculated bioavailabilities of oral TMP and SMZ were 381, 558, 695, 480, 559 and 554 micrograms/mL, respectively, and the preparation containing hydroxyethyl cellulose 4.400 H as a thickness agent showed the best bioavailability (AUC 0-infinity = 695.24; micrograms/mL; Cmax = 35.2 micrograms/mL).",Comparative bioavailability of sulfamethoxazole in co-trimoxazole suspensions containing different thickness agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10682404/),[μg] / [ml],559,151200,DB00440,Trimethoprim
,10682404,bioavailabilities,"The calculated bioavailabilities of oral TMP and SMZ were 381, 558, 695, 480, 559 and 554 micrograms/mL, respectively, and the preparation containing hydroxyethyl cellulose 4.400 H as a thickness agent showed the best bioavailability (AUC 0-infinity = 695.24; micrograms/mL; Cmax = 35.2 micrograms/mL).",Comparative bioavailability of sulfamethoxazole in co-trimoxazole suspensions containing different thickness agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10682404/),[μg] / [ml],554,151201,DB00440,Trimethoprim
,10682404,AUC 0-infinity,"The calculated bioavailabilities of oral TMP and SMZ were 381, 558, 695, 480, 559 and 554 micrograms/mL, respectively, and the preparation containing hydroxyethyl cellulose 4.400 H as a thickness agent showed the best bioavailability (AUC 0-infinity = 695.24; micrograms/mL; Cmax = 35.2 micrograms/mL).",Comparative bioavailability of sulfamethoxazole in co-trimoxazole suspensions containing different thickness agents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10682404/),[μg] / [ml],695.24,151202,DB00440,Trimethoprim
,10682404,Cmax,"The calculated bioavailabilities of oral TMP and SMZ were 381, 558, 695, 480, 559 and 554 micrograms/mL, respectively, and the preparation containing hydroxyethyl cellulose 4.400 H as a thickness agent showed the best bioavailability (AUC 0-infinity = 695.24; micrograms/mL; Cmax = 35.2 micrograms/mL).",Comparative bioavailability of sulfamethoxazole in co-trimoxazole suspensions containing different thickness agents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10682404/),[μg] / [ml],35.2,151203,DB00440,Trimethoprim
,28314188,mean residence time,The compound was shown to have a mean residence time of 26.2±1.0min and a half-life of 18.2±0.7min after intraperitoneal delivery at 5mgkg-1.,Pharmaceutical analysis of a novel propargyl-linked antifolate antibiotic in the mouse. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28314188/),min,26.2,151287,DB00440,Trimethoprim
,28314188,half-life,The compound was shown to have a mean residence time of 26.2±1.0min and a half-life of 18.2±0.7min after intraperitoneal delivery at 5mgkg-1.,Pharmaceutical analysis of a novel propargyl-linked antifolate antibiotic in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28314188/),min,18.2,151288,DB00440,Trimethoprim
,4095069,half-lives,"The SMZ and TMP half-lives were 8.2 and 2.4 hr, respectively.",Pharmacokinetics of sulfamethoxazole and trimethoprim association in hens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095069/),h,8.2,151345,DB00440,Trimethoprim
,4095069,half-lives,"The SMZ and TMP half-lives were 8.2 and 2.4 hr, respectively.",Pharmacokinetics of sulfamethoxazole and trimethoprim association in hens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095069/),h,2.4,151346,DB00440,Trimethoprim
,4095069,S/T ratio,"The ratio between SMZ and TMP serum levels (S/T ratio), after iv administration of the 4:1 dosage, was approximately 20 and remained constant for only 1 hr, while after 5:1 and 2.5:1 oral dosages, the S/T ratio was 40 and 20, respectively, and remained invariable for 12 hr.",Pharmacokinetics of sulfamethoxazole and trimethoprim association in hens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095069/),,40,151347,DB00440,Trimethoprim
,4095069,S/T ratio,"The ratio between SMZ and TMP serum levels (S/T ratio), after iv administration of the 4:1 dosage, was approximately 20 and remained constant for only 1 hr, while after 5:1 and 2.5:1 oral dosages, the S/T ratio was 40 and 20, respectively, and remained invariable for 12 hr.",Pharmacokinetics of sulfamethoxazole and trimethoprim association in hens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095069/),,20,151348,DB00440,Trimethoprim
,4095069,oral bioavailability,"The oral bioavailability of SMZ and TMP was .46 and .36, respectively.",Pharmacokinetics of sulfamethoxazole and trimethoprim association in hens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095069/),,.46,151349,DB00440,Trimethoprim
,4095069,oral bioavailability,"The oral bioavailability of SMZ and TMP was .46 and .36, respectively.",Pharmacokinetics of sulfamethoxazole and trimethoprim association in hens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095069/),,.36,151350,DB00440,Trimethoprim
,4095069,S/T ratio,"Finally, the 2.5:1 combination, after oral administration, resulted in an appropriate synergistic ratio (S/T ratio = 20:1) of the drugs in the serum.",Pharmacokinetics of sulfamethoxazole and trimethoprim association in hens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095069/),,20:1,151351,DB00440,Trimethoprim
,2287901,serum half-life values (t1/2),"Once the levels in serum and extravascular fluids have equilibrated, extravascular levels tend to be similar to the remainder of the dosage intervals in the case of substances with serum half-life values (t1/2) of 8-12 hours or more (e.g. sulphadiazine, trimethoprim).",Pharmacokinetic parameters and characteristics relevant to antimicrobial surgical prophylaxis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287901/),h,8-12,152764,DB00440,Trimethoprim
,2247946,absorption half-lives,"The mean values of the absorption half-lives of sulphadiazine and trimethoprim were 0.9-1.6 h and 0.5-0.8 h, respectively.",A comparison of some of the pharmacokinetic parameters of three commercial sulphadiazine/trimethoprim combined preparations given orally to pigs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2247946/),h,0.9-1.6,155169,DB00440,Trimethoprim
,2247946,absorption half-lives,"The mean values of the absorption half-lives of sulphadiazine and trimethoprim were 0.9-1.6 h and 0.5-0.8 h, respectively.",A comparison of some of the pharmacokinetic parameters of three commercial sulphadiazine/trimethoprim combined preparations given orally to pigs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2247946/),h,0.5-0.8,155170,DB00440,Trimethoprim
,2247946,elimination half-lives,"The corresponding values for the elimination half-lives of sulphadiazine and trimethoprim were 3.1-4.3 h and 3.4-6.0 h, respectively.",A comparison of some of the pharmacokinetic parameters of three commercial sulphadiazine/trimethoprim combined preparations given orally to pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2247946/),h,3.1-4.3,155171,DB00440,Trimethoprim
,2247946,elimination half-lives,"The corresponding values for the elimination half-lives of sulphadiazine and trimethoprim were 3.1-4.3 h and 3.4-6.0 h, respectively.",A comparison of some of the pharmacokinetic parameters of three commercial sulphadiazine/trimethoprim combined preparations given orally to pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2247946/),h,3.4-6.0,155172,DB00440,Trimethoprim
,7695325,clearance,"The pharmacokinetics of trimethoprim and sulfamethoxazole were compared in eight critically ill versus nine non-critically ill male patients and were as follows, respectively: clearance, 1.88 +/- 0.44 versus 1.73 +/- 0.64 ml/min/kg for trimethoprim and 0.40 +/- 0.12 versus 0.34 +/- 0.11 ml/min/kg for sulfamethoxazole; volume of distribution, 1.6 +/- 0.5 versus 1.5 +/- 0.5 liters/kg for trimethoprim and 0.5 +/- 0.3 versus 0.4 +/- 0.1 liters/kg for sulfamethoxazole; and half-life, 10.9 +/- 7.4 versus 11.3 +/- 4.0 h for trimethoprim, and 15.5 +/- 9.5 versus 14.3 +/- 4.7 h for sulfamethoxazole.",Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695325/),[ml] / [kg·min],1.88,157662,DB00440,Trimethoprim
,7695325,clearance,"The pharmacokinetics of trimethoprim and sulfamethoxazole were compared in eight critically ill versus nine non-critically ill male patients and were as follows, respectively: clearance, 1.88 +/- 0.44 versus 1.73 +/- 0.64 ml/min/kg for trimethoprim and 0.40 +/- 0.12 versus 0.34 +/- 0.11 ml/min/kg for sulfamethoxazole; volume of distribution, 1.6 +/- 0.5 versus 1.5 +/- 0.5 liters/kg for trimethoprim and 0.5 +/- 0.3 versus 0.4 +/- 0.1 liters/kg for sulfamethoxazole; and half-life, 10.9 +/- 7.4 versus 11.3 +/- 4.0 h for trimethoprim, and 15.5 +/- 9.5 versus 14.3 +/- 4.7 h for sulfamethoxazole.",Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695325/),[ml] / [kg·min],1.73,157663,DB00440,Trimethoprim
,7695325,clearance,"The pharmacokinetics of trimethoprim and sulfamethoxazole were compared in eight critically ill versus nine non-critically ill male patients and were as follows, respectively: clearance, 1.88 +/- 0.44 versus 1.73 +/- 0.64 ml/min/kg for trimethoprim and 0.40 +/- 0.12 versus 0.34 +/- 0.11 ml/min/kg for sulfamethoxazole; volume of distribution, 1.6 +/- 0.5 versus 1.5 +/- 0.5 liters/kg for trimethoprim and 0.5 +/- 0.3 versus 0.4 +/- 0.1 liters/kg for sulfamethoxazole; and half-life, 10.9 +/- 7.4 versus 11.3 +/- 4.0 h for trimethoprim, and 15.5 +/- 9.5 versus 14.3 +/- 4.7 h for sulfamethoxazole.",Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695325/),[ml] / [kg·min],0.40,157664,DB00440,Trimethoprim
,7695325,clearance,"The pharmacokinetics of trimethoprim and sulfamethoxazole were compared in eight critically ill versus nine non-critically ill male patients and were as follows, respectively: clearance, 1.88 +/- 0.44 versus 1.73 +/- 0.64 ml/min/kg for trimethoprim and 0.40 +/- 0.12 versus 0.34 +/- 0.11 ml/min/kg for sulfamethoxazole; volume of distribution, 1.6 +/- 0.5 versus 1.5 +/- 0.5 liters/kg for trimethoprim and 0.5 +/- 0.3 versus 0.4 +/- 0.1 liters/kg for sulfamethoxazole; and half-life, 10.9 +/- 7.4 versus 11.3 +/- 4.0 h for trimethoprim, and 15.5 +/- 9.5 versus 14.3 +/- 4.7 h for sulfamethoxazole.",Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695325/),[ml] / [kg·min],0.34,157665,DB00440,Trimethoprim
,7695325,volume of distribution,"The pharmacokinetics of trimethoprim and sulfamethoxazole were compared in eight critically ill versus nine non-critically ill male patients and were as follows, respectively: clearance, 1.88 +/- 0.44 versus 1.73 +/- 0.64 ml/min/kg for trimethoprim and 0.40 +/- 0.12 versus 0.34 +/- 0.11 ml/min/kg for sulfamethoxazole; volume of distribution, 1.6 +/- 0.5 versus 1.5 +/- 0.5 liters/kg for trimethoprim and 0.5 +/- 0.3 versus 0.4 +/- 0.1 liters/kg for sulfamethoxazole; and half-life, 10.9 +/- 7.4 versus 11.3 +/- 4.0 h for trimethoprim, and 15.5 +/- 9.5 versus 14.3 +/- 4.7 h for sulfamethoxazole.",Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695325/),[l] / [kg],1.6,157666,DB00440,Trimethoprim
,7695325,volume of distribution,"The pharmacokinetics of trimethoprim and sulfamethoxazole were compared in eight critically ill versus nine non-critically ill male patients and were as follows, respectively: clearance, 1.88 +/- 0.44 versus 1.73 +/- 0.64 ml/min/kg for trimethoprim and 0.40 +/- 0.12 versus 0.34 +/- 0.11 ml/min/kg for sulfamethoxazole; volume of distribution, 1.6 +/- 0.5 versus 1.5 +/- 0.5 liters/kg for trimethoprim and 0.5 +/- 0.3 versus 0.4 +/- 0.1 liters/kg for sulfamethoxazole; and half-life, 10.9 +/- 7.4 versus 11.3 +/- 4.0 h for trimethoprim, and 15.5 +/- 9.5 versus 14.3 +/- 4.7 h for sulfamethoxazole.",Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695325/),[l] / [kg],1.5,157667,DB00440,Trimethoprim
,7695325,volume of distribution,"The pharmacokinetics of trimethoprim and sulfamethoxazole were compared in eight critically ill versus nine non-critically ill male patients and were as follows, respectively: clearance, 1.88 +/- 0.44 versus 1.73 +/- 0.64 ml/min/kg for trimethoprim and 0.40 +/- 0.12 versus 0.34 +/- 0.11 ml/min/kg for sulfamethoxazole; volume of distribution, 1.6 +/- 0.5 versus 1.5 +/- 0.5 liters/kg for trimethoprim and 0.5 +/- 0.3 versus 0.4 +/- 0.1 liters/kg for sulfamethoxazole; and half-life, 10.9 +/- 7.4 versus 11.3 +/- 4.0 h for trimethoprim, and 15.5 +/- 9.5 versus 14.3 +/- 4.7 h for sulfamethoxazole.",Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695325/),[l] / [kg],0.5,157668,DB00440,Trimethoprim
,7695325,volume of distribution,"The pharmacokinetics of trimethoprim and sulfamethoxazole were compared in eight critically ill versus nine non-critically ill male patients and were as follows, respectively: clearance, 1.88 +/- 0.44 versus 1.73 +/- 0.64 ml/min/kg for trimethoprim and 0.40 +/- 0.12 versus 0.34 +/- 0.11 ml/min/kg for sulfamethoxazole; volume of distribution, 1.6 +/- 0.5 versus 1.5 +/- 0.5 liters/kg for trimethoprim and 0.5 +/- 0.3 versus 0.4 +/- 0.1 liters/kg for sulfamethoxazole; and half-life, 10.9 +/- 7.4 versus 11.3 +/- 4.0 h for trimethoprim, and 15.5 +/- 9.5 versus 14.3 +/- 4.7 h for sulfamethoxazole.",Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695325/),[l] / [kg],0.4,157669,DB00440,Trimethoprim
,7695325,half-life,"The pharmacokinetics of trimethoprim and sulfamethoxazole were compared in eight critically ill versus nine non-critically ill male patients and were as follows, respectively: clearance, 1.88 +/- 0.44 versus 1.73 +/- 0.64 ml/min/kg for trimethoprim and 0.40 +/- 0.12 versus 0.34 +/- 0.11 ml/min/kg for sulfamethoxazole; volume of distribution, 1.6 +/- 0.5 versus 1.5 +/- 0.5 liters/kg for trimethoprim and 0.5 +/- 0.3 versus 0.4 +/- 0.1 liters/kg for sulfamethoxazole; and half-life, 10.9 +/- 7.4 versus 11.3 +/- 4.0 h for trimethoprim, and 15.5 +/- 9.5 versus 14.3 +/- 4.7 h for sulfamethoxazole.",Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695325/),h,10.9,157670,DB00440,Trimethoprim
,7695325,half-life,"The pharmacokinetics of trimethoprim and sulfamethoxazole were compared in eight critically ill versus nine non-critically ill male patients and were as follows, respectively: clearance, 1.88 +/- 0.44 versus 1.73 +/- 0.64 ml/min/kg for trimethoprim and 0.40 +/- 0.12 versus 0.34 +/- 0.11 ml/min/kg for sulfamethoxazole; volume of distribution, 1.6 +/- 0.5 versus 1.5 +/- 0.5 liters/kg for trimethoprim and 0.5 +/- 0.3 versus 0.4 +/- 0.1 liters/kg for sulfamethoxazole; and half-life, 10.9 +/- 7.4 versus 11.3 +/- 4.0 h for trimethoprim, and 15.5 +/- 9.5 versus 14.3 +/- 4.7 h for sulfamethoxazole.",Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695325/),h,11.3,157671,DB00440,Trimethoprim
,7695325,half-life,"The pharmacokinetics of trimethoprim and sulfamethoxazole were compared in eight critically ill versus nine non-critically ill male patients and were as follows, respectively: clearance, 1.88 +/- 0.44 versus 1.73 +/- 0.64 ml/min/kg for trimethoprim and 0.40 +/- 0.12 versus 0.34 +/- 0.11 ml/min/kg for sulfamethoxazole; volume of distribution, 1.6 +/- 0.5 versus 1.5 +/- 0.5 liters/kg for trimethoprim and 0.5 +/- 0.3 versus 0.4 +/- 0.1 liters/kg for sulfamethoxazole; and half-life, 10.9 +/- 7.4 versus 11.3 +/- 4.0 h for trimethoprim, and 15.5 +/- 9.5 versus 14.3 +/- 4.7 h for sulfamethoxazole.",Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695325/),h,15.5,157672,DB00440,Trimethoprim
,7695325,half-life,"The pharmacokinetics of trimethoprim and sulfamethoxazole were compared in eight critically ill versus nine non-critically ill male patients and were as follows, respectively: clearance, 1.88 +/- 0.44 versus 1.73 +/- 0.64 ml/min/kg for trimethoprim and 0.40 +/- 0.12 versus 0.34 +/- 0.11 ml/min/kg for sulfamethoxazole; volume of distribution, 1.6 +/- 0.5 versus 1.5 +/- 0.5 liters/kg for trimethoprim and 0.5 +/- 0.3 versus 0.4 +/- 0.1 liters/kg for sulfamethoxazole; and half-life, 10.9 +/- 7.4 versus 11.3 +/- 4.0 h for trimethoprim, and 15.5 +/- 9.5 versus 14.3 +/- 4.7 h for sulfamethoxazole.",Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695325/),h,14.3,157673,DB00440,Trimethoprim
,7695325,bioavailability,"Absorption appeared to be similar between the critically ill and non-critically patients: bioavailability was 97.5% +/- 22.4% versus 101.8% +/- 22.7% for trimethoprim and 86.2% +/- 17.9% versus 99.1% +/- 20.5% for sulfamethoxazole, respectively.",Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695325/),%,97.5,157674,DB00440,Trimethoprim
,7695325,bioavailability,"Absorption appeared to be similar between the critically ill and non-critically patients: bioavailability was 97.5% +/- 22.4% versus 101.8% +/- 22.7% for trimethoprim and 86.2% +/- 17.9% versus 99.1% +/- 20.5% for sulfamethoxazole, respectively.",Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695325/),%,101.8,157675,DB00440,Trimethoprim
,7695325,bioavailability,"Absorption appeared to be similar between the critically ill and non-critically patients: bioavailability was 97.5% +/- 22.4% versus 101.8% +/- 22.7% for trimethoprim and 86.2% +/- 17.9% versus 99.1% +/- 20.5% for sulfamethoxazole, respectively.",Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695325/),%,86.2,157676,DB00440,Trimethoprim
,7695325,bioavailability,"Absorption appeared to be similar between the critically ill and non-critically patients: bioavailability was 97.5% +/- 22.4% versus 101.8% +/- 22.7% for trimethoprim and 86.2% +/- 17.9% versus 99.1% +/- 20.5% for sulfamethoxazole, respectively.",Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695325/),%,99.1,157677,DB00440,Trimethoprim
,11459198,apparent Ki,"Using uptake of 3H-vinblastine in L-MDR1 cells, atovaquone was shown to inhibit P-glycoprotein with an apparent Ki of 95.6 microM.",The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459198/),μM,95.6,159828,DB00440,Trimethoprim
,11050747,time of half-life of elimination phase (t1/2),"After intravenous administration of product A the mean time of half-life of elimination phase (t1/2) for sulphadoxine was 12.9 h, steady-state volume of distribution (Vd(ss)) was 0.44 L.kg-1 and clearance was 0.024 L.kg-1.h-1.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),h,12.9,162744,DB00440,Trimethoprim
,11050747,steady-state volume of distribution (Vd(ss)),"After intravenous administration of product A the mean time of half-life of elimination phase (t1/2) for sulphadoxine was 12.9 h, steady-state volume of distribution (Vd(ss)) was 0.44 L.kg-1 and clearance was 0.024 L.kg-1.h-1.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),[l] / [kg],0.44,162745,DB00440,Trimethoprim
,11050747,clearance,"After intravenous administration of product A the mean time of half-life of elimination phase (t1/2) for sulphadoxine was 12.9 h, steady-state volume of distribution (Vd(ss)) was 0.44 L.kg-1 and clearance was 0.024 L.kg-1.h-1.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),[l] / [h·kg],0.024,162746,DB00440,Trimethoprim
,11050747,bioavailability,"After subcutaneous administration, the bioavailability of sulphadoxine was 96% and 98% and the time to reach a maximum concentration was 6.3 and 8.0 h for products A and B, respectively.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),%,96,162747,DB00440,Trimethoprim
,11050747,bioavailability,"After subcutaneous administration, the bioavailability of sulphadoxine was 96% and 98% and the time to reach a maximum concentration was 6.3 and 8.0 h for products A and B, respectively.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),%,98,162748,DB00440,Trimethoprim
,11050747,time to reach a maximum concentration,"After subcutaneous administration, the bioavailability of sulphadoxine was 96% and 98% and the time to reach a maximum concentration was 6.3 and 8.0 h for products A and B, respectively.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),h,6.3,162749,DB00440,Trimethoprim
,11050747,time to reach a maximum concentration,"After subcutaneous administration, the bioavailability of sulphadoxine was 96% and 98% and the time to reach a maximum concentration was 6.3 and 8.0 h for products A and B, respectively.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),h,8.0,162750,DB00440,Trimethoprim
,11050747,Cmax,The Cmax for trimethoprim was higher for product A (0.49 microgram.,Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),μg,0.49,162751,DB00440,Trimethoprim
,11050747,apparent elimination t1/2,"Slow absorption from the injection site appeared to delay the elimination of trimethoprim after subcutaneous administration when compared to that after intravenous administration: apparent elimination t1/2 for trimethoprim after intravenous administration of product A was 1.9 h compared to 3.9 h and 3.6 h after subcutaneous administration of products A and B, respectively.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),h,1.9,162752,DB00440,Trimethoprim
,11050747,apparent elimination t1/2,"Slow absorption from the injection site appeared to delay the elimination of trimethoprim after subcutaneous administration when compared to that after intravenous administration: apparent elimination t1/2 for trimethoprim after intravenous administration of product A was 1.9 h compared to 3.9 h and 3.6 h after subcutaneous administration of products A and B, respectively.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),h,3.9,162753,DB00440,Trimethoprim
,11050747,apparent elimination t1/2,"Slow absorption from the injection site appeared to delay the elimination of trimethoprim after subcutaneous administration when compared to that after intravenous administration: apparent elimination t1/2 for trimethoprim after intravenous administration of product A was 1.9 h compared to 3.9 h and 3.6 h after subcutaneous administration of products A and B, respectively.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),h,3.6,162754,DB00440,Trimethoprim
,11050747,mean residence time,Also the mean residence time was significantly shorter (p < 0.05) after intravenous administration (2.4 h) than that after subcutaneous administration of product A (6.9 h) and B (7.1 h).,Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),h,2.4,162755,DB00440,Trimethoprim
,11050747,mean residence time,Also the mean residence time was significantly shorter (p < 0.05) after intravenous administration (2.4 h) than that after subcutaneous administration of product A (6.9 h) and B (7.1 h).,Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),h,6.9,162756,DB00440,Trimethoprim
,11050747,mean residence time,Also the mean residence time was significantly shorter (p < 0.05) after intravenous administration (2.4 h) than that after subcutaneous administration of product A (6.9 h) and B (7.1 h).,Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),h,7.1,162757,DB00440,Trimethoprim
,11050747,bioavailability,"The bioavailability of trimethoprim was lower than that of sulphadoxine: 76% and 74% for products A and B, respectively.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),%,76,162758,DB00440,Trimethoprim
,11050747,bioavailability,"The bioavailability of trimethoprim was lower than that of sulphadoxine: 76% and 74% for products A and B, respectively.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),%,74,162759,DB00440,Trimethoprim
,9579709,MICs,The range of MICs was 0.12-0.5 mg/L for both roxithromycin and erythromycin.,The comparative in-vitro activity of roxithromycin and other antibiotics against Bordetella pertussis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579709/),[mg] / [l],0.12-0.5,162953,DB00440,Trimethoprim
,9579709,MBC,"Roxithromycin was bactericidal, with an MBC of 1 mg/L (as compared with 0.5 mg/L for erythromycin).",The comparative in-vitro activity of roxithromycin and other antibiotics against Bordetella pertussis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579709/),[mg] / [l],1,162954,DB00440,Trimethoprim
,9579709,MBC,"Roxithromycin was bactericidal, with an MBC of 1 mg/L (as compared with 0.5 mg/L for erythromycin).",The comparative in-vitro activity of roxithromycin and other antibiotics against Bordetella pertussis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579709/),[mg] / [l],0.5,162955,DB00440,Trimethoprim
,3363307,half-life,Sulphadiazine (SDZ) and trimethoprim (TMP) combined into co-trimazine has a half-life of 10 h in the adult and therefore the use of 1 dose/day has been introduced in the treatment of patients with urinary tract infections (UTI).,Plasma and urine concentrations of trimethoprim-sulphadiazine (co-trimazine) in children given one dose per day. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3363307/),h,10,165931,DB00440,Trimethoprim
greater,3363307,peak plasma levels,In all patients the peak plasma levels of SDZ at steady state were greater than 15 mg/l and after 12 h mostly greater than 10 (range 7-22) mg/l.,Plasma and urine concentrations of trimethoprim-sulphadiazine (co-trimazine) in children given one dose per day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3363307/),[mg] / [l],15,165932,DB00440,Trimethoprim
greater,3363307,peak plasma levels,In all patients the peak plasma levels of SDZ at steady state were greater than 15 mg/l and after 12 h mostly greater than 10 (range 7-22) mg/l.,Plasma and urine concentrations of trimethoprim-sulphadiazine (co-trimazine) in children given one dose per day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3363307/),[mg] / [l],10,165933,DB00440,Trimethoprim
,3363307,concentrations,The concentrations in urine at 24 h were in the children about 40 mg/l of SDZ and 10 mg/l of TMP and in the infants 35 and 2 mg/l respectively.,Plasma and urine concentrations of trimethoprim-sulphadiazine (co-trimazine) in children given one dose per day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3363307/),[mg] / [l],40,165934,DB00440,Trimethoprim
,3363307,concentrations,The concentrations in urine at 24 h were in the children about 40 mg/l of SDZ and 10 mg/l of TMP and in the infants 35 and 2 mg/l respectively.,Plasma and urine concentrations of trimethoprim-sulphadiazine (co-trimazine) in children given one dose per day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3363307/),[mg] / [l],10,165935,DB00440,Trimethoprim
,3363307,concentrations,The concentrations in urine at 24 h were in the children about 40 mg/l of SDZ and 10 mg/l of TMP and in the infants 35 and 2 mg/l respectively.,Plasma and urine concentrations of trimethoprim-sulphadiazine (co-trimazine) in children given one dose per day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3363307/),[mg] / [l],35,165936,DB00440,Trimethoprim
,3363307,concentrations,The concentrations in urine at 24 h were in the children about 40 mg/l of SDZ and 10 mg/l of TMP and in the infants 35 and 2 mg/l respectively.,Plasma and urine concentrations of trimethoprim-sulphadiazine (co-trimazine) in children given one dose per day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3363307/),[mg] / [l],2,165937,DB00440,Trimethoprim
,8460257,distribution half-lives,Following intravenous administration both drugs dispersed rapidly with distribution half-lives of about 12 minutes for SMM and about 18 minutes for TMP.,"Pharmacokinetic profile of sulphamonomethoxine-trimethoprim in horses after intravenous, intramuscular and oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8460257/),min,12,166984,DB00440,Trimethoprim
,8460257,distribution half-lives,Following intravenous administration both drugs dispersed rapidly with distribution half-lives of about 12 minutes for SMM and about 18 minutes for TMP.,"Pharmacokinetic profile of sulphamonomethoxine-trimethoprim in horses after intravenous, intramuscular and oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8460257/),min,18,166985,DB00440,Trimethoprim
,8460257,Bioavailability,"Bioavailability of the drugs in aqueous solution was good: about 72 per cent and 84 per cent for SMM and about 84 per cent and 98 per cent for TMP following intramuscular and oral administration, respectively.","Pharmacokinetic profile of sulphamonomethoxine-trimethoprim in horses after intravenous, intramuscular and oral administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8460257/),%,72,166986,DB00440,Trimethoprim
,8460257,Bioavailability,"Bioavailability of the drugs in aqueous solution was good: about 72 per cent and 84 per cent for SMM and about 84 per cent and 98 per cent for TMP following intramuscular and oral administration, respectively.","Pharmacokinetic profile of sulphamonomethoxine-trimethoprim in horses after intravenous, intramuscular and oral administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8460257/),%,84,166987,DB00440,Trimethoprim
,8460257,Bioavailability,"Bioavailability of the drugs in aqueous solution was good: about 72 per cent and 84 per cent for SMM and about 84 per cent and 98 per cent for TMP following intramuscular and oral administration, respectively.","Pharmacokinetic profile of sulphamonomethoxine-trimethoprim in horses after intravenous, intramuscular and oral administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8460257/),%,98,166988,DB00440,Trimethoprim
,3402523,maximal concentration,"The maximal concentration in plasma after a single oral dose of 400 mg trimethoprim was 3.95 +/- 1.08 mg/l, and it was observed after 2 h, whereas in skin blister fluid the level was 2.21 +/- 0.62 mg/l, and it was delayed for up to 6 h.",Plasma and skin blister fluid concentrations of trimethoprim following its oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402523/),[mg] / [l],3.95,167320,DB00440,Trimethoprim
,3402523,maximal concentration,"The maximal concentration in plasma after a single oral dose of 400 mg trimethoprim was 3.95 +/- 1.08 mg/l, and it was observed after 2 h, whereas in skin blister fluid the level was 2.21 +/- 0.62 mg/l, and it was delayed for up to 6 h.",Plasma and skin blister fluid concentrations of trimethoprim following its oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402523/),[mg] / [l],2.21,167321,DB00440,Trimethoprim
,3402523,steady-state concentration,The steady-state concentration of trimethoprim in plasma during routine treatment with 200-mg doses ranged between 2 and 3.5 mg/l.,Plasma and skin blister fluid concentrations of trimethoprim following its oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402523/),[mg] / [l],2 and 3.5,167322,DB00440,Trimethoprim
greater,2490565,recoveries,The mean recoveries for 4'-demethyl trimethoprim were greater than 80% while the mean recoveries for the other compounds were greater than 90%.,"Determination of sulfadimethoxine, sulfamethoxazole, trimethoprim and their main metabolites in porcine plasma by column switching HPLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2490565/),%,80,168618,DB00440,Trimethoprim
greater,2490565,recoveries,The mean recoveries for 4'-demethyl trimethoprim were greater than 80% while the mean recoveries for the other compounds were greater than 90%.,"Determination of sulfadimethoxine, sulfamethoxazole, trimethoprim and their main metabolites in porcine plasma by column switching HPLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2490565/),%,90,168619,DB00440,Trimethoprim
,32434196,minimum inhibitory concentrations (MICs),Five S. aureus isolates with TMP/SMX (1:5 fixed ratio) minimum inhibitory concentrations (MICs) of 0.032-64 μg/mL were tested.,The First Report on Pharmacokinetic/Pharmacodynamic Study of Trimethoprim/Sulfamethoxazole against Staphylococcus aureus with a Neutropenic Murine Thigh Infection Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32434196/),[μg] / [ml],0.032-64,169888,DB00440,Trimethoprim
,32434196,half-life,"After TMP/SMX single dose (130 mg/kg), the half-life, area under the blood concentration curve (AUC0-∞), and the protein binding ratio of SMX were 1.5 h, 718.2 μg h/mL, and 73.0 ± 8.3%, respectively.",The First Report on Pharmacokinetic/Pharmacodynamic Study of Trimethoprim/Sulfamethoxazole against Staphylococcus aureus with a Neutropenic Murine Thigh Infection Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32434196/),h,1.5,169889,DB00440,Trimethoprim
,32434196,area under the blood concentration curve (AUC0-∞),"After TMP/SMX single dose (130 mg/kg), the half-life, area under the blood concentration curve (AUC0-∞), and the protein binding ratio of SMX were 1.5 h, 718.2 μg h/mL, and 73.0 ± 8.3%, respectively.",The First Report on Pharmacokinetic/Pharmacodynamic Study of Trimethoprim/Sulfamethoxazole against Staphylococcus aureus with a Neutropenic Murine Thigh Infection Model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32434196/),[h·μg] / [ml],718.2,169890,DB00440,Trimethoprim
,32434196,protein binding ratio,"After TMP/SMX single dose (130 mg/kg), the half-life, area under the blood concentration curve (AUC0-∞), and the protein binding ratio of SMX were 1.5 h, 718.2 μg h/mL, and 73.0 ± 8.3%, respectively.",The First Report on Pharmacokinetic/Pharmacodynamic Study of Trimethoprim/Sulfamethoxazole against Staphylococcus aureus with a Neutropenic Murine Thigh Infection Model. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32434196/),%,73.0,169891,DB00440,Trimethoprim
,12668082,limits of detection,"The limits of detection were 0.019 microg/ml of sulfadiazine and 0.024 microg/ml of trimethoprim for the LC-UV method, and 0.020 microg/ml of sulfadiazine and 0.062 microg/ml of trimethoprim for the LC-MS-MS method.",Comparison of a liquid chromatographic method with ultraviolet and ion-trap tandem mass spectrometric detection for the simultaneous determination of sulfadiazine and trimethoprim in plasma from dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12668082/),[μg] / [ml],0.019,171603,DB00440,Trimethoprim
,12668082,limits of detection,"The limits of detection were 0.019 microg/ml of sulfadiazine and 0.024 microg/ml of trimethoprim for the LC-UV method, and 0.020 microg/ml of sulfadiazine and 0.062 microg/ml of trimethoprim for the LC-MS-MS method.",Comparison of a liquid chromatographic method with ultraviolet and ion-trap tandem mass spectrometric detection for the simultaneous determination of sulfadiazine and trimethoprim in plasma from dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12668082/),[μg] / [ml],0.024,171604,DB00440,Trimethoprim
,12668082,limits of detection,"The limits of detection were 0.019 microg/ml of sulfadiazine and 0.024 microg/ml of trimethoprim for the LC-UV method, and 0.020 microg/ml of sulfadiazine and 0.062 microg/ml of trimethoprim for the LC-MS-MS method.",Comparison of a liquid chromatographic method with ultraviolet and ion-trap tandem mass spectrometric detection for the simultaneous determination of sulfadiazine and trimethoprim in plasma from dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12668082/),[μg] / [ml],0.020,171605,DB00440,Trimethoprim
,12668082,limits of detection,"The limits of detection were 0.019 microg/ml of sulfadiazine and 0.024 microg/ml of trimethoprim for the LC-UV method, and 0.020 microg/ml of sulfadiazine and 0.062 microg/ml of trimethoprim for the LC-MS-MS method.",Comparison of a liquid chromatographic method with ultraviolet and ion-trap tandem mass spectrometric detection for the simultaneous determination of sulfadiazine and trimethoprim in plasma from dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12668082/),[μg] / [ml],0.062,171606,DB00440,Trimethoprim
,6981172,peak levels,"The mean peak levels of TMP and SMZ in plasma were 3.22 and 100 micrograms/ml, respectively, on day 1 and 5.91 and 178 micrograms/ml, respectively, on day 4, when a steady state was achieved.",Intravenous pharmacokinetics and in vitro bactericidal activity of trimethoprim-sulfamethoxazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6981172/),[μg] / [ml],3.22,172269,DB00440,Trimethoprim
,6981172,peak levels,"The mean peak levels of TMP and SMZ in plasma were 3.22 and 100 micrograms/ml, respectively, on day 1 and 5.91 and 178 micrograms/ml, respectively, on day 4, when a steady state was achieved.",Intravenous pharmacokinetics and in vitro bactericidal activity of trimethoprim-sulfamethoxazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6981172/),[μg] / [ml],100,172270,DB00440,Trimethoprim
,6981172,peak levels,"The mean peak levels of TMP and SMZ in plasma were 3.22 and 100 micrograms/ml, respectively, on day 1 and 5.91 and 178 micrograms/ml, respectively, on day 4, when a steady state was achieved.",Intravenous pharmacokinetics and in vitro bactericidal activity of trimethoprim-sulfamethoxazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6981172/),[μg] / [ml],5.91,172271,DB00440,Trimethoprim
,6981172,peak levels,"The mean peak levels of TMP and SMZ in plasma were 3.22 and 100 micrograms/ml, respectively, on day 1 and 5.91 and 178 micrograms/ml, respectively, on day 4, when a steady state was achieved.",Intravenous pharmacokinetics and in vitro bactericidal activity of trimethoprim-sulfamethoxazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6981172/),[μg] / [ml],178,172272,DB00440,Trimethoprim
,3566861,Elimination half-lives,Elimination half-lives ranged from 8 to 13 h for TMP and from 9 to 15 h for SDZ.,Pharmacokinetics of co-trimazine after single and multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566861/),h,8 to 13,173104,DB00440,Trimethoprim
,3566861,Elimination half-lives,Elimination half-lives ranged from 8 to 13 h for TMP and from 9 to 15 h for SDZ.,Pharmacokinetics of co-trimazine after single and multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566861/),h,9 to 15,173105,DB00440,Trimethoprim
,3566861,urinary recovery,"For TMP, the urinary recovery during the 24 h following the single dose averaged 39%.",Pharmacokinetics of co-trimazine after single and multiple doses. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566861/),%,39,173106,DB00440,Trimethoprim
,8225622,serum trough concentrations,"Despite administration of a loading dose of twice the regular dose, serum trough concentrations continuously rose from 12 h to 96 h by 63% for trimethoprim and 102% for sulfamethoxazole.",Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225622/),h,12,173851,DB00440,Trimethoprim
,8225622,trough concentrations,"After 4-6 days mean trough concentrations of trimethoprim and sulfamethoxazole were 7.7 +/- 3.0 and 198 +/- 74 mg/l, with individual values of < 4.6 and < 103 mg/l in two patients and > 11.4 and > 307 mg/l in two others.",Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225622/),[mg] / [l],7.7,173852,DB00440,Trimethoprim
,8225622,trough concentrations,"After 4-6 days mean trough concentrations of trimethoprim and sulfamethoxazole were 7.7 +/- 3.0 and 198 +/- 74 mg/l, with individual values of < 4.6 and < 103 mg/l in two patients and > 11.4 and > 307 mg/l in two others.",Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225622/),[mg] / [l],198,173853,DB00440,Trimethoprim
<,8225622,trough concentrations,"After 4-6 days mean trough concentrations of trimethoprim and sulfamethoxazole were 7.7 +/- 3.0 and 198 +/- 74 mg/l, with individual values of < 4.6 and < 103 mg/l in two patients and > 11.4 and > 307 mg/l in two others.",Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225622/),[mg] / [l],4.6,173854,DB00440,Trimethoprim
<,8225622,trough concentrations,"After 4-6 days mean trough concentrations of trimethoprim and sulfamethoxazole were 7.7 +/- 3.0 and 198 +/- 74 mg/l, with individual values of < 4.6 and < 103 mg/l in two patients and > 11.4 and > 307 mg/l in two others.",Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225622/),[mg] / [l],103,173855,DB00440,Trimethoprim
>,8225622,trough concentrations,"After 4-6 days mean trough concentrations of trimethoprim and sulfamethoxazole were 7.7 +/- 3.0 and 198 +/- 74 mg/l, with individual values of < 4.6 and < 103 mg/l in two patients and > 11.4 and > 307 mg/l in two others.",Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225622/),[mg] / [l],11.4,173856,DB00440,Trimethoprim
>,8225622,trough concentrations,"After 4-6 days mean trough concentrations of trimethoprim and sulfamethoxazole were 7.7 +/- 3.0 and 198 +/- 74 mg/l, with individual values of < 4.6 and < 103 mg/l in two patients and > 11.4 and > 307 mg/l in two others.",Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225622/),[mg] / [l],307,173857,DB00440,Trimethoprim
,7618357,terminal elimination t1/2,"3. In contrast with pharmacokinetic data of TMP in mammals, the present study documented a long terminal elimination t1/2(36.1 h), large Vdss(5980 ml/kg) and small Clb(2.4 ml/min/kg) for TMP in rainbow trout, thus illustrating the slow biotransformation and elimination capacity, particularly the strong 'holding' capacity (storage) for the drug in trout.",Disposition kinetics of trimethoprim in rainbow trout (Oncorhynchus mykiss). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7618357/),h,36.1,173917,DB00440,Trimethoprim
,7618357,Vdss,"3. In contrast with pharmacokinetic data of TMP in mammals, the present study documented a long terminal elimination t1/2(36.1 h), large Vdss(5980 ml/kg) and small Clb(2.4 ml/min/kg) for TMP in rainbow trout, thus illustrating the slow biotransformation and elimination capacity, particularly the strong 'holding' capacity (storage) for the drug in trout.",Disposition kinetics of trimethoprim in rainbow trout (Oncorhynchus mykiss). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7618357/),[ml] / [kg],5980,173918,DB00440,Trimethoprim
,7618357,Clb,"3. In contrast with pharmacokinetic data of TMP in mammals, the present study documented a long terminal elimination t1/2(36.1 h), large Vdss(5980 ml/kg) and small Clb(2.4 ml/min/kg) for TMP in rainbow trout, thus illustrating the slow biotransformation and elimination capacity, particularly the strong 'holding' capacity (storage) for the drug in trout.",Disposition kinetics of trimethoprim in rainbow trout (Oncorhynchus mykiss). ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7618357/),[ml] / [kg·min],2.4,173919,DB00440,Trimethoprim
,7618357,Urinary excretion,5. Urinary excretion of TMP was a minor elimination route in trout (14.4% dose).,Disposition kinetics of trimethoprim in rainbow trout (Oncorhynchus mykiss). ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7618357/),%,14.4,173920,DB00440,Trimethoprim
,33903114,MIC,"Nonetheless, both models supported TMP-SMX dose increases in infants and young children for resistant pathogens with a MIC of 1 mg/liter, although the required dose increase based on the external model was lower.",External Evaluation of Two Pediatric Population Pharmacokinetics Models of Oral Trimethoprim and Sulfamethoxazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33903114/),[mg] / [l],1,174002,DB00440,Trimethoprim
,30528339,Ki,"Trimethoprim is a more potent inhibitor of MATE2-K than MATE1 with Ki values (μM) of 0.030-0.28 and 2.4-5.9, respectively.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),μM,0.030-0.28,174947,DB00440,Trimethoprim
,30528339,Ki,"Trimethoprim is a more potent inhibitor of MATE2-K than MATE1 with Ki values (μM) of 0.030-0.28 and 2.4-5.9, respectively.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),μM,2.4-5.9,174948,DB00440,Trimethoprim
,30528339,Km,"Trimethoprim is a substrate of human MATE1 and MATE2-K with Km values of 2.3 ± 0.9 and 0.018 ± 0.004 μM, and mouse Mate1, but not human OCT2, mouse Oct1 and Oct2.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),μM,2.3,174949,DB00440,Trimethoprim
,30528339,Km,"Trimethoprim is a substrate of human MATE1 and MATE2-K with Km values of 2.3 ± 0.9 and 0.018 ± 0.004 μM, and mouse Mate1, but not human OCT2, mouse Oct1 and Oct2.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),μM,0.018,174950,DB00440,Trimethoprim
,30528339,renal clearance (CLR),Pyrimethamine significantly reduced the renal clearance (CLR) of trimethoprim (mL/min/kg) from 40.0 ± 5.1 to 20.1 ± 3.7 (p < 0.05).,Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),[ml] / [kg·min],40.0,174951,DB00440,Trimethoprim
,30528339,renal clearance (CLR),Pyrimethamine significantly reduced the renal clearance (CLR) of trimethoprim (mL/min/kg) from 40.0 ± 5.1 to 20.1 ± 3.7 (p < 0.05).,Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),[ml] / [kg·min],20.1,174952,DB00440,Trimethoprim
,30528339,CLR,"Together with an increase in the plasma concentrations of trimethoprim, the CLR (mL/min/kg) of trimethoprim decreased to 25.9 ± 3.2, 13.5 ± 5.7, and 8.92 ± 1.50 at the respective rates.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),[ml] / [kg·min],25.9,174953,DB00440,Trimethoprim
,30528339,CLR,"Together with an increase in the plasma concentrations of trimethoprim, the CLR (mL/min/kg) of trimethoprim decreased to 25.9 ± 3.2, 13.5 ± 5.7, and 8.92 ± 1.50 at the respective rates.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),[ml] / [kg·min],13.5,174954,DB00440,Trimethoprim
,30528339,CLR,"Together with an increase in the plasma concentrations of trimethoprim, the CLR (mL/min/kg) of trimethoprim decreased to 25.9 ± 3.2, 13.5 ± 5.7, and 8.92 ± 1.50 at the respective rates.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),[ml] / [kg·min],8.92,174955,DB00440,Trimethoprim
,30528339,CLR,"Trimethoprim decreased the CLR of rhodamine 123 in an infusion rate-dependent manner: 11.5 ± 1.3 (control), 5.17 ± 1.55, 1.31 ± 0.50, and 0.532 ± 0.180.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),,11.5,174956,DB00440,Trimethoprim
,30528339,CLR,"Trimethoprim decreased the CLR of rhodamine 123 in an infusion rate-dependent manner: 11.5 ± 1.3 (control), 5.17 ± 1.55, 1.31 ± 0.50, and 0.532 ± 0.180.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),,5.17,174957,DB00440,Trimethoprim
,30528339,CLR,"Trimethoprim decreased the CLR of rhodamine 123 in an infusion rate-dependent manner: 11.5 ± 1.3 (control), 5.17 ± 1.55, 1.31 ± 0.50, and 0.532 ± 0.180.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),,1.31,174958,DB00440,Trimethoprim
,30528339,CLR,"Trimethoprim decreased the CLR of rhodamine 123 in an infusion rate-dependent manner: 11.5 ± 1.3 (control), 5.17 ± 1.55, 1.31 ± 0.50, and 0.532 ± 0.180.",Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30528339/),,0.532,174959,DB00440,Trimethoprim
,7062219,half-lives,"The mean half-lives for SMZ and TMP were 16.5 hours and 19.0 hours, respectively.",Pharmacology of trimethoprim-sulfamethoxazole in newborn infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7062219/),h,16.5,175810,DB00440,Trimethoprim
,7062219,half-lives,"The mean half-lives for SMZ and TMP were 16.5 hours and 19.0 hours, respectively.",Pharmacology of trimethoprim-sulfamethoxazole in newborn infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7062219/),h,19.0,175811,DB00440,Trimethoprim
,7062219,volumes of distribution,The mean volumes of distribution were SMZ 0.48 L/kg and TMP 2.7 L/kg.,Pharmacology of trimethoprim-sulfamethoxazole in newborn infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7062219/),[l] / [kg],0.48,175812,DB00440,Trimethoprim
,7062219,volumes of distribution,The mean volumes of distribution were SMZ 0.48 L/kg and TMP 2.7 L/kg.,Pharmacology of trimethoprim-sulfamethoxazole in newborn infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7062219/),[l] / [kg],2.7,175813,DB00440,Trimethoprim
,7062219,drug clearances,The mean drug clearances were SMZ 0.65 ml/minute and TMP 3.31 ml/minute.,Pharmacology of trimethoprim-sulfamethoxazole in newborn infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7062219/),[ml] / [min],0.65,175814,DB00440,Trimethoprim
,7062219,drug clearances,The mean drug clearances were SMZ 0.65 ml/minute and TMP 3.31 ml/minute.,Pharmacology of trimethoprim-sulfamethoxazole in newborn infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7062219/),[ml] / [min],3.31,175815,DB00440,Trimethoprim
,1964447,Sul,"Sulphamethoxazole/trimethoprim ratios (30 min, 1 and 3 h) were lower in BAL-fluid (4.9 +/- 0.5) and in AM (1.4 +/- 0.5) than in serum (30.7 +/- 1.6).",The penetration of co-trimoxazole into alveolar macrophages and its effect on inflammatory and immunoregulatory functions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1964447/),,4.,177236,DB00440,Trimethoprim
,1964447,Sul,"Sulphamethoxazole/trimethoprim ratios (30 min, 1 and 3 h) were lower in BAL-fluid (4.9 +/- 0.5) and in AM (1.4 +/- 0.5) than in serum (30.7 +/- 1.6).",The penetration of co-trimoxazole into alveolar macrophages and its effect on inflammatory and immunoregulatory functions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1964447/),,1.4,177237,DB00440,Trimethoprim
,1964447,Sul,"Sulphamethoxazole/trimethoprim ratios (30 min, 1 and 3 h) were lower in BAL-fluid (4.9 +/- 0.5) and in AM (1.4 +/- 0.5) than in serum (30.7 +/- 1.6).",The penetration of co-trimoxazole into alveolar macrophages and its effect on inflammatory and immunoregulatory functions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1964447/),,30.7,177238,DB00440,Trimethoprim
,1964447,ratios,"Sulphamethoxazole/trimethoprim ratios (30 min, 1 and 3 h) were lower in BAL-fluid (4.9 +/- 0.5) and in AM (1.4 +/- 0.5) than in serum (30.7 +/- 1.6).",The penetration of co-trimoxazole into alveolar macrophages and its effect on inflammatory and immunoregulatory functions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1964447/),,4.,177239,DB00440,Trimethoprim
,1964447,ratios,"Sulphamethoxazole/trimethoprim ratios (30 min, 1 and 3 h) were lower in BAL-fluid (4.9 +/- 0.5) and in AM (1.4 +/- 0.5) than in serum (30.7 +/- 1.6).",The penetration of co-trimoxazole into alveolar macrophages and its effect on inflammatory and immunoregulatory functions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1964447/),,1.4,177240,DB00440,Trimethoprim
,1964447,ratios,"Sulphamethoxazole/trimethoprim ratios (30 min, 1 and 3 h) were lower in BAL-fluid (4.9 +/- 0.5) and in AM (1.4 +/- 0.5) than in serum (30.7 +/- 1.6).",The penetration of co-trimoxazole into alveolar macrophages and its effect on inflammatory and immunoregulatory functions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1964447/),,30.7,177241,DB00440,Trimethoprim
,2684593,elimination half-life,"Cefixime is distinguished by its 3-hour elimination half-life which permits twice daily, or in many instances once daily, administration.",Cefixime. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic potential. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2684593/),h,3,179443,DB00440,Trimethoprim
,26838160,half-life,"The radioactivity in the liver was eliminated much more slowly than in other tissues, with a half-life of 4.26, 3.38, 6.69, and 5.21 d in swine, broilers, carp, and rats, respectively.","Metabolism and Disposition of Aditoprim in Swine, Broilers, Carp and Rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838160/),d,4.26,179643,DB00440,Trimethoprim
,26838160,half-life,"The radioactivity in the liver was eliminated much more slowly than in other tissues, with a half-life of 4.26, 3.38, 6.69, and 5.21 d in swine, broilers, carp, and rats, respectively.","Metabolism and Disposition of Aditoprim in Swine, Broilers, Carp and Rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838160/),d,3.38,179644,DB00440,Trimethoprim
,26838160,half-life,"The radioactivity in the liver was eliminated much more slowly than in other tissues, with a half-life of 4.26, 3.38, 6.69, and 5.21 d in swine, broilers, carp, and rats, respectively.","Metabolism and Disposition of Aditoprim in Swine, Broilers, Carp and Rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838160/),d,6.69,179645,DB00440,Trimethoprim
,26838160,half-life,"The radioactivity in the liver was eliminated much more slowly than in other tissues, with a half-life of 4.26, 3.38, 6.69, and 5.21 d in swine, broilers, carp, and rats, respectively.","Metabolism and Disposition of Aditoprim in Swine, Broilers, Carp and Rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838160/),d,5.21,179646,DB00440,Trimethoprim
,9098664,oral bioavailability,"In its new formulation as the oral tromethamine salt, fosfomycin has 34 to 41% oral bioavailability, has a mean elimination half-life of 5.7 hours, and is primarily excreted unchanged in the urine.","Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098664/),%,34 to 41,179835,DB00440,Trimethoprim
,9098664,elimination half-life,"In its new formulation as the oral tromethamine salt, fosfomycin has 34 to 41% oral bioavailability, has a mean elimination half-life of 5.7 hours, and is primarily excreted unchanged in the urine.","Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098664/),h,5.7,179836,DB00440,Trimethoprim
,9098664,eradication rates,"Bacteriological eradication rates of 75 to 90% were achieved 5 to 11 days after therapy, with eradication rates of 62 to 93% 4 to 6 weeks after therapy.","Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098664/),%,75 to 90,179837,DB00440,Trimethoprim
,9098664,eradication rates,"Bacteriological eradication rates of 75 to 90% were achieved 5 to 11 days after therapy, with eradication rates of 62 to 93% 4 to 6 weeks after therapy.","Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098664/),%,62 to 93,179838,DB00440,Trimethoprim
,12423221,initial plasma concentration (C0),After i.v. administration of 15 mg/kg of TMP-SMX the mean initial plasma concentration (C0) was 10.75 +/- 2.12 microg/mL for trimethoprim (TMP) and 158.3 +/- 189.3 microg/mL for sulfamethoxazole (SMX).,Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),[μg] / [ml],10.75,183052,DB00440,Trimethoprim
,12423221,initial plasma concentration (C0),After i.v. administration of 15 mg/kg of TMP-SMX the mean initial plasma concentration (C0) was 10.75 +/- 2.12 microg/mL for trimethoprim (TMP) and 158.3 +/- 189.3 microg/mL for sulfamethoxazole (SMX).,Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),[μg] / [ml],158.3,183053,DB00440,Trimethoprim
,12423221,Elimination half-lives,Elimination half-lives were 0.74 +/- 0.1 h for TMP and 2.2 +/- 0.6 h for SMX.,Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),h,0.74,183054,DB00440,Trimethoprim
,12423221,Elimination half-lives,Elimination half-lives were 0.74 +/- 0.1 h for TMP and 2.2 +/- 0.6 h for SMX.,Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),h,2.2,183055,DB00440,Trimethoprim
,12423221,mean residence times,The mean residence times were 1.45 +/- 0.72 h for TMP and 2.8 +/- 0.6 h for SMX.,Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),h,1.45,183056,DB00440,Trimethoprim
,12423221,mean residence times,The mean residence times were 1.45 +/- 0.72 h for TMP and 2.8 +/- 0.6 h for SMX.,Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),h,2.8,183057,DB00440,Trimethoprim
,12423221,areas under the respective concentration vs. time curves (AUC),The areas under the respective concentration vs. time curves (AUC) were 2.49 +/- 1.62 microg h/mL for TMP and 124 +/- 60 microg h/mL for SMX.,Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),[h·μg] / [ml],2.49,183058,DB00440,Trimethoprim
,12423221,areas under the respective concentration vs. time curves (AUC),The areas under the respective concentration vs. time curves (AUC) were 2.49 +/- 1.62 microg h/mL for TMP and 124 +/- 60 microg h/mL for SMX.,Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),[h·μg] / [ml],124,183059,DB00440,Trimethoprim
,12423221,Total clearance (Clt),Total clearance (Clt) for TMP was 21.63 +/- 9.85 and 1.90 +/- 0.77 mL/min kg for SMX.,Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),[ml] / [kg·min],21.63,183060,DB00440,Trimethoprim
,12423221,Total clearance (Clt),Total clearance (Clt) for TMP was 21.63 +/- 9.85 and 1.90 +/- 0.77 mL/min kg for SMX.,Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),[ml] / [kg·min],1.90,183061,DB00440,Trimethoprim
,12423221,volume of distribution at steady state,The volume of distribution at steady state was 2.32 +/- 1.15 L/kg for TMP and 0.35 +/- 0.09 L/kg for SMX.,Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),[l] / [kg],2.32,183062,DB00440,Trimethoprim
,12423221,volume of distribution at steady state,The volume of distribution at steady state was 2.32 +/- 1.15 L/kg for TMP and 0.35 +/- 0.09 L/kg for SMX.,Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),[l] / [kg],0.35,183063,DB00440,Trimethoprim
,12423221,peak concentration (Cmax),"After intragastric administration of 15, 30 and 60 mg/kg the peak concentration (Cmax) of SMX were 1.9 +/- 0.8, 2.6 +/- 0.4 and 2.8 +/- 0.7 microg/mL, respectively.",Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),[μg] / [ml],1.9,183064,DB00440,Trimethoprim
,12423221,peak concentration (Cmax),"After intragastric administration of 15, 30 and 60 mg/kg the peak concentration (Cmax) of SMX were 1.9 +/- 0.8, 2.6 +/- 0.4 and 2.8 +/- 0.7 microg/mL, respectively.",Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),[μg] / [ml],2.6,183065,DB00440,Trimethoprim
,12423221,peak concentration (Cmax),"After intragastric administration of 15, 30 and 60 mg/kg the peak concentration (Cmax) of SMX were 1.9 +/- 0.8, 2.6 +/- 0.4 and 2.8 +/- 0.7 microg/mL, respectively.",Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),[μg] / [ml],2.8,183066,DB00440,Trimethoprim
,12423221,AUC,"The AUC was 9.1 +/- 5, 25.9 +/- 3.3 and 39.1 +/- 4.1 microg h/mL, respectively.",Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),[h·μg] / [ml],9.1,183067,DB00440,Trimethoprim
,12423221,AUC,"The AUC was 9.1 +/- 5, 25.9 +/- 3.3 and 39.1 +/- 4.1 microg h/mL, respectively.",Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),[h·μg] / [ml],25.9,183068,DB00440,Trimethoprim
,12423221,AUC,"The AUC was 9.1 +/- 5, 25.9 +/- 3.3 and 39.1 +/- 4.1 microg h/mL, respectively.",Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),[h·μg] / [ml],39.1,183069,DB00440,Trimethoprim
,12423221,bioavailabilities,"Based upon these AUC values and correcting for dose, the respective bioavailabilities were 7.7, 10.5 and 7.94%.",Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),%,7.7,183070,DB00440,Trimethoprim
,12423221,bioavailabilities,"Based upon these AUC values and correcting for dose, the respective bioavailabilities were 7.7, 10.5 and 7.94%.",Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),%,10.5,183071,DB00440,Trimethoprim
,12423221,bioavailabilities,"Based upon these AUC values and correcting for dose, the respective bioavailabilities were 7.7, 10.5 and 7.94%.",Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423221/),%,7.94,183072,DB00440,Trimethoprim
,2778654,terminal elimination rate constant,"For the compartmental analysis, the terminal elimination rate constant, elimination half-life, apparent volume of distribution in the central compartment, apparent volume of distribution in the central compartment based on the area under the plasma concentration-time curve, and volume of distribution at steady state, were determined to be 0.007 min-1, 99 min, 2059 mL/kg, 5729 mL/kg, and 2473 mL/kg, respectively.",Pharmacokinetics of trimethoprim in the rat. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778654/),1/[min],0.007,184038,DB00440,Trimethoprim
,2778654,elimination half-life,"For the compartmental analysis, the terminal elimination rate constant, elimination half-life, apparent volume of distribution in the central compartment, apparent volume of distribution in the central compartment based on the area under the plasma concentration-time curve, and volume of distribution at steady state, were determined to be 0.007 min-1, 99 min, 2059 mL/kg, 5729 mL/kg, and 2473 mL/kg, respectively.",Pharmacokinetics of trimethoprim in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778654/),[ml] / [kg],5729,184039,DB00440,Trimethoprim
,2778654,apparent volume of distribution in the central compartment,"For the compartmental analysis, the terminal elimination rate constant, elimination half-life, apparent volume of distribution in the central compartment, apparent volume of distribution in the central compartment based on the area under the plasma concentration-time curve, and volume of distribution at steady state, were determined to be 0.007 min-1, 99 min, 2059 mL/kg, 5729 mL/kg, and 2473 mL/kg, respectively.",Pharmacokinetics of trimethoprim in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778654/),min,99,184040,DB00440,Trimethoprim
,2778654,apparent volume of distribution in the central compartment,"For the compartmental analysis, the terminal elimination rate constant, elimination half-life, apparent volume of distribution in the central compartment, apparent volume of distribution in the central compartment based on the area under the plasma concentration-time curve, and volume of distribution at steady state, were determined to be 0.007 min-1, 99 min, 2059 mL/kg, 5729 mL/kg, and 2473 mL/kg, respectively.",Pharmacokinetics of trimethoprim in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778654/),[ml] / [kg],2059,184041,DB00440,Trimethoprim
,2778654,apparent volume of distribution in the central compartment,"For the compartmental analysis, the terminal elimination rate constant, elimination half-life, apparent volume of distribution in the central compartment, apparent volume of distribution in the central compartment based on the area under the plasma concentration-time curve, and volume of distribution at steady state, were determined to be 0.007 min-1, 99 min, 2059 mL/kg, 5729 mL/kg, and 2473 mL/kg, respectively.",Pharmacokinetics of trimethoprim in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778654/),[ml] / [kg],5729,184042,DB00440,Trimethoprim
,2778654,apparent volume of distribution in the central compartment based on the area under the plasma concentration-time curve,"For the compartmental analysis, the terminal elimination rate constant, elimination half-life, apparent volume of distribution in the central compartment, apparent volume of distribution in the central compartment based on the area under the plasma concentration-time curve, and volume of distribution at steady state, were determined to be 0.007 min-1, 99 min, 2059 mL/kg, 5729 mL/kg, and 2473 mL/kg, respectively.",Pharmacokinetics of trimethoprim in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778654/),min,99,184043,DB00440,Trimethoprim
,2778654,apparent volume of distribution in the central compartment based on the area under the plasma concentration-time curve,"For the compartmental analysis, the terminal elimination rate constant, elimination half-life, apparent volume of distribution in the central compartment, apparent volume of distribution in the central compartment based on the area under the plasma concentration-time curve, and volume of distribution at steady state, were determined to be 0.007 min-1, 99 min, 2059 mL/kg, 5729 mL/kg, and 2473 mL/kg, respectively.",Pharmacokinetics of trimethoprim in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778654/),[ml] / [kg],2059,184044,DB00440,Trimethoprim
,2778654,apparent volume of distribution in the central compartment based on the area under the plasma concentration-time curve,"For the compartmental analysis, the terminal elimination rate constant, elimination half-life, apparent volume of distribution in the central compartment, apparent volume of distribution in the central compartment based on the area under the plasma concentration-time curve, and volume of distribution at steady state, were determined to be 0.007 min-1, 99 min, 2059 mL/kg, 5729 mL/kg, and 2473 mL/kg, respectively.",Pharmacokinetics of trimethoprim in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778654/),[ml] / [kg],5729,184045,DB00440,Trimethoprim
,2778654,volume of distribution at steady state,"For the compartmental analysis, the terminal elimination rate constant, elimination half-life, apparent volume of distribution in the central compartment, apparent volume of distribution in the central compartment based on the area under the plasma concentration-time curve, and volume of distribution at steady state, were determined to be 0.007 min-1, 99 min, 2059 mL/kg, 5729 mL/kg, and 2473 mL/kg, respectively.",Pharmacokinetics of trimethoprim in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778654/),[ml] / [kg],2473,184046,DB00440,Trimethoprim
,2778654,mean residence time,"The estimates for mean residence time, clearance, and volume of distribution at steady state of trimethoprim were calculated to be 52 min, 40 mL.min-1kg-1, and 2097 mL, respectively.",Pharmacokinetics of trimethoprim in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778654/),min,52,184047,DB00440,Trimethoprim
,2778654,clearance,"The estimates for mean residence time, clearance, and volume of distribution at steady state of trimethoprim were calculated to be 52 min, 40 mL.min-1kg-1, and 2097 mL, respectively.",Pharmacokinetics of trimethoprim in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778654/),[ml] / [min],40,184048,DB00440,Trimethoprim
,2778654,volume of distribution at steady state,"The estimates for mean residence time, clearance, and volume of distribution at steady state of trimethoprim were calculated to be 52 min, 40 mL.min-1kg-1, and 2097 mL, respectively.",Pharmacokinetics of trimethoprim in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778654/),ml,2097,184049,DB00440,Trimethoprim
,3266736,elimination half-life,The elimination half-life of the untreated control group (n = 27) was 4.62 h.,Effects of drugs on aminophylline elimination in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,4.62,184893,DB00440,Trimethoprim
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.09,184894,DB00440,Trimethoprim
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.47,184895,DB00440,Trimethoprim
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.19,184896,DB00440,Trimethoprim
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2,184897,DB00440,Trimethoprim
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.85,184898,DB00440,Trimethoprim
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.74,184899,DB00440,Trimethoprim
,3802953,recovery,The 12-hour recovery was 69% SDZ + acetyl-SDZ recovered in the patients compared to 66.0% in the volunteers.,Pharmacokinetics of co-trimazine (sulphadiazine plus trimethoprim) in geriatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802953/),%,69,184962,DB00440,Trimethoprim
,3802953,recovery,The 12-hour recovery was 69% SDZ + acetyl-SDZ recovered in the patients compared to 66.0% in the volunteers.,Pharmacokinetics of co-trimazine (sulphadiazine plus trimethoprim) in geriatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802953/),%,66.0,184963,DB00440,Trimethoprim
,3802953,peak serum concentration,The mean peak serum concentration for SDZ was 16.7 +/- 4.2 mg/l after the first dose and 44.7 +/- 11.3 mg/l on day 10.,Pharmacokinetics of co-trimazine (sulphadiazine plus trimethoprim) in geriatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802953/),[mg] / [l],16.7,184964,DB00440,Trimethoprim
,3802953,peak serum concentration,The mean peak serum concentration for SDZ was 16.7 +/- 4.2 mg/l after the first dose and 44.7 +/- 11.3 mg/l on day 10.,Pharmacokinetics of co-trimazine (sulphadiazine plus trimethoprim) in geriatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802953/),[mg] / [l],44.7,184965,DB00440,Trimethoprim
,8723472,renal clearance,Trimethoprim significantly decreased the renal clearance of zidovudine by 58% (5.0 +/- 1.8 versus 2.1 +/- 0.5 ml/min/kg of body weight [P < 0.05]).,"Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723472/),[ml] / [kg·min],5.0,185465,DB00440,Trimethoprim
,8723472,renal clearance,Trimethoprim significantly decreased the renal clearance of zidovudine by 58% (5.0 +/- 1.8 versus 2.1 +/- 0.5 ml/min/kg of body weight [P < 0.05]).,"Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723472/),[ml] / [kg·min],2.1,185466,DB00440,Trimethoprim
,8723472,urinary recovery,"There was a concurrent 54% decrease in the mean urinary recovery of zidovudine (11.7 +/- 3.5 versus 5.4 +/- 3.0 [P < 0.05]), and the metabolic ratio was decreased by 78% (0.32 +/- 0.4 versus 0.07 +/- 0.05 [P < 0.05]).","Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723472/),,11.7,185467,DB00440,Trimethoprim
,8723472,urinary recovery,"There was a concurrent 54% decrease in the mean urinary recovery of zidovudine (11.7 +/- 3.5 versus 5.4 +/- 3.0 [P < 0.05]), and the metabolic ratio was decreased by 78% (0.32 +/- 0.4 versus 0.07 +/- 0.05 [P < 0.05]).","Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723472/),,5.4,185468,DB00440,Trimethoprim
,8723472,metabolic,"There was a concurrent 54% decrease in the mean urinary recovery of zidovudine (11.7 +/- 3.5 versus 5.4 +/- 3.0 [P < 0.05]), and the metabolic ratio was decreased by 78% (0.32 +/- 0.4 versus 0.07 +/- 0.05 [P < 0.05]).","Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723472/),,0,185469,DB00440,Trimethoprim
,7387137,minimum effective plasma concentrations,"Digital computer simulations of plasma concentration-time profiles of single intravenous infusions of trimethoprim (160 mg)/sulfamethoxazole (800 mg) based on data from other workers showed that increasing the infusion period from the hitherto generally recommended 1 to 1.5 h to 6 h did not significantly affect the interval (approximately 10 h and 8.5 h, respectively) during which trimethoprim and sulfamethoxazole plasma concentrations were maintained above their minimum effective plasma concentrations (selected as 0.6 microgram/ml and 25 microgram/ml, respectively).",Evaluation of slow infusions of co-trimoxazole by using predictive pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7387137/),[μg] / [ml],0.6,186230,DB00440,Trimethoprim
,7387137,minimum effective plasma concentrations,"Digital computer simulations of plasma concentration-time profiles of single intravenous infusions of trimethoprim (160 mg)/sulfamethoxazole (800 mg) based on data from other workers showed that increasing the infusion period from the hitherto generally recommended 1 to 1.5 h to 6 h did not significantly affect the interval (approximately 10 h and 8.5 h, respectively) during which trimethoprim and sulfamethoxazole plasma concentrations were maintained above their minimum effective plasma concentrations (selected as 0.6 microgram/ml and 25 microgram/ml, respectively).",Evaluation of slow infusions of co-trimoxazole by using predictive pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7387137/),[μg] / [ml],25,186231,DB00440,Trimethoprim
,8882301,protein binding to serum albumin,A mean protein binding to serum albumin of 42 to 57% is usually reported.,Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),%,42 to 57,186895,DB00440,Trimethoprim
,8882301,steady-state volume of distribution,The steady-state volume of distribution is approximately 1 L/kg.,Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),[l] / [kg],1,186896,DB00440,Trimethoprim
,8882301,elimination half-life,"The usually reported mean values for the elimination half-life and the total body clearance of methotrexate are 5 to 8 hours and 4.8 to 7.8 L/h, respectively.",Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),h,5 to 8,186897,DB00440,Trimethoprim
,8882301,total body clearance,"The usually reported mean values for the elimination half-life and the total body clearance of methotrexate are 5 to 8 hours and 4.8 to 7.8 L/h, respectively.",Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),[l] / [h],4.8 to 7.8,186898,DB00440,Trimethoprim
,16570188,CL/F,"Estimates [95% confidence interval (CI)] of CL/F, V(ss)/F and t(1/2)(z) were found to be 56.4 (29-84) l/h, 6,000 (3,500-8,500) l and 11.7 (8.3-15.7) days, respectively.",Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16570188/),[l] / [h],56.4,188815,DB00440,Trimethoprim
,16570188,V(ss)/F,"Estimates [95% confidence interval (CI)] of CL/F, V(ss)/F and t(1/2)(z) were found to be 56.4 (29-84) l/h, 6,000 (3,500-8,500) l and 11.7 (8.3-15.7) days, respectively.",Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16570188/),l,"6,000",188816,DB00440,Trimethoprim
,16570188,t(1/2)(z),"Estimates [95% confidence interval (CI)] of CL/F, V(ss)/F and t(1/2)(z) were found to be 56.4 (29-84) l/h, 6,000 (3,500-8,500) l and 11.7 (8.3-15.7) days, respectively.",Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16570188/),d,11.7,188817,DB00440,Trimethoprim
,1952863,maximum serum drug concentrations,"In the seven subjects that completed the study, the mean maximum serum drug concentrations after the last dose were 13.6 +/- 2.0, 372 +/- 64, and 50.1 +/- 10.9 micrograms/ml for trimethoprim, sulfamethoxazole, and N4-acetylsulfamethoxazole, respectively.",Pharmacokinetics and adverse effects of 20-mg/kg/day trimethoprim and 100-mg/kg/day sulfamethoxazole in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1952863/),[μg] / [ml],13.6,189032,DB00440,Trimethoprim
,1952863,maximum serum drug concentrations,"In the seven subjects that completed the study, the mean maximum serum drug concentrations after the last dose were 13.6 +/- 2.0, 372 +/- 64, and 50.1 +/- 10.9 micrograms/ml for trimethoprim, sulfamethoxazole, and N4-acetylsulfamethoxazole, respectively.",Pharmacokinetics and adverse effects of 20-mg/kg/day trimethoprim and 100-mg/kg/day sulfamethoxazole in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1952863/),[μg] / [ml],372,189033,DB00440,Trimethoprim
,1952863,maximum serum drug concentrations,"In the seven subjects that completed the study, the mean maximum serum drug concentrations after the last dose were 13.6 +/- 2.0, 372 +/- 64, and 50.1 +/- 10.9 micrograms/ml for trimethoprim, sulfamethoxazole, and N4-acetylsulfamethoxazole, respectively.",Pharmacokinetics and adverse effects of 20-mg/kg/day trimethoprim and 100-mg/kg/day sulfamethoxazole in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1952863/),[μg] / [ml],50.1,189034,DB00440,Trimethoprim
,1952863,half-lives,"The mean half-lives were 13.6 +/- 3.5, 14.0 +/- 2.3, and 18.6 +/- 4.3 h, respectively.",Pharmacokinetics and adverse effects of 20-mg/kg/day trimethoprim and 100-mg/kg/day sulfamethoxazole in healthy adult subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1952863/),h,13.6,189035,DB00440,Trimethoprim
,1952863,half-lives,"The mean half-lives were 13.6 +/- 3.5, 14.0 +/- 2.3, and 18.6 +/- 4.3 h, respectively.",Pharmacokinetics and adverse effects of 20-mg/kg/day trimethoprim and 100-mg/kg/day sulfamethoxazole in healthy adult subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1952863/),h,14.0,189036,DB00440,Trimethoprim
,1952863,half-lives,"The mean half-lives were 13.6 +/- 3.5, 14.0 +/- 2.3, and 18.6 +/- 4.3 h, respectively.",Pharmacokinetics and adverse effects of 20-mg/kg/day trimethoprim and 100-mg/kg/day sulfamethoxazole in healthy adult subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1952863/),h,18.6,189037,DB00440,Trimethoprim
,32378219,peak sulfamethoxazole,"The peak sulfamethoxazole and trimethoprim concentrations were 122 mg/L and 5.3 mg/L, respectively.",Pharmacokinetics of Sulfamethoxazole and Trimethoprim During Venovenous Extracorporeal Membrane Oxygenation: A Case Report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32378219/),[mg] / [l],122,189068,DB00440,Trimethoprim
,32378219,concentrations,"The peak sulfamethoxazole and trimethoprim concentrations were 122 mg/L and 5.3 mg/L, respectively.",Pharmacokinetics of Sulfamethoxazole and Trimethoprim During Venovenous Extracorporeal Membrane Oxygenation: A Case Report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32378219/),[mg] / [l],122,189069,DB00440,Trimethoprim
,32378219,concentrations,"The peak sulfamethoxazole and trimethoprim concentrations were 122 mg/L and 5.3 mg/L, respectively.",Pharmacokinetics of Sulfamethoxazole and Trimethoprim During Venovenous Extracorporeal Membrane Oxygenation: A Case Report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32378219/),[mg] / [l],5.3,189070,DB00440,Trimethoprim
,32378219,volume of distribution,The volume of distribution for sulfamethoxazole was 0.37 and 2.30 L/kg for trimethoprim.,Pharmacokinetics of Sulfamethoxazole and Trimethoprim During Venovenous Extracorporeal Membrane Oxygenation: A Case Report. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32378219/),[l] / [kg],0.37,189071,DB00440,Trimethoprim
,32378219,volume of distribution,The volume of distribution for sulfamethoxazole was 0.37 and 2.30 L/kg for trimethoprim.,Pharmacokinetics of Sulfamethoxazole and Trimethoprim During Venovenous Extracorporeal Membrane Oxygenation: A Case Report. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32378219/),[l] / [kg],2.30,189072,DB00440,Trimethoprim
,32378219,clearance,The clearance for sulfamethoxazole was 0.35 ml/minute/kg and for trimethoprim was 1.64 ml/minute/kg.,Pharmacokinetics of Sulfamethoxazole and Trimethoprim During Venovenous Extracorporeal Membrane Oxygenation: A Case Report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32378219/),[ml] / [kg·min],0.35,189073,DB00440,Trimethoprim
,32378219,clearance,The clearance for sulfamethoxazole was 0.35 ml/minute/kg and for trimethoprim was 1.64 ml/minute/kg.,Pharmacokinetics of Sulfamethoxazole and Trimethoprim During Venovenous Extracorporeal Membrane Oxygenation: A Case Report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32378219/),[ml] / [kg·min],1.64,189074,DB00440,Trimethoprim
,23551893,peak concentrations (Cmax),Observed peak concentrations (Cmax) were 7.51 mg/l for TMP and 80.80 mg/l for SMX.,"Cotrimoxazole plasma levels, dialyzer clearance and total removal by extended dialysis in a patient with acute kidney injury: risk of under-dosing using current dosing recommendations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23551893/),[mg] / [l],7.51,191409,DB00440,Trimethoprim
,23551893,peak concentrations (Cmax),Observed peak concentrations (Cmax) were 7.51 mg/l for TMP and 80.80 mg/l for SMX.,"Cotrimoxazole plasma levels, dialyzer clearance and total removal by extended dialysis in a patient with acute kidney injury: risk of under-dosing using current dosing recommendations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23551893/),[mg] / [l],80.80,191410,DB00440,Trimethoprim
,23551893,clearances,"Decline of blood levels during extended dialysis (TMP 64%; SMX 84%) was mainly due to removal by the dialysis procedure, illustrated by the high dialyzer clearances (median of 4 extended dialysis sessions: TMP 94.0 / SMX 51.0 ml/min), as well as by the absolute amount of both substances in the collected spent dialysate (median of 6 extended dialysis sessions: TMP 556 mg / SMX 130 mg).","Cotrimoxazole plasma levels, dialyzer clearance and total removal by extended dialysis in a patient with acute kidney injury: risk of under-dosing using current dosing recommendations. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23551893/),[ml] / [min],94,191411,DB00440,Trimethoprim
,23551893,clearances,"Decline of blood levels during extended dialysis (TMP 64%; SMX 84%) was mainly due to removal by the dialysis procedure, illustrated by the high dialyzer clearances (median of 4 extended dialysis sessions: TMP 94.0 / SMX 51.0 ml/min), as well as by the absolute amount of both substances in the collected spent dialysate (median of 6 extended dialysis sessions: TMP 556 mg / SMX 130 mg).","Cotrimoxazole plasma levels, dialyzer clearance and total removal by extended dialysis in a patient with acute kidney injury: risk of under-dosing using current dosing recommendations. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23551893/),[ml] / [min],51.0,191412,DB00440,Trimethoprim
,19546364,50% effective dose,"Using a nonoptimized formulation, the dihydrophthalazines displayed acceptable oral bioavailabilities in mice, and efficacy studies with a septicemia model of mice infected with trimethoprim-resistant, methicillin-resistant Staphylococcus aureus gave 50% effective dose values in the range of 1.6 to 6.25 mg/kg.","In vitro and in vivo properties of dihydrophthalazine antifolates, a novel family of antibacterial drugs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19546364/),[mg] / [kg],1.6 to 6.25,191485,DB00440,Trimethoprim
,12213115,peak concentration,The peak concentration of TMP (mean +/- SD) was 2.92 +/- 0.86 microg/mL for plasma and 1.09 +/- 0.25 microg/mL for TCF.,Distribution of orally administered trimethoprim and sulfadiazine into noninfected subcutaneous tissue chambers in adult ponies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213115/),[μg] / [ml],2.92,193489,DB00440,Trimethoprim
,12213115,peak concentration,The peak concentration of TMP (mean +/- SD) was 2.92 +/- 0.86 microg/mL for plasma and 1.09 +/- 0.25 microg/mL for TCF.,Distribution of orally administered trimethoprim and sulfadiazine into noninfected subcutaneous tissue chambers in adult ponies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213115/),[μg] / [ml],1.09,193490,DB00440,Trimethoprim
,12213115,peak concentration,"For SDZ, the mean peak concentration was 40.20 +/- 14.74 microg/mL for plasma and 23.48 +/- 5.84 microg/mL for TCF.",Distribution of orally administered trimethoprim and sulfadiazine into noninfected subcutaneous tissue chambers in adult ponies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213115/),[μg] / [ml],40.20,193491,DB00440,Trimethoprim
,12213115,peak concentration,"For SDZ, the mean peak concentration was 40.20 +/- 14.74 microg/mL for plasma and 23.48 +/- 5.84 microg/mL for TCF.",Distribution of orally administered trimethoprim and sulfadiazine into noninfected subcutaneous tissue chambers in adult ponies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213115/),[μg] / [ml],23.48,193492,DB00440,Trimethoprim
,8195843,peaks,In bronchial mucosa and in bronchial secretion the peaks were reached at 8th hour (9.7 +/- 5.3 mg/kg and 4.57 +/- 1 mg/l respectively) while in middle car effusion were reached at 4th hour (4.8 +/- 2.5 mg/l).,"Brodimoprim concentrations in bronchial mucosa, bronchial secretions and middle ear effusions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195843/),[mg] / [kg],9.7,196603,DB00440,Trimethoprim
,8195843,peaks,In bronchial mucosa and in bronchial secretion the peaks were reached at 8th hour (9.7 +/- 5.3 mg/kg and 4.57 +/- 1 mg/l respectively) while in middle car effusion were reached at 4th hour (4.8 +/- 2.5 mg/l).,"Brodimoprim concentrations in bronchial mucosa, bronchial secretions and middle ear effusions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195843/),[mg] / [l],4.57,196604,DB00440,Trimethoprim
,8195843,peaks,In bronchial mucosa and in bronchial secretion the peaks were reached at 8th hour (9.7 +/- 5.3 mg/kg and 4.57 +/- 1 mg/l respectively) while in middle car effusion were reached at 4th hour (4.8 +/- 2.5 mg/l).,"Brodimoprim concentrations in bronchial mucosa, bronchial secretions and middle ear effusions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195843/),[mg] / [l],4.8,196605,DB00440,Trimethoprim
,28971610,permeability,"Whilst all inhibited OCT1, none enhanced metformin's absorptive permeability (~0.5 × 10-6 cm/sec) suggesting that DDI AUC changes are not related to absorption.","Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28971610/),[cm] / [s],0.5 × 10-6,196647,DB00440,Trimethoprim
,8971670,absorption half-lives,"The absorption half-lives were 0.96 (TMP) and 2.24 h (SDZ), whereas elimination half-lives were 5.49 (TMP) and 4.19 h (SDZ).",A study of the pharmacokinetics and tissue residues of an oral trimethoprim/sulphadiazine formulation in healthy pigs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971670/),h,0.96,199489,DB00440,Trimethoprim
,8971670,absorption half-lives,"The absorption half-lives were 0.96 (TMP) and 2.24 h (SDZ), whereas elimination half-lives were 5.49 (TMP) and 4.19 h (SDZ).",A study of the pharmacokinetics and tissue residues of an oral trimethoprim/sulphadiazine formulation in healthy pigs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971670/),h,2.24,199490,DB00440,Trimethoprim
,8971670,elimination half-lives,"The absorption half-lives were 0.96 (TMP) and 2.24 h (SDZ), whereas elimination half-lives were 5.49 (TMP) and 4.19 h (SDZ).",A study of the pharmacokinetics and tissue residues of an oral trimethoprim/sulphadiazine formulation in healthy pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971670/),h,5.49,199491,DB00440,Trimethoprim
,8971670,elimination half-lives,"The absorption half-lives were 0.96 (TMP) and 2.24 h (SDZ), whereas elimination half-lives were 5.49 (TMP) and 4.19 h (SDZ).",A study of the pharmacokinetics and tissue residues of an oral trimethoprim/sulphadiazine formulation in healthy pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971670/),h,4.19,199492,DB00440,Trimethoprim
,8971670,ratios,The observed TMP:SDZ ratios in blood plasma after multiple dose administration ranged from 1:11.4 to 1:23.2.,A study of the pharmacokinetics and tissue residues of an oral trimethoprim/sulphadiazine formulation in healthy pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971670/),,1,199493,DB00440,Trimethoprim
,8971670,ratios,The observed TMP:SDZ ratios in blood plasma after multiple dose administration ranged from 1:11.4 to 1:23.2.,A study of the pharmacokinetics and tissue residues of an oral trimethoprim/sulphadiazine formulation in healthy pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971670/),,23.2,199494,DB00440,Trimethoprim
,8971670,maximum,The absolute TMP and SDZ tissue concentrations 1 day after the last multiple dose administration were very low (maximum TMP: 0.29 micrograms/g in liver; maximum SDZ: 0.23 micrograms/g in kidneys).,A study of the pharmacokinetics and tissue residues of an oral trimethoprim/sulphadiazine formulation in healthy pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971670/),[μg] / [g],0.29,199495,DB00440,Trimethoprim
,8971670,maximum,The absolute TMP and SDZ tissue concentrations 1 day after the last multiple dose administration were very low (maximum TMP: 0.29 micrograms/g in liver; maximum SDZ: 0.23 micrograms/g in kidneys).,A study of the pharmacokinetics and tissue residues of an oral trimethoprim/sulphadiazine formulation in healthy pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971670/),[μg] / [g],0.23,199496,DB00440,Trimethoprim
,20823279,clearance,"In both patients, CVVHDF clearance of TMP ranged from 21.5 to 28.9 mL/min, corresponding with normal renal clearance (20-80 mL/min).",Trimethoprim/Sulfamethoxazole pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20823279/),[ml] / [min],21.5 to 28.9,200154,DB00440,Trimethoprim
,20823279,renal clearance,"In both patients, CVVHDF clearance of TMP ranged from 21.5 to 28.9 mL/min, corresponding with normal renal clearance (20-80 mL/min).",Trimethoprim/Sulfamethoxazole pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20823279/),[ml] / [min],20-80,200155,DB00440,Trimethoprim
,20823279,clearance,"SMX clearance in CVVHDF showed high variability (18.7, 26.7, and 42.6 mL/min) and exceeded renal clearance values in normal renal function (1-5 mL/min).",Trimethoprim/Sulfamethoxazole pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20823279/),[ml] / [min],18.7,200156,DB00440,Trimethoprim
,20823279,clearance,"SMX clearance in CVVHDF showed high variability (18.7, 26.7, and 42.6 mL/min) and exceeded renal clearance values in normal renal function (1-5 mL/min).",Trimethoprim/Sulfamethoxazole pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20823279/),[ml] / [min],26.7,200157,DB00440,Trimethoprim
,20823279,clearance,"SMX clearance in CVVHDF showed high variability (18.7, 26.7, and 42.6 mL/min) and exceeded renal clearance values in normal renal function (1-5 mL/min).",Trimethoprim/Sulfamethoxazole pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20823279/),[ml] / [min],42.6,200158,DB00440,Trimethoprim
>,19620336,area under the concentration-time curve from 0 to 24 h/MIC ratio,"In Australia, the currently used eradication regimen (320 [TMP]/1,600 [SMX] mg every 12 h [q12h]) was predicted to achieve the PK-pharmacodynamic (PD) target (an area under the concentration-time curve from 0 to 24 h/MIC ratio of >25 for both TMP and SMX) for strains with the MIC90 of Australian strains (< or = 1/19 mg/liter).",Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620336/),,25,202199,DB00440,Trimethoprim
< or,19620336,MIC90,"In Australia, the currently used eradication regimen (320 [TMP]/1,600 [SMX] mg every 12 h [q12h]) was predicted to achieve the PK-pharmacodynamic (PD) target (an area under the concentration-time curve from 0 to 24 h/MIC ratio of >25 for both TMP and SMX) for strains with the MIC90 of Australian strains (< or = 1/19 mg/liter).",Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620336/),[mg] / [l],1/19,202200,DB00440,Trimethoprim
>,19620336,MIC,"In Thailand, the former regimen of 160/800 mg q12h would not be expected to attain the target for strains with an MIC of > or = 1/19 mg/liter, but the recently implemented weight-based regimen (<40 kg [body weight], 160/800 mg q12h; 40 to 60 kg, 240/1,200 mg q12h; >60 kg, 320/1,600 mg q12h) would be expected to achieve adequate concentrations for strains with an MIC of < or = 1/19 mg/liter.",Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620336/),[mg] / [l],1/19,202201,DB00440,Trimethoprim
<,19620336,MIC,"In Thailand, the former regimen of 160/800 mg q12h would not be expected to attain the target for strains with an MIC of > or = 1/19 mg/liter, but the recently implemented weight-based regimen (<40 kg [body weight], 160/800 mg q12h; 40 to 60 kg, 240/1,200 mg q12h; >60 kg, 320/1,600 mg q12h) would be expected to achieve adequate concentrations for strains with an MIC of < or = 1/19 mg/liter.",Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620336/),[mg] / [l],1/19,202202,DB00440,Trimethoprim
,8866920,Cmax,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),[ng] / [ml],1309.9,202614,DB00440,Trimethoprim
,8866920,Cmax,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),[μg] / [ml],1.96,202615,DB00440,Trimethoprim
,8866920,AUC,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),[h·ng] / [ml],1796.9,202616,DB00440,Trimethoprim
,8866920,AUC,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),[ng] / [ml],1751.9,202617,DB00440,Trimethoprim
,8866920,AUC,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),[h·ng] / [ml],2158.0,202618,DB00440,Trimethoprim
,8866920,AUC,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),[μg] / [ml],1.81,202619,DB00440,Trimethoprim
,8866920,AUC,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),[h·μg] / [ml],28.89,202620,DB00440,Trimethoprim
,8866920,AUC,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),h,11.4,202621,DB00440,Trimethoprim
,8866920,AUC,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),[ng] / [ml],1279.3,202622,DB00440,Trimethoprim
,8866920,t1/2,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),h,1.61,202623,DB00440,Trimethoprim
,8866920,t1/2,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),h,9.84,202624,DB00440,Trimethoprim
,8866920,t1/2,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),[ng] / [ml],1751.9,202625,DB00440,Trimethoprim
,8866920,t1/2,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),[h·ng] / [ml],2158.0,202626,DB00440,Trimethoprim
,8866920,t1/2,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),h,1.28,202627,DB00440,Trimethoprim
,8866920,t1/2,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),[μg] / [ml],1.81,202628,DB00440,Trimethoprim
,8866920,t1/2,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),[h·μg] / [ml],28.89,202629,DB00440,Trimethoprim
,8866920,t1/2,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),h,11.4,202630,DB00440,Trimethoprim
,8866920,t1/2,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),[ng] / [ml],1279.3,202631,DB00440,Trimethoprim
,8866920,t1/2,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),[h·ng] / [ml],1793.2,202632,DB00440,Trimethoprim
,8866920,t1/2,"5. Other key parameters such as Cmax, AUC, and t1/2 for didanosine (1309.9 ng ml-1, 1796.9 ng ml-1 h, and 1.61 h, respectively), trimethoprim (1.96 micrograms ml-1, 22.86 micrograms ml-1 h, and 9.03 h, respectively) or sulphamethoxazole (58.62 micrograms ml-1, 799.7 micrograms ml-1 h and 9.84 h, respectively) were not affected when didanosine was coadministered with either trimethoprim (didanosine: 1751.9 ng ml-1, 2158.0 ng ml-1 h, and 1.28 h; trimethoprim: 1.81 micrograms ml-1, 28.89 micrograms ml-1 h, and 11.4 h), sulphamethoxazole (didanosine: 1279.3 ng ml-1, 1793.2 ng ml-1 h, and 1.61 h; sulphamethoxazole: 53.57 micrograms ml-1, 732.1 micrograms ml-1 h, and 8.95 h), or the combination of trimethoprim and sulphamethoxazole (didanosine: 1283.7 ng ml-1, 1941.8 ng ml-1 h, and 1.38 h; trimethoprim: 1.59 micrograms ml-1, 26.68 micrograms ml-1 h, and 11.3 h; sulphamethoxazole: 59.48 micrograms ml-1, 760.9 micrograms ml-1 h, and 9.47 h).",A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866920/),,1.61,202633,DB00440,Trimethoprim
,33289123,Cmax,Cmax was 37.8 ± 13.4 μg/ml (SDZ) and 1.92 ± 0.25 μg/ml (TMP).,Pharmacokinetics of a sulfadiazine and trimethoprim suspension in neonatal foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33289123/),[μg] / [ml],37.8,204059,DB00440,Trimethoprim
,33289123,Cmax,Cmax was 37.8 ± 13.4 μg/ml (SDZ) and 1.92 ± 0.25 μg/ml (TMP).,Pharmacokinetics of a sulfadiazine and trimethoprim suspension in neonatal foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33289123/),[μg] / [ml],1.92,204060,DB00440,Trimethoprim
,33289123,Tmax,Tmax was 1.4 ± 0.6 hr (SDZ) and 1.4 ± 0.4 hr (TMP).,Pharmacokinetics of a sulfadiazine and trimethoprim suspension in neonatal foals. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33289123/),h,1.4,204061,DB00440,Trimethoprim
,33289123,Tmax,Tmax was 1.4 ± 0.6 hr (SDZ) and 1.4 ± 0.4 hr (TMP).,Pharmacokinetics of a sulfadiazine and trimethoprim suspension in neonatal foals. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33289123/),h,1.4,204062,DB00440,Trimethoprim
,33289123,Cmin,"Cmin for SDZ and TMP was 16.84 ± 8.46 μg/ml and 0.46 ± 0.24 μg/ml, respectively.",Pharmacokinetics of a sulfadiazine and trimethoprim suspension in neonatal foals. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33289123/),[μg] / [ml],16.84,204063,DB00440,Trimethoprim
,33289123,Cmin,"Cmin for SDZ and TMP was 16.84 ± 8.46 μg/ml and 0.46 ± 0.24 μg/ml, respectively.",Pharmacokinetics of a sulfadiazine and trimethoprim suspension in neonatal foals. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33289123/),[μg] / [ml],0.46,204064,DB00440,Trimethoprim
,33289123,Elimination half-life,Elimination half-life was 10.8 ± 6.1 hr (SDZ) and 6.5 ± 2 hr (TMP).,Pharmacokinetics of a sulfadiazine and trimethoprim suspension in neonatal foals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33289123/),h,10.8,204065,DB00440,Trimethoprim
,33289123,Elimination half-life,Elimination half-life was 10.8 ± 6.1 hr (SDZ) and 6.5 ± 2 hr (TMP).,Pharmacokinetics of a sulfadiazine and trimethoprim suspension in neonatal foals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33289123/),h,6.5,204066,DB00440,Trimethoprim
,33289123,AUC0 → ∞,AUC0 → ∞ was 667 ± 424 μg × hr/ml (SDZ) and 21.1 ± 5.3 μg × hr/ml (TMP).,Pharmacokinetics of a sulfadiazine and trimethoprim suspension in neonatal foals. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33289123/),[h·μg] / [ml],667,204067,DB00440,Trimethoprim
,33289123,AUC0 → ∞,AUC0 → ∞ was 667 ± 424 μg × hr/ml (SDZ) and 21.1 ± 5.3 μg × hr/ml (TMP).,Pharmacokinetics of a sulfadiazine and trimethoprim suspension in neonatal foals. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33289123/),[h·μg] / [ml],21.1,204068,DB00440,Trimethoprim
,33289123,MIC(90),"Foals remained healthy, and the plasma concentration of sulfadiazine-trimethoprim reached levels above MIC(90) for Streptococcus equi ssp. (SDZ/TMP): 9.5/0.5 μg/ml).",Pharmacokinetics of a sulfadiazine and trimethoprim suspension in neonatal foals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33289123/),[μg] / [ml],9.5,204069,DB00440,Trimethoprim
,33289123,MIC(90),"Foals remained healthy, and the plasma concentration of sulfadiazine-trimethoprim reached levels above MIC(90) for Streptococcus equi ssp. (SDZ/TMP): 9.5/0.5 μg/ml).",Pharmacokinetics of a sulfadiazine and trimethoprim suspension in neonatal foals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33289123/),[μg] / [ml],0.5,204070,DB00440,Trimethoprim
,2097719,peak blister fluid concentrations,The peak blister fluid concentrations after oral administration (120 +/- 18 mmol/l) was only marginally lower than the concentrations after i.v. infusion (122 +/- 28 mmol/l) and i.v. bolus injections (134 +/- 37 mmol/l).,Pharmacokinetic studies of antibacterial agents using the suction blister method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097719/),[mM] / [l],120,204452,DB00440,Trimethoprim
,2097719,peak blister fluid concentrations,The peak blister fluid concentrations after oral administration (120 +/- 18 mmol/l) was only marginally lower than the concentrations after i.v. infusion (122 +/- 28 mmol/l) and i.v. bolus injections (134 +/- 37 mmol/l).,Pharmacokinetic studies of antibacterial agents using the suction blister method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097719/),[mM] / [l],122,204453,DB00440,Trimethoprim
,2097719,peak blister fluid concentrations,The peak blister fluid concentrations after oral administration (120 +/- 18 mmol/l) was only marginally lower than the concentrations after i.v. infusion (122 +/- 28 mmol/l) and i.v. bolus injections (134 +/- 37 mmol/l).,Pharmacokinetic studies of antibacterial agents using the suction blister method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097719/),[mM] / [l],134,204454,DB00440,Trimethoprim
,28651341,Cmin,The median Cmin (IQR) was 11.3 μg/mL (6.2-27.8) and the median Cmax was 13.4 μg/mL (6.0-28.3).,Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28651341/),[μg] / [ml],11.3,207131,DB00440,Trimethoprim
,28651341,Cmax,The median Cmin (IQR) was 11.3 μg/mL (6.2-27.8) and the median Cmax was 13.4 μg/mL (6.0-28.3).,Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28651341/),[μg] / [ml],13.4,207132,DB00440,Trimethoprim
<,28651341,Cmin,"Nineteen of the 33 (58%) patients had Cmin <15 μg/mL, a threshold associated with a low rate of clinical response in PCP treatment.",Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28651341/),[μg] / [ml],15,207133,DB00440,Trimethoprim
,6975241,plasma elimination half-life in the terminal phase,"The pharmacokinetic analysis showed a plasma elimination half-life in the terminal phase of 10.39 h for TMP, 11.79 h for SMZ, 6.55 h for TXP and 10.46 h for SDZ.",Pharmacokinetics of co-trimoxazole and co-tetroxazine in geriatric patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6975241/),h,10.39,209112,DB00440,Trimethoprim
,6975241,plasma elimination half-life in the terminal phase,"The pharmacokinetic analysis showed a plasma elimination half-life in the terminal phase of 10.39 h for TMP, 11.79 h for SMZ, 6.55 h for TXP and 10.46 h for SDZ.",Pharmacokinetics of co-trimoxazole and co-tetroxazine in geriatric patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6975241/),h,11.79,209113,DB00440,Trimethoprim
,6975241,plasma elimination half-life in the terminal phase,"The pharmacokinetic analysis showed a plasma elimination half-life in the terminal phase of 10.39 h for TMP, 11.79 h for SMZ, 6.55 h for TXP and 10.46 h for SDZ.",Pharmacokinetics of co-trimoxazole and co-tetroxazine in geriatric patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6975241/),h,6.55,209114,DB00440,Trimethoprim
,6975241,plasma elimination half-life in the terminal phase,"The pharmacokinetic analysis showed a plasma elimination half-life in the terminal phase of 10.39 h for TMP, 11.79 h for SMZ, 6.55 h for TXP and 10.46 h for SDZ.",Pharmacokinetics of co-trimoxazole and co-tetroxazine in geriatric patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6975241/),h,10.46,209115,DB00440,Trimethoprim
,6975241,Recovery,"Recovery in urine, measured for up to 96 h, was 49.2% (TMP), 19.8% (SMZ), 57.03% (TXP) and 61.1% (SDZ).",Pharmacokinetics of co-trimoxazole and co-tetroxazine in geriatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6975241/),%,49.2,209116,DB00440,Trimethoprim
,6975241,Recovery,"Recovery in urine, measured for up to 96 h, was 49.2% (TMP), 19.8% (SMZ), 57.03% (TXP) and 61.1% (SDZ).",Pharmacokinetics of co-trimoxazole and co-tetroxazine in geriatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6975241/),%,19.8,209117,DB00440,Trimethoprim
,6975241,Recovery,"Recovery in urine, measured for up to 96 h, was 49.2% (TMP), 19.8% (SMZ), 57.03% (TXP) and 61.1% (SDZ).",Pharmacokinetics of co-trimoxazole and co-tetroxazine in geriatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6975241/),%,57.03,209118,DB00440,Trimethoprim
,6975241,Recovery,"Recovery in urine, measured for up to 96 h, was 49.2% (TMP), 19.8% (SMZ), 57.03% (TXP) and 61.1% (SDZ).",Pharmacokinetics of co-trimoxazole and co-tetroxazine in geriatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6975241/),%,61.1,209119,DB00440,Trimethoprim
,6975241,renal clearance,In this group of patients the renal clearance was 2.42 ml/min for SMZ and 10.7 ml/min for SDZ.,Pharmacokinetics of co-trimoxazole and co-tetroxazine in geriatric patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6975241/),[ml] / [min],2.42,209120,DB00440,Trimethoprim
,6975241,renal clearance,In this group of patients the renal clearance was 2.42 ml/min for SMZ and 10.7 ml/min for SDZ.,Pharmacokinetics of co-trimoxazole and co-tetroxazine in geriatric patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6975241/),[ml] / [min],10.7,209121,DB00440,Trimethoprim
,3157705,peak serum levels,"Mean peak serum levels were 1.45 micrograms/mL and 2.46 micrograms/mL for 250-mg and 500-mg doses, and time to peak was 1 and 1.3 hours.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),[μg] / [ml],1.45,209132,DB00440,Trimethoprim
,3157705,peak serum levels,"Mean peak serum levels were 1.45 micrograms/mL and 2.46 micrograms/mL for 250-mg and 500-mg doses, and time to peak was 1 and 1.3 hours.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),[μg] / [ml],2.46,209133,DB00440,Trimethoprim
,3157705,time to peak,"Mean peak serum levels were 1.45 micrograms/mL and 2.46 micrograms/mL for 250-mg and 500-mg doses, and time to peak was 1 and 1.3 hours.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),h,1,209134,DB00440,Trimethoprim
,3157705,time to peak,"Mean peak serum levels were 1.45 micrograms/mL and 2.46 micrograms/mL for 250-mg and 500-mg doses, and time to peak was 1 and 1.3 hours.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),h,1.3,209135,DB00440,Trimethoprim
,3157705,Half-life (T1/2)alpha,"Half-life (T1/2)alpha were 0.32 and 0.43 with T1/2 beta were 3.97 and 4.15 and volume of distribution (area) were 80L and 90L, respectively.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),,0.32,209136,DB00440,Trimethoprim
,3157705,Half-life (T1/2)alpha,"Half-life (T1/2)alpha were 0.32 and 0.43 with T1/2 beta were 3.97 and 4.15 and volume of distribution (area) were 80L and 90L, respectively.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),,0.43,209137,DB00440,Trimethoprim
,3157705,T1/2 beta,"Half-life (T1/2)alpha were 0.32 and 0.43 with T1/2 beta were 3.97 and 4.15 and volume of distribution (area) were 80L and 90L, respectively.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),,3.97,209138,DB00440,Trimethoprim
,3157705,T1/2 beta,"Half-life (T1/2)alpha were 0.32 and 0.43 with T1/2 beta were 3.97 and 4.15 and volume of distribution (area) were 80L and 90L, respectively.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),,4.15,209139,DB00440,Trimethoprim
,3157705,volume of distribution (area),"Half-life (T1/2)alpha were 0.32 and 0.43 with T1/2 beta were 3.97 and 4.15 and volume of distribution (area) were 80L and 90L, respectively.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),l,80,209140,DB00440,Trimethoprim
,3157705,volume of distribution (area),"Half-life (T1/2)alpha were 0.32 and 0.43 with T1/2 beta were 3.97 and 4.15 and volume of distribution (area) were 80L and 90L, respectively.",The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),l,90,209141,DB00440,Trimethoprim
,3157705,Area under the concentration curve (AUC),Area under the concentration curve (AUC) was 5.65 h X micrograms/mL and 10.37h X micrograms/mL.,The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),[h·μg] / [ml],5.65,209142,DB00440,Trimethoprim
,3157705,Area under the concentration curve (AUC),Area under the concentration curve (AUC) was 5.65 h X micrograms/mL and 10.37h X micrograms/mL.,The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),[h·μg] / [ml],10.37,209143,DB00440,Trimethoprim
,3157705,Serum clearance,Serum clearance was 23L for both doses.,The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157705/),l,23,209144,DB00440,Trimethoprim
,32878175,terminal half-life,"Conversely, SDM had a long terminal half-life of 18 h and excellent oral bioavailability.",Levers to Improve Antibiotic Treatment of Lambs via Drinking Water in Sheep Fattening Houses: The Example of the Sulfadimethoxine/Trimethoprim Combination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32878175/),h,18,209431,DB00440,Trimethoprim
,25552403,K i,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,27.2,209604,DB00440,Trimethoprim
,25552403,K i,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,6.3,209605,DB00440,Trimethoprim
,25552403,K i,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,28.9,209606,DB00440,Trimethoprim
,25552403,IC50,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,133.9,209607,DB00440,Trimethoprim
,25552403,IC50,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,29.1,209608,DB00440,Trimethoprim
,25552403,IC50,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,0.61,209609,DB00440,Trimethoprim
,25733012,AUC,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[h·ng] / [ml],6,209817,DB00440,Trimethoprim
,25733012,CMAX,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[ng] / [ml],6,209818,DB00440,Trimethoprim
,25733012,CMAX,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[h·ng] / [ml],541,209819,DB00440,Trimethoprim
,25733012,CMAX,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[ng] / [ml],47.8,209820,DB00440,Trimethoprim
,8195841,Urinary excretion,Urinary excretion of unchanged brodimoprim amounted to 5-10% of the administered dose.,Pharmacokinetics of brodimoprim in special populations. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195841/),%,5-10,209955,DB00440,Trimethoprim
,8195841,Renal excretion,"Renal excretion of brodimoprim and hydroxy metabolite at steady-state reached 9% and 14% per 24 hours in the elderly, compared to 9% and 24% in young adults.",Pharmacokinetics of brodimoprim in special populations. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195841/),%,9,209956,DB00440,Trimethoprim
,8195841,Renal excretion,"Renal excretion of brodimoprim and hydroxy metabolite at steady-state reached 9% and 14% per 24 hours in the elderly, compared to 9% and 24% in young adults.",Pharmacokinetics of brodimoprim in special populations. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195841/),%,14,209957,DB00440,Trimethoprim
,8195841,Renal excretion,"Renal excretion of brodimoprim and hydroxy metabolite at steady-state reached 9% and 14% per 24 hours in the elderly, compared to 9% and 24% in young adults.",Pharmacokinetics of brodimoprim in special populations. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195841/),%,24,209958,DB00440,Trimethoprim
,8195841,accumulation factor,The accumulation factor reached 3.3 +/- 0.4 and 2.7 +/- 0.3 respectively.,Pharmacokinetics of brodimoprim in special populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195841/),,3.3,209959,DB00440,Trimethoprim
,8195841,accumulation factor,The accumulation factor reached 3.3 +/- 0.4 and 2.7 +/- 0.3 respectively.,Pharmacokinetics of brodimoprim in special populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195841/),,2.7,209960,DB00440,Trimethoprim
,4075857,peaks of the mean concentration curves,"Following 400 mg brodimoprim given orally to 8 volunteers, the peaks of the mean concentration curves were 3.2 +/- 1.0 mg/l in serum and 1.0 +/- 0.2 mg/l (+/- SEM) in skin blister fluid.",Pharmacokinetics of brodimoprim in serum and skin blister fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4075857/),[mg] / [l],3.2,213436,DB00440,Trimethoprim
,4075857,peaks of the mean concentration curves,"Following 400 mg brodimoprim given orally to 8 volunteers, the peaks of the mean concentration curves were 3.2 +/- 1.0 mg/l in serum and 1.0 +/- 0.2 mg/l (+/- SEM) in skin blister fluid.",Pharmacokinetics of brodimoprim in serum and skin blister fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4075857/),[mg] / [l],1.0,213437,DB00440,Trimethoprim
,4075857,terminal half-lives,"The terminal half-lives were 25.9 +/- 2.2 h and 42.2 +/- 6.5 h in serum and blister fluid, respectively.",Pharmacokinetics of brodimoprim in serum and skin blister fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4075857/),h,25.9,213438,DB00440,Trimethoprim
,4075857,terminal half-lives,"The terminal half-lives were 25.9 +/- 2.2 h and 42.2 +/- 6.5 h in serum and blister fluid, respectively.",Pharmacokinetics of brodimoprim in serum and skin blister fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4075857/),h,42.2,213439,DB00440,Trimethoprim
,4075857,recovery,"The area under the concentration-versus-time curve for blister fluid was 73% of serum value, and the mean recovery of bioactive drug in urine during 24 h was 3.4%.",Pharmacokinetics of brodimoprim in serum and skin blister fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4075857/),%,3.4,213440,DB00440,Trimethoprim
,20950347,Bioavailability,Bioavailability was 74% for SDZ and 46% for TMP after paste administration in fed horses.,Antimicrobial disposition in pulmonary epithelial lining fluid of horses. Part I. Sulfadiazine and trimethoprim. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950347/),%,74,219161,DB00440,Trimethoprim
,20950347,Bioavailability,Bioavailability was 74% for SDZ and 46% for TMP after paste administration in fed horses.,Antimicrobial disposition in pulmonary epithelial lining fluid of horses. Part I. Sulfadiazine and trimethoprim. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950347/),%,46,219162,DB00440,Trimethoprim
,20950347,degree of penetration,"After oral administration, the degree of penetration for SDZ and TMP was 0.92 and 0.46, respectively.",Antimicrobial disposition in pulmonary epithelial lining fluid of horses. Part I. Sulfadiazine and trimethoprim. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950347/),,0.92,219163,DB00440,Trimethoprim
,20950347,degree of penetration,"After oral administration, the degree of penetration for SDZ and TMP was 0.92 and 0.46, respectively.",Antimicrobial disposition in pulmonary epithelial lining fluid of horses. Part I. Sulfadiazine and trimethoprim. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950347/),,0.46,219164,DB00440,Trimethoprim
,3500644,blood flow,All patients were dialyzed for 4 h with a 1.0 m2 cuprophane hollow-fiber dialyzer at a blood flow of 200 ml/min.,Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500644/),[ml] / [min],200,219601,DB00440,Trimethoprim
,3500644,concentration,Mean arterial TMP concentration peaked at 1.93 micrograms/ml following infusion and fell to 1.03 micrograms/ml by the end of dialysis (p less than 0.001).,Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500644/),,1.,219602,DB00440,Trimethoprim
,3500644,concentration,Mean arterial TMP concentration peaked at 1.93 micrograms/ml following infusion and fell to 1.03 micrograms/ml by the end of dialysis (p less than 0.001).,Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500644/),,1,219603,DB00440,Trimethoprim
,3500644,concentration,Mean arterial SMZ concentration peaked at 41.8 micrograms/ml at the end of the infusion and fell to 16.4 micrograms/ml by the end of dialysis (p less than 0.005).,Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500644/),[μg] / [ml],41.8,219604,DB00440,Trimethoprim
,3500644,concentration,Mean arterial SMZ concentration peaked at 41.8 micrograms/ml at the end of the infusion and fell to 16.4 micrograms/ml by the end of dialysis (p less than 0.005).,Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500644/),,16,219605,DB00440,Trimethoprim
,3500644,extraction ratio,The extraction ratio averaged 19% for TMP and 21% for SMZ.,Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500644/),%,19,219606,DB00440,Trimethoprim
,3500644,extraction ratio,The extraction ratio averaged 19% for TMP and 21% for SMZ.,Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500644/),%,21,219607,DB00440,Trimethoprim
,3500644,elimination half-life,The elimination half-life during dialysis for TMP was 6.0 h and for SMZ was 3.1 h.,Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500644/),h,6.0,219608,DB00440,Trimethoprim
,3500644,elimination half-life,The elimination half-life during dialysis for TMP was 6.0 h and for SMZ was 3.1 h.,Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500644/),h,3.1,219609,DB00440,Trimethoprim
,3500644,Di,Dialysis clearance averaged 38 ml/min for TMP and 42 ml/min for SMZ.,Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500644/),[ml] / [min],38,219610,DB00440,Trimethoprim
,3500644,Di,Dialysis clearance averaged 38 ml/min for TMP and 42 ml/min for SMZ.,Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500644/),[ml] / [min],42,219611,DB00440,Trimethoprim
,27310088,withdrawal time (WDT),"The results suggest that the liver was the residual target tissue and ADP was the marker residue, and the conclusive withdrawal time (WDT) of 20 days in pigs, 16 days in broilers and 25 days in carp was estimated using the assessment methodologies approved by the Joint FAO/WHO Expert Committee on Food Additives (JECFA).","Simultaneous determination of aditoprim and its three major metabolites in pigs, broilers and carp tissues, and its application in tissue distribution and depletion studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310088/),d,20,221009,DB00440,Trimethoprim
,27310088,withdrawal time (WDT),"The results suggest that the liver was the residual target tissue and ADP was the marker residue, and the conclusive withdrawal time (WDT) of 20 days in pigs, 16 days in broilers and 25 days in carp was estimated using the assessment methodologies approved by the Joint FAO/WHO Expert Committee on Food Additives (JECFA).","Simultaneous determination of aditoprim and its three major metabolites in pigs, broilers and carp tissues, and its application in tissue distribution and depletion studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310088/),d,16,221010,DB00440,Trimethoprim
,27310088,withdrawal time (WDT),"The results suggest that the liver was the residual target tissue and ADP was the marker residue, and the conclusive withdrawal time (WDT) of 20 days in pigs, 16 days in broilers and 25 days in carp was estimated using the assessment methodologies approved by the Joint FAO/WHO Expert Committee on Food Additives (JECFA).","Simultaneous determination of aditoprim and its three major metabolites in pigs, broilers and carp tissues, and its application in tissue distribution and depletion studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310088/),d,25,221011,DB00440,Trimethoprim
,8583537,elimination half-lives,"In healthy and pneumonic pigs, the mean elimination half-lives of SDM were 12.9 h and 13.4 h, respectively, those of SMX 2.5 h and 2.7 h, respectively, and those of TMP 2.8 h and 2.6 h, respectively.",Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583537/),h,12.9,225143,DB00440,Trimethoprim
,8583537,elimination half-lives,"In healthy and pneumonic pigs, the mean elimination half-lives of SDM were 12.9 h and 13.4 h, respectively, those of SMX 2.5 h and 2.7 h, respectively, and those of TMP 2.8 h and 2.6 h, respectively.",Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583537/),h,13.4,225144,DB00440,Trimethoprim
,8583537,elimination half-lives,"In healthy and pneumonic pigs, the mean elimination half-lives of SDM were 12.9 h and 13.4 h, respectively, those of SMX 2.5 h and 2.7 h, respectively, and those of TMP 2.8 h and 2.6 h, respectively.",Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583537/),h,2.5,225145,DB00440,Trimethoprim
,8583537,elimination half-lives,"In healthy and pneumonic pigs, the mean elimination half-lives of SDM were 12.9 h and 13.4 h, respectively, those of SMX 2.5 h and 2.7 h, respectively, and those of TMP 2.8 h and 2.6 h, respectively.",Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583537/),h,2.7,225146,DB00440,Trimethoprim
,8583537,elimination half-lives,"In healthy and pneumonic pigs, the mean elimination half-lives of SDM were 12.9 h and 13.4 h, respectively, those of SMX 2.5 h and 2.7 h, respectively, and those of TMP 2.8 h and 2.6 h, respectively.",Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583537/),h,2.8,225147,DB00440,Trimethoprim
,8583537,elimination half-lives,"In healthy and pneumonic pigs, the mean elimination half-lives of SDM were 12.9 h and 13.4 h, respectively, those of SMX 2.5 h and 2.7 h, respectively, and those of TMP 2.8 h and 2.6 h, respectively.",Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583537/),h,2.6,225148,DB00440,Trimethoprim
,8583537,Distribution volumes,"Distribution volumes in healthy and febrile pigs of SDM and SMX varied between 0.2 and 0.4 L/kg, and those of TMP between 1.1 and 1.6 L/kg.",Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583537/),[l] / [kg],0.2 and 0.4,225149,DB00440,Trimethoprim
,8583537,Distribution volumes,"Distribution volumes in healthy and febrile pigs of SDM and SMX varied between 0.2 and 0.4 L/kg, and those of TMP between 1.1 and 1.6 L/kg.",Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583537/),[l] / [kg],1.1 and 1.6,225150,DB00440,Trimethoprim
,8583537,protein binding,"The extent of protein binding of SDM, SMX and TMP was in the range 94-99%, 45-56% and 40-50%, respectively.",Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583537/),%,94-99,225151,DB00440,Trimethoprim
,8583537,protein binding,"The extent of protein binding of SDM, SMX and TMP was in the range 94-99%, 45-56% and 40-50%, respectively.",Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583537/),%,45-56,225152,DB00440,Trimethoprim
,8583537,protein binding,"The extent of protein binding of SDM, SMX and TMP was in the range 94-99%, 45-56% and 40-50%, respectively.",Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583537/),%,40-50,225153,DB00440,Trimethoprim
,27329132,trough plasma VRCZ concentration,"The trough plasma VRCZ concentration in the 10 mg/kg/d group ranged from < 0.09 μg/mL to 2.17 μg/mL, with a median level of 0.27 μg/mL, and patients with the targeted trough concentration (1-4 μg/mL) comprised only 18.8% of the evaluable patients in this group, whereas the trough plasma VRCZ concentration of the evaluable patients in the 5 mg/kg/d group were all below the limit of sensitivity (< 0.09 μg/mL).",Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27329132/),[μg] / [ml],0.09,227328,DB00440,Trimethoprim
,27329132,trough plasma VRCZ concentration,"The trough plasma VRCZ concentration in the 10 mg/kg/d group ranged from < 0.09 μg/mL to 2.17 μg/mL, with a median level of 0.27 μg/mL, and patients with the targeted trough concentration (1-4 μg/mL) comprised only 18.8% of the evaluable patients in this group, whereas the trough plasma VRCZ concentration of the evaluable patients in the 5 mg/kg/d group were all below the limit of sensitivity (< 0.09 μg/mL).",Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27329132/),[μg] / [ml],2.17,227329,DB00440,Trimethoprim
,27329132,trough concentration,"The trough plasma VRCZ concentration in the 10 mg/kg/d group ranged from < 0.09 μg/mL to 2.17 μg/mL, with a median level of 0.27 μg/mL, and patients with the targeted trough concentration (1-4 μg/mL) comprised only 18.8% of the evaluable patients in this group, whereas the trough plasma VRCZ concentration of the evaluable patients in the 5 mg/kg/d group were all below the limit of sensitivity (< 0.09 μg/mL).",Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27329132/),[μg] / [ml],1-4,227330,DB00440,Trimethoprim
,29084742,MIC,"The exposure achieved in children after oral administration of TMP-SMX at 8/40 mg/kg of body weight/day divided into administration every 12 h matched the exposure achieved in adults after administration of TMP-SMX at 320/1,600 mg/day divided into administration every 12 h and achieved the PD target for bacteria with an MIC of 0.5 mg/liter in >90% of infants and children.",Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29084742/),[mg] / [l],0.5,227971,DB00440,Trimethoprim
up to,29084742,MIC,"The exposure achieved in children after oral administration of TMP-SMX at 12/60 and 15/75 mg/kg/day divided into administration every 12 h matched the exposure achieved in adults after administration of TMP-SMX at 640/3,200 mg/day divided into administration every 12 h in subjects 6 to <21 years and 0 to <6 years of age, respectively, and was optimal for bacteria with an MIC of up to 1 mg/liter.",Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29084742/),[mg] / [l],1,227972,DB00440,Trimethoprim
,6488934,half-life (t 1/2),The half-life (t 1/2) of TMP in the children was 3.0-5.5 versus 9.3-13.6 h in the adults.,Difference in trimethoprim pharmacokinetics between children and adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6488934/),h,3.0-5.5,230498,DB00440,Trimethoprim
,6488934,half-life (t 1/2),The half-life (t 1/2) of TMP in the children was 3.0-5.5 versus 9.3-13.6 h in the adults.,Difference in trimethoprim pharmacokinetics between children and adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6488934/),h,9.3-13.6,230499,DB00440,Trimethoprim
,6488934,volume of distribution (Vd),The volume of distribution (Vd) was 0.7-1.1 1/kg in the children and 0.5-0.9 1/kg in the adults.,Difference in trimethoprim pharmacokinetics between children and adults. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6488934/),[1] / [kg],0.7-1.1,230500,DB00440,Trimethoprim
,6488934,volume of distribution (Vd),The volume of distribution (Vd) was 0.7-1.1 1/kg in the children and 0.5-0.9 1/kg in the adults.,Difference in trimethoprim pharmacokinetics between children and adults. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6488934/),[1] / [kg],0.5-0.9,230501,DB00440,Trimethoprim
,6488934,Plasma clearance (Clp),Plasma clearance (Clp) was 2.1-2.8 ml/min/kg for the children.,Difference in trimethoprim pharmacokinetics between children and adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6488934/),[ml] / [kg·min],2.1-2.8,230502,DB00440,Trimethoprim
,6488934,Clp,The adults had a smaller Clp of 0.4-1.2 ml/min/kg.,Difference in trimethoprim pharmacokinetics between children and adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6488934/),[ml] / [kg·min],0.4-1.2,230503,DB00440,Trimethoprim
,6734701,AUCss,The mean AUCss was 77 micrograms/ml X h and the mean plasma clearances was 67 and 74 ml/min on Days 8 and 9.,Steady state pharmacokinetics of trimethoprim 300 mg once daily in healthy volunteers assessed by two independent methods. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734701/),[μg] / [h·ml],77,231021,DB00440,Trimethoprim
,6734701,plasma clearances,The mean AUCss was 77 micrograms/ml X h and the mean plasma clearances was 67 and 74 ml/min on Days 8 and 9.,Steady state pharmacokinetics of trimethoprim 300 mg once daily in healthy volunteers assessed by two independent methods. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734701/),[ml] / [min],67,231022,DB00440,Trimethoprim
,6734701,plasma clearances,The mean AUCss was 77 micrograms/ml X h and the mean plasma clearances was 67 and 74 ml/min on Days 8 and 9.,Steady state pharmacokinetics of trimethoprim 300 mg once daily in healthy volunteers assessed by two independent methods. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734701/),[ml] / [min],74,231023,DB00440,Trimethoprim
,6734701,plasma half life,The average plasma half life was 10.6 h (range 8.7-15.3 h).,Steady state pharmacokinetics of trimethoprim 300 mg once daily in healthy volunteers assessed by two independent methods. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734701/),h,10.6,231024,DB00440,Trimethoprim
,6734701,minimum urinary concentration,The minimum urinary concentration of trimethoprim during treatment was always well above (range 22 to 220 micrograms/ml) the MIC values for most urinary tract pathogens.,Steady state pharmacokinetics of trimethoprim 300 mg once daily in healthy volunteers assessed by two independent methods. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734701/),[μg] / [ml],22 to 220,231025,DB00440,Trimethoprim
,729608,serum concentration,Twelve hours after dosing the serum concentration was 12 to 25 microgram/ml for SDZ and 0.3 to 1.1 microgram/ml for TMP.,Pharmacokinetics of sulfadiazine and trimethoprim in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/729608/),[μg] / [ml],12 to 25,231894,DB00440,Trimethoprim
,729608,serum concentration,Twelve hours after dosing the serum concentration was 12 to 25 microgram/ml for SDZ and 0.3 to 1.1 microgram/ml for TMP.,Pharmacokinetics of sulfadiazine and trimethoprim in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/729608/),,0.3 to 1.1,231895,DB00440,Trimethoprim
,729608,concentration ratios,"Individual concentration ratios between SDZ and TMP in serum were 4.8 (1 h)--145 (24 h), and in the urine the ratio was close to 6 throughout the 24 h collection period.",Pharmacokinetics of sulfadiazine and trimethoprim in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/729608/),,4.8,231896,DB00440,Trimethoprim
,729608,concentration ratios,"Individual concentration ratios between SDZ and TMP in serum were 4.8 (1 h)--145 (24 h), and in the urine the ratio was close to 6 throughout the 24 h collection period.",Pharmacokinetics of sulfadiazine and trimethoprim in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/729608/),,145,231897,DB00440,Trimethoprim
,729608,concentration ratios,"Individual concentration ratios between SDZ and TMP in serum were 4.8 (1 h)--145 (24 h), and in the urine the ratio was close to 6 throughout the 24 h collection period.",Pharmacokinetics of sulfadiazine and trimethoprim in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/729608/),,6,231898,DB00440,Trimethoprim
,729608,urina,The range of urinary concentrations was from 65 to 400 microgram/ml for SDZ and from 13.8 to 93.4 microgram/ml for TMP.,Pharmacokinetics of sulfadiazine and trimethoprim in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/729608/),,65 to 400,231899,DB00440,Trimethoprim
,729608,"""t1/2""","The average ""t1/2"" was 15.2 +/- 7.4 h for SDZ and 7.4 +/- 1.9 h for TMP.",Pharmacokinetics of sulfadiazine and trimethoprim in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/729608/),h,15.2,231900,DB00440,Trimethoprim
,729608,"""t1/2""","The average ""t1/2"" was 15.2 +/- 7.4 h for SDZ and 7.4 +/- 1.9 h for TMP.",Pharmacokinetics of sulfadiazine and trimethoprim in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/729608/),h,7.4,231901,DB00440,Trimethoprim
,8302685,volume,"Mean (SD) baseline parameter estimates for TMP were volume 2.1 (0.65) L/kg, half-life 9.7 (3.0) hours, and clearance 2.6 (0.80) ml/min/kg.",Trimethoprim-sulfamethoxazole pharmacokinetics in trauma patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8302685/),[l] / [kg],2.1,232369,DB00440,Trimethoprim
,8302685,half-life,"Mean (SD) baseline parameter estimates for TMP were volume 2.1 (0.65) L/kg, half-life 9.7 (3.0) hours, and clearance 2.6 (0.80) ml/min/kg.",Trimethoprim-sulfamethoxazole pharmacokinetics in trauma patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8302685/),h,9.7,232370,DB00440,Trimethoprim
,8302685,clearance,"Mean (SD) baseline parameter estimates for TMP were volume 2.1 (0.65) L/kg, half-life 9.7 (3.0) hours, and clearance 2.6 (0.80) ml/min/kg.",Trimethoprim-sulfamethoxazole pharmacokinetics in trauma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8302685/),[ml] / [kg·min],2.6,232371,DB00440,Trimethoprim
,8302685,volume,"Estimates for SMX were volume 0.51 (0.10) L/kg, half-life 7.8 (2.0) hours, and clearance 0.80 (0.29) ml/min/kg.",Trimethoprim-sulfamethoxazole pharmacokinetics in trauma patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8302685/),[l] / [kg],0.51,232372,DB00440,Trimethoprim
,8302685,half-life,"Estimates for SMX were volume 0.51 (0.10) L/kg, half-life 7.8 (2.0) hours, and clearance 0.80 (0.29) ml/min/kg.",Trimethoprim-sulfamethoxazole pharmacokinetics in trauma patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8302685/),h,7.8,232373,DB00440,Trimethoprim
,8302685,clearance,"Estimates for SMX were volume 0.51 (0.10) L/kg, half-life 7.8 (2.0) hours, and clearance 0.80 (0.29) ml/min/kg.",Trimethoprim-sulfamethoxazole pharmacokinetics in trauma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8302685/),[ml] / [kg·min],0.80,232374,DB00440,Trimethoprim
,8600759,50% inhibitory concentration (IC50),"The 50% inhibitory concentration (IC50) of epiroprim for T. gondii dihydrofolate reductase was 0.9 micromole, similar to that of pyrimethamine, but epiroprim was 650-fold more selective than pyrimethamine for T. gondii compared with human dihydrofolate reductase.","Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8600759/),μmole,0.9,233336,DB00440,Trimethoprim
,11741217,CL/F,Estimates of the apparent clearance for nevirapine (CL/F = 3.3 L/hour; 95% confidence interval [CI] 2.9 to 3.7 L/hour) and lamivudine (CL/F 27.6 L/hour; 95% CI 22 to 33.2 L/hour) were consistent with the values reported in earlier trials.,Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11741217/),[l] / [h],3.3,233677,DB00440,Trimethoprim
,11741217,CL/F,Estimates of the apparent clearance for nevirapine (CL/F = 3.3 L/hour; 95% confidence interval [CI] 2.9 to 3.7 L/hour) and lamivudine (CL/F 27.6 L/hour; 95% CI 22 to 33.2 L/hour) were consistent with the values reported in earlier trials.,Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11741217/),[l] / [h],27.6,233678,DB00440,Trimethoprim
,3184252,t1/2 beta,"For TMP, mean t1/2 beta +/- SEM (h) was 0.84 +/- 0.06 (i.v. control) and 0.90 +/- 0.06 (i.v. infected), respectively, whereas for AP values of 8.00 +/- 0.31 (i.v. control) and 10.28 +/- 0.67 (i.v. infected) were obtained (P less than 0.05).",Some pharmacokinetic data of aditoprim and trimethoprim in healthy and tick-borne fever infected dwarf goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184252/),h,0.84,234320,DB00440,Trimethoprim
,3184252,t1/2 beta,"For TMP, mean t1/2 beta +/- SEM (h) was 0.84 +/- 0.06 (i.v. control) and 0.90 +/- 0.06 (i.v. infected), respectively, whereas for AP values of 8.00 +/- 0.31 (i.v. control) and 10.28 +/- 0.67 (i.v. infected) were obtained (P less than 0.05).",Some pharmacokinetic data of aditoprim and trimethoprim in healthy and tick-borne fever infected dwarf goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184252/),h,0.90,234321,DB00440,Trimethoprim
,3184252,t1/2 beta,"For TMP, mean t1/2 beta +/- SEM (h) was 0.84 +/- 0.06 (i.v. control) and 0.90 +/- 0.06 (i.v. infected), respectively, whereas for AP values of 8.00 +/- 0.31 (i.v. control) and 10.28 +/- 0.67 (i.v. infected) were obtained (P less than 0.05).",Some pharmacokinetic data of aditoprim and trimethoprim in healthy and tick-borne fever infected dwarf goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184252/),h,8.00,234322,DB00440,Trimethoprim
,3184252,t1/2 beta,"For TMP, mean t1/2 beta +/- SEM (h) was 0.84 +/- 0.06 (i.v. control) and 0.90 +/- 0.06 (i.v. infected), respectively, whereas for AP values of 8.00 +/- 0.31 (i.v. control) and 10.28 +/- 0.67 (i.v. infected) were obtained (P less than 0.05).",Some pharmacokinetic data of aditoprim and trimethoprim in healthy and tick-borne fever infected dwarf goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184252/),h,10.28,234323,DB00440,Trimethoprim
,3184252,AP,"For TMP, mean t1/2 beta +/- SEM (h) was 0.84 +/- 0.06 (i.v. control) and 0.90 +/- 0.06 (i.v. infected), respectively, whereas for AP values of 8.00 +/- 0.31 (i.v. control) and 10.28 +/- 0.67 (i.v. infected) were obtained (P less than 0.05).",Some pharmacokinetic data of aditoprim and trimethoprim in healthy and tick-borne fever infected dwarf goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184252/),h,8.00,234324,DB00440,Trimethoprim
,3184252,AP,"For TMP, mean t1/2 beta +/- SEM (h) was 0.84 +/- 0.06 (i.v. control) and 0.90 +/- 0.06 (i.v. infected), respectively, whereas for AP values of 8.00 +/- 0.31 (i.v. control) and 10.28 +/- 0.67 (i.v. infected) were obtained (P less than 0.05).",Some pharmacokinetic data of aditoprim and trimethoprim in healthy and tick-borne fever infected dwarf goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184252/),h,10.28,234325,DB00440,Trimethoprim
,3184252,Vd beta,Mean Vd beta +/- SEM values (l/kg) were 3.84 +/- 0.27 (i.v. control) and 4.07 +/- 0.85 (i.v. infected) for TMP (NS) and 7.02 +/- 0.63 vs 9.29 +/- 0.21 (P less than 0.05) for AP.,Some pharmacokinetic data of aditoprim and trimethoprim in healthy and tick-borne fever infected dwarf goats. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184252/),[l] / [kg],3.84,234326,DB00440,Trimethoprim
,3184252,Vd beta,Mean Vd beta +/- SEM values (l/kg) were 3.84 +/- 0.27 (i.v. control) and 4.07 +/- 0.85 (i.v. infected) for TMP (NS) and 7.02 +/- 0.63 vs 9.29 +/- 0.21 (P less than 0.05) for AP.,Some pharmacokinetic data of aditoprim and trimethoprim in healthy and tick-borne fever infected dwarf goats. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184252/),[l] / [kg],4.07,234327,DB00440,Trimethoprim
,3184252,Vd beta,Mean Vd beta +/- SEM values (l/kg) were 3.84 +/- 0.27 (i.v. control) and 4.07 +/- 0.85 (i.v. infected) for TMP (NS) and 7.02 +/- 0.63 vs 9.29 +/- 0.21 (P less than 0.05) for AP.,Some pharmacokinetic data of aditoprim and trimethoprim in healthy and tick-borne fever infected dwarf goats. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184252/),[l] / [kg],7.02,234328,DB00440,Trimethoprim
,3184252,Vd beta,Mean Vd beta +/- SEM values (l/kg) were 3.84 +/- 0.27 (i.v. control) and 4.07 +/- 0.85 (i.v. infected) for TMP (NS) and 7.02 +/- 0.63 vs 9.29 +/- 0.21 (P less than 0.05) for AP.,Some pharmacokinetic data of aditoprim and trimethoprim in healthy and tick-borne fever infected dwarf goats. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184252/),[l] / [kg],9.29,234329,DB00440,Trimethoprim
,3184252,plasma,"For AP, the plasma and rumen fluid concentrations at 3 h were 1.20 +/- 0.06 micrograms/ml and 0.85 +/- 0.17 microgram/ml, respectively.",Some pharmacokinetic data of aditoprim and trimethoprim in healthy and tick-borne fever infected dwarf goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184252/),[μg] / [ml],1.20,234330,DB00440,Trimethoprim
,3184252,Cmax,"After oral administration of TMP, Cmax in plasma was 0.12 +/- 0.01 microgram/ml and the maximum was reached after 1.2 +/- 0.16 h; systemic bioavailability (F) was 10.3% (relative to AUC i.v.).",Some pharmacokinetic data of aditoprim and trimethoprim in healthy and tick-borne fever infected dwarf goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184252/),[μg] / [ml],0.12,234331,DB00440,Trimethoprim
,3184252,systemic bioavailability (F),"After oral administration of TMP, Cmax in plasma was 0.12 +/- 0.01 microgram/ml and the maximum was reached after 1.2 +/- 0.16 h; systemic bioavailability (F) was 10.3% (relative to AUC i.v.).",Some pharmacokinetic data of aditoprim and trimethoprim in healthy and tick-borne fever infected dwarf goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184252/),%,10.3,234332,DB00440,Trimethoprim
,3184252,Cmax,Oral treatment with AP resulted in a Cmax value of 0.21 +/- 0.02 microgram/ml with Tmax of 22.5 +/- 1.65 h and a F value of 71%.,Some pharmacokinetic data of aditoprim and trimethoprim in healthy and tick-borne fever infected dwarf goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184252/),[μg] / [ml],0.21,234333,DB00440,Trimethoprim
,3184252,Tmax,Oral treatment with AP resulted in a Cmax value of 0.21 +/- 0.02 microgram/ml with Tmax of 22.5 +/- 1.65 h and a F value of 71%.,Some pharmacokinetic data of aditoprim and trimethoprim in healthy and tick-borne fever infected dwarf goats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184252/),h,22.5,234334,DB00440,Trimethoprim
,3184252,F,Oral treatment with AP resulted in a Cmax value of 0.21 +/- 0.02 microgram/ml with Tmax of 22.5 +/- 1.65 h and a F value of 71%.,Some pharmacokinetic data of aditoprim and trimethoprim in healthy and tick-borne fever infected dwarf goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184252/),%,71,234335,DB00440,Trimethoprim
,12872830,half-life,There was a mean half-life of 1.61 h for trimethoprim and 3.2 h for sulfadiazine.,Pharmacokinetics and oral bioavailability of sulfadiazine and trimethoprim in broiler chickens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12872830/),h,1.61,235579,DB00440,Trimethoprim
,12872830,half-life,There was a mean half-life of 1.61 h for trimethoprim and 3.2 h for sulfadiazine.,Pharmacokinetics and oral bioavailability of sulfadiazine and trimethoprim in broiler chickens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12872830/),h,3.2,235580,DB00440,Trimethoprim
,12872830,apparent volumes of distribution,"The apparent volumes of distribution (2.2 and 0.43 L/kg, respectively, indicated that the tissue distribution of trimethoprim was more extensive than that of sulfadiazine.",Pharmacokinetics and oral bioavailability of sulfadiazine and trimethoprim in broiler chickens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12872830/),[l] / [kg],2.2,235581,DB00440,Trimethoprim
,12872830,apparent volumes of distribution,"The apparent volumes of distribution (2.2 and 0.43 L/kg, respectively, indicated that the tissue distribution of trimethoprim was more extensive than that of sulfadiazine.",Pharmacokinetics and oral bioavailability of sulfadiazine and trimethoprim in broiler chickens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12872830/),[l] / [kg],0.43,235582,DB00440,Trimethoprim
,12872830,oral bioavailability,The oral bioavailability was approximately 80% for both components.,Pharmacokinetics and oral bioavailability of sulfadiazine and trimethoprim in broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12872830/),%,80,235583,DB00440,Trimethoprim
,10366903,RSD%,RSD% of 0.5% have become standard for quality control assays.,Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366903/),%,0.5,236201,DB00440,Trimethoprim
,10366903,total analysis time,"A number of pharmaceuticals (e.g. acetaminophen, salicylic acid, sulfamethoxazole, theophylline, tolbutamide, and trimethoprim) have been determined in human plasma on underivatized fused silica capillaries by MEKC without sample pretreatment, the total analysis time being only 10 min.",Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366903/),min,10,236202,DB00440,Trimethoprim
,10366903,detection limit,"The separation system is tested in a concentration range between 10 ng/mL and 100 micrograms/mL, the detection limit being about 5 ng/mL.",Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366903/),[ng] / [ml],5,236203,DB00440,Trimethoprim
,16909188,peak serum TMP levels,"Median (25th-75th percentile) peak serum TMP levels following a 5 mg/kg, 10 mg/kg or 20 mg/kg oral loading dose were 0.93 (0.5-1.5) microg/ml, 1.94 (1.4-2.2) microg/ml and 7.68 (6.1-7.8) microg/ml respectively.",Oral trimethoprim-sulphamethoxazole levels in stable HIV-infected children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16909188/),[μg] / [ml],0.93,237033,DB00440,Trimethoprim
,16909188,peak serum TMP levels,"Median (25th-75th percentile) peak serum TMP levels following a 5 mg/kg, 10 mg/kg or 20 mg/kg oral loading dose were 0.93 (0.5-1.5) microg/ml, 1.94 (1.4-2.2) microg/ml and 7.68 (6.1-7.8) microg/ml respectively.",Oral trimethoprim-sulphamethoxazole levels in stable HIV-infected children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16909188/),[μg] / [ml],1.94,237034,DB00440,Trimethoprim
,16909188,peak serum TMP levels,"Median (25th-75th percentile) peak serum TMP levels following a 5 mg/kg, 10 mg/kg or 20 mg/kg oral loading dose were 0.93 (0.5-1.5) microg/ml, 1.94 (1.4-2.2) microg/ml and 7.68 (6.1-7.8) microg/ml respectively.",Oral trimethoprim-sulphamethoxazole levels in stable HIV-infected children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16909188/),[μg] / [ml],7.68,237035,DB00440,Trimethoprim
,16909188,Peak TMP levels,Peak TMP levels at 9 hours after a second TMP dose of 5 or 10 mg/kg were 6.98 (3.4-8.8) microg/ml and 9.25 (8.2-10.3) microg/ml respectively.,Oral trimethoprim-sulphamethoxazole levels in stable HIV-infected children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16909188/),[μg] / [ml],6.98,237036,DB00440,Trimethoprim
,16909188,Peak TMP levels,Peak TMP levels at 9 hours after a second TMP dose of 5 or 10 mg/kg were 6.98 (3.4-8.8) microg/ml and 9.25 (8.2-10.3) microg/ml respectively.,Oral trimethoprim-sulphamethoxazole levels in stable HIV-infected children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16909188/),[μg] / [ml],9.25,237037,DB00440,Trimethoprim
,7836551,area under the curve (AUC),"Glipizide area under the curve (AUC), clearance, and half life for treatment and control phases were 5758 +/- 1874 versus 5176 +/- 1505 micrograms/L/hour (P = .21), 0.41 +/- 0.15 versus 0.45 +/- 0.14 mL/min/kg (P = .27), and 5.13 +/- 2.10 versus 3.95 +/- 1.37 hours (P = .04), respectively.",Lack of interaction between glipizide and co-trimoxazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836551/),[μg] / [h·l],5758,238077,DB00440,Trimethoprim
,7836551,clearance,"Glipizide area under the curve (AUC), clearance, and half life for treatment and control phases were 5758 +/- 1874 versus 5176 +/- 1505 micrograms/L/hour (P = .21), 0.41 +/- 0.15 versus 0.45 +/- 0.14 mL/min/kg (P = .27), and 5.13 +/- 2.10 versus 3.95 +/- 1.37 hours (P = .04), respectively.",Lack of interaction between glipizide and co-trimoxazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836551/),[μg] / [h·l],5176,238078,DB00440,Trimethoprim
,7836551,clearance,"Glipizide area under the curve (AUC), clearance, and half life for treatment and control phases were 5758 +/- 1874 versus 5176 +/- 1505 micrograms/L/hour (P = .21), 0.41 +/- 0.15 versus 0.45 +/- 0.14 mL/min/kg (P = .27), and 5.13 +/- 2.10 versus 3.95 +/- 1.37 hours (P = .04), respectively.",Lack of interaction between glipizide and co-trimoxazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836551/),[ml] / [kg·min],0.41,238079,DB00440,Trimethoprim
,7836551,half life,"Glipizide area under the curve (AUC), clearance, and half life for treatment and control phases were 5758 +/- 1874 versus 5176 +/- 1505 micrograms/L/hour (P = .21), 0.41 +/- 0.15 versus 0.45 +/- 0.14 mL/min/kg (P = .27), and 5.13 +/- 2.10 versus 3.95 +/- 1.37 hours (P = .04), respectively.",Lack of interaction between glipizide and co-trimoxazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836551/),[ml] / [kg·min],0.45,238080,DB00440,Trimethoprim
,7836551,half life,"Glipizide area under the curve (AUC), clearance, and half life for treatment and control phases were 5758 +/- 1874 versus 5176 +/- 1505 micrograms/L/hour (P = .21), 0.41 +/- 0.15 versus 0.45 +/- 0.14 mL/min/kg (P = .27), and 5.13 +/- 2.10 versus 3.95 +/- 1.37 hours (P = .04), respectively.",Lack of interaction between glipizide and co-trimoxazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836551/),h,5.13,238081,DB00440,Trimethoprim
,7836551,half life,"Glipizide area under the curve (AUC), clearance, and half life for treatment and control phases were 5758 +/- 1874 versus 5176 +/- 1505 micrograms/L/hour (P = .21), 0.41 +/- 0.15 versus 0.45 +/- 0.14 mL/min/kg (P = .27), and 5.13 +/- 2.10 versus 3.95 +/- 1.37 hours (P = .04), respectively.",Lack of interaction between glipizide and co-trimoxazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836551/),h,3.95,238082,DB00440,Trimethoprim
,7836551,Twenty-four-hour,"Twenty-four-hour glucose AUCs for treatment and control phases were 112.24 +/- 8.76 versus 114.86 +/- 11.98 mmol/L/hour (P = .55), respectively.",Lack of interaction between glipizide and co-trimoxazole. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836551/),[mM] / [h·l],112.24,238083,DB00440,Trimethoprim
,7836551,glucose AUCs,"Twenty-four-hour glucose AUCs for treatment and control phases were 112.24 +/- 8.76 versus 114.86 +/- 11.98 mmol/L/hour (P = .55), respectively.",Lack of interaction between glipizide and co-trimoxazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836551/),[mM] / [h·l],112.24,238084,DB00440,Trimethoprim
,7836551,glucose AUCs,"Twenty-four-hour glucose AUCs for treatment and control phases were 112.24 +/- 8.76 versus 114.86 +/- 11.98 mmol/L/hour (P = .55), respectively.",Lack of interaction between glipizide and co-trimoxazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836551/),[mM] / [h·l],114.86,238085,DB00440,Trimethoprim
,1352810,elimination half-life,"The elimination half-life of dapsone (814 +/- 351 min) was more than doubled in the presence of trimethoprim and cimetidine compared with control (355 +/- 160 min, P less than 0.05).",Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),min,814,238476,DB00440,Trimethoprim
,1352810,elimination half-life,"The elimination half-life of dapsone (814 +/- 351 min) was more than doubled in the presence of trimethoprim and cimetidine compared with control (355 +/- 160 min, P less than 0.05).",Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),min,355,238477,DB00440,Trimethoprim
,1352810,AUC,There was a threefold increase in the AUC of trimethoprim (6296 +/- 2249 micrograms min mL-1) in the presence of dapsone compared with trimethoprim alone (2122 +/- 552 micrograms min mL-1).,Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),[min·μg] / [ml],6296,238478,DB00440,Trimethoprim
,1352810,AUC,There was a threefold increase in the AUC of trimethoprim (6296 +/- 2249 micrograms min mL-1) in the presence of dapsone compared with trimethoprim alone (2122 +/- 552 micrograms min mL-1).,Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),[min·μg] / [ml],2122,238479,DB00440,Trimethoprim
,1352810,clearance,There was also a corresponding decrease in the clearance of trimethoprim in the presence of dapsone compared with control (19.1 +/- 6.9 vs 60.8 +/- 21.0 mL min-1).,Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),[ml] / [min],19.1,238480,DB00440,Trimethoprim
,1352810,clearance,There was also a corresponding decrease in the clearance of trimethoprim in the presence of dapsone compared with control (19.1 +/- 6.9 vs 60.8 +/- 21.0 mL min-1).,Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),[ml] / [min],60.8,238481,DB00440,Trimethoprim
,1352810,elimination half-life,"However, there was no change in the elimination half-life of trimethoprim between the two experimental groups (273 +/- 120 vs 292 +/- 54 min).",Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),min,273,238482,DB00440,Trimethoprim
,1352810,elimination half-life,"However, there was no change in the elimination half-life of trimethoprim between the two experimental groups (273 +/- 120 vs 292 +/- 54 min).",Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),min,292,238483,DB00440,Trimethoprim
,1352810,AUC,The AUC of trimethoprim increased more than threefold in the presence of cimetidine (7100 +/- 1501 micrograms min mL-1) compared with trimethoprim alone (2122 +/- 552 micrograms min mL-1).,Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),[min·μg] / [ml],7100,238484,DB00440,Trimethoprim
,1352810,AUC,The AUC of trimethoprim increased more than threefold in the presence of cimetidine (7100 +/- 1501 micrograms min mL-1) compared with trimethoprim alone (2122 +/- 552 micrograms min mL-1).,Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352810/),[min·μg] / [ml],2122,238485,DB00440,Trimethoprim
,8646826,AUC infinity,"The geometric least-squares trimethoprim-sulfamethoxazole were as follows: AUC infinity, 10,124 (9,432-10,866) and 14,448 (13,461-15,508) ng . hr/ml, respectively; CLR, 16.6 (14.1-19.4) and 10.8 (9.5-12.6) L/hr, respectively.",Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646826/),[h·ng] / [ml],"10,124",238855,DB00440,Trimethoprim
,8646826,AUC infinity,"The geometric least-squares trimethoprim-sulfamethoxazole were as follows: AUC infinity, 10,124 (9,432-10,866) and 14,448 (13,461-15,508) ng . hr/ml, respectively; CLR, 16.6 (14.1-19.4) and 10.8 (9.5-12.6) L/hr, respectively.",Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646826/),[h·ng] / [ml],"14,448",238856,DB00440,Trimethoprim
,8646826,CLR,"The geometric least-squares trimethoprim-sulfamethoxazole were as follows: AUC infinity, 10,124 (9,432-10,866) and 14,448 (13,461-15,508) ng . hr/ml, respectively; CLR, 16.6 (14.1-19.4) and 10.8 (9.5-12.6) L/hr, respectively.",Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646826/),[l] / [h],16.6,238857,DB00440,Trimethoprim
,8646826,CLR,"The geometric least-squares trimethoprim-sulfamethoxazole were as follows: AUC infinity, 10,124 (9,432-10,866) and 14,448 (13,461-15,508) ng . hr/ml, respectively; CLR, 16.6 (14.1-19.4) and 10.8 (9.5-12.6) L/hr, respectively.",Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646826/),[l] / [h],10.8,238858,DB00440,Trimethoprim
,7937526,elimination half-life,"S. pneumoniae infection alone significantly shortened the middle ear elimination half-life compared with the control group: amoxicillin, 2.65 +/- 0.73 vs.",Effect of Streptococcus pneumoniae and influenza A virus on middle ear antimicrobial pharmacokinetics in experimental otitis media. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937526/),,2.65,240408,DB00440,Trimethoprim
,7937526,half-life,"The combined influenza virus and S. pneumoniae infection significantly lengthened the half-life compared with the S. pneumoniae infection alone: amoxicillin, 5.65 +/- 6.44 vs.",Effect of Streptococcus pneumoniae and influenza A virus on middle ear antimicrobial pharmacokinetics in experimental otitis media. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937526/),,5.65,240409,DB00440,Trimethoprim
,7937526,half-lives,"Influenza virus produced the longest half-lives for all 3 antimicrobials: amoxicillin 25.52 +/- 14.96 hr; sulfamethoxazole, 5.46 +/- 0.87 hr; and trimethoprim, 2.57 +/- 0.75 hr.(ABSTRACT TRUNCATED AT 250 WORDS)",Effect of Streptococcus pneumoniae and influenza A virus on middle ear antimicrobial pharmacokinetics in experimental otitis media. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937526/),h,25.52,240410,DB00440,Trimethoprim
,7937526,half-lives,"Influenza virus produced the longest half-lives for all 3 antimicrobials: amoxicillin 25.52 +/- 14.96 hr; sulfamethoxazole, 5.46 +/- 0.87 hr; and trimethoprim, 2.57 +/- 0.75 hr.(ABSTRACT TRUNCATED AT 250 WORDS)",Effect of Streptococcus pneumoniae and influenza A virus on middle ear antimicrobial pharmacokinetics in experimental otitis media. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937526/),h,5.46,240411,DB00440,Trimethoprim
,7937526,half-lives,"Influenza virus produced the longest half-lives for all 3 antimicrobials: amoxicillin 25.52 +/- 14.96 hr; sulfamethoxazole, 5.46 +/- 0.87 hr; and trimethoprim, 2.57 +/- 0.75 hr.(ABSTRACT TRUNCATED AT 250 WORDS)",Effect of Streptococcus pneumoniae and influenza A virus on middle ear antimicrobial pharmacokinetics in experimental otitis media. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937526/),h,2.57,240412,DB00440,Trimethoprim
,10610011,steady-state atovaquone concentrations,"Average steady-state atovaquone concentrations at 500 mg were 6.7 +/- 3.2 microg/ml fasted and 11.3 +/- 5.0 microg/ml with food; at 750 mg, 9.9 +/- 7.1 microg/ml fasted and 12.5 +/- 5.9 microg/ml with food; at 1000 mg, 9.7 +/- 4.3 microg/ml fasted and 13.6 +/- 5.0 microg/ml with food; and at 1500 mg, 21.1 +/- 5.0 microg/ml with food.","Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10610011/),[μg] / [ml],6.7,242970,DB00440,Trimethoprim
,10610011,steady-state atovaquone concentrations,"Average steady-state atovaquone concentrations at 500 mg were 6.7 +/- 3.2 microg/ml fasted and 11.3 +/- 5.0 microg/ml with food; at 750 mg, 9.9 +/- 7.1 microg/ml fasted and 12.5 +/- 5.9 microg/ml with food; at 1000 mg, 9.7 +/- 4.3 microg/ml fasted and 13.6 +/- 5.0 microg/ml with food; and at 1500 mg, 21.1 +/- 5.0 microg/ml with food.","Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10610011/),[μg] / [ml],11.3,242971,DB00440,Trimethoprim
,10610011,steady-state atovaquone concentrations,"Average steady-state atovaquone concentrations at 500 mg were 6.7 +/- 3.2 microg/ml fasted and 11.3 +/- 5.0 microg/ml with food; at 750 mg, 9.9 +/- 7.1 microg/ml fasted and 12.5 +/- 5.9 microg/ml with food; at 1000 mg, 9.7 +/- 4.3 microg/ml fasted and 13.6 +/- 5.0 microg/ml with food; and at 1500 mg, 21.1 +/- 5.0 microg/ml with food.","Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10610011/),[μg] / [ml],9.9,242972,DB00440,Trimethoprim
,10610011,steady-state atovaquone concentrations,"Average steady-state atovaquone concentrations at 500 mg were 6.7 +/- 3.2 microg/ml fasted and 11.3 +/- 5.0 microg/ml with food; at 750 mg, 9.9 +/- 7.1 microg/ml fasted and 12.5 +/- 5.9 microg/ml with food; at 1000 mg, 9.7 +/- 4.3 microg/ml fasted and 13.6 +/- 5.0 microg/ml with food; and at 1500 mg, 21.1 +/- 5.0 microg/ml with food.","Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10610011/),[μg] / [ml],12.5,242973,DB00440,Trimethoprim
,10610011,steady-state atovaquone concentrations,"Average steady-state atovaquone concentrations at 500 mg were 6.7 +/- 3.2 microg/ml fasted and 11.3 +/- 5.0 microg/ml with food; at 750 mg, 9.9 +/- 7.1 microg/ml fasted and 12.5 +/- 5.9 microg/ml with food; at 1000 mg, 9.7 +/- 4.3 microg/ml fasted and 13.6 +/- 5.0 microg/ml with food; and at 1500 mg, 21.1 +/- 5.0 microg/ml with food.","Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10610011/),[μg] / [ml],9.7,242974,DB00440,Trimethoprim
,10610011,steady-state atovaquone concentrations,"Average steady-state atovaquone concentrations at 500 mg were 6.7 +/- 3.2 microg/ml fasted and 11.3 +/- 5.0 microg/ml with food; at 750 mg, 9.9 +/- 7.1 microg/ml fasted and 12.5 +/- 5.9 microg/ml with food; at 1000 mg, 9.7 +/- 4.3 microg/ml fasted and 13.6 +/- 5.0 microg/ml with food; and at 1500 mg, 21.1 +/- 5.0 microg/ml with food.","Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10610011/),[μg] / [ml],13.6,242975,DB00440,Trimethoprim
,10610011,steady-state atovaquone concentrations,"Average steady-state atovaquone concentrations at 500 mg were 6.7 +/- 3.2 microg/ml fasted and 11.3 +/- 5.0 microg/ml with food; at 750 mg, 9.9 +/- 7.1 microg/ml fasted and 12.5 +/- 5.9 microg/ml with food; at 1000 mg, 9.7 +/- 4.3 microg/ml fasted and 13.6 +/- 5.0 microg/ml with food; and at 1500 mg, 21.1 +/- 5.0 microg/ml with food.","Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10610011/),[μg] / [ml],21.1,242976,DB00440,Trimethoprim
less,10610011,steady-state concentrations,"Average steady-state concentrations were less than 10 microg/ml in 21% and more than 15 microg/ml in 36% of patients at 1000 mg/day with food; at 750 mg twice/day, all five patients had levels above 15 microg/ml.","Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10610011/),[μg] / [ml],10,242977,DB00440,Trimethoprim
more,10610011,steady-state concentrations,"Average steady-state concentrations were less than 10 microg/ml in 21% and more than 15 microg/ml in 36% of patients at 1000 mg/day with food; at 750 mg twice/day, all five patients had levels above 15 microg/ml.","Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10610011/),[μg] / [ml],15,242978,DB00440,Trimethoprim
,7283250,serum elimination half-lives,"Trimethoprim and sulfadiazine were rapidly absorbed, reaching maximum concentrations in 1 and 4 hours with serum elimination half-lives of 2.5 and 9.9 hours, respectively.",Pharmacokinetics of trimethoprim and sulfadiazine in the dog: urine concentrations after oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7283250/),h,2.5,243064,DB00440,Trimethoprim
,7283250,serum elimination half-lives,"Trimethoprim and sulfadiazine were rapidly absorbed, reaching maximum concentrations in 1 and 4 hours with serum elimination half-lives of 2.5 and 9.9 hours, respectively.",Pharmacokinetics of trimethoprim and sulfadiazine in the dog: urine concentrations after oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7283250/),h,9.9,243065,DB00440,Trimethoprim
,8525600,tmax,Sulphamethoxazole showed the most rapid absorption after intraruminal administration (mean tmax +/- SD : 0.8 +/- 0.2h).,"Oral bioavailability of sulphonamides in ruminants: a comparison between sulphamethoxazole, sulphatroxazole, and sulphamerazine, using the dwarf goat as animal model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525600/),h,0.8,245995,DB00440,Trimethoprim
,8525600,t1/2 beta,"However, the drug was rapidly eliminated from the plasma (t1/2 beta : 2.4 +/- 1.5 h) and the bioavailability was only 12.4 +/- 4.7%, most likely due to an extensive 'first-pass' effect.","Oral bioavailability of sulphonamides in ruminants: a comparison between sulphamethoxazole, sulphatroxazole, and sulphamerazine, using the dwarf goat as animal model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525600/),h,2.4,245996,DB00440,Trimethoprim
,8525600,bioavailability,"However, the drug was rapidly eliminated from the plasma (t1/2 beta : 2.4 +/- 1.5 h) and the bioavailability was only 12.4 +/- 4.7%, most likely due to an extensive 'first-pass' effect.","Oral bioavailability of sulphonamides in ruminants: a comparison between sulphamethoxazole, sulphatroxazole, and sulphamerazine, using the dwarf goat as animal model. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525600/),%,12.4,245997,DB00440,Trimethoprim
,8525600,bioavailability,"The bioavailability of orally administered sulphamerazine and sulphatroxazole was much higher (67.6 +/- 13.5% and 70.2 +/- 32.3%, respectively).","Oral bioavailability of sulphonamides in ruminants: a comparison between sulphamethoxazole, sulphatroxazole, and sulphamerazine, using the dwarf goat as animal model. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525600/),%,67.6,245998,DB00440,Trimethoprim
,8525600,bioavailability,"The bioavailability of orally administered sulphamerazine and sulphatroxazole was much higher (67.6 +/- 13.5% and 70.2 +/- 32.3%, respectively).","Oral bioavailability of sulphonamides in ruminants: a comparison between sulphamethoxazole, sulphatroxazole, and sulphamerazine, using the dwarf goat as animal model. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525600/),%,70.2,245999,DB00440,Trimethoprim
,8525600,plasma peak concentration,"After intraruminal administration, sulphatroxazole showed the highest plasma peak concentration (26.1 +/- 6.3 mg/l) and the longest plasma half-life (4.7 +/- 1.8h) and mean residence time (13.9 +/- 4.5 h).","Oral bioavailability of sulphonamides in ruminants: a comparison between sulphamethoxazole, sulphatroxazole, and sulphamerazine, using the dwarf goat as animal model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525600/),[mg] / [l],26.1,246000,DB00440,Trimethoprim
,8525600,plasma half-life,"After intraruminal administration, sulphatroxazole showed the highest plasma peak concentration (26.1 +/- 6.3 mg/l) and the longest plasma half-life (4.7 +/- 1.8h) and mean residence time (13.9 +/- 4.5 h).","Oral bioavailability of sulphonamides in ruminants: a comparison between sulphamethoxazole, sulphatroxazole, and sulphamerazine, using the dwarf goat as animal model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525600/),h,4.7,246001,DB00440,Trimethoprim
,8525600,mean residence time,"After intraruminal administration, sulphatroxazole showed the highest plasma peak concentration (26.1 +/- 6.3 mg/l) and the longest plasma half-life (4.7 +/- 1.8h) and mean residence time (13.9 +/- 4.5 h).","Oral bioavailability of sulphonamides in ruminants: a comparison between sulphamethoxazole, sulphatroxazole, and sulphamerazine, using the dwarf goat as animal model. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525600/),h,13.9,246002,DB00440,Trimethoprim
,27067336,metabolic clearance (CLm),"The pharmacokinetic parameters of the population model were as follows (geometric mean ± standard deviation [SD]): metabolic clearance (CLm), 1.57 ± 3.71 liters/h; volume of distribution (V), 0.30 ± 0.05 liters · kg lean body mass(-1); drug clearance/creatinine clearance ratio (fr), 0.02 ± 0.13; gamma distribution rate constant (ktr_po), 2.18 ± 1.14; gamma distribution shape factor (n_po), 2.15 ± 0.39.",Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067336/),[l] / [h],1.57,246280,DB00440,Trimethoprim
,27067336,volume of distribution (V),"The pharmacokinetic parameters of the population model were as follows (geometric mean ± standard deviation [SD]): metabolic clearance (CLm), 1.57 ± 3.71 liters/h; volume of distribution (V), 0.30 ± 0.05 liters · kg lean body mass(-1); drug clearance/creatinine clearance ratio (fr), 0.02 ± 0.13; gamma distribution rate constant (ktr_po), 2.18 ± 1.14; gamma distribution shape factor (n_po), 2.15 ± 0.39.",Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067336/),kg·l·lean,0.30,246281,DB00440,Trimethoprim
,27067336,drug clearance/c,"The pharmacokinetic parameters of the population model were as follows (geometric mean ± standard deviation [SD]): metabolic clearance (CLm), 1.57 ± 3.71 liters/h; volume of distribution (V), 0.30 ± 0.05 liters · kg lean body mass(-1); drug clearance/creatinine clearance ratio (fr), 0.02 ± 0.13; gamma distribution rate constant (ktr_po), 2.18 ± 1.14; gamma distribution shape factor (n_po), 2.15 ± 0.39.",Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067336/),,0.02,246282,DB00440,Trimethoprim
,27067336,gamma distribution rate constant (ktr_po),"The pharmacokinetic parameters of the population model were as follows (geometric mean ± standard deviation [SD]): metabolic clearance (CLm), 1.57 ± 3.71 liters/h; volume of distribution (V), 0.30 ± 0.05 liters · kg lean body mass(-1); drug clearance/creatinine clearance ratio (fr), 0.02 ± 0.13; gamma distribution rate constant (ktr_po), 2.18 ± 1.14; gamma distribution shape factor (n_po), 2.15 ± 0.39.",Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067336/),,2.18,246283,DB00440,Trimethoprim
,27067336,free fraction,"The free fraction of sulfamethoxazole was 0.3, but ranged between 0.2 and 0.4.",Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067336/),,0.3,246284,DB00440,Trimethoprim
,27067336,MICs,"The median value of the MICs was 9.5 mg/liter (interquartile range [IQR], 4.75 to 9.5), and that of theƒAUC/MIC ratio was 14.3 (IQR, 13.0 to 17.5).",Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067336/),[mg] / [l],9.5,246285,DB00440,Trimethoprim
,27067336,ƒAUC/MIC ratio,"The median value of the MICs was 9.5 mg/liter (interquartile range [IQR], 4.75 to 9.5), and that of theƒAUC/MIC ratio was 14.3 (IQR, 13.0 to 17.5).",Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067336/),,14.3,246286,DB00440,Trimethoprim
,3879182,Cmax,However Cmax of TMP was greater (2.06 +/- 0.29 s.d. vs 1.57 +/- 0.32 s.d. mg l-1; P less than 0.01) and its area under the curve was larger (34.30 +/- 6.98 s.d. vs 23.87 +/- 3.82 s.d. mg l-1 h; P less than 0.001) in elderly people than in younger subjects.,Pharmacokinetics of the trimethoprim-sulphamethoxazole combination in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879182/),[d·mg·s] / [l],2.06,248206,DB00440,Trimethoprim
,3879182,Cmax,However Cmax of TMP was greater (2.06 +/- 0.29 s.d. vs 1.57 +/- 0.32 s.d. mg l-1; P less than 0.01) and its area under the curve was larger (34.30 +/- 6.98 s.d. vs 23.87 +/- 3.82 s.d. mg l-1 h; P less than 0.001) in elderly people than in younger subjects.,Pharmacokinetics of the trimethoprim-sulphamethoxazole combination in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879182/),[d·mg·s] / [l],1.57,248207,DB00440,Trimethoprim
,3879182,area under the curve,However Cmax of TMP was greater (2.06 +/- 0.29 s.d. vs 1.57 +/- 0.32 s.d. mg l-1; P less than 0.01) and its area under the curve was larger (34.30 +/- 6.98 s.d. vs 23.87 +/- 3.82 s.d. mg l-1 h; P less than 0.001) in elderly people than in younger subjects.,Pharmacokinetics of the trimethoprim-sulphamethoxazole combination in the elderly. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879182/),[h·mg] / [l],34.30,248208,DB00440,Trimethoprim
,3879182,area under the curve,However Cmax of TMP was greater (2.06 +/- 0.29 s.d. vs 1.57 +/- 0.32 s.d. mg l-1; P less than 0.01) and its area under the curve was larger (34.30 +/- 6.98 s.d. vs 23.87 +/- 3.82 s.d. mg l-1 h; P less than 0.001) in elderly people than in younger subjects.,Pharmacokinetics of the trimethoprim-sulphamethoxazole combination in the elderly. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879182/),[h·mg] / [l],23.87,248209,DB00440,Trimethoprim
,3879182,Renal clearance,Renal clearance of TMP was significantly lower in the elderly group (19 +/- 10 s.d. vs 55 +/- 14 s.d. ml h-1 kg-1; P less than 0.001).,Pharmacokinetics of the trimethoprim-sulphamethoxazole combination in the elderly. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879182/),[ml] / [h·kg],19,248210,DB00440,Trimethoprim
,3879182,Renal clearance,Renal clearance of TMP was significantly lower in the elderly group (19 +/- 10 s.d. vs 55 +/- 14 s.d. ml h-1 kg-1; P less than 0.001).,Pharmacokinetics of the trimethoprim-sulphamethoxazole combination in the elderly. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879182/),[ml] / [h·kg],55,248211,DB00440,Trimethoprim
,17655376,area under the plasma concentration-time curve (AUC) from 0 to 24 hours,"In the crossover study, the mean area under the plasma concentration-time curve (AUC) from 0 to 24 hours for dapsone was 417.5 ng x h/mL after 2 weeks of dapsone gel therapy (n = 10), compared with an AUC from time zero to infinity of 52,641 ng x h/mL after a single dose of oral dapsone; this represents a 126-fold lower systemic exposure for dapsone gel at typical therapeutic doses.","Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655376/),[h·ng] / [ml],417.5,249616,DB00440,Trimethoprim
,17655376,AUC from time zero to infinity,"In the crossover study, the mean area under the plasma concentration-time curve (AUC) from 0 to 24 hours for dapsone was 417.5 ng x h/mL after 2 weeks of dapsone gel therapy (n = 10), compared with an AUC from time zero to infinity of 52,641 ng x h/mL after a single dose of oral dapsone; this represents a 126-fold lower systemic exposure for dapsone gel at typical therapeutic doses.","Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655376/),[h·ng] / [ml],"52,641",249617,DB00440,Trimethoprim
,17655376,AUC from 0 to 12 hours,"In the drug-interaction study, the AUC from 0 to 12 hours for dapsone was 221.52 ng x h/mL after 3 weeks of dapsone gel monotherapy compared with 320.3 ng x h/mL after 1 week of coadministration with trimethoprim/sulfamethoxazole.","Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655376/),[h·ng] / [ml],221.52,249618,DB00440,Trimethoprim
,17655376,AUC from 0 to 12 hours,"In the drug-interaction study, the AUC from 0 to 12 hours for dapsone was 221.52 ng x h/mL after 3 weeks of dapsone gel monotherapy compared with 320.3 ng x h/mL after 1 week of coadministration with trimethoprim/sulfamethoxazole.","Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655376/),[h·ng] / [ml],320.3,249619,DB00440,Trimethoprim
,23307233,AUC ratios,"Predicted median AUC ratios of rosiglitazone in the presence and absence of trimethoprim ranged from 1.35 to 1.66 for ten virtual trials of subjects with the CYP2C8 1/1 genotype, which included the observed value of 1.42.",Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23307233/),,1.35,250327,DB00440,Trimethoprim
,23307233,AUC ratios,"Predicted median AUC ratios of rosiglitazone in the presence and absence of trimethoprim ranged from 1.35 to 1.66 for ten virtual trials of subjects with the CYP2C8 1/1 genotype, which included the observed value of 1.42.",Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23307233/),,1.66,250328,DB00440,Trimethoprim
,23307233,AUC ratios,"Predicted median AUC ratios of rosiglitazone in the presence and absence of trimethoprim ranged from 1.35 to 1.66 for ten virtual trials of subjects with the CYP2C8 1/1 genotype, which included the observed value of 1.42.",Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23307233/),,1.42,250329,DB00440,Trimethoprim
higher,23307233,AUC ratios,"In subjects with the CYP2C8 1/3 genotype, the predicted AUC ratios for all trials were higher than the observed value of 1.18 Kirchheiner et al. (Clin Pharmacol Ther 80:657-667, 2006).",Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23307233/),,1.18,250330,DB00440,Trimethoprim
,3709270,peak concentrations at steady state,"The peak concentrations at steady state were 27.7 mg/l (SD) +/- 4.3 SDZ, and 1.6 +/- 0.68 mg/l TMP.",Pharmacokinetics of oral co-trimazine and the penetration of its components sulfadiazine and trimethoprim into peripheral human lymph. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709270/),[mg] / [l],27.7,250428,DB00440,Trimethoprim
,3709270,peak concentrations at steady state,"The peak concentrations at steady state were 27.7 mg/l (SD) +/- 4.3 SDZ, and 1.6 +/- 0.68 mg/l TMP.",Pharmacokinetics of oral co-trimazine and the penetration of its components sulfadiazine and trimethoprim into peripheral human lymph. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709270/),[mg] / [l],1.6,250429,DB00440,Trimethoprim
,3709270,elimination half-life in serum during steady state,"The elimination half-life in serum during steady state was 16.5 h for SDZ, 8.6 h for acetylated SDZ and 9.4 h for TMP.",Pharmacokinetics of oral co-trimazine and the penetration of its components sulfadiazine and trimethoprim into peripheral human lymph. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709270/),h,16.5,250430,DB00440,Trimethoprim
,3709270,elimination half-life in serum during steady state,"The elimination half-life in serum during steady state was 16.5 h for SDZ, 8.6 h for acetylated SDZ and 9.4 h for TMP.",Pharmacokinetics of oral co-trimazine and the penetration of its components sulfadiazine and trimethoprim into peripheral human lymph. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709270/),h,8.6,250431,DB00440,Trimethoprim
,3709270,elimination half-life in serum during steady state,"The elimination half-life in serum during steady state was 16.5 h for SDZ, 8.6 h for acetylated SDZ and 9.4 h for TMP.",Pharmacokinetics of oral co-trimazine and the penetration of its components sulfadiazine and trimethoprim into peripheral human lymph. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709270/),h,9.4,250432,DB00440,Trimethoprim
,2015729,total plasma clearance,The total plasma clearance of sulfamethoxazole was found to be increased in cystic fibrosis (0.0262 +/- 0.0064 L/hr/kg) when compared with that found in control subjects (0.0188 +/- 0.0043 L/hr/kg).,Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015729/),[l] / [h·kg],0.0262,250667,DB00440,Trimethoprim
,2015729,total plasma clearance,The total plasma clearance of sulfamethoxazole was found to be increased in cystic fibrosis (0.0262 +/- 0.0064 L/hr/kg) when compared with that found in control subjects (0.0188 +/- 0.0043 L/hr/kg).,Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015729/),[l] / [h·kg],0.0188,250668,DB00440,Trimethoprim
,2015729,metabolic clearance,This increase in clearance was found to be primarily attributable to an increase in the metabolic clearance of sulfamethoxazole to N4-acetylsulfamethoxazole (0.00903 +/- 0.00247 versus 0.00355 +/- 0.00049 L/hr/kg) with the renal clearance of sulfamethoxazole remaining unchanged.,Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015729/),[l] / [h·kg],0.00903,250669,DB00440,Trimethoprim
,2015729,metabolic clearance,This increase in clearance was found to be primarily attributable to an increase in the metabolic clearance of sulfamethoxazole to N4-acetylsulfamethoxazole (0.00903 +/- 0.00247 versus 0.00355 +/- 0.00049 L/hr/kg) with the renal clearance of sulfamethoxazole remaining unchanged.,Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015729/),[l] / [h·kg],0.00355,250670,DB00440,Trimethoprim
,2015729,total plasma clearance,The total plasma clearance of trimethoprim was also found to be increased in cystic fibrosis (0.1808 +/- 0.0440 L/hr/kg) when compared with that found in control subjects (0.1139 +/- 0.0193 L/hr/kg).,Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015729/),[l] / [h·kg],0.1808,250671,DB00440,Trimethoprim
,2015729,total plasma clearance,The total plasma clearance of trimethoprim was also found to be increased in cystic fibrosis (0.1808 +/- 0.0440 L/hr/kg) when compared with that found in control subjects (0.1139 +/- 0.0193 L/hr/kg).,Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015729/),[l] / [h·kg],0.1139,250672,DB00440,Trimethoprim
,2015729,renal clearance,"In contrast to sulfamethoxazole, this increase in clearance was found to be primarily attributable to an increase in the renal clearance of trimethoprim (0.1240 +/- 0.0299 versus 0.0720 +/- 0.0166 L/hr/kg).",Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015729/),[l] / [h·kg],0.1240,250673,DB00440,Trimethoprim
,2015729,renal clearance,"In contrast to sulfamethoxazole, this increase in clearance was found to be primarily attributable to an increase in the renal clearance of trimethoprim (0.1240 +/- 0.0299 versus 0.0720 +/- 0.0166 L/hr/kg).",Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015729/),[l] / [h·kg],0.0720,250674,DB00440,Trimethoprim
,23873647,tissue/serum ratio,"The mean tissue/serum ratio for linezolid was 0.46 (range, 0.18-0.71).",Tissue penetration and antimicrobial activity of standard- and high-dose trimethoprim/sulfamethoxazole and linezolid in patients with diabetic foot infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873647/),,0.46,252254,DB00440,Trimethoprim
,23873647,tissue/serum ratio,"The mean tissue/serum ratio for trimethoprim was 1.2 (range, 0.3-4.5) for both standard and high doses, and 0.23 (range, 0.1-0.46) and 0.36 (range, 0.14-1.28) for standard and high doses of sulfamethoxazole, respectively.",Tissue penetration and antimicrobial activity of standard- and high-dose trimethoprim/sulfamethoxazole and linezolid in patients with diabetic foot infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873647/),,1.2,252255,DB00440,Trimethoprim
,23873647,tissue/serum ratio,"The mean tissue/serum ratio for trimethoprim was 1.2 (range, 0.3-4.5) for both standard and high doses, and 0.23 (range, 0.1-0.46) and 0.36 (range, 0.14-1.28) for standard and high doses of sulfamethoxazole, respectively.",Tissue penetration and antimicrobial activity of standard- and high-dose trimethoprim/sulfamethoxazole and linezolid in patients with diabetic foot infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873647/),,0.23,252256,DB00440,Trimethoprim
,23873647,tissue/serum ratio,"The mean tissue/serum ratio for trimethoprim was 1.2 (range, 0.3-4.5) for both standard and high doses, and 0.23 (range, 0.1-0.46) and 0.36 (range, 0.14-1.28) for standard and high doses of sulfamethoxazole, respectively.",Tissue penetration and antimicrobial activity of standard- and high-dose trimethoprim/sulfamethoxazole and linezolid in patients with diabetic foot infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873647/),,0.36,252257,DB00440,Trimethoprim
,6436778,Elimination half-life,"Elimination half-life of SMZ in the marasmic infants was prolonged, 9.6 vs 4.9 hr, in their eutrophic counterparts.",The pharmacokinetics of cotrimoxazole sulphonamide in malnourished (marasmic) infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6436778/),h,9.6,253076,DB00440,Trimethoprim
,6436778,Elimination half-life,"Elimination half-life of SMZ in the marasmic infants was prolonged, 9.6 vs 4.9 hr, in their eutrophic counterparts.",The pharmacokinetics of cotrimoxazole sulphonamide in malnourished (marasmic) infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6436778/),h,4.9,253077,DB00440,Trimethoprim
,6436778,area under the curve (AUC),"In addition, greater area under the curve (AUC), 573 vs 328 micrograms/ml/h, was noted in the malnourished group.",The pharmacokinetics of cotrimoxazole sulphonamide in malnourished (marasmic) infants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6436778/),[μg] / [h·ml],573,253078,DB00440,Trimethoprim
,6436778,area under the curve (AUC),"In addition, greater area under the curve (AUC), 573 vs 328 micrograms/ml/h, was noted in the malnourished group.",The pharmacokinetics of cotrimoxazole sulphonamide in malnourished (marasmic) infants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6436778/),[μg] / [h·ml],328,253079,DB00440,Trimethoprim
,28800382,clearance,"SMX and TPM clearance were estimated at 0.49 l h-1 /9.5 kg and 3.06 l h-1 /9.5 kg, respectively.",Suboptimal cotrimoxazole prophylactic concentrations in HIV-infected children according to the WHO guidelines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28800382/),[l] / [9.5·h·kg],3.06,253306,DB00440,Trimethoprim
,579561,half-life,The half-life of TMP in rabbits is about 40 minutes and no differences were found between the half-life in normal and febrile rabbits.,Pharmacokinetics of trimethoprim (TMP) in normal and febrile rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/579561/),min,40,255321,DB00440,Trimethoprim
,22352317,hepatic clearance,"The in vivo findings were supported by the result from the test phase where hepatic clearance (4.3 mL min⁻¹ kg⁻¹) was decreased by 29% (metabolism inhibition), 43% (transport inhibition) and 57% (metabolism + transport inhibition).",The pharmacokinetics and hepatic disposition of repaglinide in pigs: mechanistic modeling of metabolism and transport. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22352317/),kg⁻¹·min⁻¹·ml,4.3,255723,DB00440,Trimethoprim
,7100826,concentrations,"The average trimethoprim concentrations were 3.0, 4.0, 4.7 and 0.96 micrograms/ml, respectively.",Pharmacokinetics of trimethoprim given in single daily doses for three days. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7100826/),,4.7,256444,DB00440,Trimethoprim
,7100826,concentrations,"The average trimethoprim concentrations were 3.0, 4.0, 4.7 and 0.96 micrograms/ml, respectively.",Pharmacokinetics of trimethoprim given in single daily doses for three days. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7100826/),,0.96,256445,DB00440,Trimethoprim
,7975199,Vss,"The pharmacokinetic parameters of SDX showed no significant difference between lactating and pregnant sows (Vss, 0.24 +/- 0.04 L/kg; Cls, 0.25 +/- 0.05 ml/min per kg: MRT, 17.08 +/- 4.48 h).",Pharmacokinetics of sulphadoxine and trimethoprim in sows: influence of lactation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975199/),[l] / [kg],0.24,258358,DB00440,Trimethoprim
,7975199,Cls,"The pharmacokinetic parameters of SDX showed no significant difference between lactating and pregnant sows (Vss, 0.24 +/- 0.04 L/kg; Cls, 0.25 +/- 0.05 ml/min per kg: MRT, 17.08 +/- 4.48 h).",Pharmacokinetics of sulphadoxine and trimethoprim in sows: influence of lactation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975199/),[ml] / [kg·min],0.25,258359,DB00440,Trimethoprim
,7975199,MRT,"The pharmacokinetic parameters of SDX showed no significant difference between lactating and pregnant sows (Vss, 0.24 +/- 0.04 L/kg; Cls, 0.25 +/- 0.05 ml/min per kg: MRT, 17.08 +/- 4.48 h).",Pharmacokinetics of sulphadoxine and trimethoprim in sows: influence of lactation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975199/),h,17.08,258360,DB00440,Trimethoprim
,7975199,Vss,"Of the pharmacokinetic parameters for TMP, only the mean residence time was significantly different between the two groups (Vss, 1.60 +/- 0.31 L/kg; Cls, 4.62 +/- 1.07 ml/min per kg: MRTlactating, 5.43 +/- 1.26 h; MRTpregnant, 7.74 +/- 1.72 h).",Pharmacokinetics of sulphadoxine and trimethoprim in sows: influence of lactation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975199/),[l] / [kg],1.60,258361,DB00440,Trimethoprim
,7975199,Cls,"Of the pharmacokinetic parameters for TMP, only the mean residence time was significantly different between the two groups (Vss, 1.60 +/- 0.31 L/kg; Cls, 4.62 +/- 1.07 ml/min per kg: MRTlactating, 5.43 +/- 1.26 h; MRTpregnant, 7.74 +/- 1.72 h).",Pharmacokinetics of sulphadoxine and trimethoprim in sows: influence of lactation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975199/),[ml] / [kg·min],4.62,258362,DB00440,Trimethoprim
,7975199,MRTlactating,"Of the pharmacokinetic parameters for TMP, only the mean residence time was significantly different between the two groups (Vss, 1.60 +/- 0.31 L/kg; Cls, 4.62 +/- 1.07 ml/min per kg: MRTlactating, 5.43 +/- 1.26 h; MRTpregnant, 7.74 +/- 1.72 h).",Pharmacokinetics of sulphadoxine and trimethoprim in sows: influence of lactation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975199/),h,5.43,258363,DB00440,Trimethoprim
,7975199,MRTpregnant,"Of the pharmacokinetic parameters for TMP, only the mean residence time was significantly different between the two groups (Vss, 1.60 +/- 0.31 L/kg; Cls, 4.62 +/- 1.07 ml/min per kg: MRTlactating, 5.43 +/- 1.26 h; MRTpregnant, 7.74 +/- 1.72 h).",Pharmacokinetics of sulphadoxine and trimethoprim in sows: influence of lactation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975199/),h,7.74,258364,DB00440,Trimethoprim
,28410468,t1/2z,"Compared with the single dose, the t1/2z values of SMZ in hepatopancreas (8.22-11.33h) and muscle (6.53-10.92h) of Pacific white shrimps rose, but the haemolymph dropped (13.76-11.03) in the multiple-dose oral administration.","Pharmacokinetics of sulfamethoxazole and trimethoprim in Pacific white shrimp, Litopenaeus vannamei, after oral administration of single-dose and multiple-dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28410468/),h,8.22-11.33,258602,DB00440,Trimethoprim
,28410468,t1/2z,"Compared with the single dose, the t1/2z values of SMZ in hepatopancreas (8.22-11.33h) and muscle (6.53-10.92h) of Pacific white shrimps rose, but the haemolymph dropped (13.76-11.03) in the multiple-dose oral administration.","Pharmacokinetics of sulfamethoxazole and trimethoprim in Pacific white shrimp, Litopenaeus vannamei, after oral administration of single-dose and multiple-dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28410468/),h,6.53-10.92,258603,DB00440,Trimethoprim
,28410468,t1/2z,"Compared with the single dose, the t1/2z values of SMZ in hepatopancreas (8.22-11.33h) and muscle (6.53-10.92h) of Pacific white shrimps rose, but the haemolymph dropped (13.76-11.03) in the multiple-dose oral administration.","Pharmacokinetics of sulfamethoxazole and trimethoprim in Pacific white shrimp, Litopenaeus vannamei, after oral administration of single-dose and multiple-dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28410468/),,13.76-11.03,258604,DB00440,Trimethoprim
,8696062,ClT,"A marked difference in the pharmacokinetics of TMP and SMX was observed, for example; (ClT: mean +/- SD; 90.3 +/- 47.0 ml/kg/g for TMP and 13.7 +/- 6.8 ml/kg/h for SMX), (t1/2 el with 7.93 +/- 8.64 h for TMP and 10.51 +/- 3.49 h for SMX).",Kinetic effects of trimethoprim-sulfamethoxazole in children with biliary atresia: a new dosing regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8696062/),[ml] / [g·kg],90.3,258629,DB00440,Trimethoprim
,8696062,ClT,"A marked difference in the pharmacokinetics of TMP and SMX was observed, for example; (ClT: mean +/- SD; 90.3 +/- 47.0 ml/kg/g for TMP and 13.7 +/- 6.8 ml/kg/h for SMX), (t1/2 el with 7.93 +/- 8.64 h for TMP and 10.51 +/- 3.49 h for SMX).",Kinetic effects of trimethoprim-sulfamethoxazole in children with biliary atresia: a new dosing regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8696062/),[ml] / [h·kg],13.7,258630,DB00440,Trimethoprim
,8696062,t1/2 el,"A marked difference in the pharmacokinetics of TMP and SMX was observed, for example; (ClT: mean +/- SD; 90.3 +/- 47.0 ml/kg/g for TMP and 13.7 +/- 6.8 ml/kg/h for SMX), (t1/2 el with 7.93 +/- 8.64 h for TMP and 10.51 +/- 3.49 h for SMX).",Kinetic effects of trimethoprim-sulfamethoxazole in children with biliary atresia: a new dosing regimen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8696062/),h,7.93,258631,DB00440,Trimethoprim
,8696062,t1/2 el,"A marked difference in the pharmacokinetics of TMP and SMX was observed, for example; (ClT: mean +/- SD; 90.3 +/- 47.0 ml/kg/g for TMP and 13.7 +/- 6.8 ml/kg/h for SMX), (t1/2 el with 7.93 +/- 8.64 h for TMP and 10.51 +/- 3.49 h for SMX).",Kinetic effects of trimethoprim-sulfamethoxazole in children with biliary atresia: a new dosing regimen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8696062/),h,10.51,258632,DB00440,Trimethoprim
,8696062,Recommended maintenance dose,"Recommended maintenance dose varied from 8 to 30 mg/kg for SMX with a mean of 21.9 +/- 10.89 mg/kg/12 h, and from 0.8 to 4.5 mg/kg/12 h with a mean of 3.2 +/- 1.7 mg/kg/12 h.",Kinetic effects of trimethoprim-sulfamethoxazole in children with biliary atresia: a new dosing regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8696062/),mg,3,258633,DB00440,Trimethoprim
,1093656,Peak mean serum TMP concentration,Peak mean serum TMP concentration was highest at day 3 when it reached 1.63 mug/ml.,Pharmacokinetics of trimethoprim-sulfamethoxazole in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1093656/),[μg] / [ml],1.63,258983,DB00440,Trimethoprim
,18650047,m/z,"The ionization was optimized using ESI(+) and selectivity was achieved using MS/MS analysis, m/z 623.0-->381.0 and m/z 339.0-->281.0 for tetrandrine and I.S., respectively.",Establishment of a liquid chromatographic/mass spectrometry method for quantification of tetrandrine in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18650047/),,623.0,259636,DB00440,Trimethoprim
,18650047,m/z,"The ionization was optimized using ESI(+) and selectivity was achieved using MS/MS analysis, m/z 623.0-->381.0 and m/z 339.0-->281.0 for tetrandrine and I.S., respectively.",Establishment of a liquid chromatographic/mass spectrometry method for quantification of tetrandrine in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18650047/),,381.0,259637,DB00440,Trimethoprim
,18650047,m/z,"The ionization was optimized using ESI(+) and selectivity was achieved using MS/MS analysis, m/z 623.0-->381.0 and m/z 339.0-->281.0 for tetrandrine and I.S., respectively.",Establishment of a liquid chromatographic/mass spectrometry method for quantification of tetrandrine in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18650047/),,339.0,259638,DB00440,Trimethoprim
,18650047,m/z,"The ionization was optimized using ESI(+) and selectivity was achieved using MS/MS analysis, m/z 623.0-->381.0 and m/z 339.0-->281.0 for tetrandrine and I.S., respectively.",Establishment of a liquid chromatographic/mass spectrometry method for quantification of tetrandrine in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18650047/),,281.0,259639,DB00440,Trimethoprim
,2357657,clearance,The clearance of TMP was also significantly (p less than 0.05) decreased from 675 mL/h/kg to 327 mL/h/kg by DMSO administration.,Concentrations of trimethoprim and sulfamethoxazole in cerebrospinal fluid and serum in mares with and without a dimethyl sulfoxide pretreatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357657/),[ml] / [h·kg],675,260016,DB00440,Trimethoprim
,2357657,clearance,The clearance of TMP was also significantly (p less than 0.05) decreased from 675 mL/h/kg to 327 mL/h/kg by DMSO administration.,Concentrations of trimethoprim and sulfamethoxazole in cerebrospinal fluid and serum in mares with and without a dimethyl sulfoxide pretreatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357657/),[ml] / [h·kg],327,260017,DB00440,Trimethoprim
,9178183,bioavailability,The best in-vivo results were achieved with the lipohydrophilic Witepsol W 35 vehicle containing 10% polysorbate 20 and 10% polysorbate 61 (bioavailability = 63.8%) and with Witepsol W 35 containing 10% polysorbate 60 (bioavailability = 63.8%).,Experiences with the rectal use of trimethoprim. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9178183/),%,63.8,260175,DB00440,Trimethoprim
,9178183,bioavailability,The results for hydrophilic Macrogol 1540 vehicle containing 5% of Macrogol 400 were only slightly worse (bioavailability = 52.9%).,Experiences with the rectal use of trimethoprim. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9178183/),%,52.9,260176,DB00440,Trimethoprim
,9178183,bioavailability,With three vehicles the extent of absorption exceeded that for oral administration on the same model (bioavailability = 38.8%).,Experiences with the rectal use of trimethoprim. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9178183/),%,38.8,260177,DB00440,Trimethoprim
,11911569,mean residence time (MRT),"In donkeys, mean residence time (MRT) of sulfamethoxazole (2.5 hours) was less than half the MRT in mules (6.2 hours); MRT of trimethoprim in donkeys (0.8 hours) was half that in horses (1.5 hours).","Pharmacokinetics of sulfamethoxazole and trimethoprim in donkeys, mules, and horses. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11911569/),h,2.5,261868,DB00440,Trimethoprim
,11911569,mean residence time (MRT),"In donkeys, mean residence time (MRT) of sulfamethoxazole (2.5 hours) was less than half the MRT in mules (6.2 hours); MRT of trimethoprim in donkeys (0.8 hours) was half that in horses (1.5 hours).","Pharmacokinetics of sulfamethoxazole and trimethoprim in donkeys, mules, and horses. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11911569/),h,6.2,261869,DB00440,Trimethoprim
,11911569,MRT,"In donkeys, mean residence time (MRT) of sulfamethoxazole (2.5 hours) was less than half the MRT in mules (6.2 hours); MRT of trimethoprim in donkeys (0.8 hours) was half that in horses (1.5 hours).","Pharmacokinetics of sulfamethoxazole and trimethoprim in donkeys, mules, and horses. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11911569/),h,0.8,261870,DB00440,Trimethoprim
,11911569,MRT,"In donkeys, mean residence time (MRT) of sulfamethoxazole (2.5 hours) was less than half the MRT in mules (6.2 hours); MRT of trimethoprim in donkeys (0.8 hours) was half that in horses (1.5 hours).","Pharmacokinetics of sulfamethoxazole and trimethoprim in donkeys, mules, and horses. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11911569/),h,1.5,261871,DB00440,Trimethoprim
,2488182,half-life,"The mean half-life of TMP was 28 h, while for SMX it was 12.5 h.",Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis (CAPD). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2488182/),h,28,261982,DB00440,Trimethoprim
,2488182,half-life,"The mean half-life of TMP was 28 h, while for SMX it was 12.5 h.",Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis (CAPD). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2488182/),h,12.5,261983,DB00440,Trimethoprim
,2488182,bioavailability,"Relative to the i.v. dose, the bioavailability following oral administration for TMP was 98% and 87% for SMX.",Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis (CAPD). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2488182/),%,98,261984,DB00440,Trimethoprim
,2488182,bioavailability,"Relative to the i.v. dose, the bioavailability following oral administration for TMP was 98% and 87% for SMX.",Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis (CAPD). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2488182/),%,87,261985,DB00440,Trimethoprim
,2488182,Intraperitoneal bioavailability,Intraperitoneal bioavailability was 73% for TMP and 65% for SMX after a 4-h dwell.,Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis (CAPD). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2488182/),%,73,261986,DB00440,Trimethoprim
,2488182,Intraperitoneal bioavailability,Intraperitoneal bioavailability was 73% for TMP and 65% for SMX after a 4-h dwell.,Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis (CAPD). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2488182/),%,65,261987,DB00440,Trimethoprim
,2298191,overall elimination rate constant (K),"The overall elimination rate constant (K) for TMP in the pony and horse foals was 0.45/h, whereas the K values for SMZ for the pony and horse foals were 0.12/h and 0.07/h, respectively (no significant difference; P greater than 0.05).",Pharmacokinetics of trimethoprim-sulphamethoxazole in two-day-old foals after a single intravenous injection. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298191/),1/[h],0.45,263031,DB00440,Trimethoprim
,2298191,K,"The overall elimination rate constant (K) for TMP in the pony and horse foals was 0.45/h, whereas the K values for SMZ for the pony and horse foals were 0.12/h and 0.07/h, respectively (no significant difference; P greater than 0.05).",Pharmacokinetics of trimethoprim-sulphamethoxazole in two-day-old foals after a single intravenous injection. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298191/),1/[h],0.12,263032,DB00440,Trimethoprim
,2298191,K,"The overall elimination rate constant (K) for TMP in the pony and horse foals was 0.45/h, whereas the K values for SMZ for the pony and horse foals were 0.12/h and 0.07/h, respectively (no significant difference; P greater than 0.05).",Pharmacokinetics of trimethoprim-sulphamethoxazole in two-day-old foals after a single intravenous injection. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298191/),1/[h],0.07,263033,DB00440,Trimethoprim
,15371985,elimination half-life (t 1/2 ),The elimination half-life (t 1/2 ) of rosiglitazone was prolonged from 3.8 to 4.8 hours ( P =.0013).,Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371985/),h,3.8,264185,DB00440,Trimethoprim
,15371985,elimination half-life (t 1/2 ),The elimination half-life (t 1/2 ) of rosiglitazone was prolonged from 3.8 to 4.8 hours ( P =.0013).,Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371985/),h,4.8,264186,DB00440,Trimethoprim
,15371985,t 1/2,The t 1/2 of rosiglitazone was shortened from 3.8 to 1.9 hours ( P <.0001).,Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371985/),h,3.8,264187,DB00440,Trimethoprim
,15371985,t 1/2,The t 1/2 of rosiglitazone was shortened from 3.8 to 1.9 hours ( P <.0001).,Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371985/),h,1.9,264188,DB00440,Trimethoprim
,6840178,peak serum concentrations,"At steady state, mean peak serum concentrations of TMP and SD of 1.4 micrograms/ml and 27 micrograms/ml, respectively, were found within 2-4 h after a fasting morning dose.",Clinical effect and pharmacokinetics of trimethoprim-sulphadiazine in children with urinary tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840178/),[μg] / [ml],1.4,265756,DB00440,Trimethoprim
,6840178,peak serum concentrations,"At steady state, mean peak serum concentrations of TMP and SD of 1.4 micrograms/ml and 27 micrograms/ml, respectively, were found within 2-4 h after a fasting morning dose.",Clinical effect and pharmacokinetics of trimethoprim-sulphadiazine in children with urinary tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840178/),[μg] / [ml],27,265757,DB00440,Trimethoprim
,9263388,apparent rate constant for absorption (Ka),"With the nonparametric expectation maximization program, the median apparent rate constant for absorption (Ka) was 1.602 hr-1, median slope (Ks) of the relationship between creatinine clearance and elimination was 0.001168 hr-1, median apparent volume of distribution (Vs) was 1.058 l/kg, and median fraction of oral dose absorbed (Fa) was 0.955.","A population pharmacokinetic model of trimethoprim in patients with pneumocystis pneumonia, made with parametric and nonparametric methods. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263388/),1/[h],1.602,265824,DB00440,Trimethoprim
,9263388,slope (Ks),"With the nonparametric expectation maximization program, the median apparent rate constant for absorption (Ka) was 1.602 hr-1, median slope (Ks) of the relationship between creatinine clearance and elimination was 0.001168 hr-1, median apparent volume of distribution (Vs) was 1.058 l/kg, and median fraction of oral dose absorbed (Fa) was 0.955.","A population pharmacokinetic model of trimethoprim in patients with pneumocystis pneumonia, made with parametric and nonparametric methods. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263388/),1/[h],0.001168,265825,DB00440,Trimethoprim
,9263388,apparent volume of distribution (Vs),"With the nonparametric expectation maximization program, the median apparent rate constant for absorption (Ka) was 1.602 hr-1, median slope (Ks) of the relationship between creatinine clearance and elimination was 0.001168 hr-1, median apparent volume of distribution (Vs) was 1.058 l/kg, and median fraction of oral dose absorbed (Fa) was 0.955.","A population pharmacokinetic model of trimethoprim in patients with pneumocystis pneumonia, made with parametric and nonparametric methods. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263388/),[l] / [kg],1.058,265826,DB00440,Trimethoprim
,9263388,fraction of oral dose absorbed (Fa),"With the nonparametric expectation maximization program, the median apparent rate constant for absorption (Ka) was 1.602 hr-1, median slope (Ks) of the relationship between creatinine clearance and elimination was 0.001168 hr-1, median apparent volume of distribution (Vs) was 1.058 l/kg, and median fraction of oral dose absorbed (Fa) was 0.955.","A population pharmacokinetic model of trimethoprim in patients with pneumocystis pneumonia, made with parametric and nonparametric methods. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263388/),,0.955,265827,DB00440,Trimethoprim
,9263388,Peak goals,"Peak goals of 9 ug/ml and trough goals of 5 ug/ml appear reasonable for most patients in this population, and should permit most to complete an effective course of therapy with a reduced risk for treatment-terminating hematologic toxicity.","A population pharmacokinetic model of trimethoprim in patients with pneumocystis pneumonia, made with parametric and nonparametric methods. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263388/),[ug] / [ml],9,265828,DB00440,Trimethoprim
,9263388,trough,"Peak goals of 9 ug/ml and trough goals of 5 ug/ml appear reasonable for most patients in this population, and should permit most to complete an effective course of therapy with a reduced risk for treatment-terminating hematologic toxicity.","A population pharmacokinetic model of trimethoprim in patients with pneumocystis pneumonia, made with parametric and nonparametric methods. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263388/),[ug] / [ml],5,265829,DB00440,Trimethoprim
,3261143,overall elimination rate constant (K),"For TMP, the mean overall elimination rate constant (K) was 0.43/hr and the elimination half-life (t1/2) was 1.9 hours.",Pharmacokinetics and body fluid and endometrial concentrations of trimethoprim-sulfamethoxazole in mares. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261143/),1/[h],0.43,265986,DB00440,Trimethoprim
,3261143,elimination half-life (t1/2),"For TMP, the mean overall elimination rate constant (K) was 0.43/hr and the elimination half-life (t1/2) was 1.9 hours.",Pharmacokinetics and body fluid and endometrial concentrations of trimethoprim-sulfamethoxazole in mares. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261143/),h,1.9,265987,DB00440,Trimethoprim
,3261143,apparent volume of distribution (at steady state),The apparent volume of distribution (at steady state) was 1.62 L/kg and TMP clearance was 886 ml/hr/kg.,Pharmacokinetics and body fluid and endometrial concentrations of trimethoprim-sulfamethoxazole in mares. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261143/),[l] / [kg],1.62,265988,DB00440,Trimethoprim
,3261143,clearance,The apparent volume of distribution (at steady state) was 1.62 L/kg and TMP clearance was 886 ml/hr/kg.,Pharmacokinetics and body fluid and endometrial concentrations of trimethoprim-sulfamethoxazole in mares. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261143/),[ml] / [h·kg],886,265989,DB00440,Trimethoprim
,3261143,K,"For SMZ, K was 0.22/hr and t1/2 was 3.53 hours.",Pharmacokinetics and body fluid and endometrial concentrations of trimethoprim-sulfamethoxazole in mares. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261143/),1/[h],0.22,265990,DB00440,Trimethoprim
,3261143,t1/2,"For SMZ, K was 0.22/hr and t1/2 was 3.53 hours.",Pharmacokinetics and body fluid and endometrial concentrations of trimethoprim-sulfamethoxazole in mares. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261143/),h,3.53,265991,DB00440,Trimethoprim
,3261143,apparent volume of distribution at steady state,The apparent volume of distribution at steady state was 0.33 L/kg and SMZ clearance was 78.2 ml/hr/kg.,Pharmacokinetics and body fluid and endometrial concentrations of trimethoprim-sulfamethoxazole in mares. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261143/),[l] / [kg],0.33,265992,DB00440,Trimethoprim
,3261143,clearance,The apparent volume of distribution at steady state was 0.33 L/kg and SMZ clearance was 78.2 ml/hr/kg.,Pharmacokinetics and body fluid and endometrial concentrations of trimethoprim-sulfamethoxazole in mares. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261143/),[ml] / [h·kg],78.2,265993,DB00440,Trimethoprim
,884922,serum half-life (t1/2),"In normal renal function, the serum half-life (t1/2) of active sulfadiazine, total sulfadiazine, and trimethoprim were quite close: 7.7, 9.6, and 12.1 hr, respectively.",Kinetics of a sulfadiazine-trimethoprim combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/884922/),h,7.7,267903,DB00440,Trimethoprim
,884922,serum half-life (t1/2),"In normal renal function, the serum half-life (t1/2) of active sulfadiazine, total sulfadiazine, and trimethoprim were quite close: 7.7, 9.6, and 12.1 hr, respectively.",Kinetics of a sulfadiazine-trimethoprim combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/884922/),h,9.6,267904,DB00440,Trimethoprim
,884922,serum half-life (t1/2),"In normal renal function, the serum half-life (t1/2) of active sulfadiazine, total sulfadiazine, and trimethoprim were quite close: 7.7, 9.6, and 12.1 hr, respectively.",Kinetics of a sulfadiazine-trimethoprim combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/884922/),h,12.1,267905,DB00440,Trimethoprim
,3731918,serum,"The serum or plasma half-life of the agents in the above order was 3.1, 6.3, 13.9, 12.1, 9.3, and 12.0 h.",Human pharmacokinetics and skin blister levels of sulfonamides and dihydrofolate reductase inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731918/),h,3.1,270134,DB00440,Trimethoprim
,3731918,plasma half-life,"The serum or plasma half-life of the agents in the above order was 3.1, 6.3, 13.9, 12.1, 9.3, and 12.0 h.",Human pharmacokinetics and skin blister levels of sulfonamides and dihydrofolate reductase inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731918/),h,13.9,270135,DB00440,Trimethoprim
,3731918,plasma half-life,"The serum or plasma half-life of the agents in the above order was 3.1, 6.3, 13.9, 12.1, 9.3, and 12.0 h.",Human pharmacokinetics and skin blister levels of sulfonamides and dihydrofolate reductase inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731918/),h,12.1,270136,DB00440,Trimethoprim
,3731918,plasma half-life,"The serum or plasma half-life of the agents in the above order was 3.1, 6.3, 13.9, 12.1, 9.3, and 12.0 h.",Human pharmacokinetics and skin blister levels of sulfonamides and dihydrofolate reductase inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731918/),h,9.3,270137,DB00440,Trimethoprim
,3731918,plasma half-life,"The serum or plasma half-life of the agents in the above order was 3.1, 6.3, 13.9, 12.1, 9.3, and 12.0 h.",Human pharmacokinetics and skin blister levels of sulfonamides and dihydrofolate reductase inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731918/),h,12.0,270138,DB00440,Trimethoprim
,3731918,areas under the serum curves,"The respective areas under the serum curves were 97.1, 607.8, 942.6, 1423.1, 128.1 and 175.4 mg/l per dose of 1.0 g.",Human pharmacokinetics and skin blister levels of sulfonamides and dihydrofolate reductase inhibitors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731918/),[mg] / [l],97.1,270139,DB00440,Trimethoprim
,3731918,areas under the serum curves,"The respective areas under the serum curves were 97.1, 607.8, 942.6, 1423.1, 128.1 and 175.4 mg/l per dose of 1.0 g.",Human pharmacokinetics and skin blister levels of sulfonamides and dihydrofolate reductase inhibitors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731918/),[mg] / [l],607.8,270140,DB00440,Trimethoprim
,3731918,areas under the serum curves,"The respective areas under the serum curves were 97.1, 607.8, 942.6, 1423.1, 128.1 and 175.4 mg/l per dose of 1.0 g.",Human pharmacokinetics and skin blister levels of sulfonamides and dihydrofolate reductase inhibitors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731918/),[mg] / [l],942.6,270141,DB00440,Trimethoprim
,3731918,areas under the serum curves,"The respective areas under the serum curves were 97.1, 607.8, 942.6, 1423.1, 128.1 and 175.4 mg/l per dose of 1.0 g.",Human pharmacokinetics and skin blister levels of sulfonamides and dihydrofolate reductase inhibitors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731918/),[mg] / [l],1423.1,270142,DB00440,Trimethoprim
,3731918,areas under the serum curves,"The respective areas under the serum curves were 97.1, 607.8, 942.6, 1423.1, 128.1 and 175.4 mg/l per dose of 1.0 g.",Human pharmacokinetics and skin blister levels of sulfonamides and dihydrofolate reductase inhibitors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731918/),[mg] / [l],128.1,270143,DB00440,Trimethoprim
,3731918,areas under the serum curves,"The respective areas under the serum curves were 97.1, 607.8, 942.6, 1423.1, 128.1 and 175.4 mg/l per dose of 1.0 g.",Human pharmacokinetics and skin blister levels of sulfonamides and dihydrofolate reductase inhibitors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731918/),[mg] / [l],175.4,270144,DB00440,Trimethoprim
,31702484,AUC0-8h,"Rats treated with TMP-SMX showed a much broader exposure to ATV compared to the control group (AUC0-8h (ng.mL-1.h), 25975.9±4048.7 versus 2587.6±546.9, p=0.001).",Higher Atazanavir Plasma Exposure in Rats is Associated with Gut Microbiota Changes Induced by Cotrimoxazole. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31702484/),[h·ng] / [ml],25975.9,271176,DB00440,Trimethoprim
,31702484,AUC0-8h,"Rats treated with TMP-SMX showed a much broader exposure to ATV compared to the control group (AUC0-8h (ng.mL-1.h), 25975.9±4048.7 versus 2587.6±546.9, p=0.001).",Higher Atazanavir Plasma Exposure in Rats is Associated with Gut Microbiota Changes Induced by Cotrimoxazole. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31702484/),[h·ng] / [ml],2587.6,271177,DB00440,Trimethoprim
,6611547,half-life,"The average +/- SD half-life in plasma was for sulfametoxazole 12.8 +/- 0.32 h, for sulfamerazine 17.0 +/- 0.75 h and for sulfachloropyridazine 13.1 +/- 0.86 h.",Pharmacokinetic analysis of the level of sulfonamide-trimethoprim combination in calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6611547/),h,12.8,271447,DB00440,Trimethoprim
,6611547,half-life,"The average +/- SD half-life in plasma was for sulfametoxazole 12.8 +/- 0.32 h, for sulfamerazine 17.0 +/- 0.75 h and for sulfachloropyridazine 13.1 +/- 0.86 h.",Pharmacokinetic analysis of the level of sulfonamide-trimethoprim combination in calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6611547/),h,17.0,271448,DB00440,Trimethoprim
,6611547,half-life,"The average +/- SD half-life in plasma was for sulfametoxazole 12.8 +/- 0.32 h, for sulfamerazine 17.0 +/- 0.75 h and for sulfachloropyridazine 13.1 +/- 0.86 h.",Pharmacokinetic analysis of the level of sulfonamide-trimethoprim combination in calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6611547/),h,13.1,271449,DB00440,Trimethoprim
,6611547,half-life,The average half-life of trimethoprim in plasma was 11.3 +/- 0.56 h.,Pharmacokinetic analysis of the level of sulfonamide-trimethoprim combination in calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6611547/),h,11.3,271450,DB00440,Trimethoprim
,17913794,inhibition constant,"Trimethoprim inhibited M-IV formation in vitro (inhibition constant 38.2 muM), predicting the in vivo interaction.",Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17913794/),muM,38.2,271534,DB00440,Trimethoprim
,1606899,absorption half-life time,The absorption half-life time was 0.64 hours.,Blood and tissue concentrations of trimethoprim following its administration alone and in combination with josamycin. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606899/),h,0.64,272040,DB00440,Trimethoprim
,1606899,elimination half life,The elimination half life was 4.73 hours.,Blood and tissue concentrations of trimethoprim following its administration alone and in combination with josamycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606899/),h,4.73,272041,DB00440,Trimethoprim
,1606899,maximum serum concentration,"After oral administration of josamycin (18 mg/kg b. wt.) and trimethoprim (10 mg/kg b. wt.) in normal fowls, a maximum serum concentration of trimethoprim was recorded at 2 hours with half-life of absorption (t0.5(ab)) valued 0.74 hour.",Blood and tissue concentrations of trimethoprim following its administration alone and in combination with josamycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606899/),h,2,272042,DB00440,Trimethoprim
,1606899,half-life of absorption (t0.5(ab)),"After oral administration of josamycin (18 mg/kg b. wt.) and trimethoprim (10 mg/kg b. wt.) in normal fowls, a maximum serum concentration of trimethoprim was recorded at 2 hours with half-life of absorption (t0.5(ab)) valued 0.74 hour.",Blood and tissue concentrations of trimethoprim following its administration alone and in combination with josamycin. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606899/),h,0.74,272043,DB00440,Trimethoprim
,1606899,elimination half-life (t0.5 beta),The elimination half-life (t0.5 beta) was 4.37 hours.,Blood and tissue concentrations of trimethoprim following its administration alone and in combination with josamycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606899/),h,4.37,272044,DB00440,Trimethoprim
,1687853,plasma half-life (t1/2),3. The plasma half-life (t1/2) of RIF increased significantly from 1.92 +/- 0.57 h to 2.31 +/- 0.134 h after CTZ treatment.,Drug interaction between rifampicin and cotrimoxazole in patients with tuberculosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687853/),h,1.92,274098,DB00440,Trimethoprim
,1687853,plasma half-life (t1/2),3. The plasma half-life (t1/2) of RIF increased significantly from 1.92 +/- 0.57 h to 2.31 +/- 0.134 h after CTZ treatment.,Drug interaction between rifampicin and cotrimoxazole in patients with tuberculosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687853/),h,2.31,274099,DB00440,Trimethoprim
